

516,837

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
**WO 03/104273 A2**

- (51) International Patent Classification<sup>7</sup>: **C07K 14/415**
- (21) International Application Number: **PCT/GB03/02450**
- (22) International Filing Date: **5 June 2003 (05.06.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**0212885.8** **5 June 2002 (05.06.2002)** **GB**
- (71) Applicant (for all designated States except US): **ISIS INNOVATION LIMITED [GB/GB]**; Ewert House, Ewert Place, Summertown, Oxford OX2 7SG (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ANDERSON, Robert, Paul [GB/AU]**; Autoimmunity and Transplantation Division, Walter & Eliza Hall Institute, c/o Royal Melbourne Hospital PO, Grattan Street, Parkville, VIC 3050 (AU). **HILL, Adrian, Vivian, Sinton [IE/GB]**; Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN (GB). **JEWELL, Derek, Parry [GB/GB]**; Gastroenterology Unit, Gibson Building, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE (GB).
- (74) Agent: **MARSHALL, Cameron, John**; Carpmals and Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **THERAPEUTIC EPITOPES AND USES THEREOF**

(57) Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.

WO 03/104273 A2

## THERAPEUTIC EPITOPES AND USES THEREOF

The invention relates to epitopes useful in the diagnosis and therapy of coeliac disease, including diagnostics, therapeutics, kits, and methods of using the foregoing.

5       An immune reaction to gliadin (a component of gluten) in the diet causes coeliac disease. It is known that immune responses in the intestinal tissue preferentially respond to gliadin which has been modified by an intestinal transglutaminase. Coeliac disease is diagnosed by detection of anti-endomysial antibodies, but this requires confirmation by the finding of a lymphocytic  
10       inflammation in intestinal biopsies. The taking of such a biopsy is inconvenient for the patient.

Investigators have previously assumed that only intestinal T cell responses provide an accurate indication of the immune response against gliadins. Therefore they have concentrated on the investigation of T cell responses in intestinal tissue<sup>1</sup>.  
15       Gliadin epitopes which require transglutaminase modification (before they are recognised by the immune system) are known<sup>2</sup>.

The inventors have found the immunodominant T cell A-gliadin epitope recognised by the immune system in coeliac disease, and have shown that this is recognised by T cells in the peripheral blood of individuals with coeliac disease (see  
20       WO 01/25793). Such T cells were found to be present at high enough frequencies to be detectable without restimulation (i.e. a 'fresh response' detection system could be used). The epitope was identified using a non-T cell cloning based method which provided a more accurate reflection of the epitopes being recognised. The immunodominant epitope requires transglutaminase modification (causing  
25       substitution of a particular glutamine to glutamate) before immune system recognition.

Based on this work the inventors have developed a test which can be used to diagnose coeliac disease at an early stage. The test may be carried out on a sample from peripheral blood and therefore an intestinal biopsy is not required. The test is  
30       more sensitive than the antibody tests which are currently being used.

The invention thus provides a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:



(a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO:1 (PQPELPY) or SEQ ID NO:2 (QLQFPQPELPYPQPQS), or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3, (ii) an epitope comprising  
5 sequence comprising: SEQ ID NO:1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3 (shown in Table 1), which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50  
10 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining *in vitro* whether T cells in the sample recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

Through comprehensive mapping of wheat gliadin T cell epitopes (see  
15 Example 13), the inventors have also found epitopes bioactive in coeliac disease in HLA-DQ2+ patients in other wheat gliadins, having similar core sequences (e.g., SEQ ID NOS:18-22) and similar full length sequences (e.g., SEQ ID NOS:31-36), as well as in rye secalins and barley hordeins (e.g., SEQ ID NOS:39-41); see also Tables 20 and 21. Additionally, several epitopes bioactive in coeliac disease in  
20 HLA-DQ8+ patients have been identified (e.g., SEQ ID NOS:42-44, 46). This comprehensive mapping thus provides the dominant epitopes recognized by T cells in coeliac patients. Thus, the above-described method and other methods of the invention described herein may be performed using any of these additional identified epitopes, and analogues and equivalents thereof; (i) and (ii) herein include these  
25 additional epitopes. That is, the agents of the invention also include these novel epitopes.

The invention also provides use of the agent for the preparation of a diagnostic means for use in a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T  
30 cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The finding of an immunodominant epitope which is modified by transglutaminase (as well as the additional other epitopes defined herein) also allows diagnosis of coeliac disease based on determining whether other types of immune response to this epitope are present. Thus the invention also provides a method of  
5 diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to the epitope in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.

The invention additionally provides the agent, optionally in association with a  
10 carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent. Also provided is an antagonist of a T cell which has a T cell receptor that recognises (i) or (ii), optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells. Additionally provided is the agent or an analogue that binds an antibody (that  
15 binds the agent) for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.

The invention provides a method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined  
20 above is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

The invention also provides a mutant gliadin protein whose wild-type sequence can be modified by a transglutaminase to a sequence that comprises an epitope comprising sequence as defined above, but which mutant gliadin protein has  
25 been modified in such a way that it does not contain sequence which can be modified by a transglutaminase to a sequence that comprises such an epitope comprising sequence; or a fragment of such a mutant gliadin protein which is at least 15 amino acids long and which comprises sequence which has been modified in said way.

The invention also provides a protein that comprises a sequence which is able  
30 to bind to a T cell receptor, which T cell receptor recognises the agent, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

Additionally the invention provides a food that comprises the proteins defined above.

#### SUMMARY OF THE INVENTION

5 The present invention provides methods of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from: a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs:18-22, 31-36, 39-44, and 46, and equivalents thereof; and b) an analogue of a) which is capable of being recognised by a T cell  
10 receptor that recognises the peptide of a) and which is not more than 50 amino acids in length; and c) optionally, in addition to the agent selected from a) and b), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NO:1 and SEQ ID NO:2. In some embodiments, the agent is HLA-DQ2-restricted, HLA-DQ8-restricted or one agent is HLA-DQ2-restricted and a second agent is HLA-DQ8-restricted.  
15 DQ8-restricted. In some embodiments, the agent comprises a wheat epitope, a rye epitope, a barley epitope or any combination thereof either as a single agent or as multiple agents.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition  
20 comprising an agent above and pharmaceutically acceptable carrier or diluent.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined above, and a pharmaceutically acceptable carrier or diluent.

25 The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

30 The present invention also provides methods of preventing or treating coeliac disease by 1) diagnosing coeliac disease in an individual by either: a) contacting a sample from the host with at least one agent selected from: i) a peptide comprising at

least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and iii) optionally, in addition to the agent selected from i) and ii), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NOS:1 and 2; and determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease; or b) administering an agent as defined above and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease; and 2) administering to an individual diagnosed as having, or being susceptible to, coeliac disease a therapeutic agent for preventing or treating coeliac disease.

The present invention also provides agents as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.

The present invention also provides antagonists of a T cell which has a T cell receptor as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.

The present invention also provides proteins that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined above, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

The present invention also provides pharmaceutical compositions comprising an agent or antagonist as defined and a pharmaceutically acceptable carrier or diluent.

The present invention also provides compositions for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

The present invention also provides compositions for antagonising a T cell response to an agent as defined above, which composition comprises an antagonist as defined above.

The present invention also provides mutant gliadin proteins whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined in claim 1, which mutant gliadin protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined above; or a fragment of such a mutant gliadin protein which is at least 15 amino acids long and which comprises the mutation.

The present invention also provides polynucleotides that comprises a coding sequence that encodes a protein or fragment as defined above.

The present invention also provides cells comprising a polynucleotide as defined above or which has been transformed with such a polynucleotide.

The present invention also provides mammals that expresses a T cell receptor as defined above.

The present invention also provides methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) contacting a sample from the host with at least one agent selected from i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and iii) optionally, in addition to the agent selected from i) and ii), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NOS:1 and 2; and b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The present invention also provides methods of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

The present invention also provides methods of identifying an antagonist of a T cell, which T cell recognises an agent as defined above, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the

detecting of any such decrease in said ability indicating that the substance is an antagonist.

The present invention also provides kits for carrying out any of the method described above comprising an agent as defined above and a means to detect the  
5 recognition of the peptide by the T cell.

The present invention also provides methods of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined above which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the  
10 prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

The present invention also provides processes for the production of a protein encoded by a coding sequence as defined above which process comprises: a) cultivating a cell described above under conditions that allow the expression of the  
15 protein; and optionally b) recovering the expressed protein.

The present invention also provides methods of obtaining a transgenic plant cell comprising transforming a plant cell with a vector as described above to give a transgenic plant cell.

The present invention also provides methods of obtaining a first-generation  
20 transgenic plant comprising regenerating a transgenic plant cell transformed with a vector as described above to give a transgenic plant.

The present invention also provides methods of obtaining a transgenic plant seed comprising obtaining a transgenic seed from a transgenic plant obtainable as described above.

25 The present invention also provides methods of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method as described above, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

30 The present invention also provides transgenic plant cells, plants, plant seeds or progeny plants obtainable by any of the methods described above.

The present invention also provides transgenic plants or plant seeds comprising plant cells as described above.

The present invention also provides transgenic plant cell calluses comprising plant cells as described above obtainable from a transgenic plant cell, first-generation  
5 plant, plant seed or progeny as defined above.

The present invention also provides methods of obtaining a crop product comprising harvesting a crop product from a plant according to any method described above and optionally further processing the harvested product.

The present invention also provides food that comprises a protein as defined  
10 above.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is illustrated by the accompanying drawings in which:

Figure 1 shows freshly isolated PBMC (peripheral blood mononuclear cell)  
15 IFN $\gamma$  ELISPOT responses (vertical axis shows spot forming cells per 10<sup>6</sup> PBMC) to transglutaminase (tTG)-treated and untreated peptide pool 3 (each peptide 10  $\mu$ g/ml) including five overlapping 15mers spanning A-gliadin 51-85 (see Table 1) and a-chymotrypsin-digested gliadin (40  $\mu$ g/ml) in coeliac disease Subject 1, initially in remission following a gluten free diet then challenged with 200g bread daily for three  
20 days from day 1 (a). PBMC IFN $\gamma$  ELISPOT responses by Subject 2 to tTG-treated A-gliadin peptide pools 1-10 spanning the complete A-gliadin protein during ten day bread challenge (b). The horizontal axis shows days after commencing bread.

Figure 2 shows PBMC IFN $\gamma$  ELISPOT responses to tTG-treated peptide pool 3 (spanning A-gliadin 51-85) in 7 individual coeliac disease subjects (vertical axis  
25 shows spot forming cells per 10<sup>6</sup> PBMC), initially in remission on gluten free diet, challenged with bread for three days (days 1 to 3). The horizontal axis shows days after commencing bread. (a). PBMC IFN $\gamma$  Elispot responses to tTG-treated overlapping 15mer peptides included in pool 3; bars represent the mean ( $\pm$  SEM) response to individual peptides (10  $\mu$ g/ml) in 6 Coeliac disease subjects on day 6 or  
30 7(b). (In individual subjects, ELISPOT responses to peptides were calculated as a % of response elicited by peptide 12 - as shown by the vertical axis.)

Figure 3 shows PBMC IFN $\gamma$  ELISPOT responses to tTG-treated truncations of A-gliadin 56-75 (0.1  $\mu$ M). Bars represent the mean ( $\pm$  SEM) in 5 Coeliac disease subjects. (In individual subjects, responses were calculated as the % of the maximal response elicited by any of the peptides tested.)

5        Figure 4 shows how the minimal structure of the dominant A-gliadin epitope was mapped using tTG-treated 7-17mer A-gliadin peptides (0.1  $\mu$ M) including the sequence, PQPQLPY (SEQ ID NO:4) (A-gliadin 62-68) (a), and the same peptides without tTG treatment but with the substitution Q $\rightarrow$ E65 (b). Each line represents PBMC IFN $\gamma$  ELISPOT responses in each of three Coeliac disease subjects on day 6  
10 or 7 after bread was ingested on days 1-3. (In individual subjects, ELISPOT responses were calculated as a % of the response elicited by the 17mer, A-gliadin 57-73.)

Figure 5 shows the amino acids that were deamidated by tTG. A-gliadin 56-75 LQLQFPQPQLPYQPQSFP (SEQ ID NO:5) (0.1  $\mu$ M) was incubated with tTG  
15 (50  $\mu$ g/ml) at 37°C for 2 hours. A single product was identified and purified by reverse phase HPLC. Amino acid analysis allowed % deamidation (Q $\rightarrow$ E) of each Gln residue in A-gliadin 56-75 attributable to tTG to be calculated (vertical axis).

Figure 6 shows the effect of substituting Q $\rightarrow$ E in A-gliadin 57-73 at other positions in addition to Q65 using the 17mers: QLQFPQPPELPYPQPES (SEQ ID  
20 NO:6) (E57,65), QLQFPQPPELPYPQPES (SEQ ID NO:7) (E65,72),  
ELQFPQPPELPYPQPES (SEQ ID NO:8) (E57, 65, 72), and  
QLQFPQPPELPYPQPQS (SEQ ID NO:2) (E65) in three Coeliac disease subjects on day 6 or 7 after bread was ingested on days 1-3. Vertical axis shows % of the E65 response.

25        Figure 7 shows that tTG treated A-gliadin 56-75 (0.1  $\mu$ M) elicited IFN-g ELISPOT responses in (a) CD4 and CD8 magnetic bead depleted PBMC. (Bars represent CD4 depleted PBMC responses as a % of CD8 depleted PBMC responses; spot forming cells per million CD8 depleted PBMC were: Subject 4: 29, and Subject 6: 535). (b) PBMC IFN $\gamma$  ELISPOT responses (spot forming cells/million PBMC)  
30 after incubation with monoclonal antibodies to HLA-DR (L243), -DQ (L2) and -DP (B7.21) (10  $\mu$ g/ml) 1h prior to tTG-treated 56-75 (0.1  $\mu$ M) in two coeliac disease subjects homozygous for HLA-DQ a1\*0501, b1\*0201.



Figure 8 shows the effect of substituting Glu at position 65 for other amino acids in the immunodominant epitope. The vertical axis shows the % response in the 3 subjects in relation to the immunodominant epitope.

Figure 9 shows the immunoreactivity of naturally occurring gliadin peptides (measuring responses from 3 subjects) which contain the sequence PQLPY (SEQ ID NO:12) with (shaded) and without (clear) transglutaminase treatment.

Figure 10 shows CD8, CD4,  $\beta_7$ , and  $\alpha^E$ -specific immunomagnetic bead depletion of peripheral blood mononuclear cells from two coeliac subjects 6 days after commencing gluten challenge followed by interferon gamma ELISpot. A-gliadin 57-73 QE65 (25mcg/ml), tTG-treated chymotrypsin-digested gliadin (100 mcg/ml) or PPD (10 mcg/ml) were used as antigen.

Figure 11 shows the optimal T cell epitope length.

Figure 12 shows a comparison of A-gliadin 57-73 QE65 with other peptides in a dose response study.

Figure 13 shows a comparison of gliadin and A-gliadin 57-73 QE65 specific responses.

Figure 14 shows the bioactivity of gliadin polymorphisms in coeliac subjects.

Figures 15 and 16 show the defining of the core epitope sequence.

Figures 17 to 27 show the agonist activity of A-gliadin 57-73 QE65 variants.

Figure 28 shows responses in different patient groups.

Figure 29 shows bioactivity of prolamin homologues of A-gliadin 57-73.

Figure 30 shows, for healthy HLA-DQ2 subjects, the change in IFN-gamma ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 31 shows, for coeliac HLA-DQ2 subjects, the change in IFN-gamma ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 32 shows individual peptide contributions to "summed" gliadin peptide response.

Figure 33 shows, for coeliac HLA-DQ2/8 subject C08, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 34 shows, for coeliac HLA-DQ2/8 subject C07, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 35 shows, for coeliac HLA-DQ8/7 subject C12, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 36 shows, for coeliac HLA-DQ6/8 subject C11, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

5

### Detailed Description of the Invention

The term "coeliac disease" encompasses a spectrum of conditions caused by varying degrees of gluten sensitivity, including a severe form characterised by a flat small intestinal mucosa (hyperplastic villous atrophy) and other forms characterised by milder symptoms.

The individual mentioned above (in the context of diagnosis or therapy) is human. They may have coeliac disease (symptomatic or asymptomatic) or be suspected of having it. They may be on a gluten free diet. They may be in an acute phase response (for example they may have coeliac disease, but have only ingested gluten in the last 24 hours before which they had been on a gluten free diet for 14 to 28 days).

The individual may be susceptible to coeliac disease, such as a genetic susceptibility (determined for example by the individual having relatives with coeliac disease or possessing genes which cause predisposition to coeliac disease).

20

### The agent

The agent is typically a peptide, for example of length 7 to 50 amino acids, such as 10 to 40, or 15 to 30 amino acids in length.

SEQ ID NO:1 is PQPELPY. SEQ ID NO:2 is QLQPFPPQPELPYPQPQS. SEQ ID NO:3 is shown in Table 1 and is the sequence of a whole A-gliadin. The glutamate at position 4 of SEQ ID NO:1 (equivalent to position 9 of SEQ ID NO:2) is generated by transglutaminase treatment of A-gliadin.

The agent may be the peptide represented by SEQ ID NO:1 or 2 or an epitope comprising sequence that comprises SEQ ID NO:1 which is an isolated oligopeptide derived from a gliadin protein; or an equivalent of these sequences from a naturally occurring gliadin protein which is a homologue of SEQ ID NO:3. Thus the epitope may be a derivative of the protein represented by SEQ ID NO:3. Such a derivative is

30

typically a fragment of the gliadin, or a mutated derivative of the whole protein or fragment. Therefore the epitope of the invention does not include this naturally occurring whole gliadin protein, and does not include other whole naturally occurring gliadins.

5       The epitope may thus be a fragment of A-gliadin (e.g. SEQ ID NO:3), which comprises the sequence of SEQ ID NO:1, obtainable by treating (fully or partially) with transglutaminase, i.e. with 1, 2, 3 or more glutamines substituted to glutamates (including the substitution within SEQ ID NO:1).

10       Such fragments may be or may include the sequences represented by positions 55 to 70, 58 to 73, 61 to 77 of SEQ ID NO:3 shown in Table 1. Typically such fragments will be recognised by T cells to at least the same extent that the peptides represented by SEQ ID NO:1 or 2 are recognised in any of the assays described herein using samples from coeliac disease patients.

15       Additionally, the agent may be the peptide represented by any of SEQ ID NOS:18-22, 31-36, 39-44, and 46 or a protein comprising a sequence corresponding to any of SEQ ID NOS:18-22, 31-36, 39-44, and 46 (such as fragments of a gliadin comprising any of SEQ ID NOS:18-22, 31-36, 39-44, and 46, for example after the gliadin has been treated with transglutaminase). Bioactive fragments of such sequences are also agents of the invention. Sequences equivalent to any of SEQ ID  
20       NOS:18-22, 31-36, 39-44, and 46 or analogues of these sequences are also agents of the invention.

25       In the case where the epitope comprises a sequence equivalent to the above epitopes (including fragments) from another gliadin protein (e.g. any of the gliadin proteins mentioned herein or any gliadins which cause coeliac disease), such equivalent sequences will correspond to a fragment of a gliadin protein typically treated (partially or fully) with transglutaminase. Such equivalent peptides can be determined by aligning the sequences of other gliadin proteins with the gliadin from which the original epitope derives, such as with SEQ ID NO:3 (for example using  
30       any of the programs mentioned herein). Transglutaminase is commercially available (e.g. Sigma T-5398). Table 4 provides a few examples of suitable equivalent sequences.

The agent which is an analogue is capable of being recognised by a TCR which recognises (i) or (ii). Therefore generally when the analogue is added to T cells in the presence of (i) or (ii), typically also in the presence of an antigen presenting cell (APC) (such as any of the APCs mentioned herein), the analogue  
5 inhibits the recognition of (i) or (ii), i.e. the analogue is able to compete with (i) or (ii) in such a system.

The analogue may be one which is capable of binding the TCR which recognises (i) or (ii). Such binding can be tested by standard techniques. Such TCRs can be isolated from T cells which have been shown to recognise (i) or (ii) (e.g. using  
10 the method of the invention). Demonstration of the binding of the analogue to the TCRs can then shown by determining whether the TCRs inhibit the binding of the analogue to a substance that binds the analogue, e.g. an antibody to the analogue. Typically the analogue is bound to a class II MHC molecule (e.g. HLA-DQ2) in such an inhibition of binding assay.

15 Typically the analogue inhibits the binding of (i) or (ii) to a TCR. In this case the amount of (i) or (ii) which can bind the TCR in the presence of the analogue is decreased. This is because the analogue is able to bind the TCR and therefore competes with (i) or (ii) for binding to the TCR.

T cells for use in the above binding experiments can be isolated from patients  
20 with coeliac disease, for example with the aid of the method of the invention.

Other binding characteristics of the analogue may also be the same as (i) or (ii), and thus typically the analogue binds to the same MHC class II molecule to which the peptide binds (HLA-DQ2 or -DQ8). The analogue typically binds to antibodies specific for (i) or (ii), and thus inhibits binding of (i) or (ii) to such  
25 antibodies.

The analogue is typically a peptide. It may have homology with (i) or (ii), typically at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology with (i) or (ii), for example over a region of at least 15 more (such as the entire length of the analogue and/or (i) or (ii), or across the region which contacts the  
30 TCR or binds the MHC molecule) contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill

in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings)

5 (Devereux *et al* (1984) *Nucleic Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F *et al* (1990) *J Mol Biol* 215:403-10.

Software for performing BLAST analyses is publicly available through the  
10 National Center for Biotechnology Information on the world wide web through the internet at, for example, "www.ncbi.nlm.nih.gov". This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is  
15 referred to as the neighbourhood word score threshold (Altschul *et al*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off  
20 by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-  
25 10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci.*  
30 *USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences

would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

- 5 The homologous peptide analogues typically differ from (i) or (ii) by 1, 2, 3, 4, 5, 6, 7, 8 or more mutations (which may be substitutions, deletions or insertions). These mutations may be measured across any of the regions mentioned above in relation to calculating homology. The substitutions are preferably 'conservative'. These are defined according to the following Table. Amino acids in the same block  
10 in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar – uncharged	C S T M
		N Q
AROMATIC	Polar – charged	D E
		K R
		H F W Y

- Typically the amino acids in the analogue at the equivalent positions to amino  
15 acids in (i) or (ii) that contribute to binding the MHC molecule or are responsible for the recognition by the TCR, are the same or are conserved.

- Typically the analogue peptide comprises one or more modifications, which may be natural post-translation modifications or artificial modifications. The modification may provide a chemical moiety (typically by substitution of a  
20 hydrogen, e.g. of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group. Typically the modification is present on the N or C terminus.

The analogue may comprise one or more non-natural amino acids, for example amino acids with a side chain different from natural amino acids.

Generally, the non-natural amino acid will have an N terminus and/or a C terminus. The non-natural amino acid may be an L- or a D- amino acid.

The analogue typically has a shape, size, flexibility or electronic configuration that is substantially similar to (i) or (ii). It is typically a derivative of (i) or (ii). In one embodiment the analogue is a fusion protein comprising the sequence of SEQ ID NO:1 or 2, or any of the other peptides mentioned herein; and non-gliadin sequence.

In one embodiment the analogue is or mimics (i) or (ii) bound to a MHC class II molecule. 2, 3, 4 or more of such complexes may be associated or bound to each other, for example using a biotin/streptavidin based system, in which typically 2, 3 or 4 biotin labelled MHC molecules bind to a streptavidin moiety. This analogue typically inhibits the binding of the (i) or (ii)/MHC Class II complex to a TCR or antibody which is specific for the complex.

The analogue is typically an antibody or a fragment of an antibody, such as a Fab or (Fab)<sub>2</sub> fragment. The analogue may be immobilised on a solid support, particularly an analogue that mimics peptide bound to a MHC molecule.

The analogue is typically designed by computational means and then synthesised using methods known in the art. Alternatively the analogue can be selected from a library of compounds. The library may be a combinatorial library or a display library, such as a phage display library. The library of compounds may be expressed in the display library in the form of being bound to a MHC class II molecule, such as HLA-DQ2 or -DQ8. Analogues are generally selected from the library based on their ability to mimic the binding characteristics (i) or (ii). Thus they may be selected based on ability to bind a TCR or antibody which recognises (i) or (ii).

Typically analogues will be recognised by T cells to at least the same extent as any of the agents (i) or (ii), for example at least to the same extent as the equivalent epitope and preferably to the same extent as the peptide represented by SEQ ID NO:2, is recognised in any of the assays described herein, typically using T cells from coeliac disease patients. Analogues may be recognised to these extents *in vivo* and thus may be able to induce coeliac disease symptoms to at least the same

extent as any of the agents mentioned herein (e.g. in a human patient or animal model).

Analogue may be identified in a method comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope of the invention, recognition of the substance indicating that the substance is an analogue. Such TCRs may be any of the TCRs mentioned herein, and may be present on T cells. Any suitable assay mentioned herein can be used to identify the analogue. In one embodiment this method is carried out *in vivo*. As mentioned above preferred analogues are recognised to at least the same extent as the peptide SEQ ID NO:2, and so the method may be used to identify analogues which are recognised to this extent.

In one embodiment the method comprises determining whether a candidate substance is able to inhibit the recognition of an epitope of the invention, inhibition of recognition indicating that the substance is an analogue.

The agent may be a product comprising at least 2, 5, 10 or 20 agents as defined by (i), (ii) or (iii). Typically the composition comprises epitopes of the invention (or equivalent analogues) from different gliadins, such as any of the species or variety of or types of gliadin mentioned herein. Preferred compositions comprise at least one epitope of the invention, or equivalent analogue, from all of the gliadins present in any of the species or variety mentioned herein, or from 2, 3, 4 or more of the species mentioned herein (such as from the panel of species consisting of wheat, rye, barley, oats and triticale). Thus, the agent may be monovalent or multivalent.

## Diagnosis

As mentioned above the method of diagnosis of the invention may be based on the detection of T cells that bind the agent or on the detection of antibodies that recognise the agent.

The T cells that recognise the agent in the method (which includes the use mentioned above) are generally T cells that have been pre-sensitised *in vivo* to gliadin. As mentioned above such antigen-experienced T cells have been found to be present in the peripheral blood.



In the method the T cells can be contacted with the agent *in vitro* or *in vivo*, and determining whether the T cells recognise the agent can be performed *in vitro* or *in vivo*. Thus the invention provides the agent for use in a method of diagnosis practiced on the human body. Different agents are provided for simultaneous,  
5 separate or sequential use in such a method.

The *in vitro* method is typically carried out in aqueous solution into which the agent is added. The solution will also comprise the T cells (and in certain embodiments the APCs discussed below). The term 'contacting' as used herein includes adding the particular substance to the solution.

10 Determination of whether the T cells recognise the agent is generally accomplished by detecting a change in the state of the T cells in the presence of the agent or determining whether the T cells bind the agent. The change in state is generally caused by antigen specific functional activity of the T cell after the TCR binds the agent. The change of state may be measured inside (e.g. change in  
15 intracellular expression of proteins) or outside (e.g. detection of secreted substances) the T cells.

The change in state of the T cell may be the start of or increase in secretion of a substance from the T cell, such as a cytokine, especially IFN- $\gamma$ , IL-2 or TNF- $\alpha$ . Determination of IFN- $\gamma$  secretion is particularly preferred. The substance can  
20 typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex. The specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.

25 Typically the specific binding agent is immobilised on a solid support. After the substance is allowed to bind the solid support can optionally be washed to remove material which is not specifically bound to the agent. The agent/substance complex may be detected by using a second binding agent that will bind the complex. Typically the second agent binds the substance at a site which is different  
30 from the site which binds the first agent. The second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.

Thus the second agent may be detected by a third agent that is typically labelled directly or indirectly by a detectable label. For example the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.

5 In one embodiment the detection system which is used is the *ex-vivo* ELISPOT assay described in WO 98/23960. In that assay IFN- $\gamma$  secreted from the T cell is bound by a first IFN- $\gamma$  specific antibody that is immobilised on a solid support. The bound IFN- $\gamma$  is then detected using a second IFN- $\gamma$  specific antibody which is labelled with a detectable label. Such a labelled antibody can be obtained from  
10 MABTECH (Stockholm, Sweden). Other detectable labels which can be used are discussed below.

The change in state of the T cell that can be measured may be the increase in the uptake of substances by the T cell, such as the uptake of thymidine. The change in state may be an increase in the size of the T cells, or proliferation of the T cells, or  
15 a change in cell surface markers on the T cell.

In one embodiment the change of state is detected by measuring the change in the intracellular expression of proteins, for example the increase in intracellular expression of any of the cytokines mentioned above. Such intracellular changes may be detected by contacting the inside of the T cell with a moiety that binds the  
20 expressed proteins in a specific manner and which allows sorting of the T cells by flow cytometry.

In one embodiment when binding the TCR the agent is bound to an MHC class II molecule (typically HLA-DQ2 or -DQ8), which is typically present on the surface of an antigen presenting cell (APC). However as mentioned herein other  
25 agents can bind a TCR without the need to also bind an MHC molecule.

Generally the T cells which are contacted in the method are taken from the individual in a blood sample, although other types of samples which contain T cells can be used. The sample may be added directly to the assay or may be processed first. Typically the processing may comprise diluting of the sample, for example  
30 with water or buffer. Typically the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.

The processing may comprise separation of components of the sample. Typically mononuclear cells (MCs) are separated from the samples. The MCs will comprise the T cells and APCs. Thus in the method the APCs present in the separated MCs can present the peptide to the T cells. In another embodiment only T cells, such as only CD4 T cells, can be purified from the sample. PBMCs, MCs and T cells can be separated from the sample using techniques known in the art, such as those described in Lalvani *et al* (1997) *J. Exp. Med.* 186, p859-865.

In one embodiment, the T cells used in the assay are in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of freshly isolated MCs or PBMCs) which are used directly *ex vivo*, i.e. they are not cultured before being used in the method. Thus the T cells have not been restimulated in an antigen specific manner *in vitro*. However the T cells can be cultured before use, for example in the presence of one or more of the agents, and generally also exogenous growth promoting cytokines. During culturing the agent(s) are typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an increase in the sensitivity of the method. Thus the T cells can be converted into cell lines, such as short term cell lines (for example as described in Ota *et al* (1990) *Nature* 346, p183-187).

The APC that is typically present in the method may be from the same individual as the T cell or from a different host. The APC may be a naturally occurring APC or an artificial APC. The APC is a cell that is capable of presenting the peptide to a T cell. It is typically a B cell, dendritic cell or macrophage. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus the APC may be present in MCs or PBMCs. The APC is typically a freshly isolated *ex vivo* cell or a cultured cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class II molecules on its surface.

In the method one or more (different) agents may be used. Typically the T cells derived from the sample can be placed into an assay with all the agents which it is intended to test or the T cells can be divided and placed into separate assays each of which contain one or more of the agents.

The invention also provides the agents such as two or more of any of the agents mentioned herein (e.g. the combinations of agents which are present in the composition agent discussed above) for simultaneous separate or sequential use (eg. for *in vivo* use).

5           In one embodiment agent *per se* is added directly to an assay comprising T cells and APCs. As discussed above the T cells and APCs in such an assay could be in the form of MCs. When agents that can be recognised by the T cell without the need for presentation by APCs are used then APCs are not required. Analogues which mimic the original (i) or (ii) bound to a MHC molecule are an example of such  
10   an agent.

          In one embodiment the agent is provided to the APC in the absence of the T cell. The APC is then provided to the T cell, typically after being allowed to present the agent on its surface. The peptide may have been taken up inside the APC and presented, or simply be taken up onto the surface without entering inside the APC.

15           The duration for which the agent is contacted with the T cells will vary depending on the method used for determining recognition of the peptide. Typically  $10^5$  to  $10^7$ , preferably  $5 \times 10^5$  to  $10^6$  PBMCs are added to each assay. In the case where agent is added directly to the assay its concentration is from  $10^{-1}$  to  $10^3 \mu\text{g/ml}$ , preferably 0.5 to  $50 \mu\text{g/ml}$  or 1 to  $10 \mu\text{g/ml}$ .

20           Typically the length of time for which the T cells are incubated with the agent is from 4 to 24 hours, preferably 6 to 16 hours. When using *ex vivo* PBMCs it has been found that  $0.3 \times 10^6$  PBMCs can be incubated in  $10 \mu\text{g/ml}$  of peptide for 12 hours at  $37^\circ\text{C}$ .

          The determination of the recognition of the agent by the T cells may be done  
25   by measuring the binding of the agent to the T cells (this can be carried out using any suitable binding assay format discussed herein). Typically T cells which bind the agent can be sorted based on this binding, for example using a FACS machine. The presence of T cells that recognise the agent will be deemed to occur if the frequency of cells sorted using the agent is above a "control" value. The frequency of antigen-experienced T cells is generally 1 in  $10^6$  to 1 in  $10^3$ , and therefore whether or not the  
30   sorted cells are antigen-experienced T cells can be determined.

The determination of the recognition of the agent by the T cells may be measured *in vivo*. Typically the agent is administered to the host and then a response which indicates recognition of the agent may be measured. The agent is typically administered intradermally or epidermally. The agent is typically administered by contacting with the outside of the skin, and may be retained at the site with the aid of a plaster or dressing. Alternatively the agent may be administered by needle, such as by injection, but can also be administered by other methods such as ballistics (e.g. the ballistics techniques which have been used to deliver nucleic acids). EP-A-0693119 describes techniques that can typically be used to administer the agent. Typically from 0.001 to 1000 µg, for example from 0.01 to 100 µg or 0.1 to 10 µg of agent is administered.

In one embodiment a product can be administered which is capable of providing the agent *in vivo*. Thus a polynucleotide capable of expressing the agent can be administered, typically in any of the ways described above for the administration of the agent. The polynucleotide typically has any of the characteristics of the polynucleotide provided by the invention which is discussed below. The agent is expressed from the polynucleotide *in vivo*. Typically from 0.001 to 1000 µg, for example from 0.01 to 100 µg or 0.1 to 10 µg of polynucleotide is administered.

Recognition of the agent administered to the skin is typically indicated by the occurrence of inflammation (e.g. induration, erythema or oedema) at the site of administration. This is generally measured by visual examination of the site.

The method of diagnosis based on the detection of an antibody that binds the agent is typically carried out by contacting a sample from the individual (such as any of the samples mentioned here, optionally processed in any manner mentioned herein) with the agent and determining whether an antibody in the sample binds the agent, such a binding indicating that the individual has, or is susceptible to coeliac disease. Any suitable format of binding assay may be used, such as any such format mentioned herein.

30

## Therapy

The identification of the immunodominant epitope and other epitopes described herein allows therapeutic products to be made which target the T cells which recognise this epitope (such T cells being ones which participate in the immune response against gliadin). These findings also allow the prevention or  
5 treatment of coeliac disease by suppressing (by tolerisation) an antibody or T cell response to the epitope(s).

Certain agents of the invention bind the TCR that recognises the epitope of the invention (as measured using any of the binding assays discussed above) and cause tolerisation of the T cell that carries the TCR. Such agents, optionally in  
10 association with a carrier, can therefore be used to prevent or treat coeliac disease.

Generally tolerisation can be caused by the same peptides which can (after being recognised by the TCR) cause antigen specific functional activity of the T cell (such as any such activity mentioned herein, e.g. secretion of cytokines). Such agents cause tolerisation when they are presented to the immune system in a  
15 'tolerising' context.

Tolerisation leads to a decrease in the recognition of a T cell or antibody epitope by the immune system. In the case of a T cell epitope this can be caused by the deletion or anergising of T cells that recognise the epitope. Thus T cell activity (for example as measured in suitable assays mentioned herein) in response to the  
20 epitope is decreased. Tolerisation of an antibody response means that a decreased amount of specific antibody to the epitope is produced when the epitope is administered.

Methods of presenting antigens to the immune system in such a context are known and are described for example in Yoshida et al. Clin. Immunol.  
25 Immunopathol. 82, 207-215 (1997), Thureau et al. Clin. Exp. Immunol. 109, 370-6 (1997), and Weiner et al. Res. Immunol. 148, 528-33 (1997). In particular certain routes of administration can cause tolerisation, such as oral, nasal or intraperitoneal. Tolerisation may also be accomplished via dendritic cells and tetramers presenting peptide. Particular products which cause tolerisation may be administered (e.g. in a  
30 composition that also comprises the agent) to the individual. Such products include cytokines, such as cytokines that favour a Th2 response (e.g. IL-4, TGF- $\beta$  or IL-10). Products or agent may be administered at a dose that causes tolerisation.

The invention provides a protein that comprises a sequence able to act as an antagonist of the T cell (which T cell recognises the agent). Such proteins and such antagonists can also be used to prevent or treat coeliac disease. The antagonist will cause a decrease in the T cell response. In one embodiment, the antagonist binds the TCR of the T cell (generally in the form of a complex with HLA-DQ2 or -DQ8) but instead of causing normal functional activation causing an abnormal signal to be passed through the TCR intracellular signalling cascade, which causes the T cell to have decreased function activity (e.g. in response to recognition of an epitope, typically as measured by any suitable assay mentioned herein).

In one embodiment the antagonist competes with epitope to bind a component of MHC processing and presentation pathway, such as an MHC molecule (typically HLA-DQ2 or -DQ8). Thus the antagonist may bind HLA-DQ2 or -DQ8 (and thus be a peptide presented by this MHC molecule), such as peptide TP (Table 10) or a homologue thereof.

Methods of causing antagonism are known in the art. In one embodiment the antagonist is a homologue of the epitopes mentioned above and may have any of the sequence, binding or other properties of the agent (particularly analogues). The antagonists typically differ from any of the above epitopes (which are capable of causing a normal antigen specific function in the T cell) by 1, 2, 3, 4 or more mutations (each of which may be a substitution, insertion or deletion). Such antagonists are termed "altered peptide ligands" or "APL" in the art. The mutations are typically at the amino acid positions that contact the TCR.

The antagonist may differ from the epitope by a substitution within the sequence that is equivalent to the sequence represented by amino acids 65 to 67 of A-gliadin (such antagonists are shown in Table 9). Thus preferably the antagonist has a substitution at the equivalent of position 64, 65 or 67. Preferably the substitution is 64W, 67W, 67M or 65T.

Since the T cell immune response to the epitope of the invention in an individual is polyclonal, more than one antagonist may need to be administered to cause antagonism of T cells of the response which have different TCRs. Therefore the antagonists may be administered in a composition which comprises at least 2, 4, 6 or more different antagonists, which each antagonise different T cells.

The invention also provides a method of identifying an antagonist of a T cell (which recognises the agent), comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response (e.g. using any suitable assay mentioned  
5 herein), the detecting of any such decrease in said ability indicating that the substance is an antagonist.

In one embodiment, the antagonists (including combinations of antagonists to a particular epitope) or tolerising (T cell and antibody tolerising) agents are present in a composition comprising at least 2, 4, 6 or more antagonists or agents which  
10 antagonise or tolerise to different epitopes of the invention, for example to the combinations of epitopes discussed above in relation to the agents which are a product comprising more than one substance.

#### **Testing whether a composition is capable of causing coeliac disease**

15 As mentioned above the invention provides a method of determining whether a composition is capable of causing coeliac disease comprising detecting the presence of a protein sequence which is capable of being modified by a transglutaminase to a sequence comprising the agent or epitope of the invention (such transglutaminase activity may be a human intestinal transglutaminase activity).  
20 Typically this is performed by using a binding assay in which a moiety which binds to the sequence in a specific manner is contacted with the composition and the formation of sequence/moiety complex is detected and used to ascertain the presence of the agent. Such a moiety may be any suitable substance (or type of substance) mentioned herein, and is typically a specific antibody. Any suitable format of  
25 binding assay can be used (such as those mentioned herein).

In one embodiment, the composition is contacted with at least 2, 5, 10 or more antibodies which are specific for epitopes of the invention from different gliadins, for example a panel of antibodies capable of recognising the combinations of epitopes discussed above in relation to agents of the invention which are a product  
30 comprising more than one substance.

The composition typically comprises material from a plant that expresses a gliadin which is capable of causing coeliac disease (for example any of the gliadins



or plants mentioned herein). Such material may be a plant part, such as a harvested product (e.g. seed). The material may be processed products of the plant material (e.g. any such product mentioned herein), such as a flour or food that comprises the gliadin. The processing of food material and testing in suitable binding assays is  
5 routine, for example as mentioned in Kricka LJ, J. Biolumin. Chemilumin. 13, 189-93 (1998).

### **Binding assays**

The determination of binding between any two substances mentioned herein  
10 may be done by measuring a characteristic of either or both substances that changes upon binding, such as a spectroscopic change.

The binding assay format may be a 'band shift' system. This involves determining whether the presence of one substance (such as a candidate substance) advances or retards the progress of the other substance during gel electrophoresis.

15 The format may be a competitive binding method which determines whether the one substance is able to inhibit the binding of the other substance to an agent which is known to bind the other substance, such as a specific antibody.

### **Mutant gliadin proteins**

20 The invention provides a gliadin protein in which an epitope sequence of the invention, or sequence which can be modified by a transglutaminase to provide such a sequence has been mutated so that it no longer causes, or is recognised by, a T cell response that recognises the epitope. In this context the term recognition refers to the TCR binding the epitope in such a way that normal (not antagonistic) antigen-  
25 specific functional activity of the T cell occurs.

Methods of identifying equivalent epitopes in other gliadins are discussed above. The wild type of the mutated gliadin is one which causes coeliac disease. Such a gliadin may have homology with SEQ ID NO:3, for example to the degree mentioned above (in relation to the analogue) across all of SEQ ID NO:3 or across  
30 15, 30, 60, 100 or 200 contiguous amino acids of SEQ ID NO:3. Likewise, for other non-A-gliadins, homology will be present between the mutant and the native form of that gliadin. The sequences of other natural gliadin proteins are known in the art.

The mutated gliadin will not cause coeliac disease or will cause decreased symptoms of coeliac disease. Typically the mutation decreases the ability of the epitope to induce a T cell response. The mutated epitope may have a decreased binding to HLA-DQ2 or -DQ8, a decreased ability to be presented by an APC or a decreased ability to bind to or to be recognised (i.e. cause antigen-specific functional activity) by T cells that recognise the agent. The mutated gliadin or epitope will therefore show no or reduced recognition in any of the assays mentioned herein in relation to the diagnostic aspects of the invention.

The mutation may be one or more deletions, additions or substitutions of length 1 to 3, 4 to 6, 6 to 10, 11 to 15 or more in the epitope, for example across sequence SEQ ID NO:2 or across any of SEQ ID NOS: 18-22, 31-36, 39-44, and 46; or across equivalents thereof. Preferably the mutant gliadin has at least one mutation in the sequence SEQ ID NO:1. A preferred mutation is at position 65 in A-gliadin (or in an equivalent position in other gliadins). Typically the naturally occurring glutamine at this position is substituted to any of the amino acids shown in Table 3, preferably to histidine, tyrosine, tryptophan, lysine, proline, or arginine.

The invention thus also provides use of a mutation (such any of the mutations in any of the sequences discussed herein) in an epitope of a gliadin protein, which epitope is an epitope of the invention, to decrease the ability of the gliadin protein to cause coeliac disease.

In one embodiment the mutated sequence is able to act as an antagonist. Thus the invention provides a protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent of the invention, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

The invention also provides proteins which are fragments of the above mutant gliadin proteins, which are at least 15 amino acids long (e.g. at least 30, 60, 100, 150, 200, or 250 amino acids long) and which comprise the mutations discussed above which decrease the ability of the gliadin to be recognised. Any of the mutant proteins (including fragments) mentioned herein may also be present in the form of fusion proteins, for example with other gliadins or with non-gliadin proteins.

The equivalent wild type protein to the mutated gliadin protein is typically from a graminaceous monocotyledon, such as a plant of genus *Triticum*, e.g. wheat, rye, barley, oats or triticale. The protein is typically an  $\alpha$ ,  $\alpha\beta$ ,  $\beta$ ,  $\gamma$  or  $\omega$  gliadin. The gliadin may be an A-gliadin.

5

### Kits

The invention also provides a kit for carrying out the method comprising one or more agents and optionally a means to detect the recognition of the agent by the T cell. Typically the different agents are provided for simultaneous, separate or sequential use. Typically the means to detect recognition allows or aids detection based on the techniques discussed above.

Thus the means may allow detection of a substance secreted by the T cells after recognition. The kit may thus additionally include a specific binding moiety for the substance, such as an antibody. The moiety is typically specific for IFN- $\gamma$ . The moiety is typically immobilised on a solid support. This means that after binding the moiety the substance will remain in the vicinity of the T cell which secreted it. Thus "spots" of substance/moiety complex are formed on the support, each spot representing a T cell which is secreting the substance. Quantifying the spots, and typically comparing against a control, allows determination of recognition of the agent.

The kit may also comprise a means to detect the substance/moiety complex. A detectable change may occur in the moiety itself after binding the substance, such as a colour change. Alternatively a second moiety directly or indirectly labelled for detection may be allowed to bind the substance/moiety complex to allow the determination of the spots. As discussed above the second moiety may be specific for the substance, but binds a different site on the substance than the first moiety.

The immobilised support may be a plate with wells, such as a microtitre plate. Each assay can therefore be carried out in a separate well in the plate.

The kit may additionally comprise medium for the T cells, detection moieties or washing buffers to be used in the detection steps. The kit may additionally comprise reagents suitable for the separation from the sample, such as the separation of PBMCs or T cells from the sample. The kit may be designed to allow detection of

the T cells directly in the sample without requiring any separation of the components of the sample.

The kit may comprise an instrument which allows administration of the agent, such as intradermal or epidermal administration. Typically such an instrument  
5 comprises plaster, dressing or one or more needles. The instrument may allow ballistic delivery of the agent. The agent in the kit may be in the form of a pharmaceutical composition.

The kit may also comprise controls, such as positive or negative controls. The positive control may allow the detection system to be tested. Thus the positive  
10 control typically mimics recognition of the agent in any of the above methods. Typically in the kits designed to determine recognition *in vitro* the positive control is a cytokine. In the kit designed to detect *in vivo* recognition of the agent the positive control may be antigen to which most individuals should response.

The kit may also comprise a means to take a sample containing T cells from  
15 the host, such as a blood sample. The kit may comprise a means to separate mononuclear cells or T cells from a sample from the host.

#### **Polynucleotides, cells, transgenic mammals and antibodies**

The invention also provides a polynucleotide which is capable of expression  
20 to provide the agent or mutant gliadin proteins. Typically the polynucleotide is DNA or RNA, and is single or double stranded. The polynucleotide will preferably comprise at least 50 bases or base pairs, for example 50 to 100, 100 to 500, 500 to 1000 or 1000 to 2000 or more bases or base pairs. The polynucleotide therefore comprises a sequence which encodes the sequence of SEQ ID NO: 1 or 2 or any of  
25 the other agents mentioned herein. To the 5' and 3' of this coding sequence the polynucleotide of the invention has sequence or codons which are different from the sequence or codons 5' and 3' to these sequences in the corresponding gliadin gene.

5' and/or 3' to the sequence encoding the peptide the polynucleotide has coding or non-coding sequence. Sequence 5' and/or 3' to the coding sequence may  
30 comprise sequences which aid expression, such as transcription and/or translation, of the sequence encoding the agent. The polynucleotide may be capable of expressing the agent prokaryotic or eukaryotic cell. In one embodiment the polynucleotide is

capable of expressing the agent in a mammalian cell, such as a human, primate or rodent (e.g. mouse or rat) cell.

A polynucleotide of the invention may hybridise selectively to a polynucleotide that encodes SEQ ID NO:3 at a level significantly above background.

5 Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C). However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook *et al* (1989), Molecular Cloning: A Laboratory Manual). For example, if high stringency is required, suitable

10 conditions include 0.2 x SSC at 60°C. If lower stringency is required, suitable conditions include 2 x SSC at 60°C.

Agents or proteins of the invention may be encoded by the polynucleotides described herein.

The polynucleotide may form or be incorporated into a replicable vector.

15 Such a vector is able to replicate in a suitable cell. The vector may be an expression vector. In such a vector the polynucleotide of the invention is operably linked to a control sequence which is capable of providing for the expression of the polynucleotide. The vector may contain a selectable marker, such as the ampicillin resistance gene.

20 The polynucleotide or vector may be present in a cell. Such a cell may have been transformed by the polynucleotide or vector. The cell may express the agent. The cell will be chosen to be compatible with the said vector and may for example be a prokaryotic (bacterial), yeast, insect or mammalian cell. The polynucleotide or vector may be introduced into host cells using conventional techniques including

25 calcium phosphate precipitation, DEAE-dextran transfection, or electroporation.

The invention provides processes for the production of the proteins of the invention by recombinant means. This may comprise (a) cultivating a transformed cell as defined above under conditions that allow the expression of the protein; and preferably (b) recovering the expressed polypeptide. Optionally, the polypeptide

30 may be isolated and/or purified, by techniques known in the art.

The invention also provides TCRs which recognise (or bind) the agent, or fragments thereof which are capable of such recognition (or binding). These can be

present in the any form mentioned herein (e.g. purity) discussed herein in relation to the protein of the invention. The invention also provides T cells which express such TCRs which can be present in any form (e.g. purity) discussed herein for the cells of the invention.

5           The invention also provides monoclonal or polyclonal antibodies which specifically recognise the agents (such as any of the epitopes of the invention) and which recognise the mutant gliadin proteins (and typically which do not recognise the equivalent wild-type gliadins) of the invention, and methods of making such antibodies. Antibodies of the invention bind specifically to these substances of the  
10 invention.

For the purposes of this invention, the term "antibody" includes antibody fragments such as Fv, F(ab) and F(ab)<sub>2</sub> fragments, as well as single-chain antibodies.

A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and  
15 isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour  
20 cells (Kohler and Milstein (1975) *Nature* 256, 495-497).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in*  
25 *vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled,  
30 for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

The polynucleotide, agent, protein or antibody of the invention, may carry a detectable label. Detectable labels which allow detection of the secreted substance by visual inspection, optionally with the aid of an optical magnifying means, are preferred. Such a system is typically based on an enzyme label which causes colour change in a substrate, for example alkaline phosphatase causing a colour change in a substrate. Such substrates are commercially available, e.g. from BioRad. Other suitable labels include other enzymes such as peroxidase; or protein labels, such as biotin; or radioisotopes, such as  $^{32}\text{P}$  or  $^{35}\text{S}$ . The above labels may be detected using known techniques.

Polynucleotides, agents, proteins, antibodies or cells of the invention may be in substantially purified form. They may be in substantially isolated form, in which case they will generally comprise at least 80% e.g. at least 90, 95, 97 or 99% of the polynucleotide, peptide, antibody, cells or dry mass in the preparation. The polynucleotide, agent, protein or antibody is typically substantially free of other cellular components. The polynucleotide, agent, protein or antibody may be used in such a substantially isolated, purified or free form in the method or be present in such forms in the kit.

The invention also provides a transgenic non-human mammal which expresses a TCR of the invention. This may be any of the mammals discussed herein (e.g. in relation to the production of the antibody). Preferably the mammal has, or is susceptible, to coeliac disease. The mammal may also express HLA-DQ2 or -DQ8 or HLA-DR3-DQ2 and/or may be given a diet comprising a gliadin which cause coeliac disease (e.g. any of the gliadin proteins mentioned herein). Thus the mammal may act as an animal model for coeliac disease.

The invention also provides a method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal of the invention which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product. Such a product may be used to treat or prevent coeliac disease.

The invention provides therapeutic (including prophylactic) agents or diagnostic substances (the agents, proteins and polynucleotides of the invention).

These substances are formulated for clinical administration by mixing them with a pharmaceutically acceptable carrier or diluent. For example they can be formulated for topical, parenteral, intravenous, intramuscular, subcutaneous, intraocular, intradermal, epidermal or transdermal administration. The substances may be mixed  
5 with any vehicle which is pharmaceutically acceptable and appropriate for the desired route of administration. The pharmaceutically carrier or diluent for injection may be, for example, a sterile or isotonic solution such as Water for Injection or physiological saline, or a carrier particle for ballistic delivery.

The dose of the substances may be adjusted according to various parameters,  
10 especially according to the agent used; the age, weight and condition of the patient to be treated; the mode of administration used; the severity of the condition to be treated; and the required clinical regimen. As a guide, the amount of substance administered by injection is suitably from 0.01 mg/kg to 30 mg/kg, preferably from 0.1 mg/kg to 10 mg/kg.

15 The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The substances of the invention may thus be used in a method of treatment of the human or animal body, or in a diagnostic method practised on the human body.  
20 In particular they may be used in a method of treating or preventing coeliac disease. The invention also provide the agents for use in a method of manufacture of a medicament for treating or preventing coeliac disease. Thus the invention provides a method of preventing or treating coeliac disease comprising administering to a human in need thereof a substance of the invention (typically a non-toxic effective  
25 amount thereof).

The agent of the invention can be made using standard synthetic chemistry techniques, such as by use of an automated synthesizer. The agent may be made from a longer polypeptide e.g. a fusion protein, which polypeptide typically comprises the sequence of the peptide. The peptide may be derived from the  
30 polypeptide by for example hydrolysing the polypeptide, such as using a protease; or by physically breaking the polypeptide. The polynucleotide of the invention can be made using standard techniques, such as by using a synthesiser.



**Plant cells and plants that express mutant gliadin proteins or express proteins comprising sequences which can act as antagonists**

The cell of the invention may be a plant cell, such as a cell of a graminaceous monocotyledonous species. The species may be one whose wild-type form expresses gliadins, such as any of the gliadin proteins mentioned herein (including gliadins with any degree of homology to SEQ ID NO:3 mentioned herein). Such a gliadin may cause coeliac disease in humans. The cell may be of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane. Typically the cell is of the *Triticum* genus, such as *aestivum*, *spelta*, *polonicum* or *monococcum*.

The plant cell of the invention is typically one which does not express a wild-type gliadin (such as any of the gliadins mentioned herein which may cause coeliac disease), or one which does not express a gliadin comprising a sequence that can be recognised by a T cell that recognises the agent. Thus if the wild-type plant cell did express such a gliadin then it may be engineered to prevent or reduce the expression of such a gliadin or to change the amino acid sequence of the gliadin so that it no longer causes coeliac disease (typically by no longer expressing the epitope of the invention).

This can be done for example by introducing mutations into 1, 2, 3 or more or all of such gliadin genes in the cell, for example into coding or non-coding (e.g. promoter regions). Such mutations can be any of the type or length of mutations discussed herein (e.g., in relation to homologous proteins). The mutations can be introduced in a directed manner (e.g., using site directed mutagenesis or homologous recombination techniques) or in a random manner (e.g. using a mutagen, and then typically selecting for mutagenised cells which no longer express the gliadin (or a gliadin sequence which causes coeliac disease)).

In the case of plants or plant cells that express a protein that comprises a sequence able to act as an antagonist such a plant or plant cell may express a wild-type gliadin protein (e.g. one which causes coeliac disease). Preferably though the presence of the antagonist sequence will cause reduced coeliac disease symptoms (such as no symptoms) in an individual who ingests a food comprising protein from the plant or plant cell.

The polynucleotide which is present in (or which was transformed into) the plant cell will generally comprise promoter capable of expressing the mutant gliadin protein the plant cell. Depending on the pattern of expression desired, the promoter may be constitutive, tissue- or stage-specific; and/or inducible. For example, strong constitutive expression in plants can be obtained with the CAMV 35S, Rubisco ssu, or histone promoters. Also, tissue-specific or stage-specific promoters may be used to target expression of protein of the invention to particular tissues in a transgenic plant or to particular stages in its development. Thus, for example seed-specific, root-specific, leaf-specific, flower-specific etc promoters may be used. Seed-specific promoters include those described by Dalta *et al* (Biotechnology Ann. Rev. (1997), 3, pp.269-296). Particular examples of seed-specific promoters are napin promoters (EP-A-0 255, 378), phaseolin promoters, glutenine promoters, helianthine promoters (WO92/17580), albumin promoters (WO98/45460), oleosin promoters (WO98/45461) and ATS1 and ATS3 promoters (PCT/US98/06798).

The cell may be in any form. For example, it may be an isolated cell, e.g. a protoplast, or it may be part of a plant tissue, e.g. a callus, or a tissue excised from a plant, or it may be part of a whole plant. The cell may be of any type (e.g. of any type of plant part). For example, an undifferentiated cell, such as a callus cell; or a differentiated cell, such as a cell of a type found in embryos, pollen, roots, shoots or leaves. Plant parts include roots; shoots; leaves; and parts involved in reproduction, such as pollen, ova, stamens, anthers, petals, sepals and other flower parts.

The invention provides a method of obtaining a transgenic plant cell comprising transforming a plant cell with a polynucleotide or vector of the invention to give a transgenic plant cell. Any suitable transformation method may be used (in the case of wheat the techniques disclosed in Vasil V et al, Biotechnology 10, 667-674 (1992) may be used). Preferred transformation techniques include electroporation of plant protoplasts and particle bombardment. Transformation may thus give rise to a chimeric tissue or plant in which some cells are transgenic and some are not.

The cell of the invention or thus obtained cell may be regenerated into a transgenic plant by techniques known in the art. These may involve the use of plant growth substances such as auxins, gibberellins and/or cytokinins to stimulate the

growth and/or division of the transgenic cell. Similarly, techniques such as somatic embryogenesis and meristem culture may be used. Regeneration techniques are well known in the art and examples can be found in, e.g. US 4,459,355, US 4,536,475, US 5,464,763, US 5,177,010, US 5,187,073, EP 267,159, EP 604,662, EP 672,752, 5 US 4,945,050, US 5,036,006, US 5,100,792, US 5,371,014, US 5,478,744, US 5,179,022, US 5,565,346, US 5,484,956, US 5,508,468, US 5,538,877, US 5,554,798, US 5,489,520, US 5,510,318, US 5,204,253, US 5,405,765, EP 442,174, EP 486,233, EP 486,234, EP 539,563, EP 674,725, WO91/02071 and WO 95/06128.

In many such techniques, one step is the formation of a callus, i.e. a plant 10 tissue comprising expanding and/or dividing cells. Such calli are a further aspect of the invention as are other types of plant cell cultures and plant parts. Thus, for example, the invention provides transgenic plant tissues and parts, including embryos, meristems, seeds, shoots, roots, stems, leaves and flower parts. These may be chimeric in the sense that some of their cells are cells of the invention and some 15 are not. Transgenic plant parts and tissues, plants and seeds of the invention may be of any of the plant species mentioned herein.

Regeneration procedures will typically involve the selection of transformed cells by means of marker genes.

The regeneration step gives rise to a first generation transgenic plant. The 20 invention also provides methods of obtaining transgenic plants of further generations from this first generation plant. These are known as progeny transgenic plants. Progeny plants of second, third, fourth, fifth, sixth and further generations may be obtained from the first generation transgenic plant by any means known in the art.

Thus, the invention provides a method of obtaining a transgenic progeny 25 plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant of the invention, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

Progeny plants may be produced from their predecessors of earlier 30 generations by any known technique. In particular, progeny plants may be produced by:

obtaining a transgenic seed from a transgenic plant of the invention belonging to a previous generation, then obtaining a transgenic progeny plant of the invention belonging to a new generation by growing up the transgenic seed; and/or

propagating clonally a transgenic plant of the invention belonging to a  
5 previous generation to give a transgenic progeny plant of the invention belonging to a new generation; and/or

crossing a first-generation transgenic plant of the invention belonging to a previous generation with another compatible plant to give a transgenic progeny plant of the invention belonging to a new generation; and optionally

10 obtaining transgenic progeny plants of one or more further generations from the progeny plant thus obtained.

These techniques may be used in any combination. For example, clonal propagation and sexual propagation may be used at different points in a process that gives rise to a transgenic plant suitable for cultivation. In particular, repetitive back-  
15 crossing with a plant taxon with agronomically desirable characteristics may be undertaken. Further steps of removing cells from a plant and regenerating new plants therefrom may also be carried out.

Also, further desirable characteristics may be introduced by transforming the cells, plant tissues, plants or seeds, at any suitable stage in the above process, to  
20 introduce desirable coding sequences other than the polynucleotides of the invention. This may be carried out by the techniques described herein for the introduction of polynucleotides of the invention.

For example, further transgenes may be selected from those coding for other herbicide resistance traits, e.g. tolerance to: Glyphosate (e.g. using an EPSP synthase  
25 gene (e.g. EP-A-0 293,358) or a glyphosate oxidoreductase (WO 92/000377) gene); or tolerance to fosametin; a dihalobenzonitrile; glufosinate, e.g. using a phosphinothrycin acetyl transferase (PAT) or glutamine synthase gene (cf. EP-A-0 242,236); asulam, e.g. using a dihydropteroate synthase gene (EP-A-0 369,367); or a sulphonylurea, e.g. using an ALS gene); diphenyl ethers such as acifluorfen or  
30 oxyfluorfen, e.g. using a protoporphyrinogen oxidase gene); an oxadiazole such as oxadiazon; a cyclic imide such as chlorophthalim; a phenyl pyrazole such as TNP, or a phenopylate or carbamate analogue thereof.

Similarly, genes for beneficial properties other than herbicide tolerance may be introduced. For example, genes for insect resistance may be introduced, notably genes encoding *Bacillus thuringiensis* (Bt) toxins. Likewise, genes for disease resistance may be introduced, e.g. as in WO91/02701 or WO95/06128.

5 Typically, a protein of the invention is expressed in a plant of the invention. Depending on the promoter used, this expression may be constitutive or inducible. Similarly, it may be tissue- or stage-specific, i.e. directed towards a particular plant tissue (such as any of the tissues mentioned herein) or stage in plant development.

The invention also provides methods of obtaining crop products by  
10 harvesting, and optionally processing further, transgenic plants of the invention. By crop product is meant any useful product obtainable from a crop plant.

**Products that contain mutant gliadin proteins or proteins that comprise  
15 sequence capable of acting as an antagonist**

The invention provides a product that comprises the mutant gliadin proteins or protein that comprises sequence capable of acting as an antagonist. This is typically derived from or comprise plant parts from plants mentioned herein which express such proteins. Such a product may be obtainable directly by harvesting or  
20 indirectly, by harvesting and further processing the plant of the invention. Directly obtainable products include grains. Alternatively, such a product may be obtainable indirectly, by harvesting and further processing. Examples of products obtainable by further processing are flour or distilled alcoholic beverages; food products made from directly obtained or further processed material, e.g. baked products (e.g. bread)  
25 made from flour. Typically such food products, which are ingestible and digestible (i.e. non-toxic and of nutrient value) by human individuals.

In the case of food products that comprise the protein which comprises an antagonist sequence the food product may also comprise wild-type gliadin, but preferably the antagonist is able to cause a reduction (e.g. completely) in the coeliac  
30 disease symptoms after such food is ingested.

The invention is illustrated by the following nonlimiting Examples:

**Example 1**

We carried out epitope mapping in Coeliac disease by using a set of 51 synthetic 15-mer peptides that span the complete sequence of a fully characterized a-gliadin, "A-gliadin" (see Table 1). A-Gliadin peptides were also individually treated with tTG to generate products that might mimic those produced in-vivo<sup>1</sup>. We also sought to study Coeliac disease patients at the point of initiation of disease relapse to avoid the possibility that epitope "spreading" or "exhaustion" may have occurred, as described in experimental infectious and autoimmune diseases.

*Clinical and A-gliadin specific T-cell responses with 3 and 10 day bread challenge*

In a pilot study, two subjects with Coeliac disease in remission, defined by absence of serum anti-endomysial antibody (EMA), on a gluten free diet were fed four slices of standard gluten-containing white bread daily in addition to their usual gluten free diet. Subject 1 ceased bread because of abdominal pain, mouth ulcers and mild diarrhoea after three days, but Subject 2 continued for 10 days with only mild nausea at one week. The EMA became positive in Subject 2 one week after the bread challenge, indicating the bread used had caused a relapse of Coeliac disease. But in Subject 1, EMA remained negative up to two months after bread challenge. In both subjects, symptoms that appeared with bread challenge resolved within two days after returning to gluten free diet.

PBMC responses in IFN $\gamma$  ELISPOT assays to A-gliadin peptides were not found before or during bread challenge. But from the day after bread withdrawal (Day 4) in Subject 1 a single pool of 5 overlapping peptides spanning A-gliadin 51-85 (Pool 3) treated with tTG showed potent IFN $\gamma$  responses (see Figure 1a). In Subject 1, the PBMC IFN $\gamma$  response to A-gliadin peptide remained targeted to Pool 3 alone and was maximal on Day 8. The dynamics and magnitude of the response to Pool 3 was similar to that elicited by  $\alpha$ -chymotrypsin digested gliadin. PBMC IFN $\gamma$  responses to tTG-treated Pool 3 were consistently 5 to 12-fold greater than Pool 3 not treated with tTG, and responses to  $\alpha$ -chymotrypsin digested gliadin were 3 to 10-fold greater if treated with tTG. In Subject 2, Pool 3 treated with tTG was also the only immunogenic set of A-gliadin peptides on Day 8, but this response was weaker than Subject 1, was not seen on Day 4 and by Day 11 the response to Pool 3 had diminished and other tTG-treated pools of A-gliadin peptides elicited stronger IFN $\alpha$ .

responses (see Figure 1b).

The pilot study indicated that the initial T cell response in these Coeliac disease subjects was against a single tTG-treated A-gliadin pool of five peptides and was readily measured in peripheral blood. But if antigen exposure is continued for  
5 ten days instead of three, T cell responses to other A-gliadin peptides appear, consistent with epitope spreading.

*Coeliac disease-specific IFN- $\gamma$  induction by tTG-treated A-gliadin peptides*

In five out of six further Coeliac disease subjects on gluten free diet (see  
10 Table 1), bread challenge for three days identified tTG-treated peptides in Pool 3, and in particular, peptides corresponding to 56-70 (12) and 60-75 (13) as the sole A-gliadin components eliciting IFN $\gamma$  from PBMC (see Figure 2). IL-10 ELISPOT assays run in parallel to IFN $\gamma$  ELISPOT showed no IL-10 response to tTG-treated peptides 12 or 13. In one subject, there were no IFN $\gamma$  responses to any A-gliadin  
15 peptide or  $\alpha$ -chymotrypsin digested gliadin before, during or up to four days after bread challenge. In none of these Coeliac disease subjects did EMA status change from baseline when measured for up to two months after bread challenge.

PBMC from four healthy, EMA-negative subjects with the HLA-DQ alleles  $\alpha 1^*0501$ ,  $\beta 1^*0201$  (ages 28-52, 2 females) who had been challenged for three days  
20 with bread after following a gluten free diet for one month, showed no IFN $\gamma$  responses above the negative control to any of the A-gliadin peptides with or without tTG treatment. Thus, induction of IFN $\gamma$  in PBMC to tTG-treated Pool 3 and A-gliadin peptides 56-70 (12) and 60-75 (13) were Coeliac disease specific (7/8 vs. 0/4,  $p < 0.01$  by Chi-squared analysis).

25

*Fine mapping of the minimal A-gliadin T cell epitope*

tTG-treated peptides representing truncations of A-gliadin 56-75 revealed that the same core peptide sequence QPQLP (SEQ ID NO:9) was essential for antigenicity in all of the five Coeliac disease subjects assessed (see Figure 3). PBMC  
30 IFN $\gamma$  responses to tTG-treated peptides spanning this core sequence beginning with the 7-mer PQPQLPY (SEQ ID NO:4) and increasing in length, indicated that the tTG-treated 17-mer QLQFPQPQLPYQPQS (SEQ ID NO:10) (A-gliadin 57-73)

possessed optimal activity in the IFN $\gamma$  ELISPOT (see Figure 4).

*Deamidation of Q65 by tTG generates the immunodominant T cell epitope in A-gliadin*

5 HPLC analysis demonstrated that tTG treatment of A-gliadin 56-75 generated a single product that eluted marginally later than the parent peptide. Amino acid sequencing indicated that out of the six glutamine (Q) residues contained in A-gliadin 56-75, Q65 was preferentially deamidated by tTG (see Figure 5). Bioactivity of peptides corresponding to serial expansions from the core A-gliadin 62-68  
10 sequence in which glutamate (E) replaced Q65, was equivalent to the same peptides with Q65 after tTG-treatment (see Figure 4a). Replacement of Q57 and Q72 by E together or alone, with E65 did not enhance antigenicity of the 17-mer in the three Coeliac disease subjects studied (see Figure 6). Q57 and Q72 were investigated because glutamine residues followed by proline in gliadin peptides are not  
15 deamidated by tTG in vitro (W. Vader et al, Proceedings 8th International Symposium Coeliac Disease). Therefore, the immunodominant T cell epitope was defined as QLQPF $\underline{P}$ QPELPYPQPQS (SEQ ID NO:2).

*Immunodominant T cell epitope response is DQ2-restricted and CD4 dependent*

20 In two Coeliac disease subjects homozygous for HLA-DQ  $\alpha$ 1\*0501,  $\beta$ 1\*0201, anti-DQ monoclonal antibody blocked the ELISPOT IFN $\gamma$  response to tTG-treated A-gliadin 56-75, but anti-DP and -DR antibody did not (see Figure 7). Anti-CD4 and anti-CD8 magnetic bead depletion of PBMC from two Coeliac disease subjects indicated the IFN $\gamma$  response to tTG-treated A-gliadin 56-75 is CD4 T cell-  
25 mediated.

*Discussion*

In this study we describe a rather simple dietary antigen challenge using standard white bread to elicit a transient population of CD4 T cells in peripheral  
30 blood of Coeliac disease subjects responsive to a tTG-treated A-gliadin 17-mer with the sequence: QLQPF $\underline{P}$ QPELPYPQPQS (SEQ ID NO:2) (residues 57-73). The immune response to A-gliadin 56-75 (Q $\rightarrow$ E65) is restricted to the Coeliac disease-



associated HLA allele, DQ  $\alpha 1^*0501$ ,  $\beta 1^*0201$ . Tissue transglutaminase action in vitro selectively deamidates Q65. Elicited peripheral blood IFN $\gamma$  responses to synthetic A-gliadin peptides with the substitution Q $\rightarrow$ E65 is equivalent to tTG-treated Q65 A-gliadin peptides; both stimulate up to 10-fold more T cells in the IFN $\gamma$  ELISPOT than unmodified Q65 A-gliadin peptides.

We have deliberately defined this Coeliac disease-specific T cell epitope using in vivo antigen challenge and short-term ex vivo immune assays to avoid the possibility of methodological artifacts that may occur with the use of T cell clones in epitope mapping. Our findings indicate that peripheral blood T cell responses to ingestion of gluten are rapid but short-lived and can be utilized for epitope mapping. In vivo antigen challenge has also shown there is a temporal hierarchy of immune responses to A-gliadin peptides; A-gliadin 57-73 modified by tTG not only elicits the strongest IFN $\gamma$  response in PBMC but it is also the first IFN $\gamma$  response to appear.

Because we have assessed only peptides spanning A-gliadin, there may be other epitopes in other gliadins of equal or greater importance in the pathogenesis of Coeliac disease. Indeed, the peptide sequence at the core of the epitope in A-gliadin that we have identified PQQQLPY (SEQ ID NO:4) is shared by several other gliadins (SwissProt and TrEMBL accession numbers: P02863, Q41528, Q41531, Q41533, Q9ZP09, P04722, P04724, P18573). However, A-gliadin peptides that have previously been shown to possess bioactivity in biopsy challenge and in vivo studies (for example: 31-43, 44-55, and 206-217)<sup>4,5</sup> did not elicit IFN $\gamma$  responses in PBMC following three day bread challenge in Coeliac disease subjects. These peptides may be "secondary" T cell epitopes that arise with spreading of the immune response.

## Example 2

### *The effect on T cell recognition of substitutions in the immunodominant epitope*

The effect of substituting the glutamate at position 65 in the 57-73 A-gliadin epitope was determined by measuring peripheral blood responses against the substituted epitopes in an IFN $\gamma$  ELISPOT assay using synthetic peptides (at 50  $\mu$ g/ml). The responses were measured in 3 Coeliac disease subjects 6 days after commencing gluten challenge (4 slices bread daily for 3 days). Results are shown in table 3 and Figure 8. As can be seen substitution of the glutamate to histidine,

tyrosine, tryptophan, lysine, proline or arginine stimulated a response whose magnitude was less than 10% of the magnitude of the response to the immunodominant epitope. Thus mutation of A-gliadin at this position could be used to produce a mutant gliadin with reduce or absent immunoreactivity.

5

### Example 3

#### *Testing the immunoreactivity of equivalent peptides from other naturally occurring gliadins*

The immunoreactivity of equivalent peptides from other naturally occurring wheat gliadins was assessed using synthetic peptides corresponding to the naturally occurring sequences which were then treated with transglutaminase. These peptides were tested in an ELISPOT in the same manner and with PBMCs from the same subjects as described in Example 2. At least five of the peptides show immunoreactivity comparable to the A-gliadin 57-73 E65 peptide (after transglutaminase treatment) indicating that other gliadin proteins in wheat are also likely to induce this Coeliac disease-specific immune response (Table 4 and Figure 9).

15

### Methods

*Subjects:* Patients used in the study attended a Coeliac Clinic in Oxford, United Kingdom. Coeliac disease was diagnosed on the basis of typical small intestinal histology, and normalization of symptoms and small intestinal histology with gluten free diet.

*Tissue typing:* Tissue typing was performed using DNA extracted from EDTA-anticoagulated peripheral blood. HLA-DQA and DQB genotyping was performed by PCR using sequence-specific primer mixes<sup>6-8</sup>.

25

*Anti-endomysial antibody assay:* EMA were detected by indirect immunofluorescence using patient serum diluted 1:5 with monkey oesophagus, followed by FITC-conjugated goat anti-human IgA. IgA was quantitated prior to EMA, none of the subjects were IgA deficient.

30

*Antigen Challenge:* Coeliac disease subjects following a gluten free diet, consumed 4 slices of gluten-containing bread (50g/slice, Sainsbury's "standard white sandwich bread") daily for 3 or 10 days. EMA was assessed the week before and up to two months after commencing the bread challenge. Healthy subjects who had followed a gluten free diet for four weeks, consumed their usual diet including four slices of gluten-containing bread for three days, then returned to gluten free diet for a further six days.

10 *IFN $\gamma$  and IL-10 ELISPOT:* PBMC were prepared from 50-100 ml of venous blood by Ficoll-Hypaque density centrifugation. After three washes, PBMC were resuspended in complete RPMI containing 10% heat inactivated human AB serum. ELISPOT assays for single cell secretion of IFN $\gamma$  and IL-10 were performed using commercial kits (Mabtech; Stockholm, Sweden) with 96-well plates (MAIP-S-45; Millipore, Bedford, MA) according to the manufacturers instructions (as described elsewhere<sup>9</sup>) with 2-5x10<sup>5</sup> (IFN $\gamma$ ) or 0.4-1x10<sup>5</sup> (IL-10) PBMC in each well. Peptides were assessed in duplicate wells, and Mycobacterium tuberculosis purified protein derivative (PPD RT49) (Serum Institute; Copenhagen, Denmark) (20  $\mu$ g/ml) was included as a positive control in all assays.

20

*Peptides:* Synthetic peptides were purchased from Research Genetics (Huntsville, Alabama) Mass-spectroscopy and HPLC verified peptides' authenticity and >70% purity. Digestion of gliadin (Sigma; G-3375) (100 mg/ml) with  $\alpha$ -chymotrypsin (Sigma; C-3142) 200:1 (w/w) was performed at room temperature in 0.1 M NH<sub>4</sub>HCO<sub>3</sub> with 2M urea and was halted after 24 h by heating to 98°C for 10 minutes. After centrifugation (13,000g, 10 minutes), the gliadin digest supernatant was filter-sterilized (0.2  $\mu$ m). Digestion of gliadin was verified by SDS-PAGE and protein concentration assessed.  $\alpha$ -Chymotrypsin-digested gliadin (640  $\mu$ g/ml) and synthetic gliadin peptides (15-mers: 160  $\mu$ g/ml, other peptides: 0.1 mM) were individually treated with tTG (Sigma; T-5398) (50  $\mu$ g/ml) in PBS + CaCl<sub>2</sub> 1 mM for 2 h at 37°C. Peptides and peptide pools were aliquotted into sterile 96-well plates and stored frozen at -20°C until use.

30

*Amino acid sequencing of peptides:* Reverse phase HPLC was used to purify the peptide resulting from tTG treatment of A-gliadin 56-75. A single product was identified and subjected to amino acid sequencing (automated sequencer Model 5 494A, Applied Biosystems, Foster City, California). The sequence of unmodified G56-75 was confirmed as: LQLQFPQPQLPYQPQSFP (SEQ ID NO:5), and tTG treated G56-75 was identified as: LQLQFPQPELPYQPQSFP (SEQ ID NO:11). Deamidation of glutamyl residues was defined as the amount (pmol) of glutamate recovered expressed as a percent of the combined amount of glutamine and 10 glutamate recovered in cycles 2, 4, 8, 10, 15 and 17 of the amino acid sequencing. Deamidation attributable to tTG was defined as (% deamidation of glutamine in the tTG treated peptide - % deamidation in the untreated peptide) / (100 - % deamidation in the untreated peptide).

*CD4/CD8 and HLA Class II Restriction:* Anti-CD4 or anti-CD8 coated magnetic 15 beads (Dynal, Oslo, Norway) were washed four times with RPMI then incubated with PBMC in complete RPMI containing 10% heat inactivated human AB serum ( $5 \times 10^6$  cells/ml) for 30 minutes on ice. Beads were removed using a magnet and cells remaining counted. In vivo HLA-class II restriction of the immune response to tTG-treated A-gliadin 56-75 was established by incubating PBMC ( $5 \times 10^6$  cells/ml) 20 with anti-HLA-DR (L243), -DQ (L2), and -DP (B7.21) monoclonal antibodies (10  $\mu$ g/ml) at room temperature for one hour prior to the addition of peptide.

#### Example 4

##### *Mucosal integrin expression by gliadin-specific peripheral blood lymphocytes*

25 Interaction between endothelial and lymphocyte adhesion molecules facilitates homing of organ-specific lymphocytes. Many adhesion molecules are known. The heterodimer  $\alpha_4\beta_7$  is specific for lamina propria gut and other mucosal lymphocytes, and  $\alpha^E\beta_7$  is specific and intra-epithelial lymphocytes in the gut and skin. Approximately 30% of peripheral blood CD4 T cells express  $\alpha_4\beta_7$  and are presumed to be in transit to a 30 mucosal site, while 5% of peripheral blood T cells express  $\alpha^E\beta_7$ . Immunomagnetic beads coated with antibody specific for  $\alpha^E$  or  $\beta_7$  deplete PBMC of cells expressing  $\alpha^E\beta_7$  or  $\alpha_4\beta_7$  and  $\alpha_4\beta_7$ , respectively. In combination with ELISpot assay,

immunomagnetic bead depletion allows determination of gliadin-specific T cell addressin expression that may identify these cells as homing to a mucosal surface. Interestingly, gluten challenge in vivo is associated with rapid influx of CD4 T cells to the small intestinal lamina propria (not intra-epithelial sites), where over 90%  
5 lymphocytes express  $\alpha_4\beta_7$ .

Immunomagnetic beads were prepared and used to deplete PBMC from coeliac subjects on day 6 or 7 after commencing 3 day gluten challenge. FACS analysis demonstrated  $\alpha^E$  beads depleted approximately 50% of positive CD4 T cells, while  $\beta_7$  beads depleted all  $\beta_7$  positive CD4 T cells. Depletion of PBMC using  
10 CD4- or  $\beta_7$ -beads, but not CD8- or  $\alpha^E$ -beads, abolished responses in the interferon gamma ELISpot. tTG gliadin and PPD responses were abolished by CD4 depletion, but consistently affected by integrin-specific bead depletion.

Thus A-gliadin 57-73 QE65-specific T cells induced after gluten challenge in coeliac disease express the integrin,  $\alpha_4\beta_7$ , present on lamina propria CD4 T cells in  
15 the small intestine.

### Example 5

#### *Optimal T cell Epitope Length*

Previous data testing peptides from 7 to 17 amino acids in length spanning  
20 the core of the dominant T cell epitope in A-gliadin indicated that the 17mer, A-gliadin 57-73 QE65 (SEQ ID NO:2) induced maximal responses in the interferon gamma Elispot using peripheral blood mononuclear cells (PBMC) from coeliac volunteers 6 days after commencing a 3-day gluten challenge.

25 Peptides representing expansions form the core sequence of the dominant T cell epitope in A-gliadin were assessed in the IFN gamma ELISPOT using peripheral blood mononuclear cells (PBMC) from coeliac volunteers in 6 days after commencing a 3-day gluten challenge (n=4). Peptide 13: A-gliadin 59-71 QE65 (13mer), peptide 15: 58-72 QE65 (15mer), ..., peptide 27: 52-78 SE65 (27mer).

30 As shown in Figure 11 expansion of the A-gliadin 57-73 QE65 sequence does not substantially enhance response in the IFNgamma Elispot. Subsequent Examples

characterise the agonist and antagonist activity of A-gliadin 57-73 QE65 using 17mer peptides.

#### Example 6

##### 5 *Comparison of A-gliadin 57-73 QE65 with other DQ2-restricted T cell epitopes in coeliac disease*

Dose response studies were performed using peptides corresponding to unmodified and transglutaminase-treated peptides corresponding to T cell epitopes of gluten-specific T cell clones and lines from intestinal biopsies of coeliac subjects.

10 Responses to peptides were expressed as percent of response to A-gliadin 57-73 QE65. All subjects were HLA-DQ2+ (none were DQ8+).

The studies indicate that A-gliadin 57-73 QE65 is the most potent gliadin peptide for induction of interferon gamma in the ELISpot assay using coeliac PBMC after gluten challenge (see Figure 12a-h, and Tables 5 and 6). The second and third

15 epitopes are suboptimal fragments of larger peptides i.e. A-gliadin 57-73 QE65 and GDA4\_WHEAT P04724-84-100 QE92. The epitope is only modestly bioactive (approximately 1/20<sup>th</sup> as active as A-gliadin 57-73 QE65 after blank is subtracted).

A-gliadin 57-73 QE65 is more potent than other known T cell epitopes in coeliac disease. There are 16 polymorphisms of A-gliadin 57-73 (including the

20 sequence PQLPY (SEQ ID NO:12)) amongst sequenced gliadin genes, their bioactivity is assessed next.

#### Example 7

##### 25 *Comparison of gliadin- and A-gliadin 57-73 QE65-specific responses in peripheral blood*

The relative contribution of the dominant epitope, A-gliadin 57-73 QE65, to the total T cell response to gliadin in coeliac disease is a critical issue. Pepsin-trypsin and chymotrypsin-digested gliadin have been traditionally used as antigen for development of T cell lines and clones in coeliac disease. However, it is possible

30 that these proteases may cleave through certain peptide epitopes. Indeed, chymotrypsin digestion of recombinant  $\alpha$ 9-gliadin generates the peptide QLQFPQPELPY (SEQ ID NO:13), that is a truncation of the optimal epitope

sequence QLQFPQPELPYPQPQS (SEQ ID NO:2) (see above).

Transglutaminase-treatment substantially increases the potency of chymotrypsin-digested gliadin in proliferation assays of gliadin-specific T cell clones and lines.

Hence, transglutaminase-treated chymotrypsin-digested gliadin (tTG gliadin) may  
5 not be an ideal antigen, but responses against this mixture may approximate the  
“total” number of peripheral blood lymphocyte specific for gliadin. Comparison of  
responses against A-gliadin 57-73 QE65 and tTG gliadin in the ELISpot assay gives  
an indication of the contribution of this dominant epitope to the overall immune  
response to gliadin in coeliac disease, and also be a measure of epitope spreading.

10 PBMC collected on day 6 or 7 after commencing gluten challenge in 4  
coeliac subjects were assessed in dose response studies using chymotrypsin-digested  
gliadin +/- tTG treatment and compared with ELISpot responses to an optimal  
concentration of A-gliadin 57-73 QE65 (25mcg/ml). TTG treatment of gliadin  
enhanced PBMC responses in the ELISpot approximately 10-fold (tTG was  
15 comparable to blank when assessed alone) (see Figure 13a-c). In the four coeliac  
subjects studied, A-gliadin 57-73 QE65 (25 mcg/ml) elicited responses between 14  
and 115% those of tTG gliadin (500 mcg/ml), and the greater the response to A-  
gliadin 57-73 QE65 the greater proportion it represented of the tTG gliadin response.

Relatively limited data suggest that A-gliadin 57-73 QE65 responses are  
20 comparable to tTG gliadin in some subjects. Epitope spreading associated with more  
evolved anti-gliadin T cell responses may account for the smaller contribution of A-  
gliadin 57-73 QE65 to “total” gliadin responses in peripheral blood in some  
individuals. Epitope spreading may be maintained in individuals with less strictly  
gluten free diets.

25

### Example 8

*Definition of gliadin peptides bioactive in coeliac disease: polymorphisms of A-  
gliadin 57-73*

Overlapping 15mer peptides spanning the complete sequence of A-gliadin  
30 were assessed in order to identify the immunodominant sequence in coeliac disease.  
A-gliadin was the first fully sequenced alpha gliadin protein and gene, but is one of  
approximately 30-50 related alpha gliadin proteins in wheat. Twenty five distinct

alpha-gliadin genes have been identified by searching protein data bases, Swiss-Prot and TREMBL describing a further 8 alpha-gliadins. Contained within these 25 alpha-gliadins, there are 16 distinct polymorphisms of the sequence corresponding to A-gliadin 57-73 (see Table 7).

5 Synthetic peptides corresponding to these 16 polymorphisms, in an unmodified form, after treatment with transglutaminase in vitro, as well as with glutamate substituted at position 10 (equivalent to QE65 in A-gliadin 57-73) were assessed using PBMC from coeliac subjects, normally following a gluten free diet, day 6 or 7 after gluten challenge in interferon gamma ELISpot assays. Glutamate-  
10 substituted peptides were compared at three concentrations (2.5, 25 and 250 mcg/ml), unmodified peptide and transglutaminase-treated peptides were assessed at 25 mcg/ml only. Bioactivity was expressed as % of response associated with A-gliadin 57-73 QE65 25 mcg/ml in individual subjects (n=4). (See Fig 14).

Bioactivity of "wild-type" peptides was substantially increased (>5-fold) by  
15 treatment with transglutaminase. Transglutaminase treatment of wild-type peptides resulted in bioactivity similar to that of the same peptides substituted with glutamate at position 10. Bioactivities of five glutamate-substituted peptides (B, C, K, L, M), were >70% that of A-gliadin 57-73 QE65 (A), but none was significantly more bioactive than A-gliadin 57-73 QE65. PBMC responses to glutamate-substituted  
20 peptides at concentrations of 2.5 and 250 mcg/ml were comparable to those at 25 mcg/ml. Six glutamate-substituted gliadin peptides (H, I, J, N, O, P) were <15% as bioactive as A-gliadin 57-73 QE65. Other peptides were intermediate in bioactivity.

At least six gliadin-derived peptides are equivalent in potency to A-gliadin 57-73 QE65 after modification by transglutaminase. Relatively non-bioactive  
25 polymorphisms of A-gliadin 57-73 also exist. These data indicate that transglutaminase modification of peptides from several gliadins of *Triticum aestivum*, *T. uarzu* and *T. spelta* may be capable of generating the immunodominant T cell epitope in coeliac disease.

Genetic modification of wheat to generate non-coeliac-toxic wheat may likely  
30 require removal or modification of multiple gliadin genes. Generation of wheat containing gliadins or other proteins or peptides incorporating sequences defining altered peptide ligand antagonists of A-gliadin 57-73 is an alternative strategy to



generate genetically modified wheat that is therapeutic rather than "non-toxic" in coeliac disease.

### Example 9

#### 5 *Definition of Core Epitope Sequence:*

Comparison of peptides corresponding to truncations of A-gliadin 56-75 from the N- and C-terminal indicated that the core sequence of the T cell epitope is PELPY (A-gliadin 64-68). Attempts to define non-agonists and antagonists will focus on variants of A-gliadin that are substituted at residues that substantially  
10 contribute to its bioactivity.

Peptides corresponding to A-gliadin 57-73 QE65 with alanine (Figure 15) or lysine (Figure 16) substituted for residues 57 to 73 were compared in the IFN gamma ELISPOT using peripheral blood mononuclear cells (PBMC) from coeliac volunteers 6 days after commencing a 3-day gluten challenge (n=8). (BL is blank, E is A-gliadin 57-73 QE65: QLQPFQPELPYPQPQS (SEQ ID NO:2)).  
15

It was found that residues corresponding to A-gliadin 60-70 QE65 (PFPQPELPYPQ (SEQ ID NO:14)) contribute substantially to the bioactivity in A-gliadin 57-73 QE65. Variants of A-gliadin 57-73 QE65 substituted at positions 60-70 are assessed in a 2-step procedure. Initially, A-gliadin 57-73 QE65 substituted at  
20 positions 60-70 using 10 different amino acids with contrasting properties are assessed. A second group of A-gliadin 57-73 QE65 variants (substituted with all other naturally occurring amino acids except cysteine at positions that prove are sensitive to modification) are assessed in a second round.

### 25 **Example 10**

#### *Agonist activity of substituted variants of A-gliadin 57-73 QE65*

A-gliadin 60-70 QE65 is the core sequence of the dominant T cell epitope in A-gliadin. Antagonist and non-agonist peptide variants of this epitope are most likely generated by modification of this core sequence. Initially, A-gliadin 57-73  
30 QE65 substituted at positions 60-70 using 10 different amino acids with contrasting properties will be assessed in the IFN gamma ELISPOT using PBMC from coeliac subjects 6 days after starting 3 day gluten challenge. A second group of A-gliadin

57-73 QE65 variants (substituted with all other naturally occurring amino acids except cysteine) at positions 61-70 were also assessed. Both groups of peptides (all at 50 mcg/ml, in duplicate) were assessed using PBMC from 8 subjects and compared to the unmodified peptide (20 replicates per assay). Previous studies  
5 indicate that the optimal concentration for A-gliadin 57-73 QE65 in this assay is between 10 and 100 mcg/ml.

Results are expressed as mean response in spot forming cells (95% confidence interval) as % A-G 57-73 QE65 mean response in each individual. Unpaired t-tests will be used to compare ELISPOT responses of modified peptides  
10 with A-G 57-73 QE65. Super-agonists were defined as having a greater response than A-G 57-73 QE65 at a level of significance of  $p < 0.01$ ; partial agonists as having a response less than A-G 57-73 QE65 at a level of significance of  $p < 0.01$ , and non-agonists as being not significantly different ( $p > 0.01$ ) from blank (buffer without peptide). Peptides with agonist activity 30% or less that of A-gliadin 57-73 QE65  
15 were considered "suitable" partial or non-agonists to assess for antagonistic activity (see Table 8 and Figures 17-27).

The IFNgamma ELISPOT response of PBMC to A-gliadin 57-73 QE65 is highly specific at a molecular level. Proline at position 64 (P64), glutamate at 65 (E65) and leucine at position 66 (L66), and to a lesser extent Q63, P67, Y68 and P69  
20 are particularly sensitive to modification. The substitutions Y61 and Y70 both generate super-agonists with 30% greater bioactivity than the parent peptide, probably by enhancing binding to HLA-DQ2 since the motif for this HLA molecule indicates a preference for bulky hydrophobic residues at positions 1 and 9. Eighteen non-agonist peptides were identified. Bioactivities of the variants (50 mcg/ml): P65,  
25 K64, K65 and Y65 (bioactivity 7-8%) were comparable to blank (7%). In total, 57 mutated variants of A-gliadin 57-73 QE65 were 30% or less bioactive than A-gliadin 57-73 QE65.

The molecular specificity of the peripheral blood lymphocyte (PBL) T cell response to the dominant epitope, A-gliadin 57-73 QE65, is consistently reproducible  
30 amongst HLA-DQ2+ coeliac subjects, and is highly specific to a restricted number of amino acids in the core 7 amino acids. Certain single-amino acid variants of A-gliadin 57-73 QE65 are consistently non-agonists in all HLA-DQ2+ coeliac subjects.

**Example 11***Antagonist activity of substituted variants*

The homogeneity of the PBL T cell response to A-gliadin 57-73 QE65 in HLA-DQ2+ coeliac disease suggests that altered peptide ligands (APL) capable of antagonism in PBMC ex vivo may exist, even though the PBL T cell response is likely to be poly- or oligo-clonal. APL antagonists are generally weak agonists. Fifty-seven single amino acid-substituted variants of A-gliadin 57-73 QE65 with agonist activity 30% or less have been identified and are suitable candidates as APL antagonists. In addition, certain weakly bioactive naturally occurring polymorphisms of A-gliadin 57-73 QE65 have also been identified (see below) and may be “naturally occurring” APL antagonists. It has also been suggested that competition for binding MHC may also antagonise antigen-specific T cell immune. Hence, non-gliadin peptides that do not induce IFN $\gamma$  responses in coeliac PBMC after gluten challenge but are known to bind to HLA-DQ2 may be capable of reducing T cell responses elicited by A-gliadin 57-73 QE65. Two peptides that bind avidly to HLA-DQ2 are HLA class I  $\alpha$  46-60 (HLA 1a) (PRAPWIEQEGPEYW (SEQ ID NO:15)) and thyroid peroxidase (tp) 632-645Y (IDVWLGGLLAENFLPY (SEQ ID NO:16)).

Simultaneous addition of peptide (50 $\mu$ g/ml) or buffer and A-gliadin 57-73 QE65 (10 $\mu$ g/ml) in IFN $\gamma$  ELISPOT using PBMC from coeliac volunteers 6 days after commencing 3 day gluten challenge (n=5). Results were expressed as response with peptide plus A-G 57-73 QE65 (mean of duplicates) as % response with buffer plus A-G 57-73 QE65 (mean of 20 replicates). (See Table 9).

Four single amino acid-substituted variants of A-gliadin 57-73 QE65 reduce the interferon gamma PBMC ELISPOT response to A-gliadin 57-73 QE65 (p<0.01) by between 25% and 28%, 13 other peptide variants reduce the ELISPOT response by between 18% and 24% (p<0.06). The HLA-DQ2 binder, thyroid peroxidase (tp) 632-645Y reduces PBMC interferon gamma responses to A-gliadin 57-73 QE65 by 31% (p<0.0001) but the other HLA-DQ2 binder, HLA class I  $\alpha$  46-60, does not alter responses (see Tables 9 and 10). The peptide corresponding to a transglutaminase-modified polymorphism of A-gliadin 57-73, SwissProt accession no.: P04725 82-98

QE90 (PQPQFPPELPYPQPQS (SEQ ID NO:17)) reduces responses to A-gliadin 57-73 QE65 by 19% ( $p < 0.009$ ) (see Table 11).

Interferon gamma responses of PBMC to A-gliadin 57-73 QE65 in ELISPOT assays are reduced by co-administration of certain single-amino acid A-gliadin 57-73 QE65 variants, a polymorphism of A-gliadin 57-73 QE65, and an unrelated peptide known to bind HLA-DQ2 in five-fold excess. These findings suggest that altered peptide ligand antagonists of A-gliadin 57-73 QE65 exist. Not only putative APL antagonists but also certain peptides that bind HLA-DQ2 effectively reduce PBL T cell responses to A-gliadin 57-73 QE65.

These findings support two strategies to interrupt the T cell response to the dominant A-gliadin epitope in HLA-DQ2+ coeliac disease.

1. Optimisation of APL antagonists by substituting amino acids at more than one position (64-67) for use as "traditional" peptide pharmaceuticals or for specific genetic modification of gliadin genes in wheat.
2. Use of high affinity HLA-DQ2 binding peptides to competitively inhibit presentation of A-gliadin 57-73 QE65 in association with HLA-DQ2.

These two approaches may be mutually compatible. Super-agonists were generated by replacing F61 and Q70 with tyrosine residues. It is likely these super-agonists resulted from improved binding to HLA-DQ2 rather than enhanced contact with the T cell receptor. By combining these modifications with other substitutions that generate modestly effective APL antagonists might substantially enhance the inhibitory effect of substituted A-gliadin 57-73 QE65 variants.

## Example 12

*Development of interferon gamma ELISpot using PBMC and A-gliadin 57-73 QE65 and P04724 84-100 QE92 as a diagnostic for coeliac disease: Definition of immune-responsiveness in newly diagnosed coeliac disease*

Induction of responsiveness to the dominant A-gliadin T cell epitope in PBMC measured in the interferon gamma ELISpot follows gluten challenge in almost all DQ2+ coeliac subjects following a long term strict gluten free diet (GFD) but not in healthy DQ2+ subjects after 4 weeks following a strict GFD. A-gliadin

57-73 QE65 responses are not measurable in PBMC of coeliac subjects before gluten challenge and pilot data have suggested these responses could not be measured in PBMC of untreated coeliacs. These data suggest that in coeliac disease immune-responsiveness to A-gliadin 57-73 QE65 is restored following antigen exclusion (GFD). If a diagnostic test is to be developed using the ELISpot assay and PBMC, it is desirable to define the duration of GFD required before gluten challenge is capable of inducing responses to A-gliadin 57-73 QE65 and other immunoreactive gliadin peptides in blood.

Newly diagnosed DQ2+ coeliac subjects were recruited from the gastroenterology outpatient service. PBMC were prepared and tested in interferon gamma ELISpot assays before subjects commenced GFD, and at one or two weeks after commencing GFD. In addition, gluten challenge (3 days consuming 4 slices standard white bread, 200g/day) was performed at one or two weeks after starting GFD. PBMC were prepared and assayed on day six after commencing gluten challenge. A-gliadin 57-73 QE65 (A), P04724 84-100 QE92 (B) (alone and combined) and A-gliadin 57-73 QP65 (P65) (non-bioactive variant, see above) (all 25 mcg/ml) were assessed.

All but one newly diagnosed coeliac patient was DQ2+ (one was DQ8+) (n=11). PBMC from newly diagnosed coeliacs that were untreated, or after 1 or 2 weeks following GFD did not show responses to A-gliadin 57-73 QE65 and P04724 84-100 QE92 (alone or combined) that were not significantly different from blank or A-gliadin 57-73 QP65 (n=9) (see Figure 28). Gluten challenge in coeliacs who had followed GFD for only one week did not substantially enhance responses to A-gliadin 57-73 QE65 or P04724 84-100 QE92 (alone or combined). But gluten challenge 2 weeks after commencing GFD did induce responses to A-gliadin 57-73 QE65 and P04724 84-100 QE92 (alone or combined) that were significantly greater than the non-bioactive variant A-gliadin 57-73 QP65 and blank. Although these responses after gluten challenge at 2 weeks were substantial they appear to be less than in subjects >2 months after commencing GFD. Responses to A-gliadin 57-73 QE65 alone were equivalent or greater than responses to P04724 84-100 QE92 alone or when mixed with A-gliadin 57-73 QE65. None of the subjects experienced troubling symptoms with gluten challenge.

Immune responsiveness (as measured in PBMC after gluten challenge) to A-gliadin is partially restored 2 weeks after commencing GFD, implying that "immune unresponsiveness" to this dominant T cell epitope prevails in untreated coeliac disease and for at least one week after starting GFD. The optimal timing of a  
5 diagnostic test for coeliac disease using gluten challenge and measurement of responses to A-gliadin 57-73 QE65 in the ELISpot assay is at least 2 weeks after commencing a GFD.

Interferon gamma-secreting T cells specific to A-gliadin 57-73 QE65 cannot be measured in the peripheral blood in untreated coeliacs, and can only be induced  
10 by gluten challenge after at least 2 weeks GFD (antigen exclusion). Therefore, timing of a diagnostic test using this methodology is crucial and further studies are needed for its optimization. These findings are consistent with functional anergy of T cells specific for the dominant epitope, A-gliadin 57-73 QE65, reversed by antigen exclusion (GFD). This phenomenon has not been previously demonstrated in a  
15 human disease, and supports the possibility that T cell anergy may be inducible with peptide therapy in coeliac disease.

### Example 13

#### *Comprehensive Mapping of Wheat Gliadin T Cell Epitopes*

20 Antigen challenge induces antigen-specific T cells in peripheral blood. In coeliac disease, gluten is the antigen that maintains this immune-mediated disease. Gluten challenge in coeliac disease being treated with a gluten free diet leads to the appearance of gluten-specific T cells in peripheral blood, so enabling determination of the molecular specificity of gluten T cell epitopes. As described above, we have  
25 identified a single dominant T cell epitope in a model gluten protein, A-gliadin (57-73 deamidated at Q65). In this Example, gluten challenge in coeliac patients was used to test all potential 12 amino acid sequences in every known wheat gliadin protein derived from 111 entries in Genbank. In total, 652 20mer peptides were tested in HLA-DQ2 and HLA-DQ8 associated coeliac disease. Seven of the 9  
30 coeliac subjects with the classical HLA-DQ2 complex (HLA-DQA1\*05, HLA-DQB1\*02) present in over 90% of coeliacs had an inducible A-gliadin 57-73 QE65- and gliadin-specific T cell response in peripheral blood. A-gliadin 57-73 was the

only significant  $\alpha$ -gliadin T cell epitope, as well as the most potent gliadin T cell epitope, in HLA-DQ2-associated coeliac disease. In addition, there were as many as 5 families of structurally related peptides that were between 10 and 70% as potent as A-gliadin 57-73 in the interferon- $\gamma$  ELISpot assay. These new T cell epitopes were  
5 derived from  $\gamma$ - and  $\omega$ -gliadins and included common sequences that were structurally very similar, but not identical to the core sequence of A-gliadin 57-73 (core sequence: FPQPQLPYP (SEQ ID NO:18)), for example: FPQPQQPFP (SEQ ID NO:19) and PQQPQQPFP (SEQ ID NO:20). Although no homologues of A-gliadin 57-73 have been found in rye or barley, the other two cereals toxic in coeliac  
10 disease, the newly defined T cell epitopes in  $\gamma$ - and  $\omega$ -gliadins have exact matches in rye and barley storage proteins (secalins and hordeins, respectively).

Coeliac disease not associated with HLA-DQ2 is almost always associated with HLA-DQ8. None of the seven HLA-DQ8+ coeliac subjects had inducible A-gliadin 57-73-specific T cell responses following gluten challenge, unless they also  
15 possessed the complete HLA-DQ2 complex. Two of 4 HLA-DQ8+ coeliac subjects who did not possess the complete HLA-DQ2 complex, had inducible gliadin peptide-specific T cell responses following gluten challenge. In one HLA-DQ8 subject, a novel dominant T cell epitope was identified with the core sequence LQPQNPSQQQPQ (SEQ ID NO:21). The transglutaminase-deamidated version of  
20 this peptide was more potent than the non-deamidated peptide. Previous studies suggest that the transglutaminase-deamidated peptide would have the sequence LQPENPSQEQPE (SEQ ID NO:22); but further studies are required to confirm this sequence. Amongst the healthy HLA-DQ2 (10) and HLA-DQ8 (1) subjects who followed a gluten free diet for a month, gliadin peptide-specific T cell responses  
25 were uncommon, seldom changed with gluten challenge, and were never potent T cell epitopes revealed with gluten challenge in coeliac subjects. In conclusion, there are unlikely to be more than six important T cell epitopes in HLA-DQ2-associated coeliac disease, of which A-gliadin 57-73 is the most potent. HLA-DQ2- and HLA-DQ8-associated coeliac disease do not share the same T cell specificity.

30 We have shown that short-term gluten challenge of individuals with coeliac disease following a gluten free diet induces gliadin-specific T cells in peripheral blood. The frequency of these T cells is maximal in peripheral blood on day 6 and

then rapidly wanes over the following week. Peripheral blood gliadin-specific T cells express the integrin  $\alpha 4 \beta 7$  that is associated with homing to the gut lamina propria. We exploited this human antigen-challenge design to map T cell epitopes relevant to coeliac disease in the archetypal gluten  $\alpha$ -gliadin protein, A-gliadin.

- 5 Using 15mer peptides overlapping by 10 amino acids with and without deamidation by transglutaminase (tTG), we demonstrated that T cells induced in peripheral blood initially target only one A-gliadin peptide, residues 57-73 in which glutamine at position 65 is deamidated. The epitope is HLA-DQ2-restricted, consistent with the intimate association of coeliac disease with HLA-DQ2.

- 10 Coeliac disease is reactivated by wheat, rye and barley exposure. The  $\alpha/\beta$ -gliadin fraction of wheat gluten is consistently toxic in coeliac disease, and most studies have focused on these proteins. The gene cluster coding for  $\alpha/\beta$ -gliadins is located on wheat chromosome 6C. There are no homologues of  $\alpha/\beta$ -gliadins in rye or barley. However, all three of the wheat gliadin subtypes ( $\alpha/\beta$ ,  $\gamma$ , and  $\omega$ ) are toxic  
15 in coeliac disease. The  $\gamma$ - and  $\omega$ -gliadin genes are located on chromosome 1A in wheat, and are homologous to the secalins and hordeins in rye and barley.

- There are now genes identified for 61  $\alpha$ -gliadins in wheat (*Triticum aestivum*). The  $\alpha$ -gliadin sequences are closely homologous, but the dominant epitope in A-gliadin derives from the most polymorphic region in the  $\alpha$ -gliadin  
20 sequence. Anderson et al (1997) have estimated that there are a total of about 150 distinct  $\alpha$ -gliadin genes in *T. aestivum*, but many are pseudogenes. Hence, it is unlikely that T-cell epitopes relevant to coeliac disease are not included within known  $\alpha$ -gliadin sequences.

- Our work has identified a group of deamidated  $\alpha$ -gliadin peptides almost  
25 identical to A-gliadin 57-73 as potent T cell epitopes specific to coeliac disease. Over 90% of coeliac patients are HLA-DQ2+, and so far, we have only assessed HLA-DQ2+ coeliac subjects after gluten challenge. However, coeliac patients who do not express HLA-DQ2 nearly all carry HLA-DQ8. Hence, it is critical to know whether A-gliadin 57-73 and its homologues in other wheat, rye and barley gluten  
30 proteins are the only T-cell epitopes recognized by T cells induced by gluten challenge in both HLA-DQ2+ and HLA-DQ8+ coeliac disease. If this were the case, design of peptide therapeutics for coeliac disease might only require one peptide.



### *Homologues of A-gliadin 57-73 as T-cell epitopes*

Initial searches of SwissProt and Trembl gene databases for cereal genes coding for the core sequence of A-gliadin 57-73 (PQLPY <SEQ ID NO:12>) only revealed  $\alpha/\beta$ -gliadins. However, our fine-mapping studies of the A-gliadin 57-73 QE65 epitope revealed a limited number of permissive point substitutions in the core region (PQLP) (note Q65 is actually deamidated in the epitope). Hence, we extended our search to genes in SwissProt or Trembl databases encoding for peptides with the sequence XXXXXXXXPQ[ILMP][PST]XXXXXX (SEQ ID NO:23). Homologues were identified amongst  $\gamma$ -gliadins, glutenins, hordeins and secalins (see Table 12). A further homologue was identified in  $\omega$ -gliadin by visual search of the three  $\omega$ -gliadin entries in Genbank.

These homologues of A-gliadin 57-73 were assessed after deamidation by tTG (or synthesis of the glutamate(QE)-substituted variant in four close homologues) using the IFN $\gamma$  ELISpot assay with peripheral blood mononuclear cells after gluten challenge in coeliac subjects. The  $\omega$ -gliadin sequence (AAG17702 141-157) was the only bioactive peptide, approximately half as potent as A-gliadin 57-73 (see Table 12, and Figure 29). Hence, searches for homologues of the dominant A-gliadin epitope failed to account for the toxicity of  $\gamma$ -gliadin, secalins, and hordeins.

### 20 *Methods*

#### *Design of a set of peptides spanning all possible wheat gliadin T-cell epitopes*

In order to identify all possible T cell epitopes coded by the known wheat (*Triticum aestivum*) gliadin genes or gene fragments (61  $\alpha/\beta$ -, 47  $\gamma$ -, and 3  $\omega$ -gliadin entries in Genbank), gene-derived protein sequences were aligned using the CustalW software (MegAlign) and arranged into phylogenetic groupings (see Table 22). Many entries represented truncations of longer sequences, and many gene segments were identical except for the length of polyglutamine repeats or rare substitutions. Hence, it was possible to rationalize all potential unique 12 amino acid sequences encoded by known wheat genes to be included in a set of 652 20mer peptides. (Signal peptide sequences were not included). Peptide sequences are listed in Table 23.

#### *Comprehensive epitope mapping*

Healthy controls (HLA-DQ2+ n=10, and HLA-DQ8+ n=1) who had followed a gluten free diet for 4 weeks, and coeliac subjects (six HLA-DQ2, four complex heterozygotes HLA-DQ2/8, and three HLA-DQ8/X) (see Table 13) following long-term gluten free diet were studied before and on day 6 and 7 after 3-day gluten challenge (four 50g slices of standard white bread – Sainsbury's sandwich bread, each day). Peripheral blood (a total of 300ml over seven days) was collected and peripheral blood mononuclear cells (PBMC) were separated by Lymphoprep density gradient. PBMC were incubated with pools of 6 or 8 20mer peptides, or single peptides with or without deamidation by tTG in overnight interferon gamma (IFN $\gamma$ ) ELISpot assays.

Peptides were synthesized in batches of 96 as Pepsets (Mimotopes Inc., Melbourne Australia). Approximately 0.6 micromole of each of 652 20mers was provided. Two marker 20mer peptides were included in each set of 96 (VLQQHNI AHGSSQVLQESTY – peptide 161 (SEQ ID NO:24), and IKDFHVYFRESRDALWKGP (SEQ ID NO:25)) and were characterized by reverse phase-HPLC and amino acid sequence analysis. Average purities of these marker peptides were 50% and 19%, respectively. Peptides were initially dissolved in acetonitrile (10%) and Hepes 100mM to 10mg/ml.

The final concentration of individual peptides in pools (or alone) incubated with PBMC for the IFN $\gamma$  ELISpot assays was 20  $\mu$ g/ml. Five-times concentrated solutions of peptides and pools in PBS with calcium chloride 1mM were aliquotted and stored in 96-well plates according to the template later used in ELISpot assays. Deamidated peptides and pools of peptides were prepared by incubation with guinea pig tissue tTG (Sigma T5398) in the ratio 100:32  $\mu$ g/ml for two hours at 37°C. Peptides solutions were stored at -20°C and freshly thawed prior to use.

Gliadin (Sigma G3375) (100 mg/ml) in endotoxin-free water and 2M urea was boiled for 10 minutes, cooled to room temperature and incubated with filter (0.2  $\mu$ m)-sterilised pepsin (Sigma P6887) (2 mg/ml) in HCl 0.02M or chymotrypsin (C3142) (4mg/ml) in ammonium bicarbonate (0.2M). After incubation for 4 hours, pepsin-digested gliadin was neutralized with sodium hydroxide, and then both pepsin- and chymotrypsin-digested gliadin were boiled for 15 minutes. Identical incubations with protease in which gliadin was omitted were also performed.

Samples were centrifuged at 15 000g, then protein concentrations were estimated in supernatants by the BCA method (Pierce, USA). Before final use in IFN $\gamma$  ELISpot assays, aliquots of gliadin-protease were incubated with tTG in the ratio 2500:64  $\mu$ g/ml.

5 IFN $\gamma$  ELISpot assays (Mabtech, Sweden) were performed in 96-well plates (MAIP S-45, Millipore) in which each well contained 25 $\mu$ l of peptide solution and 100 $\mu$ l of PBMC ( $2-8 \times 10^5$ /well) in RPMI containing 10% heat inactivated human AB serum. Deamidated peptide pools were assessed in one 96-well ELISpot plate, and peptides pools without deamidation in a second plate (with an identical layout) on  
10 both day 0 and day 6. All wells in the plate containing deamidated peptides included tTG (64  $\mu$ g/ml). In each ELISpot plate there were 83 wells with peptide pools (one unique pool in each well), and a series of wells for "control" peptides (peptides all >90% purity, characterized by MS and HPLC, Research Genetics): P04722 77-93 (QLQFPQPQLPYQPQP (SEQ ID NO:26)), P04722 77-93 QE85 (in duplicate)  
15 (QLQFPQPQLPYQPQP (SEQ ID NO:27)), P02863 77-93 (QLQFPQPQLPYSQPQP (SEQ ID NO:28)), P02863 77-93 QE85 (QLQFPQPQLPYSQPQP (SEQ ID NO:29)), and chymotrypsin-digested gliadin (500  $\mu$ g/ml), pepsin-digested gliadin (500  $\mu$ g/ml), chymotrypsin (20  $\mu$ g/ml) alone, pepsin (10  $\mu$ g/ml) alone, and blank (PBS+/-tTG) (in triplicate).

20 After development and drying, IFN $\gamma$  ELISpot plates were assessed using the MAIP automated ELISpot plate counter. In HLA-DQ2 healthy and coeliac subjects, induction of spot forming cells (sfc) by peptide pools in the IFN $\gamma$  ELISpot assay was tested using a one-tailed Wilcoxon Matched-Pairs Signed-Ranks test (using SPSS software) applied to spot forming cells (sfc) per million PBMC minus blank on day 6  
25 versus day 0 ("net response"). Significant induction of an IFN $\gamma$  response to peptide pools in PBMC by *in vivo* gluten challenge was defined as a median "net response" of at least 10 sfc/million PBMC and  $p < 0.05$  level of significance. Significant response to a particular pool of peptides on day 6 was followed by assessment of individual peptides within each pool using PBMC drawn the same day or on day 7.

30 For IFN $\gamma$  ELISpot assays of individual peptides, bioactivity was expressed as a percent of response to P04722 77-93 QE85 assessed in the same ELISpot plate. Median response to blank (PBS alone) was 0.2 (range 0-5) sfc per well, and the

positive control (P04722 77-93 QE85) 76.5 (range: 25-282) sfc per well using a median of 0.36 million (range: 0.3-0.72) PBMC. Hence, median response to blank expressed as a percentage of P04722 77-93 QE65 was 0.2% (range: 0-6.7).

Individual peptides with mean bioactivity greater than 10% that of P04722 QE85  
5 were analyzed for common structural motifs.

## Results

### *Healthy HLA-DQ2 subjects*

None of the healthy HLA-DQ2+ subjects following a gluten free diet for a month had IFN $\gamma$  ELISpot responses to homologues of A-gliadin 57-73 before or after  
10 gluten challenge. However, in 9/10 healthy subjects, gluten challenge was associated with a significant increase in IFN $\gamma$  responses to both peptic- and chymotryptic-digests of gliadin, from a median of 0-4 sfc/million on day 0 to a median of 16-29 sfc/million (see Table 14). Gliadin responses in healthy subjects were unaffected by deamidation (see Table 15). Amongst healthy subjects, there was no consistent  
15 induction of IFN $\gamma$  responses to specific gliadin peptide pools with gluten challenge (see Figure 30, and Table 16). IFN $\gamma$  ELISpot responses were occasionally found, but these were weak, and not altered by deamidation. Many of the strongest responses to pools were also present on day 0 (see Table 17, subjects H2, H8 and H9). Four healthy subjects did show definite responses to pool 50, and the two with strongest  
20 responses on day 6 also had responses on day 0. In both subjects, the post-challenge responses to pool 50 responses were due to peptide 390 (QQTYPQRPQQPFPTQQPQQ (SEQ ID NO:30)).

### *HLA-DQ2 coeliac subjects*

Following gluten challenge in HLA-DQ2+ coeliac subjects, median IFN $\gamma$   
25 ELISpot responses to P04722 77-93 E85 rose from a median of 0 to 133 sfc/million (see Table 4). One of the six coeliac subjects (C06) did not respond to P04722 77-93 QE85 (2 sfc/million) and had only weak responses to gliadin peptide pools (maximum: Pool 50+tTG 27 sfc/million). Consistent with earlier work, bioactivity of wild-type P04722 increased 6.5 times with deamidation by tTG (see Table 15).  
30 Interferon-gamma responses to gliadin-digests were present at baseline, but were substantially increased by gluten challenge from a median of 20 up to 92 sfc/million for chymotryptic-gliadin, and from 44 up to 176 sfc/million for peptide-gliadin.

Deamidation of gliadin increased bioactivity by a median of 3.2 times for chymotryptic-gliadin and 1.9 times for peptic-gliadin (see Table 15). (Note that the acidity required for digestion by pepsin is likely to result in partial deamidation of gliadin.)

5 In contrast to healthy subjects, gluten challenge induced IFN $\gamma$  ELISpot responses to 22 of the 83 tTG-treated pools including peptides from  $\alpha$ -,  $\gamma$ - and  $\omega$ -gliadins (see Figure 31, and Table 17). Bioactivity of pools was highly consistent between subjects (see Table 18). IFN $\gamma$  ELISpot responses elicited by peptide pools were almost always increased by deamidation (see Table 17). But enhancement of  
10 bioactivity of pools by deamidation was not as marked as for P04722 77-73 Q85, even for pools including homologues of A-gliadin 57-73. This suggests that Pepset peptides were partially deamidated during synthesis or in preparation, for example the Pepset peptides are delivered as salts of trifluoroacetic acid (TFA) after lyophilisation from a TFA solution.

15 One hundred and seventy individual tTG-deamidated peptides from 21 of the most bioactive pools were separately assessed. Seventy-two deamidated peptides were greater than 10% as bioactive as P04722 77-93 QE85 at an equivalent concentration (20  $\mu$ g/ml) (see Table 19). The five most potent peptides (85-94% bioactivity of P04722 QE85) were previously identified  $\alpha$ -gliadin homologues A-  
20 gliadin 57-73. Fifty of the bioactive peptides were not homologues of A-gliadin 57-73, but could be divided into six families of structurally related sequences (see Table 20). The most bioactive sequence of each of the peptide families were:  
PQQPQQPQQPFPQPPQFPW (SEQ ID NO:31) (peptide 626, median 72%  
bioactivity of P04722 QE85), QQPQQPFPQPPQPPQLPFPQQ (SEQ ID NO:32)  
25 (343, 34%), QAFPPQPPQTFPHQPPQQFPQ (SEQ ID NO:33) (355, 27%),  
TQQPQQPFPQPPQPPQFPQTQ (SEQ ID NO:34) (396, 23%),  
PIQPQQPFPQPPQPPQPPFP (SEQ ID NO:35) (625, 22%),  
PQQSFSYQQPPFPQPPYPQQ (SEQ ID NO:36) (618, 18%) (core sequences are  
underlined). All of these sequences include glutamine residues predicted to be  
30 susceptible to deamidation by transglutaminase (e.g. QXP, QXPF (SEQ ID NO:37),  
QXX[FY] (SEQ ID NO:38)) (see Vader et al 2002). Some bioactive peptides  
contain two core sequences from different families.

Consistent with the possibility that different T-cell populations respond to peptides with distinct core sequences, bioactivity of peptides from different families appear to be additive. For example, median bioactivity of tTG-treated Pool 81 was 141% of P04722 QE85, while bioactivity of individual peptides was in rank order:

5 Peptide 631 (homologue of A-gliadin 57-73) 61%, 636 (homologue of 626) 51%, and 635 19%, 629 16%, and 634 13% (all homologues of 396).

Although likely to be an oversimplification, the contribution of each "peptide family" to the summed IFN $\gamma$  ELISpot response to gliadin peptides was compared in the HLA-DQ2+ coeliac subjects (see Figure 32). Accordingly, the contribution of

10 P04722 77-73 E85 to the summed response to gliadin peptides is between 1/5 and 2/3.

Using the peptide homology search programme, WWW PepPepSearch, which can be accessed through the world wide web of the internet at, for example, "cbrg.inf.ethz.ch/subsection3\_1\_5.html.", and by direct comparison with Genbank

15 sequences for rye secalins, exact matches were found for the core sequences QQPFPPQQPFPP (SEQ ID NO:39) in barley hordeins (HOR8) and rye secalins (A23277, CAA26449, AAG35598), QQPFPPQQPFPP (SEQ ID NO:40) in barley hordeins (HOG1 and HOR8), and for PIQPQQPFPPQQP (SEQ ID NO:41) also in barley hordeins (HOR8).

20

#### *HLA-DQ8-associated coeliac disease*

Seven HLA-DQ8+ coeliac subjects were studied before and after gluten challenge. Five of these HLA-DQ8+ (HLA-DQA0\*0301-3, HLA-DQB0\*0302) subjects also carried one or both of the coeliac disease-associated HLA-DQ2

25 complex (DQA0\*05, DQB0\*02). Two of the three subjects with both coeliac-associated HLA-DQ complexes had potent responses to gliadin peptide pools (and individual peptides including P04722 77-93 E85) that were qualitatively and quantitatively identical to HLA-DQ2 coeliac subjects (see Figures 33 and 34, and Table 18). Deamidated peptide pool 74 was bioactive in both HLA-DQ2/8 subjects,

30 but only in one of the 6 HLA-DQ2/X subjects. Pretreatment of pool 74 with tTG enhances bioactivity between 3.8 and 22-times, and bioactivity of tTG-treated pool 74 in the three responders is equivalent to between 78% and 350% the bioactivity of

P04722 77-93 E85. Currently, it is not known which peptides are bioactive in Pool 74 in subject C02, C07, and C08.

Two of the four HLA-DQ8 coeliac subjects that lacked both or one of the HLA-DQ2 alleles associated with coeliac disease showed very weak IFN $\gamma$  ELISpot responses to gliadin peptide pools, but the other two did respond to both protease-digested gliadin and specific peptide pools. Subject C12 (HLA-DQ7/8) responded vigorously to deamidated Pools 1-3 (see Figure 35). Assessment of individual peptides in these pools identified a series of closely related bioactive peptides including the core sequence LQPQNPSQQQPQ (SEQ ID NO:42) (see Table 20). Previous work (by us) has demonstrated that three glutamine residues in this sequence are susceptible to tTG-mediated deamidation (underlined). Homology searches using WWW PepPepSearch have identified close matches to LQPQNPSQQQPQ (SEQ ID NO:43) only in wheat  $\alpha$ -gliadins.

The fourth HLA-DQ8 subject (C11) had inducible IFN $\gamma$  ELISpot responses to tTG-treated Pool 33 (see Figure 36). Pools 32 and 33 include polymorphisms of a previously defined HLA-DQ8 restricted gliadin epitope (QQYPSGQGSFQPSQQNPQ (SEQ ID NO:44)) active after deamidation by tTG (underlined Gln are deamidated and convey bioactivity) (van der Wal et al 1998). Currently, it is not known which peptides are bioactive in Pool 33 in subject C11.

Comprehensive T cell epitope mapping in HLA-DQ2-associated coeliac disease using in vivo gluten challenge and a set of 652 peptides spanning all known 12 amino acid sequences in wheat gliadin has thus identified at least 72 peptides at 10% as bioactive as the known  $\alpha$ -gliadin epitope, A-gliadin 57-73 E65. However, these bioactive peptides can be reduced to a set of perhaps as few as 5 distinct but closely related families of peptides. Almost all these peptides are rich in proline, glutamine, phenylalanine, and/or tyrosine and include the sequence PQ(QL)P(FY)P (SEQ ID NO:45). This sequence facilitates deamidation of Q in position 2 by tTG. By analogy with deamidation of A-gliadin 57-68 (Arentz-Hansen 2000), the enhanced bioactivity of these peptides generally found with deamidation by tTG may be due to increased affinity of binding for HLA-DQ2.

Cross-reactivity amongst T cells in vivo recognizing more than one of these bioactive gliadin peptides is possible. However, if each set of related peptides does

activate a distinct T cell population in vivo, the epitope corresponding to A-gliadin 57-73 E65 is the most potent and is generally recognized by at least 40% of the peripheral blood T cells that secrete IFN $\gamma$  in response to gliadin after gluten challenge.

5. No gliadin-peptide specific responses were found in HLA-DQ2/8 coeliac disease that differed qualitatively from those in HLA-DQ2/X-associated coeliac disease. However, peripheral blood T cells in HLA-DQ8+ coeliac subjects without both HLA-DQ2 alleles did not recognize A-gliadin 57-73 E65 homologues. Two different epitopes were dominant in two HLA-DQ8+ coeliacs. The dominant epitope  
 10 in one of these HLA-DQ8+ individuals has not been identified previously (LQPQNPSQQQPQ (SEQ ID NO:46)).

Given the teaching herein, design of an immunotherapy for coeliac disease utilizing all the commonly recognised T cell epitopes is practical and may include fewer than six distinct peptides. Epitopes in wheat  $\gamma$ - and  $\omega$ -gliadins are also present  
 15 in barley hordeins and rye secalins.

#### Example 14

Several ELISpot assays were performed as previously described and yielded the following results and/or conclusions:

##### 20 *Examination of multiple $\alpha$ -gliadin polymorphisms with PQLPY*

Potent agonists of A-gliadin 57-73QE (G01) include QLQPFPPQELPYPQPQS (G01), PQL-Y-----P (G10), and PQPQPFL----- (G12). Less potent include -----L-----P (G04), -----R-----P (G05), and -----S-----P (G06). Less potent yet  
 25 include -----L-----S-----P (G07), -----S-----S-----P (G08), -----S--S-----P (G09), and PQPQPFP----- (G13). Dashes indicate identity with the G01 sequence in the particular position.

##### 30 *Gluten challenge induces A-gliadin 57-73 QE65 T cells only after two weeks of gluten-free diet in newly diagnosed coeliac disease*

Additional analyses indicated that tTG-deamidated gliadin responses change after two weeks of gluten-free diet in newly diagnosed coeliac disease. Other



analyses indicated that deamidated gliadin-specific T cells are CD4<sup>+</sup>α<sub>4</sub>β<sub>7</sub><sup>+</sup> HLA-DQ2 restricted.

*Optimal epitope (clones versus gluten challenge)*

5 A "dominant" epitope is defined by γIFN ELISpot after gluten challenge. QLQPFQPELPYPQPQS (100% ELISpot response). Epitopes defined by intestinal T cell clones: QLQPFQPELPY (27%), PQPELPYPQPELPY (52%), and QQLPQPEQPQSFPEQERPF (9%).

10

*Dominance among individual peptide responses*

Dominance depends on wheat or rye. For wheat, dominant peptides include peptide numbers 89, 90 and 91 (referring to sequence numbers in Table 23). For rye,  
15 dominant peptides include peptide numbers 368, 369, 370, 371, and 372 (referring to sequence numbers in Table 23). Some peptides, including 635 and 636 (referring to sequence numbers in Table 23) showed activity in both rye and wheat.

20 *In vivo gluten challenge allows T cell epitope hierarchy to be defined for coeliac disease*

The epitope hierarchy is consistent among HLA-DQ2<sup>+</sup> coeliacs but different for HLA-DQ8<sup>+</sup> coeliacs. The hierarchy depends on what cereal is consumed. Deamidation generates almost all gliadin epitopes. HLA-DQ2, DQ8, and DR4 present deamidated peptides. HLA-DQ2/8-associated coeliac disease preferentially  
25 present DQ2-associated gliadin epitopes. Gliadin epitopes are sufficiently restricted to justify development of epitope-based therapeutics.

Other analyses indicated the following: HLA-DR3-DQ2 (85-95%) and HLA-DR4-DQ8 (5-15%).

Other analyses indicated the following:

30	HLA-DQ	HLA-DQA1	HLA-DQB1	Duodenal	Gluten	EMA on
	allele	allele	allele	histology	free	gluten
						(on GFD)

67

	C01	2,6	102/6, 501	201, 602	SVA	1 yr	+(-)
	C02	2,2	501	201	SVA	1 yr	+(-)
	C03	2,5	101/4/5, 501	201, 501	PVA	1 yr	+(-)
	C04	2,5	101/4/5, 501	201, 501	SVA	7 yr	+(-)
5	C05	2,2	201, 501	201, 202	SVA	4 mo	+(ND)
	C06	2,2	201, 501	201, 202	SVA	2 yr	+(-)
	C07	2,8	301-3, 501	201, 302	SVA	1 yr	+(-)
	C08	2,8	301-3, 501	201,302/8	SVA	11 yr	ND (-)
	C09	2,8	301-3, 501	201, 302	SVA	29 yr	+(-)
10	C10	2,8	201, 301-3	202, 302	IEL	1 yr	+(-)
	C11	6,8	102/6, 301-3	602/15, 302/8	IEL	9 mo	- (ND)
	C12	8,7	301-3, 505	302, 301/9-10	SVA	2 yr	- (-)
	C13	8,8	301	302	SVA	1 yr	+ (+)

15 Another analysis was carried out to determine the bioactivity of individual tTG-deamidated peptides in pools 1-3 in subject C12. The results are as follows (sequence numbers refer to the peptides listed in Table 23): Sequence 8 (100%), Sequence 5 (85%), Sequence 6 (82%), Sequence 3 (77%), Sequence 1 (67%), Sequence 2 (59%), Sequence 9 (49%), Sequence 7 (49%), Sequence 10 (33%),

20 Sequence 4 (15%), Sequence 12 (8%), Sequence 11 (0%), Sequence 23 (26%), Sequence 14 (18%), Sequence 15 (18%), Sequence 17 (18%), Sequence 16 (13%), Sequence 14 (8%), Sequence 22 (5%), Sequence 18 (3%), Sequence 19 (3%), Sequence 20 (0%), Sequence 21 (0%). The predicted deamidated sequence is LQPENPSQEQPE.

25

*Individual ELISpot responses by PBMC (Spot forming cells determined by ELISpot Reader)*

Peptide (see Table 23)	C01	C02	C03	C04	C05
65	16	2	1	2	3
30 66	32	6	13	0	6
67	16	3	4	0	4
68	25	8	4	2	2

68

	69	4	0	0	0	0
	70	2	1	0	0	0
	71	1	1	0	0	1
	72	0	0	0	0	0
5	73	95	21	42	31	31
	74	122	15	29	21	28
	75	5	1	2	2	5
	76	108	13	28	16	22
	77	3	0	1	0	1
10	78	21	2	3	5	3
	79	20	0	2	0	2
	80	5	2	0	0	3
	81	4	1	2	3	1
	82	3	3	5	2	2
15	83	14	2	0	0	1
	84	3	0	0	0	0
	85	14	1	2	1	2
	86	11	0	2	0	2

## 20 *Cross-reactivity*

To deal with data from 652 peptides in 29 subjects, or to determine when a particular response is a true positive peptide-specific T-cell response, or to determine when a response to a peptide is due to cross-reactivity with another structurally related peptide, expression of a particular peptide response can be as a percentage of a "dominant" peptide response. Alternately, the expression can be a "relatedness" as correlation coefficients between peptide responses, or via bioinformatics.

## *Additional epitopes*

30 A representative result is as follows:

Combination of peptides with P04722E (all 20mcg/ml) (n=4)

Alone

P04722E+

69

Pep 626	60	135
P04722E	100	110
HLAa	0	85

(expressed as percent P04722E)

- 5 626+tT: PQQPQQPQQPFPQPQQPFPW  
P04724E: QLQPFPQPELPYPQPQL

TTG-deamidation of peptide 626 (n=12)

- 10 No tTG = 100%

TTG = 170%

*Substitution at particular positions*

Substitution of Peptide 626 PQQP[Q1]QP[Q2]QPFPQP[Q3]QPFPV (n=12)

15		Glu	Arg
	Q1	95	90
	Q2	145	80
	Q3	155	10

(expressed as percent wild-type peptide)

20

Bioactivity of tTG-treated 15mers spanning Peptide 626/627

(PQQPQQPQQPFPQPQQPFPWQP) (n=8)

	P1-15	5
	P2-16	4
25	P3-17	3
	P4-18	38
	P5-19	65
	P6-20	95
	P7-21	65
30	P8-22	90

(expressed as percent of maximal 15mer response)

*Multiple epitopes:*

P04724E: QLQPFPPQLPYPQPQL

626+tTG: PQQPQQPQQPFPQQPFPW

Minimal epitope: QPQQPFPQQPFPW

5 Immunomagnetic depletion of PBMC by beads coated with anti-CD4 and by anti-integrin  $\beta_7$  depleted IFN $\gamma$  ELISpot responses, while immunomagnetic depletion of PBMC by beads coated with anti-CD8 or anti-alphaE integrin. Thus, the PBMC secreting IFN $\gamma$  are CD4+ and  $\alpha_4\beta_7$ +, associated with homing to the lamina propria in the gut.

10 Blocked by anti-DQ antibody but not by anti-DR antibody in heterozygotes and homozygotes for HLA-DQ2. This may imply multiple epitopes within one sequence.

*T cell epitopes in coeliac disease*

15 Other investigators have characterized certain intestinal T cell clone epitopes. See, e.g., Vader et al., Gastroenterology 2002, 122:1729-37; Arentz-Hansen et al., Gastroenterology 2002, 123:803-809. These are examples of epitopes whose relevance is at best unclear because of the in vitro techniques used to clone T cells.

*20 Intestinal versus peripheral blood clones*

Intestinal: 1) intestinal biopsies, 2) T cell clones raised against peptic-tryptic digest of gluten, 3) all HLA-DQ2 restricted, 4) clones respond to gliadin deamidated by transglutaminase.

Peripheral blood: 1) T cell clones raised against gluten are HLA-DR, DQ and DP  
25 restricted. Result: Intestinal T cell clones can be exclusively used to map coeliac disease associated epitopes

GDA\_9Wheat 307 aa Definition Alpha/Beta-Gliadin MM1 Precursor (Prolamin)  
Accession P18573 -- Genbank (which is incorporated herein by reference in its  
30 entirety)

*Intestinal T cell clone epitopes*

A definition of intestinal T cell clone epitopes can be found in, for example, Arentz-Hansen et al., J Exp Med. 2000, 191:603-12. Also disclosed therein are gliadin epitopes for intestinal T cell clones. Deamidated QLQPFQPQLPY is an epitope, with a deamidated sequence of QLQPFQPPELPY. There is an HLA-DQ2 restriction. A homology search shows other bioactive rAlpha-gliadins include PQPQLPY singly or duplicated. A majority of T cell clones respond to either/or DQ2- $\alpha$ I: QLQPFQPPELPY DQ2- $\alpha$ II: PQPELPYPQPELPY

*Dominant gliadin T cell epitopes*

10 All deamidated by transglutaminase.

Peripheral blood day 6 after gluten challenge: A-gliadin 57-73:

QLQPFQPPELPYPQPQS

Intestinal T cell clones: DQ2- $\alpha$ I: QLQPFQPPELPY DQ2- $\alpha$ II: PQPELPYPQPELPY

15 *Intestinal T-cell Clone Epitope Mapping*

	$\alpha$ -Gliadins	A1	PFPQPQLPY
		A2	PQPQLPYPQ
		A3	PYPQPQLPY
		Glia-20	PQQPYQPQPQ
20	$\Gamma$ -Gliadins	G1	PQSFPPQQQ
		G2	IPQQPAQ
		G3	FPQQPQQPYQPQP
		G4	FSQPQQQFPQPQ
		G5	LQPQQPFPPQQPYPQQPQ
25		Glu-21	QSEQSQQPFPQQF
		Glu-5	Q(IL)PQQPQQF
	Glutenin	Glt-156	PFSQQQQSPF
		Glt-17	PFSQQQQQ

*Gluten exposure and induction of IFN $\gamma$ -secreting A-Gliadin 57-73QE65-specific T cells in peripheral blood*

Untreated coeliac disease, followed by gluten free diet for 1, 2, or 8 weeks, followed by gluten exposure (3 days bread 200g/day), followed by gluten free diet

5        Result 1: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: A-gliadin 57-73 QE65 (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (5), 1 week (1), 2 weeks (2), 8 weeks (1)

Day 6: none (0), 1 week (4), 2 weeks (28), 8 weeks (48)

10       Result 2: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: tTG-gliadin (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (45), 1 week (62), 2 weeks (5), 8 weeks (5)

Day 6: none (0), 1 week (67), 2 weeks (40), 8 weeks (60)

15       Result 3: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: A-gliadin 57-73 P65 (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (1), 1 week (2), 2 weeks (1), 8 weeks (1)

Day 6: none (0), 1 week (0), 2 weeks (0), 8 weeks (0)

20       Result 4: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: PPD (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (90), 1 week (88), 2 weeks (210), 8 weeks (150)

Day 6: none (0), 1 week (100), 2 weeks (210), 8 weeks (100)

25       Result 5: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: tTG (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (5), 1 week (4), 2 weeks (3), 8 weeks (2)

Day 6: none (0), 1 week (4), 2 weeks (1), 8 weeks (2)

30

*Gluten challenge in HLA-DQ2 coeliac disease on long term gluten*

Characterization of anti-gliadin T cell response was carried out in peripheral blood on day 6-8 after 3-day gluten challenge.

Result 1: PBMC Day 6 Long-term gluten free diet (preincubation with anti-HLA-DR and -DQ antibody) (expressed as % inhibition)

5 DR-: tTG-gliadin 100 mcg/ml (105), A-gliadin 57-73 QE65 50 mcg/ml (90), PPD 5 mcg/ml (30)

DQ-: tTG-gliadin 100 mcg/ml (5), A-gliadin 57-73 QE65 50 mcg/ml (22), PPD 5 mcg/ml (78).

Result 2: PBMC Day 6 Long-term gluten free diet (expressed as % CD8-depleted PBMC response)

B7 depletion: tTG-gliadin n=6 (7), A-gliadin 57-73 n=9 (6), PPD n=8 (62)

AE depletion: tTG-gliadin n=6 (120), A-gliadin 57-73 n=9 (80), PPD n=8 (110).

CD4 depletion: tTG-gliadin n=6 (10), A-gliadin 57-73 n=9 (9), PPD n=8 (10).

*Therapeutic peptides include, but are not limited to*

QLQFFPQPQLPYPQPQS (AG01)

QLQFFPQPQLPYPQPQP (AG02)

20 QLQFFPQPQLPYPQPQL (AG03)

QLQFFPQPQLPYLQPQP (AG04)

QLQFFPRPQLPYPQPQP (AG05)

QLQFFPQPQLPYSQPQP (AG06)

QLQPFLQPQLPYSQPQP (AG07)

25 QLQPFSQPQLPYSQPQP (AG08)

QLQFFPQPQLSYSQPQP (AG09)

PQLPYPQPQLPYPQPQP (AG10)

PQLPYPQPQLPYPQPQL (AG11)

PQPQPFLPQLPYPQPQS (AG12)

30 PQPQFFPPQLPYPQPQS (AG13)

PQPQFFPPQLPYPQYQP (AG14)

PQPQFFPPQLPYPQPPP (AG015)



Briefly after oral antigen challenge, specificities of peripheral blood T cells reflect those of intestinal T cell clones. In peripheral blood, epitopes of intestinal T cell clones are sub-optimal compared to A-gliadin 57-73 QE65, which is an optimal  $\alpha$ -gliadin epitope.

### Example 15

ELISpot assays were also carried out for mapping purposes as follows.

#### *Fine-mapping the dominant DQ-8 associated epitope*

Sequence / sfc	tTG-treated sequence / sfc
VPQLQPQNPSQQQPQEQV / 76	RWPVPQLQPQNPSQQ / 60
	WPVPQLQPQNPSQQQ / 90
VPQLQPENPSQQQPQEQV / 3	PVPQLQPQNPSQQQP / 130
VPQLQPRNPSQQQPQEQV / 76	VPQLQPQNPSQQQPQ / 140
	PQLQPQNPSQQQPQE / 59
VPQLQPQNPSQEQPQEQV / 100	QLQPQNPSQQQPQEQ / 95
VPQLQPQNPSQRQPQEQV / 1	LQPQNPSQQQPQEQV / 30
	QPQNPSQQQPQEQVP / 4
VPQLQPQNPSQQQPQEEQV / 71	
VPQLQPQNPSQQQPQREQV / 27	DQ8 Gliadin Epitope
	GDA09 202Q / 6
VPQLQPQNPSQEQPQEEQV / 81	GDA09 202E / 83
VPQLQPENPSQQQPQEEQV / 2	GDA09 202Q+tTG / 17
VPQLQPENPSQEQPQEQV / 6	BI + tTG / 0
VPQLQPENPSQEQPQEEQV / 5	BI / 0

#### *Fine-mapping dominant epitope (2)*

Pool 33 (deamidated) / sfc

A2b3 301 qqyp sgqg ffqp sqqn pqaq / 2
A2b5 301 qqyp sgqg ffqp fqqn pqaq / 1
A3a1 301 qqyp sgqg ffqp sqqn pqaq / 0
A3b1 301 qqyp ssqv sfqp sqln pqaq / 0

A3b2 301 qqyp ssqg sfqp sqqn pqaq / 2

A4a 301 eqyp sgqv sfqs sqqn pqaq / 28

A1b1 309 sfrp sqqn plaq gsvq pqq1 / 2

A1a1 309 sfrp sqqn pqaq gsvq pqq1 / 2

5

#### Example 16

*Bioactivity of gliadin epitopes in IFN $\gamma$ -ELISpot (25 mcg/ml, n=6) (expressed as % A-gliadin 57-73 QE65 response)*

DQ2-AII: wild type (WT) (4), WT + tTG (52), Glu-substituted (52)

10 DQ2-AI: wild type (WT) (2), WT + tTG (22), Glu-substituted (28)

GDA09: wild type (WT) (1), WT + tTG (7), Glu-substituted (8)

A-G31-49: wild type (WT) (2), WT + tTG (3), Glu-substituted (0)

*Dose response of A-Gliadin 57-73 QE65 (G01E) (n=8) (expressed as %G01E maximal response)*

15

0.025 mcg/ml (1), 0.05 mcg/ml (8), 0.1 mcg/ml (10), 0.25 mcg/ml (22), 0.5 mcg/ml (38), 1 mcg/ml (43), 2.5 mcg/ml (52), 5 mcg/ml (70), 10 mcg/ml (81), 25 mcg/ml (95), 50 mcg/ml (90), 100 mcg/ml (85).

IFN $\gamma$  ELISpot response to gliadin epitopes alone or mixed with A-gliadin

20 57-75 (G01E) (all 50 mcg/ml, tTG-gliadin 100 mcg/ml, PPD 5 mcg/ml; n=9)

(expressed as % G01E response)

Alone: DQ2-A1 (20), DQ2-A2 (55), Omega G1 (50), tTG Gliadin (80), PPD (220), DQ2 binder (0)

G01E+: DQ2-A1 (90), DQ2-A2 (95), Omega G1 (100), tTG Gliadin (120),

25 PPD (280), DQ2 binder (80)

*Effect of alanine and lysine substitution of A-gliadin 57-73 QE65 on IFN $\gamma$  ELISpot responses in individual coeliac subjects (n=8)*

Epitope sequence: QLQFPQPPELPYPQPQS

30

Alanine substitution at positions 57-59 and 72-73 showed little to no decrease in % A-gliadin 57-73 QE65 response. Alanine substitution at positions 60-62 and 68-71 showed moderate decrease in % A-gliadin 57-73 QE65 response.

Alanine substitution at positions 63-67 showed most decrease in % A-gliadin 57-73 QE65 response.

Effect of lysine substitution of A-gliadin 57-73 QE65 on IFN $\gamma$  ELISpot responses in individual coeliac subjects (n=8);

5 Epitope sequence: QLQFPQPELPYPQPQS

Lysine substitution at positions 57-59 and 71-73 showed little to no decrease in % A-gliadin 57-73 QE65 response. Lysine substitution at positions 60-61 and 69-70 showed moderate decrease in % A-gliadin 57-73 QE65 response. Lysine substitution at positions 62-68 showed most decrease in % A-gliadin 57-73 QE65 response.

#### Example 17

Table 24 shows the results of analyses examining the 652 peptides with several patients challenged with wheat or rye.

#### References

1. Molberg O, et al. Nature Med. 4, 713-717 (1998).
2. Quarsten H, et al. Eur. J. Immunol. 29, 2506-2514 (1999).
- 20 3. Greenberg CS et al. FASEB 5, 3071-3077 (1991).
4. Mantzaris G, Jewell D. Scand. J. Gastroenterol. 26, 392-398 (1991).
5. Mauri L, et al. Scand. J. Gastroenterol. 31, 247-253 (1996).
6. Bunce M, et al. Tissue Antigens 46, 355-367 (1995).
7. Olerup O, et al. Tissue antigens 41, 119-134 (1993).
- 25 8. Mullighan CG, et al. Tissue-Antigens. 50, 688-92 (1997).
9. Plebanski M et al. Eur. J. Immunol. 28, 4345-4355 (1998).
10. Anderson DO, Greene FC. The alpha-gliadin gene family. II. DNA and protein sequence variation, subfamily structure, and origins of pseudogenes. Theor Appl Genet (1997) 95:59-65.
- 30 11. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Van der Wal Y, Kooy YMC, Lundin KEA, Koning F, Roepstorff P, Sollid LM, McAdam SN. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a

single deamidated glutamine targeted by tissue transglutaminase. *J Exp Med.* 2000; 191:603-12.

5 12. Vader LW, de Ru A, van der Wal, Kooy YMC, Benckhuijsen W, Mearin ML, Drijfhout JW, van Veelen P, Koning F. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. *J Exp Med* 2002; 195:643-649.

10 13. van der Wal Y, Kooy Y, van Veelan P, Pena S, Mearin L, Papadopoulos G, Koning F. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. *J Immunol.* 1998; 161:1585-8.

14. van der Wal Y, Kooy Y, van Veelan P, Pena S, Mearin L, Molberg O, Lundin KEA, Sollid L, Mutis T, Benckhuijsen WE, Drijfhout JW, Koning F. *Proc Natl Acad Sci USA* 1998; 95:10050-10054.

15 15. Vader W, Kooy Y, Van Veelen P et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. *Gastroenterology* 2002, 122:1729-37

20 16. Arentz-Hansen H, McAdam SN, Molberg O, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadin rich in proline residues. *Gastroenterology* 2002, 123:803-809.

25 Each of the PCT publications, U.S. patents, other patents, journal references, and any other publications cited or referred to herein is incorporated herein by reference in their entirety.

**Table 1. A-Gliadin protein sequence (based on amino acid sequencing)**

	VRVPVPQLQP	QNPSQQQPQE	QVPLVQQQQF	PGQQQQFPPQ	QPYPQPQFPF	SQQPYLQLQP	FPQPQLPYPQ
5	1	11	21	31	41	51	61
	PQSFPQPQPY	PQFPQYSQP	QQPISQQQAQ	QQQQQQQQQQ	QQQILQQILQ	QQLPCMDVV	LQQHNIAHAR
	71	81	91	101	111	121	131
	SQVLQQSTYQ	LLQELCCQHL	WQIPEQSQCQ	AIHNVVHAI	LHQQQKQQQQ	PSSQVSFQQP	LQQYP LGQGS
	141	151	161	171	181	191	201
10	FRPSQQNPQA	QGSVQPQQLP	QFEEIRNLAL	QTLPAMCNVY	IAPYCTIAPF	GIFGTN	
	211	221	231	241	251	261	

**Table 2. Coeliac disease subjects studied**

	Age Sex	Gluten free diet	HLA-DQ2	Bread. challenge	Symptoms with bread
1	64 f	14 yr	Homozygote	3 days	Abdominal pain, lethargy, mouth ulcers, diarrhoea
2	57 m	1 yr	Heterozygote	10 days	Lethargy, nausea
3	35 f	7 yr	Heterozygote	3 days	Nausea
4	36 m	6 wk	Homozygote	3 days	Abdominal pain, mouth ulcers, diarrhoea
5	26 m	19 yr	Heterozygote	3 days	None
6	58 m	35 yr	Heterozygote	3 days	None
7	55 m	1 yr	Heterozygote	3 days	Diarrhoea
8	48 f	15 yr	Homozygote	3 days	Abdominal pain, diarrhoea

Aminoacid at position 65	Range	Mean
Glutamate	(100)	100%
Asparagine	(50-84)	70%
Aspartate	(50-94)	65%
Alanine	(44-76)	64%
Cysteine	(45-83)	62%
Serine	(45-75)	62%
Valine	(24-79)	56%
Threonine	(46-66)	55%
Glycine	(34-47)	40%
Leucine	(8-46)	33%
Glutamine	(16-21)	19%
Isoleucine	(3-25)	14%
Methionine	(3-32)	14%
Phenylalanine	(0-33)	12%
Histidine	(0-13)	8%
Tyrosine	(0-17)	8%
Tryptophan	(0-17)	8%
Lysine	(0-11)	4%
Proline	(0-4)	2%
Arginine	(0-2)	1%

Table 3

pt response	Peptide sequence	Corresponding residues in gliadin protein sequences (Accession no.)
G TG		
13)	QLQPFPPQQLPYPQPQS	57-73 $\alpha$ -Gliadin (T. aestivum) Q41545
100 (100)	QLQPFPPQQLPYPQPQS	57-73 $\alpha$ -Gliadin (T. aestivum) Q41545
7) 53 (44-67)	QLQPFPPQQLPYSQPQP	77-93 $\alpha/\beta$ -Gliadin precursor (Triticum. aestivum) P02863
		76-92 $\alpha$ -Gliadin (T. aestivum) Q41528
		77-93 $\alpha$ -Gliadin storage protein (T. aestivum) Q41531
		57-73 $\alpha$ -Gliadin mature peptide (T. aestivum) Q41533
		77-93 $\alpha$ -Gliadin precursor (T. spelta) Q9ZP09
-20) 83 (61-113)	QLQPFPPQQLPYPQPQP	77-93 $\alpha/\beta$ -Gliadin A-II precursor (T. aestivum) P0472
-33) 83 (74-97)	QLQPFPPQQLPYPQPQL	77-93 $\alpha/\beta$ -Gliadin A-IV precursor (T. aestivum) P04724
		77-93 $\alpha/\beta$ -Gliadin MM1 precursor (T. aestivum) P18573
7) 109 (41-152)	PQLPYPQPQLPYPQPQP	84-100 $\alpha/\beta$ -Gliadin A-IV precursor (T. aestivum) P04724
	PQLPYPQPQLPYPQPQL	84-100 $\alpha/\beta$ -Gliadin MM1 precursor (T. aestivum) P18573
1) 3 (0-7)	QLQPFPPQQLPYSQPQP	77-93 $\alpha/\beta$ -Gliadin A-I precursor (T. aestivum) P04721
		77-93 $\alpha$ -Gliadin (T. aestivum) Q41509
1) 2 (0-7)	QLQPFPPQQLPYSQPQP	77-93 $\alpha$ -Gliadin storage protein (T. aestivum) Q41530
	PQPQPFPPQLPYPQTQP	77-93 $\alpha/\beta$ -Gliadin A-III precursor (T. aestivum) P04723
-40) 24 (11-43)	PQPQPFPPQLPYPQPQS	82-98 $\alpha/\beta$ -Gliadin A-V precursor (T. aestivum) P04725
-30) 19 (11-33)	PQPQPFPPQLPYPQPPP	82-98 $\alpha/\beta$ -Gliadin clone PW1215 precursor (T. aestivum) P04726
		82-98 $\alpha/\beta$ -Gliadin (T. urartu) Q41632
-30) 21 (11-33)	PQPQPFPPQLPYPQPQS	79-95 $\alpha/\beta$ -Gliadin clone PW8142 precursor (T. aestivum) P04726
		79-95 $\alpha$ -Gliadin (T. aestivum) Q41529
		79-95 $\alpha/\beta$ -Gliadin precursor (T. aestivum) Q41546

Table 4

Table 5. T cell epitopes described in coeliac disease

Source	Restriction	Frequency	Sequence*
Ummma-gliadin	DQ2	3/NS (iTCC)	QQLPQPEQPQQSFPEQERPF
pha-gliadin	DQ2	12/17 (iTCL)	QLQFPFQPELPY
pha-gliadin	DQ2	11/17 (iTCL)	PQPELPYPQPELPY
pha-gliadin	DQ2	1/23 (bTCC)	LGQQQPFPPQQPYQPQPF
pha-gliadin	DQ8	3/NS (iTCC)	QQYPSGEGSFQPSQENPQ
utenin	DQ8	1/1 (iTCC)	GQQGYPTSPQQSGQ
pha-gliadin	DQ2	11/12 in vivo	QLQFPFQPELPYPQPQS

\* not stated in original publication, iTCC intestinal T cell clone, iTCL intestinal polyclonal T cell line, bTCC peripheral blood cell clone

All peptides are the products of transglutaminase modifying wild type gluten peptides except the fourth and sixth peptides

Table 6. Relative bioactivity of gliadin T cell epitopes in coeliac PBMC after gluten challenge

Sequence*	ELISpot response as % A-gliadin 57-73 QE65 (all 25mcg/ml)		
	Wild type	Wildtype+tTG	E-substituted
QLPQPEQPQQSFPEQERPF	9 (3)	18 (7)	10 (5)
QLQFPFQPELPY	6 (2)	19 (1)	8 (3)
PQPELPYPQPELPY	13 (6)	53 (8)	48 (9)
LYPSGEGSFQPSQENPQ	10 (3)	9 (3)	14 (8)
QFPFQPELPYPQPQS	18 (7)	87 (7)	100
LPYPQPELPYPQPQP	14 (4)	80 (17)	69 (20)

\* sequence refers that of transglutaminase (tTG) modified peptide and the T cell epitope. Wild type is the unmodified gliadin peptide. Data from 4 subjects. Blank was 5 (1) %.

**Table 7. Polymorphisms of A-gliadin 57-73****A. Sequences derived from Nordic autumn wheat strain Mjoelner**

Alpha-gliadin protein (single letter code refers to Fig. 14 peptides)	Polymorphism
Q41545 A-gliadin (from sequenced protein) 57-73 (A)	QLQPFPPQQLPYQPQPS
Gli alpha 1,6: (EMBL: AJ133605 & AJ133602 58-74) (J)	QQQPFPPQQLPYPQTQP
Gli alpha 3,4,5: (EMBL: AJ133606, AJ133607, AJ133608 57-73) (I)	QLQPFPPQQLSYSQPQP
Gli alpha 7: (EMBL: AJ133604 57-73) (E)	QLQPFPPQQLPYPQPQP
Gli alpha 8, 9, 11: (EMBL: ) (F)	QLQPFPPQQLPYSQPQP
Gli alpha 10: (EMBL: AJ133610 57-73) (D)	QLQPFPPQQLPYLQPS

5 **B. SWISSPROT and TREMBL scan (10.12.99) for gliadins containing the sequence: XXXXXXXXPQLPYXXXXX**

Wheat ( <i>Triticum aestivum</i> unless stated) gliadin accession number	Polymorphism
Q41545 A-gliadin (from sequenced protein) 57-73 (A)	QLQPFPPQQLPYQPQPS
SWISSPROT:	
GDA0_WHEAT P02863 77-93 (F)	QLQPFPPQQLPYSQPQP
GDA1_WHEAT P04721 77-93 (G)	QLQPFLLQQLPYSQPQP
GDA2_WHEAT P04722 77-93 (B)	QLQPFPPQQLPYPQPQP
GDA3_WHEAT P04723 77-93 (O)	POQPFPPQQLPYPQTQP
GDA4_WHEAT P04724 77-93 (C)	QLQPFPPQQLPYPQPQL
GDA4_WHEAT P04724 84-100 (K)	PQLPYPQPQLPYPQPQP
GDA5_WHEAT P04725 82-98 (N)	POQPFPPQQLPYPQPQS
GDA6_WHEAT P04726 82-98 (P)	POQPFPPQQLPYQPFPF
GDA7_WHEAT P04727 79-95 (M)	POQPFLLQQLPYPQPQS
GDA9_WHEAT P18573 77-93 (C)	QLQPFPPQQLPYPQPQL
GDA9_WHEAT P18573 84-100 (L)	PQLPYPQPQLPYPQPQL
GDA9_WHEAT P18573 91-107 (K)	PQLPYPQPQLPYPQPQP
TREMBL	
Q41509 ALPHA-GLIADIN 77-93 (G)	QLQPFLLQQLPYSQPQP
Q41528 ALPHA-GLIADIN 76-92 (F)	QLQPFPPQQLPYSQPQP
Q41529 ALPHA-GLIADIN 79-95 (M)	POQPFLLQQLPYPQPQS
Q41530 ALPHA-GLIADIN 77-93 (H)	QLQPFPSQQLPYSQPQP
Q41531 ALPHA-GLIADIN 77-93 (F)	QLQPFPPQQLPYSQPQP
Q41533 ALPHA-GLIADIN 57-73 (F)	QLQPFPPQQLPYSQPQP
Q41546 ALPHA/BETA-GLIADIN 79-95 (M)	POQPFLLQQLPYPQPQS
Q41632 ALPHA/BETA-TYPE GLIADIN. <i>Triticum urartu</i> 82-98 (P)	POQPFPPQQLPYQPFPF
Q9ZP09 ALPHA-GLIADIN <i>Triticum spelta</i> 77-93 (F)	QLQPFPPQQLPYSQPQP



Table 8. Bioactivity of substituted variants of A-gliadin 57-73 QE65 (Subst) compared to unmodified A-gliadin 57-73 QE65 (G) (mean 100%, 95% CI 97-104) and blank (no peptide, bl) (mean 7.1%, 95% CI: 5.7-8.5)

Subst	%	P vs G	Subst	%	P vs G	Subst	%	P vs G	Subst	%	P vs G	P vs bl
Super-agonists			F62	71	0.001	H62	47	<0.0001	N66	24	<0.0001	
Y61	129	<0.0001	V63	70	<0.0001	G69	47	<0.0001	R64	24	<0.0001	
Y70	129	0.0006	S69	70	<0.0001	N63	47	<0.0001	K63	23	<0.0001	
Agonists			H63	70	<0.0001	H68	47	<0.0001	V65	23	<0.0001	
W70	119	0.017	F63	70	0.008	M68	46	<0.0001	H66	23	<0.0001	
K57	118	0.02	P70	69	<0.0001	D68	46	<0.0001	H67	22	<0.0001	
Y59	117	0.04	T62	69	<0.0001	V69	46	<0.0001	L64	22	<0.0001	
A57	116	0.046	L61	69	<0.0001	G63	45	<0.0001	S66	22	<0.0001	
S70	116	0.045	S61	69	<0.0001	V64	45	<0.0001	F67	21	<0.0001	
K58	114	0.08	T61	69	<0.0001	E61	45	<0.0001	W66	21	<0.0001	
W59	110	0.21	T63	69	<0.0001	A69	43	<0.0001	G64	21	<0.0001	
A73	109	0.24	M66	68	<0.0001	R62	42	<0.0001	G65	21	<0.0001	
I59	108	0.37	T69	67	<0.0001	G68	42	<0.0001	D64	21	<0.0001	
G59	108	0.34	K60	66	<0.0001	A64	42	<0.0001	I65	21	<0.0001	
A58	108	0.35	S62	66	<0.0001	C65	42	<0.0001	M64	20	<0.0001	<0.0001
W60	105	0.62	M61	66	<0.0001	N67	41	<0.0001	G67	19	<0.0001	<0.0001
A59	104	0.61	P61	65	<0.0001	W63	41	<0.0001	T65	19	<0.0001	0.003
K72	104	0.65	M62	64	<0.0001	F69	41	<0.0001	A66	19	<0.0001	<0.0001
S59	103	0.76	Q61	64	<0.0001	N68	40	<0.0001	I64	19	<0.0001	0.0003
K73	102	0.8	G61	64	<0.0001	V66	40	<0.0001	R63	19	<0.0001	<0.0001
A70	102	0.81	A63	64	<0.0001	H69	40	<0.0001	W67	19	<0.0001	<0.0001
Y60	101	0.96	L62	60	<0.0001	M69	40	<0.0001	K68	18	<0.0001	<0.0001
A72	100	0.94	I68	60	<0.0001	R69	40	<0.0001	H64	18	<0.0001	<0.0001
S63	98	0.67	S67	59	<0.0001	W69	40	<0.0001	W64	18	<0.0001	0.0001
K59	96	0.46	N61	59	<0.0001	Q69	39	<0.0001	Q65	18	<0.0001	0.0002
I60	96	0.5	I69	59	<0.0001	L67	38	<0.0001	F64	16	<0.0001	0.0008
G70	95	0.41	V61	58	<0.0001	K69	38	<0.0001	L65	16	<0.0001	0.0022
D65	95	0.44	D61	58	<0.0001	K62	38	<0.0001	N64	16	<0.0001	<0.0001
E70	93	0.27	E60	57	<0.0001	E67	37	<0.0001	F65	16	<0.0001	0.12
I63	92	0.19	A61	57	<0.0001	L69	37	<0.0001	Q67	15	<0.0001	0.0012
S60	92	0.23	Q62	56	<0.0001	S64	36	<0.0001	M65	14	<0.0001	0.015
P59	88	0.08	F68	56	<0.0001	G62	36	<0.0001	D66	14	<0.0001	0.013
M63	87	0.03	N65	56	<0.0001	E69	36	<0.0001	R67	14	<0.0001	0.002
K71	85	0.047	A62	56	<0.0001	E68	36	<0.0001	Non-agonists			
V62	84	0.04	A68	53	<0.0001	V67	35	<0.0001	P63	13	<0.0001	0.012
I70	84	0.04	P66	53	<0.0001	D62	35	<0.0001	E64	12	<0.0001	0.053
I61	83	0.01	R61	53	<0.0001	R68	34	<0.0001	W65	11	<0.0001	0.24
V68	82	0.0045	S68	53	<0.0001	Q66	34	<0.0001	Q64	11	<0.0001	0.15
E59	81	0.01	Y63	52	<0.0001	A67	33	<0.0001	G66	11	<0.0001	0.07
Partial agonists			N69	51	<0.0001	N62	32	<0.0001	R65	11	<0.0001	0.26
W61	79	0.002	E63	51	<0.0001	F66	31	<0.0001	Y67	10	<0.0001	0.13
A60	78	0.002	T64	51	<0.0001	E62	31	<0.0001	E66	10	<0.0001	0.17
Y62	78	0.006	T67	51	<0.0001	D69	31	<0.0001	K66	10	<0.0001	0.21
G60	77	0.003	Y69	50	<0.0001	D67	30	<0.0001	R66	10	<0.0001	0.23
A71	77	0.003	D63	50	<0.0001	M67	29	<0.0001	K67	10	<0.0001	0.11
W62	76	0.0009	A65	49	<0.0001	Y66	28	<0.0001	P65	8	<0.0001	0.57
Q60	76	0.001	K61	49	<0.0001	I67	28	<0.0001	K64	8	<0.0001	0.82
L63	74	0.0002	I66	49	<0.0001	H65	26	<0.0001	K65	8	<0.0001	0.63
I62	74	0.0005	T68	48	<0.0001	P68	26	<0.0001	Y65	7	<0.0001	0.9
K70	74	0.001	S65	48	<0.0001	Y64	25	<0.0001				
H61	72	<0.0001	L68	48	<0.0001	EK65	25	<0.0001				
W68	72	<0.0001	Q68	48	<0.0001	T66	25	<0.0001				

5 Table 9. Antagonism of A-gliadin 57-73 QE65 interferon gamma ELISPOT response by substituted variants of A-gliadin 57-73 QE65 (Subst) (P is significance level in unpaired t-test). Agonist activity (% agonist) of peptides compared to A-gliadin 57-73 QE65 is also shown.

Subst	% Inhibit.	P	% agonist.	Subst	% Inhibit.	P	% agonist.
Antagonists							
65T	28	0.004	19	65M	13	0.16	14
67M	27	0.0052	29	68P	13	0.16	26
64W	26	0.007	18	63R	13	0.19	19
67W	25	0.0088	19	66G	12	0.19	11
Potential antagonists				65Q	12	0.2	18
67I	24	0.013	10	65Y	12	0.22	7
67Y	24	0.013	21	66S	12	0.22	22
64G	21	0.03	21	67F	11	0.25	21
64D	21	0.029	16	66R	10	0.29	10
65L	20	0.046	26	67K	10	0.29	10
66N	20	0.037	24	64F	10	0.29	16
65H	20	0.038	16	65F	9	0.41	16
64N	19	0.05	16	63P	8	0.42	13
64Y	19	0.06	25	65EK	8	0.39	25
66Y	19	0.048	28	64Q	7	0.49	11
64E	19	0.049	12	64I	5	0.6	21
67A	18	0.058	30	68K	5	0.56	19
67H	18	0.052	22	67Q	5	0.61	18
Non-antagonists				65G	5	0.62	15
65V	17	0.07	23	64M	4	0.7	20
65I	17	0.086	21	66H	4	0.66	23
66T	17	0.069	25	66E	3	0.76	10
65W	15	0.11	11	66D	1	0.9	14
67R	15	0.13	14	63K	1	0.88	23
65P	15	0.13	8	64H	1	0.93	18
65K	15	0.11	8	66K	0	0.98	10
66W	15	0.12	21	64K	-2	0.88	8
67G	14	0.14	19	64L	-11	0.26	22
66A	14	0.14	19				

Table 10. Inhibition of A-gliadin 57-73 QE65 interferon gamma ELISPOT response by peptides known to bind HLA-DQ2 (P is significance level in unpaired t-test).

20

Peptide	% Inhibit.	P
TP	31	<0.0001
HLA1a	0	0.95

Table 11. Antagonism of A-gliadin 57-73 QE65 interferon gamma ELISpot response by naturally occurring polymorphisms of A-gliadin 57-73 QE65 (P is significance level in unpaired t-test).

A-gliadin 57-73 QE65 polymorphism	% Inhibit.	P
P04725 82-98 QE90 <u>POQOPFPPELPYPQPQS</u>	19	0.009
Q41509 77-93 QE85 <u>QLQPFLQPELPYSQPQP</u>	11	0.15
Gli $\alpha$ 1,6 58-74 QE66 <u>QPQPFPPELPYPQTQP</u>	11	0.11
P04723 77-93 QE85 <u>POQOPFPPELPYPQTQP</u>	10	0.14
Gli $\alpha$ 3-5 57-73 QE65 <u>QLQPFPQPELSYSQPQP</u>	7	0.34
P02863 77-93 QE85 <u>QLQPFPQPELPYSQPQP</u>	6	0.35
Q41509 77-93 QE85 <u>QLQPFLQPELPYSQPQP</u>	6	0.41
P04727 79-95 QE65 <u>POQOPFLPELPYPQPQS</u>	6	0.39
P04726 82-98 QE90 <u>POQOPFPPELPYPQPPP</u>	5	0.43

**Table 12. Prolamin homologues of A-gliadin 57-73 (excluding alpha/beta-gliadins)**

Prolamin	Accession number	Sequence	% Bioactivity*
Wheat: $\alpha$ -gliadin	A-gliadin (57-73)	QLQPFPPQLPYQPQS	100 (0)
Wheat: $\omega$ -gliadin	AAG17702 (141-157)	PQ.....F.....QSE	32 (6.4)
Barley: C-hordein	Q40055 (166-182)	...QPFP.....F.....Q	2.3 (2.0)
Wheat $\gamma$ -gliadin	P21292 (96-112)	...QTFPQ.....F.....QPQ	2.1 (4.2)
Rye: secalin	Q43639 (335-351)	...QPSPQ.....F.....Q	1.6 (1.4)
Barley: $\gamma$ -hordein	P80198 (52-68)	...QPFPQ.....HQQFP	-1.0 (1.8)
Wheat: LMW glutenin	P16315 (67-83)	LQ...QPIL.....FS...Q...Q	-0.9 (1.0)
Wheat: HMW glutenin	P08489 (718-734)	HGYYPST.....SGQGQRP	6.4 (4.0)
Wheat $\gamma$ -gliadin	P04730 (120-136)	...QCCQQL.....I...QSSRYQ	0.7 (0.9)
Wheat: LMW glutenin	P10386 (183-199)	...QCCQQL.....I...QSSRYE	-0.7 (0.5)
Wheat: LMW glutenin	O49958 (214-230)	...QCCRQL.....I...EQSRYD	-1.1 (0.3)
Barley: B1-hordein	P06470 (176-192)	...QCCQQL.....I...EQFRHE	1.8 (1.4)
Barley: B-hordein	Q40026 (176-192)	...QCCQQL.....ISEQFRHE	0.5 (0.9)

\*Bioactivity is expressed as 100x(spot forming cells with peptide 25mcg/ml plus tTG 8mcg/ml minus blank)/(spot forming cells with A-gliadin 57-73 25mcg/ml plus tTG 8mcg/ml minus blank) (mean (SEM), n=5).

Peptides were preincubated with tTG for 2h 37°C. Note, Q is deamidated in A-gliadin 57-73 by tTG.

**Table 13. Clinical details of coeliac subjects.**

	HLA-DQ	HLA-DQA1 alleles	HLA-DQB1 alleles	Duodenal histology	Gluten free	EMA on gluten (on GFD)
C01	2, 6	102/6, 501	201, 602	SVA	1 yr	+ (-)
C02	2, 2	501	201	SVA	1 yr	+ (-)
C03	2, 5	101/4/5, 501	201, 501	PVA	1 yr	+ (-)
C04	2, 5	101/4-5, 501	201, 501	SVA	7 yr	+ (-)
C05	2, 2	201, 501	201, 202	SVA	4 mo	+ (ND)
C06	2, 2	201, 501	201, 202	SVA	2 yr	+ (-)
C07	2, 8	301-3, 501	201, 302	SVA	1 yr	+ (-)
C08	2, 8	301-3, 501	201, 302/8	SVA	11 yr	ND (-)
C09	2, 8	301-3, 501	201, 302	SVA	29 yr	+ (-)
C10	2, 8	201, 301-3	202, 302	IEL	1 yr	+ (-)
C11	6, 8	102/6, 301-3	602/15, 302/8	IEL	9 mo	- (ND)
C12	8, 7	301-3, 505	302, 301/9-10	SVA	2 yr	- (-)
C13	8, 8	301	302	SVA	1 yr	+ (+)

SVA subtotal villous atrophy, PVA partial villous atrophy, IEL increased intra-epithelial atrophy, GFD gluten-free diet, ND not done.

**Table 14. HLA-DQ2+ Coeliac (C01-6) and healthy control (H01-10) IFN $\gamma$  ELISpot responses to control peptides (20  $\mu$ g/ml) and gliadin (500  $\mu$ g/ml) before and after gluten challenge (sfc/million PBMC minus response to PBS alone)**

Peptide	Healthy Day 0	Healthy Day 6	Coeliac Day 0	Coeliac Day 6
P04722 77-93	0 (-4 to 17)	0 (-5 to 9)	-2 (-3 to 0)	27 (0-100)*
P04722 77-93 + tTG	0 (-5 to 4)	0 (-9 to 3)	0 (-4 to 11)	141 (8 to 290)**
P04722 77-93 QE85	0 (-5 to 5)	0 (-3 to 4)	0 (-6 to 14)	133 (10 to 297)*
P02863 77-93	0 (-4 to 13)	2 (-3 to 5)	-2 (-3 to 2)	8 (-2 to 42)**
P02863 77-93 + tTG	-1 (-5 to 4)	-1 (-4 to 11)	1 (-4 to 6)	65 (8-164)**
P02863 77-93 QE85	0 (-4 to 13)	0 (-4 to 14)	-1 (-4 to 6)	42 (-2 to 176)*
Gliadin chymotrypsin	2 (-5 to 20)	18 (0 to 185)*	20 (11 to 145)	92 (50 to 154)
Gliadin chymotrypsin + tTG	0 (-1 to 28)	16 (-9 to 171)*	55 (29 to 248)	269 (206 to 384)**
Chymotrypsin	0 (-4 to 5)	1 (-4 to 11)	-2 (-5 to 5)	1 (-4 to 8)
Chymotrypsin + tTG	0 (-5 to 8)	6 (0 to 29)	-2 (-3 to 11)	2 (-3 to 18)*
Gliadin pepsin	4 (-4 to 28)	29 (0 to 189)***	44 (10 to 221)	176 (54 to 265)**
Gliadin pepsin + tTG	2 (-3 to 80)	27 (-4 to 241)***	61 (8 to 172)	280 (207 to 406)**
Pepsin	0 (-4 to 10)	0 (-3 to 12)	0 (-2 to 3)	2 (-2 to 8)
Pepsin + tTG	0 (-3 to 8)	0 (-5 to 9)	1 (-6 to 3)	0 (-3 to 14)
PBS alone	4 (0 to 6)	2 (0 to 6)	4 (1 to 12)	4 (0 to 4)
PBS + tTG	3 (0 to 8)	3 (0 to 11)	4 (2 to 10)	4 (2 to 11)

5 Day 6 vs. Day 0: \*P<0.05 \*\*P,0.02, \*\*\*P<0.01 by one-tailed Wilcoxon Matched-Pairs Signed-Ranks test

Table 15. Effect of deamidation by tTG to gliadin (0.5 mg/ml) and A-gliadin 57-73 homologues on IFN $\gamma$  ELISpot responses in HLA-DQ2+ coeliac (C01-6) and healthy control subjects (H01-10) (median ratio tTG:no tTG pretreatment, range)

Peptide	Healthy Day 6	Coeliac Day 0	Coeliac Day 6
Gliadin chymotrypsin	0.94 (0.4-9.0)	2.1 (0.8-6.8)*	3.2 (1.8-4.2)**
Gliadin pepsin	1.4 (0.5-1.4)	1.4 (0.8-4.0)*	1.9 (1.1-4.4)**
P04722 77-93 Q85			6.5 (2.3-12)**
P04722 77-93 E85			0.7 (0.6-1.1)
P02863 77-93 Q85			7.5 (3.9-19.9)**
P02863 77-93 E85			1.0 (0.8-1.2)

tTG>no tTG: \*P<0.05 \*\*P,0.02, \*\*\*P<0.01 by one-tailed Wilcoxon Matched-Pairs Signed-Ranks test





[illegible]

Table 17: tTG-deamidated gliadin peptide pools showing significant increase in IFN gamma responses between Day 0 and Day 6 of gluten challenge in HLA-DQ2 coeliac subjects C01-6 (Day 6 -Day 0 response, and ratio of responses to tTG-deamidated pool and same pool without tTG treatment)

IFN $\gamma$ ELISpot			IFN $\gamma$ ELISpot		
Pool	(Median sfc/million)	tTG: no tTG (Median)	Pool	(Median sfc/million)	tTG: no tTG (Median)
9	59***	1.0	49	46***	1.4
10	116**	1.7	50	50***	4.6
11	24***	2.5	51	40***	1.7
12	133***	1.1	52	30***	3.1
13	26**	2.1	53	27**	1.4
42	30**	1.2	76	17***	1.1
43	32***	1.3	79	20***	0.9
44	24***	1.5	80	83***	1
45	10***	1.1	81	141***	1.1
46	12***	2.1	82	22***	1.5
48	17***	1.4	83	16**	1.8

Day 6 vs. Day 0 \*\*P<0.02, \*\*\*P<0.01 by one-tailed Wilcoxon Matched-Pairs Signed-Ranks test

**Table 18. Coeliac subjects: IFN $\gamma$  ELISpot Responses >10 sfc/million PBMC and >4 x buffer only to tTG-treated Pepset Pools on Day 6 of gluten challenge (sfc/million PBMC) (*italic*: response also present on Day 0):**

**Group 1 – HLA-DQ2 (DQA1\*0501-5, DQB1\*0201/2),**

5 **Group 2 – HLA-DQ2/8 (DQA1\*0501-5, \*0301, and DQB1\*0201/2, \*0302), and**

**Group 3 – HLA-DQ8 (DQA1\*0301, DQB1\*0302) and absent or “incomplete” DQ2 (only DQA1\*0501-5 or DQB1\*0201/2)**

Group 1:							Group 2:			Group 3			
Subject	C01	C02	C03	C04	C05	C06	C07	C08	C09	C10	C11	C12	C13
HLA-DQ	2, 6	2, 2	2, 5	2, 5	2, 2	2, 2	2, 8	2, 8	2, 8	2, 8	6, 8	7, 8	8, 8
Pool 1	.	.	.	.	.	.	23	.	.	.	.	223	.
2	.	.	.	.	.	.	.	.	.	.	.	155	.
3	.	.	.	.	.	.	.	.	.	.	.	41	.
4	11	.	.	.	.	.	.	.	.	22	.	.	.
5	.	.	.	.	.	.	.	.	.	.	.	.	.
6	18	.	.	21	.	.	20	17	.	.	.	.	.
7	.	.	.	.	.	.	.	353	.	.	.	.	.
8	11	64	.	.	.	14	20	480	.	.	.	.	13
9	93	127	.	92	25	.	32	460	.	.	.	.	18
10	175	491	58	200	48	.	84	787	.	.	.	.	.
11	32	118	.	33	14	.	26	27	.	12	.	.	.
12	204	379	54	225	61	.	129	587	.	12	.	.	.
13	93	142	.	29	18	.	.	60	.	.	.	.	11
14	.	45	.	21	.	.	17	.	.	.	.	.	.
15	18	30	.	.	.	.	38	43	.	.	.	.	.
16	.	.	.	.	.	.	.	37	.	.	.	.	.
17	.	.	.	.	.	.	.	.	.	.	.	.	.
18	.	.	.	.	.	.	.	.	.	.	.	.	.
19	11	.	.	.	.	.	.	.	.	.	.	.	.
20	11	215	.	.	.	.	51	167	.	.	.	.	.
21	.	.	.	.	.	.	.	.	11	.	.	.	.
22	.	21	.	.	.	.	.	.	.	12	.	.	.
23	.	18	.	21	.	.	.	.	.	.	.	.	.
24	.	15	.	.	.	.	.	10	.	12	.	.	.
25	.	15	.	.	.	.	.	.	.	12	.	.	.
26	.	18	.	.	.	.	.	13	.	12	.	.	.
27	.	15	.	.	.	.	.	.	.	.	.	.	.
28	.	.	.	.	.	.	.	.	.	.	.	.	11
29	.	.	.	.	.	.	11	.	.	.	.	.	.
30	11	.	.	.	.	.	11	.	.	.	.	.	.
31	.	70	.	.	.	.	.	.	.	.	.	.	.
32	.	18	.	.	.	.	20	.	.	.	.	.	.
33	11	.	.	10	.	.	14	.	11	.	40	.	11
34	.	.	.	.	.	.	.	.	11	.	.	.	.
35	.	.	.	.	.	.	.	.	.	.	.	.	.
36	.	.	.	.	.	.	.	.	.	.	.	.	.
37	.	.	.	23	.	14	.	.	.	.	.	.	.
38	.	24	.	19	.	.	20	.	.	.	.	.	.
39	.	49	.	15	.	.	.	.	11	.	.	.	.
40	.	.	.	.	.	.	14	.	.	.	.	.	.

41		21				
42	39	42		44	21	
43	50	91	13	75	14	
44	32	97	17	96	13	
45		21	10	100	11	
46	14	55		102	18	
47	14	58		38		
48	21	106		60	14	
49	75	170	17	142	30	
50	57	245	23	140	61	27
51	68	106	10	127		
52	43	121		79	13	16
53	36	94		92	29	
54	36			35	11	
55						
56	29					
57		36				
58						
59			10			
60		18		15		
61						
62	14	18		13		
63			10			14
64		15				
65		36		25	23	
66				31	11	10
67				17		
68			19	127		14
69		15		10		
70		12	31		13	10
71	11	21	13			
72						16
73				13		14
74		239				
75						
76	18	21	19	15		
77		88				10
78		18	17	69		
79	11	85		44	29	12
80	132	133	33	240	39	12
81	171	318	113	367	104	12
82	18	300	17	125	32	16
83	14	164		31	21	
P04722 77-93	211	291	75	281	66	
P04722 77-93 E	164	297	108	221	64	10
P04722 77-93 E	161	182	98	256	73	16
P02863 77-93	139	164	35	94	36	
P02863 77-93 E	46	176	19	88	41	
Gliadin+C	214	273	265	360	384	206
Chymotrypsin						18
Gliadin+Pepsin	239	315	269	406	207	292
Pepsin						14

11	63	
190	113	
87	107	
38	110	
63	163	
223	97	
144	353	
202	293	
248	143	
220	267	
175	180	
69	53	
166	27	
		11
20	13	
	53	
11	53	
20		
60		
35	27	
17		
17		
20	20	
14		
11		
254	447	
	13	
44	43	
208	467	
211	530	
241	723	
163	277	
78	740	
84	653	
63	500	
29	603	
23	520	
278	543	17
357	557	

.	.		
12	.		
.	.	21	
.	.		
.	.		
.	.		
.	.	31	
.	.	57	
.	.	39	
.	.		11
.	.	29	
.	.		
.	.		
.	.	19	13
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
28	.		
18	.		
.	II		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	18		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.	12	
.	.		
.	.		
.	.		
12	.	70	
.	.	74	
.	.		
15	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	.		
.	25	527	71
.	.		
42	89	335	87

**Table 19. Deamidated peptides with mean bioactivity > 10% of P04722 E85 (20  $\mu$ g/ml) in HLA-DQ2 coeliac subjects C01-5**

Rank	No.	Sequence	Mean (SEM)	Rank	No.	Sequence	Mean (SEM)
	89	PQLPYPQQLPYPPQQLPY	94 (18)	37	413	SKQPQQPFPQPPQQSHQ	18 (4)
*2	91	PQFFPQLPYPPQQLPYPP	89 (12)	38	380	QPQQPQQPFPQPPQQLPFP	18 (6)
*3	74	MQLQFPFPQQLPYPPQQLPY	88 (14)	39	618	PQQSFSYQQQFPFQQFYPPQ	18 (7)
*4	90	PQLPYPQQLPYPPQPPFR	87 (16)	*40	78	LQLQFPFPQQLPYPPQPPFR	17 (8)
*5	76	LQLQFPFPQQLPYPPQPPFR	85 (15)	41	390	QQTYPQRPPQPPFTQTQQPQQ	17 (9)
6	626	PQQPQQPQQPFPQPPQPPFW	72 (23)	42	348	QQTFFPQQQTFFPQQPQQFP	16 (10)
7	627	QFPFPQQPFPFWQPPQPPFR	66 (30)	43	409	QPQQPFPQLQQPQQPLPQPQ	16 (2)
*8	631	FPQQPQQPFPQQLPFPQQS	61 (12)	44	382	QPPFPQQPQQPFPQTQQPQQ	16 (6)
9	636	PQQPQQPFPQPPQPPVPPQ	51 (10)	45	629	PPFTQTQSFFLPQQPFPPPQ	16 (5)
*10	73	LQLQFPFPQQLPYPPQQLPY	49 (11)	46	643	PLQPQQPFPQQPQQPFPQQP	16 (6)
11	412	SQQPQQPFPQPPQPPQPPQQ	34 (19)	47	389	QQPFPQTQQPQQPFPQPPQQ	16 (6)
12	343	QQPQQPFPQPPQPPQPPQQ	34 (11)	48	350	QQFPFPQQQTFFPQQPQAFP	15 (8)
*13	68	LQLQFPFPQQLPYLPQPPFR	33 (10)	49	65	PPFSQPPYPPQPPFPQPPFP	15 (5)
*14	66	LQLQFPFPQQLPYSPQPPFR	32 (7)	50	349	QQFPFPQQQTFFPQQPQQFP	15 (9)
*15	96	PQFPFPQLPYPPQPPFPQQ	28 (6)	51	610	PWQQQLPFPQQSFSQPPFS	15 (11)
16	393	QLFPFPQQPQQPFPQQPQQ	27 (8)	*52	81	PQPFPFPQLPYPPQTQFPFP	15 (5)
17	355	QAFPQQQTFFPQQPQQPFPQ	27 (15)	*53	75	MQLQFPFPQPPFPQQLPYPPQ	14 (5)
*18	67	LQLQFPFPQQLPYSPQPPFR	26 (6)	54	368	QQFPQPQQPQQPFPQQPQQ	14 (7)
19	335	QQQQPFPQPPQPPQPPFPQ	25 (11)	*55	82	PQPFPFPQPPFPQLPYPPQ	14 (3)
*20	95	PQFPFPQLPYPPQPPFPQQ	24 (6)	*56	80	LQLQFPFPQPPFPQLPYPPQ	14 (4)
21	396	TQQPQQPFPQQPQQPFPQTQ	23 (9)	57	624	FTQPQQPFTHQPPFPQQP	14 (6)
22	609	SCISGLERPQQQLPFPQQS	23 (18)	58	407	QPQQPFPQSPQPPQPPFPQ	14 (5)
23	385	QQPFPFPQPPQLPFPQQPQQ	23 (7)	59	337	QQPFPFPQPPFPQQPQRTI	13 (4)
24	375	PQQPFPFPQPPQPPFPQPPQ	23 (10)	60	634	PQQLQPPFPQLPQQPFPQPP	13 (3)
25	406	QPQQPFPQLQPPQPPFPQ	22 (8)	61	388	QQFYPPQQPQQPFPQTQQPQQ	13 (3)
26	625	PIQPQQPFPQPPQPPQPPFP	22 (9)	62	641	FPELQQPFPQPPQPPFPPLQ	13 (7)
27	378	QQPQQPFPQPPQPPFPQPPQ	22 (10)	63	399	QQPFPQTQQPQQPFPQLQQP	13 (5)
28	371	PQQQFPFPQPPQPPFPQPPQ	22 (10)	64	387	QQTFFPQQPQLPFPQQPQQPP	13 (4)
29	642	PQQPQQPFPQLPQQPFPFPQ	20 (8)	65	628	PFPWQPQQPFPQTQQSFFLQ	12 (4)
30	635	PLQPQQPFPQQPQQPFPFPQ	19 (5)	*66	88	PQFPFPQLPYSPQPPFPPPQ	12 (3)
*31	93	PQFPFPQLPYPPQPPFPPPQ	19 (5)	67	408	QPQQPFPQSKPQQPFPFPQ	12 (5)
32	377	PQQQFPFPQPPQPPFPFPQ	19 (9)	*68	77	LQLQFPFPQPPFPQLPYPPQ	11 (4)
33	411	LQQPQQPFPQPPQPPFPQPPQ	19 (4)	69	370	PQQQFLQPPQPPFPQPPQPPY	11 (5)
34	415	SQQPQQPFPQPPQPPQPPFPQ	18 (5)	*70	79	LQLQFPFPQPPFPQLPYPPQ	11 (5)
*35	94	PQFPFPQLPYPPFPFPFPQ	18 (3)	71	379	QQPQQPFPQPPQPPFPFPQ	11 (5)
36	329	PSGQVQWFPQQPFPQPPFPQ	18 (4)	72	397	PQQPQQPFPQTQQPFPFPQ	11 (3)

\* Indicates homologue of A-gliadin 57-73 with the core sequence PQLP(Y/F)

Table 20. Peptides &gt;10% as bioactive as P04722 QE65 grouped by structure.

Rank	Peptide no. (Pool) Gliadin-subtype	Sequence	IFN $\gamma$ ELISpot response compared to P04722 77-93 QE85: mean (SEM)
<b>Group 1: Homologues of A-gliadin 57-73</b>			
	P04722 77-93	QLQPFPPQQLPYQPQP	
1	89 (12) $\alpha$	PQL...Y.....LPYP	94 (18)
2	91 (12) $\alpha$	PQPFPPQL...Y.....	89 (12)
3	74 (10) $\alpha$	M.....LPY	88 (14)
4	90 (12) $\alpha$	PQL...Y.....PFRP	87 (16)
5	76 (10) $\alpha$	L.....PFR	85 (15)
8	631 (81) $\omega$	FPPQPPQ.....F.....QS	61 (12)
10	73 (10) $\alpha$	L.....LPY	49 (11)
13	68 (9) $\alpha$	L.....L.....PFR	33 (10)
14	66 (9) $\alpha$	L.....S.....PFR	32 (7)
18	67 (9) $\alpha$	L.....S.....QFR	26 (6)
20	95 (13) $\alpha$	PQPFL.....FPPQQ	24 (6)
31	93 (12) $\alpha$	PQFPF.....PFRPQQ	19 (5)
35	94 (12) $\alpha$	PQFPF.....PPFSPQQ	18 (3)
40	78 (10) $\alpha$	L.....R.....PFR	17 (8)
52	81 (11) $\alpha$	PQPQFPF.....T...PFPF	15 (5)
53	75 (10) $\alpha$	MQLPFPFPQPFF.....	14 (5)
55	82 (11) $\alpha$	PQPFPFPQPFPF.....	14 (3)
56	80 (10) $\alpha$	LQLQFPFPQPFPF.....	14 (4)
66	88 (11) $\alpha$	PQFPF.....S.....PFRPQQ	12 (3)
68	77 (10) $\alpha$	LQLQFPFPQPFPF.....	11 (4)
70	79 (10) $\alpha$	LQLQFPFPQPFPF.....	11 (5)
<b>Group 2: Homologues of peptide 626</b>			
		QQPFPPQPPFP	
6	626(80) $\omega$	PQQPQQP.....W	72 (23)
7	627(80) $\omega$	.....WQPQQPFPQ	66 (30)
9	636(81) $\omega$	PQQP.....I...VQPQ	51 (10)
11	412(53) $\gamma$	SQQP.....Q.....PQQ	34 (19)
33	411(53) $\gamma$	LQQP.....Q.....PQQ	19 (4)
36	329(42) $\gamma$	PSGQVQWPQ.....	18 (4)
41	390(50) $\gamma$	QQTYPQRP.....T.....QQ	17 (9)
59	337(43) $\gamma$	Q.....CQQPQRTI	13 (4)
61	388(50) $\gamma$	QQPYPQQP.....T.....QQ	13 (3)
<b>Group 3: Homologues of peptide 355</b>			
		FPQPQQTFPHQPQQQFP	
17	355(46) $\gamma$	QA.....Q	27 (15)
42	348(45) $\gamma$	QQT.....	16 (10)
48	350(45) $\gamma$	QQI.....A.....	15 (8)
50	349(45) $\gamma$	QQI.....	15 (9)
<b>Group 4: Homologues of Peptide 396</b>			
		QQPFPQQPQQPFP	
21	396(51) $\gamma$	TQQP.....QTQ	23 (9)
27	378(49) $\gamma$	QQP.....QPQQ	22 (10)
28	371(48) $\gamma$	PQQQFIQP.....TY	22 (10)
29	642(82) $\omega$	PQQP.....L.....QQP	20 (8)
30	635(81) $\omega$	PLQP.....QPQ	19 (5)
44	382(49) $\gamma$	.....QTQQPQQ	16 (6)
45	629(81) $\omega$	PFPQT.....S.....L.....QQ	16 (5)
46	643(82) $\omega$	PLQP.....QQP	16 (6)
60	634(81) $\omega$	PQQL.....L.....QQP	13 (3)
64	387(50) $\gamma$	.....T.....L.....QQPQQPF	13 (4)
62	641(82) $\omega$	FPFL.....I.....LQP	13 (7)

Group 5: Homologues of Peptide 343 (overlap Groups 2 and 4)			
		QQFFPQPQQPQLPFPQ	
12	343(44) $\gamma$	QQP.....Q	34 (11)
16	393(51) $\gamma$	QLPFPQQP.....	27 (8)
19	335(43) $\gamma$	QQ.....Q.....PQ	25 (11)
23	385(50) $\gamma$	.....QPQQ	23 (7)
24	375(48) $\gamma$	P.....Q.....PQQ	23 (10)
25	406(52) $\gamma$	QP.....L.....Q.....PQ	22 (8)
32	377(49) $\gamma$	P.....Q.....Q.....QPQ	19 (9)
34	415(53) $\gamma$	SQQP.....QS.....	18 (5)
37	413(53) $\gamma$	SKQP.....QS.....	18 (4)
38	380(49) $\gamma$	QPQQP.....	18 (6)
43	409(53) $\gamma$	QP.....L.....Q...L.....PQ	16 (2)
47	389(50) $\gamma$	.....T.....Q.....QPQQ	16 (6)
58	407(52) $\gamma$	QP.....S.....Q.....PQ	14 (5)
63	399(51) $\gamma$	.....T.....Q.....LQQP	13 (5)
67	408(52) $\gamma$	QP.....SK.....Q.....PQ	12 (5)
71	379(49) $\gamma$	QQP.....Q.....Q.....P	11 (5)
72	397(51) $\gamma$	PQQP.....T.....Q.....	11 (3)
Group 6: Peptide 625			
		PIQPQQPFPQQP	
26	625(80) $\omega$	.....QQPQQPFP	22 (9)
57	624(80) $\omega$	FTQPQQPT.....	14 (6)
65	628(80) $\omega$	PF...W.....TQQSFPLQ	12 (4)
Group 7: Peptide 618			
39	618(79) $\omega$	PQQSFSYQQQFPQQPYPQQ	18 (7)

**Table 21. Bioactivity of individual tTG-deamidated Pools 1-3 peptides in Subject C12:**

No.	Sequence	%	No.	Sequence	%
8	AVRWPVPQ <u>LOPONPSOOQPO</u>	100	23	<u>LOPONPSOOQPO</u> EQVPLMQQ	26
		85			18
5	MVRVTVPQ.....	82	14	.....EQVPLVQQ	18
6	AVRVSPVQ.....	77	15	.....H.....EQVPLVQQ	18
3	MVRVPVPQ.....H.....	67	17	.....KQVPLVQQ	13
1	AVRFPVPQ.....L.....	59	16	.....D.....EQVPLVQQ	8
2	MVRVPVPQ.....	49	13	.....EQVPLVQQ	5
9	AVRVVPVQ.....L.....	49	22	.....K.....EQVPLVQQ	3
7	AVRVVPVQ.....	33	18	.....L.....EQVPLVQE	3
10	MVRVPVPQ.....L.....		19	.....L.....EQVPLVQE	
4	MVRVPMPQ.....D.....	15	20	P.....P.....GQVPLVQQ	0
12	AVRVVPVQ.....K.....	8	21	P.....P.....RQVPLVQQ	0
11	AVRVVPVQP.....P.....	0			
Core sequence of epitope is underlined. Predicted deamidated sequence is: LQPENPSQEQPE					



Table 22: Phylogenetic groupings of wheat (*Triticum aestivum*) gliadins

Alpha/beta-gliadins (n=61)			
A1a1	AAA96525, EEWTA, P02863	A1b13	B22364, P04271
A1a2	CAB76963	A2a1	AAB23109, CAA35238, P18573, S10015
A1a3	AAA96276	A2a2	CAB76964
A1a4	CAA26384, S07923	A2b1	P04724, T06500, AAA348282
A1a5	AAA34280	A2b2	D22364
A1a6	P04728	A2b3	P04722, T06498, AAA34276
A1b1	CAB76962	A2b4	C22364
A1b2	CAB76961	A2b5	CAB76956
A1b3	BAA12318	A3a1	AAA34277, CAA26383, P04726, S07361
A1b4	CAB76960	A3a2	I307187B, A27319, S13333
A1b5	CAB76958	A3b1	AAA96522
A1b6	CAB76959	A3b2i	AAA34279, P04727,
A1b7	CAB76955	A3b2ii	CAA26385, S07924
A1b8	AAA96524	A3b3	A22364, AAA34278, AAB23108, C61218, P04725
A1b9	CAA10257	A4a	P04723, AAA34283, T06504
A1b10	AAA96523, T06282	A4b	E22364
A1b11	AAA17741, S52124	A4c	CAB76957
A1b12	AAA34281	A4d	CAB76954
Gamma-gliadins (n=47)		Gamma-gliadins	
GI1a	P08079, AAA34288, PS0094, CAC11079, AAD30556, CAC11057, CAC11065, CAC11056	GI5a	AAK84774, AAK84772
GI1b	CAC11089, CAC11064, CAC11080, CAC11078, AAD30440	GI5b	AAK84773
GI1c	CAC11087	GI5c	AAK84776
GI1d	CAC11088	GI6a	JA0153, P21292, AAA34272, I507333A
GI1e	CAC11055	GI6b	AAK84777
GI2a	JS0402, P08453, AAA34289	GI6c	I802407A, AAK84775, AAK84780
GI2b	AAF42989, AAK84779, AAK84779	GI7	AAB31090
GI3a	AAK84778	GI1a	AAA34287, P04730, S07398
GI3b	CAB75404	GI1b	I209306A
GI3c	BAA11251	GI11a	P04729
GI4	EEWTG, P06659, AAA34274	GI11b	AAA34286
Omega-gliadins (n=3)			
O1a	AAG17702		
O1b	P02865		
O1c	A59156		

**Table 23. Synthetic peptides spanning all known wheat gliadin 12mers**

Protein	Position*	Sequence	No.	Protein	Position*	Sequence	No.
<b>POOL 1</b>				<b>POOL 43</b>			
A1A1	20	AVRF PVPQ LQPQ NPSQ QLPQ		1	G12A 33	QQQL VPQL QQPL SQQP QQTf	331
A1A2	20	MVRV PVPQ LQPQ NPSQ QQPQ		2	G13A 33	QQQP FPQP HQPF SQQP QQTf	332
A1B1	20	MVRV PVPQ LQPQ NPSQ QHPQ		3	G14 33	QQQP FLQP HQPF SQQP QQIF	333
A1B2	20	MVRV PMPQ LQPQ DPSQ QQPQ		4	G15A 33	QQQQ PFPQ PQQP FSQQ PQQI	334
A1B7	20	MVRV TVPQ LQPQ NPSQ QQPQ		5	G15B 33	QQQQ PFPQ PQQP QQPF PQPQ	335
A1B8	20	AVRV SVFQ LQPQ NPSQ QQPQ		6	G15C 33	QQQP FRQP QQPF YQQP QHTF	336
A1B8	20	AVRV PVPQ LQPQ NPSQ QQPQ		7	G16A 33	QQQP FPQP QQPF CQQP QRTI	337
A1B10	20	AVRW PVPQ LQPQ NPSQ QQPQ		8	G16C 42	QQQP FPQP QQPF CEQP QRTI	338
<b>POOL 2</b>				<b>POOL 44</b>			
A2B3	20	AVRV PVPQ LQLQ NPSQ QQPQ		9	G11A 42	HQPF SQQP QQTf PQPQ QTFF	339
A2B5	20	MVRV PVPQ LQLQ NPSQ QQPQ		10	G12A 42	QQPL SQQP QQTf PQPQ QTFF	340
A3A1	20	AVRV PVPQ PQQP NPSQ PQQP		11	G14 42	HQPF SQQP QQIF PQPQ QTFF	341
A3B1	20	AVRV PVPQ LQPK NPSQ QQPQ		12	G15A 42	QQPF SQQP QQIF PQPQ QTFF	342
A1A1	28	LQPQ NPSQ QLPQ EQVP LVQQ		13	G15B 42	QQPQ QQPF PQPQ PQLP FPQQ	343
A1A2	28	LQPQ NPSQ QQPQ EQVP LVQQ		14	G15C 42	QQPF YQQP QHTF PQPQ QTCP	344
A1B1	28	LQPQ NPSQ QHPQ EQVP LVQQ		15	G16A 42	QQPF CQQP QRTI PQPH QTFF	345
A1B2	28	LQPQ DPSQ QQPQ EQVP LVQQ		16	G16B 42	QQPF CQQP QQTf PQPH QTFF	346
<b>POOL 3</b>				<b>POOL 45</b>			
A2B1	28	LQPQ NPSQ QQPQ KQVP LVQQ		17	G16C 42	QQPF CEQP QRTI PQPH QTFF	347
A2B3	28	LQLQ NPSQ QQPQ EQVP LVQE		18	G11A 50	QQTf PQPQ QTFF HQPQ QQFF	348
A2B5	28	LQLQ NPSQ QQPQ EQVP LVQE		19	G14 50	QQIF PQPQ QTFF HQPQ QQFF	349
A3A1	28	PQPQ NPSQ PQQP GQVP LVQQ		20	G15A 50	QQIF PQPQ QTFF HQPQ QAFF	350
A3A2	28	PQPQ NPSQ PQQP RQVP LVQQ		21	G16A 50	QRTI PQPH QTFF HQPQ QTFF	351
A3B1	28	LQPK NPSQ QQPQ EQVP LVQQ		22	G15A 58	QTFF HQPQ QAFF PQPQ TFFH	352
A4A	28	LQPQ NPSQ QQPQ EQVP LMQQ		23	G16A 58	QTFF HQPQ QTFF PQPQ TYPH	353
A1A1	36	QLPQ EQVP LVQQ QQFL GQQQ		24	G16C 58	QTFF HQPQ QTFF QPEQ TYPH	354
<b>POOL 4</b>				<b>POOL 46</b>			
A1B1	36	QHPQ EQVP LVQQ QQFL GQQQ		25	G15A 66	QAFF PQPQ TFFH PQPQ QFPQ	355
A1B2	36	QQPQ EQVP LVQQ QQFL GQQQ		26	G15C 66	QHTF PQPQ QTCP HQPQ QQFF	356
A1B12	36	QQPQ EQVP LVQQ QQFL GQQQ		27	G16A 66	QTFF PQPQ TYPH PQPQ QFPQ	357
A2A1	36	QQPQ EQVP LVQQ QQFF GQQQ		28	G16C 66	QTFF QPEQ TYPH PQPQ QFPQ	358
A2B1	36	QQPQ KQVP LVQQ QQFF GQQQ		29	G11A 73	QTFF HQPQ QQFF PQPQ PQPQ	359
A2B3	36	QQPQ EQVP LVQE QQFQ GQQQ		30	G12A 73	QTFF HQPQ QQVP PQPQ PQPQ	360
A3A1	36	PQPQ GQVP LVQQ QQFF GQQQ		31	G13A 73	QTFF HQPQ QQFS PQPQ PQPQ	361
A3A2	36	PQPQ RQVP LVQQ QQFF GQQQ		32	G15C 73	QTCP HQPQ QQFF PQPQ PQPQ	362
<b>POOL 5</b>				<b>POOL 47</b>			
A4A	36	QQPQ EQVP LMQQ QQQF PGQQ		33	G16A 73	QTYF HQPQ QQFF QTQQ PQPQ	363
A1A1	44	LVQQ QQFL GQQQ PFFP QQPY		34	G11A 81	QQFF PQPQ PQPQ FLQP QQPF	364
A1B1	44	LVQQ QQFL GQQQ SFFP QQPY		35	G12A 81	QQVP PQPQ PQPQ FLQP QQPF	365
A1B12	44	LVQQ QQFL GQQQ PFFP QQPY		36	G13A 81	QQFS PQPQ PQPQ FIQP QQPF	366
A2A1	44	LVQQ QQFF GQQQ PFFP QQPY		37	G14 81	QQFF PQPQ PQPQ FLQP RQPF	367
A2B3	44	LVQE QQFQ GQQQ PFFP QQPY		38	G15A 81	QQFF PQPQ PQPQ FPQP PQPQ	368
A3A1	44	LVQQ QQFF GQQQ QQFF QQPY		39	G16A 81	QQFF QTQQ PQPQ FPQP QQTf	369
A4A	44	LMQQ QQQF PGQQ EQFP PQQP		40	G11A 89	PQQQ FLQP QQPF PQPQ QQPY	370
<b>POOL 6</b>				<b>POOL 48</b>			
A4D	44	LMQQ QQQF PGQQ ERFP PQQP		41	G13A 89	PQQQ FIQP QQPF PQPQ QQTY	371
A1A1	53	GQQQ PFFP QQPY PQPQ PFFS		42	G13B 89	PQQQ FIQP QQPF QTYF QRPQ	372
A1A3	53	GQQQ PFFP QQPY PQPQ FPSQ		43	G14 89	PQQQ FLQP RQPF PQPQ QQPY	373
A1B1	53	GQQQ SFFP QQPY PQPQ PFFS		44	G15A 89	PQQP FPQP PQPQ FPQP QQPF	374
A2B1	53	GQQQ PFFP QQPY PQPQ PFFS		45	G15C 89	PQQP FPQP QQPF PQPQ QQPF	375
A3A1	53	GQQQ QQFF QQPY PQPQ PFFS		46	G16A 89	PQQP FPQP QQTf PQPQ QLPF	376
A4A	53	GQQE RFFP QQPY PHQQ PFFS		<b>POOL 49</b>			
A4D	53	GQQE RFFP QQPY PHQQ PFFS		47	G15A 97	PQQQ FPQP QQPQ QQPF QQPQ	377
<b>POOL 7</b>				48	G15A 105	QQPQ QQPF QQPQ QQPF PQPQ	378
A1A1	61	QQPY PQPQ PFFS QLPY LQLQ		49	G15A 113	QQPQ QQPF PQPQ PQPQ FPQP	379
A1A3	61	QQPY PQPQ FPSQ LPYL QLPQ		50	G15A 121	QPQQ PQPQ FPQP QQPQ LPFF	380
A1B1	61	QQPY PQPQ PFFS QQPY LQLQ		51	G11A 126	QQPF PQPQ QQPY PQPQ QQPF	381
A2B1	61	QQPY PQPQ PFFS QQPY MQLQ		52	G12A 126	QQPF PQPQ QQPF PQTQ PQPQ	382
A4A	61	QQPY PHQQ PFFS QQPY PQPQ		53	G13A 126	QQPF PQPQ QQTY PQRP QQPF	383
A1A1	69	PFFS QLPY LQLQ PFPQ PQLP		54	G14 126	RQPF PQPQ QQPY PQPQ QQPF	384
A1B1	69	PFFS QQPY LQLQ PFPQ PQLP		<b>POOL 50</b>			
A1B10	69	PFFS QQPY LQLQ PFSQ PQLP		55	G15A 126	QQPF PQPQ QPQL PFPQ PQPQ	385
<b>POOL 8</b>				56	G15C 126	QQPF PQPQ QAQL PFPQ PQPQ	386
A1B11	69	PFFS QQPY LQLQ PFLQ PQLP		57	G16A 126	QQTf PQPQ QLPF PQPQ QQPF	387
A1B12	69	PFFS QQPY LQLQ PFLQ PQLP		58	G11A 134	QQPY PQPQ QQPF PQTQ PQPQ	388
A2A1	69	PFFS QQPY LQLQ PFPQ PQLP		59	G12A 134	QQPF PQTQ PQPQ PFPQ PQPQ	389
A2B1	69	PFFS QQPY MQLQ PFPQ PQLP		60	G13A 134	QQTY PQRP QQPF PQTQ PQPQ	390
A2B2	69	PFFS QQPY MQLQ PFPQ PQLP		61	G15A 134	QPQL PFPQ PQPQ PQPQ PFPQ	391

A2B4 69 PFPS QOPY LQLQ PFPQ PQFF  
 A2B5 69 PFPS QOPY LQLQ PFPQ PQLP  
 A4A 69 PFPS QOPY PQPQ PFPQ QLPY  
 POOL 9  
 A4B 69 PFPS QOPY PQPQ PFPQ PQFF  
 A1A1 77 LQLQ PFPQ PQLP YSQP QPFR  
 A1A4 77 LQLQ PFPQ PQLP YSQP QPFR  
 A1B1 77 LQLQ PFPQ PQLP YLQP QPFR  
 A1B4 77 LQLQ PFPQ PQLS YSQP QPFR  
 A1B10 77 LQLQ PFSQ PQLP YSQP QPFR  
 A1B11 77 LQLQ PFLQ PQLP YSQP QPFR  
 A1B12 77 LQLQ PFLQ PQPF PPQL PYSQ  
 POOL 10  
 A2A1 77 LQLQ PFPQ PQLP YPQP QLPY  
 A2B1 77 MQLQ PFPQ PQLP YPQP QLPY  
 A2B2 77 MQLQ PFPQ PQPF PPQL PYPQ  
 A2B3 77 LQLQ PFPQ PQLP YPQP QPFR  
 A2B4 77 LQLQ PFPQ PQPF PPQL PYPQ  
 A2B5 77 LQLQ PFPQ PQLP YPQP QPFR  
 A3B1 77 LQLQ PFPQ PQPF LPQL PYPQ  
 A3B3 77 LQLQ PFPQ PQPF PPQL PYPQ  
 POOL 11  
 A4A 77 PQPQ PFPQ QLPY PQTQ PFPQ  
 A4B 77 PQPQ PFPQ PQPF PPQL PYPQ  
 A1A1 85 PQLP YSQP QPFR PQQP YPQP  
 A1A6 85 PQLP YSQP QPFR PQQP YPQP  
 A1B1 85 PQLP YLQP QPFR PQQP YPQP  
 A1B4 85 PQLS YSQP QPFR PQQP YPQP  
 A1B6 85 PQLS YSQP QPFR PQQL YPQP  
 A1B12 85 PQPF PPQL PYSQ PQPF RPQQ  
 POOL 12  
 A2A1 85 PQLP YPQP QLPY PQPQ LPYP  
 A2B1 85 PQLP YPQP QLPY PQPQ PFRP  
 A2B2 85 PQPF PPQL PYPQ PQLP YPQP  
 A2B3 85 PQLP YPQP QPFR PQQP YPQP  
 A2B4 85 PQPF PPQL PYPQ PQPF RPQQ  
 A3A1 85 PQPF PPQL PYPQ PFPQ SPQQ  
 POOL 13  
 A3B1 85 PQPF LPQL PYPQ PQSF PPQQ  
 A3B3 85 PQPF PPQL PYPQ PQSF PPQQ  
 A4A 85 QLPY PQTQ PFPQ QOPY PQPQ  
 A4B 85 PQPF PPQL PYPQ TQPF PPQQ  
 A2A1 106 LPYP PQPQ FRPQ QPYP QSQP  
 A2B1 106 LPYP PQPQ FRPQ QPYP QPQP  
 A3A1 106 LPYP PFPQ FSPQ QPYP QPQP  
 A3B1 106 LPQL PYPQ PQSF PPQQ PYPQ  
 POOL 14  
 A4A 106 PPQL PYPQ TQPF PPQQ PYPQ  
 A1A1 112 QPFR PQQP YPQP PQPQ SQPQ  
 A1B6 112 QPFR PQQL YPQP PQPQ SQPQ  
 A2A1 112 QPFR PQQP YPQS QPQP SQPQ  
 A2B1 112 QPFR PQQS YPQP PQPQ SQPQ  
 A3A1 112 PFPQ PQQP YPQP PQPQ PQPQ  
 A3B1 112 QSPF PQQP YPQP RPKY LQPQ  
 A3B2 112 QSPF PQQP YPQP RPYM LQPQ  
 POOL 15  
 A3B3 112 QSPF PQQP YPQP PQPQ LQPQ  
 A4A 112 QPFP PQQP YPQP PQPQ PQPQ  
 A1A1 120 YPQP PQPQ SQPQ QPIS QQQQ  
 A1B3 120 YPQP PQPQ SQPQ QPIS QQQQ  
 A2A1 120 YPQS PQPQ SQPQ QPIS QQQQ  
 A3A1 120 YPQP PQPQ PQPQ QPIS QQQQ  
 A3B1 120 YPQP RPKY LQPQ QPIS QQQQ  
 A3B2 120 YPQP RPYM LQPQ QPIS QQQQ  
 POOL 16  
 A3B3 120 YPQP PQPQ LQPQ QPIS QQQQ  
 A1A1 128 SQPQ QPIS QQQQ QQQQ QQQQ  
 A1B3 128 SQPQ QPIS QQQQ QQQQ QQQQ  
 A3A1 128 PQPQ QPIS QQQQ QQQQ QQQQ  
 A1A1 138 QQQQ QQQQ QQQQ QQQQ ILQQ  
 A1A6 138 QQQQ QQQQ QQQQ QQQQ ILQQ  
 A1B11 138 QQQQ QQQQ QQQQ QQQQ IIQQ

62 G15C 134 QAQL PFPQ PQPQ PLPQ PQQP 392  
 63 POOL 51  
 64 G16A 134 QLFF PQQP QPFF PQPQ PQPQ 393  
 G12A 142 PQPQ PFPQ PQPQ PFPQ TQQP 394  
 65 G12A 150 PQPQ PFPQ TQQP QPFF PQQP 395  
 66 G12A 158 TQQP QPFF PQQP QPFF PQTQ 396  
 67 G12A 166 PQPQ QPFF PQTQ PQPQ PFPQ 397  
 68 G11A 170 QPFF PQTQ PQPQ LFPQ SQQP 398  
 69 G12A 170 QPFF PQTQ PQPQ PFPQ LQQP 399  
 70 G13A 170 QPFF PQTQ PQPQ PFPQ SQQP 400  
 71 POOL 52  
 72 G14 170 QPFF PQTQ PQPQ PFPQ SKQP 401  
 G15A 170 QPFF PQPQ PQPQ PFPQ LQQP 402  
 73 G15C 170 QPPL PQPQ PQPQ PFPQ SQQP 403  
 74 G16A 170 QPFF PQPQ PQPQ PFPQ SQQP 404  
 75 G11A 178 PQPQ LFPQ SQQP QQQF SQPQ 405  
 76 G12A 178 PQPQ PFPQ LQQP QPFF PQPQ 406  
 77 G13A 178 PQPQ PFPQ SQQP QPFF PQPQ 407  
 78 G14 178 PQPQ PFPQ SKQP QPFF PQPQ 408  
 79 POOL 53  
 80 G15A 178 PQPQ PFPQ LQQP QPPL PQPQ 409  
 G11A 186 SQQP QQQF SQPQ QPFF PQPQ 410  
 81 G12A 186 LQQP QPFF PQPQ QQLP PQPQ 411  
 82 G13A 186 SQQP QPFF PQPQ QPFF PQPQ 412  
 83 G14 186 SKQP QPFF PQPQ PQPQ SFPQ 413  
 84 G15A 186 LQQP QPPL PQPQ PQPQ PFPQ 414  
 85 G15C 186 SQQP QPFF PQPQ PQPQ SFPQ 415  
 86 G11A 194 SQPQ QPFF PQPQ PQQS FFPQ 416  
 87 POOL 54  
 88 G12A 194 PQPQ QQLP PQPQ PQQS FFPQ 417  
 G13A 194 PQPQ QPFF PQPQ PQQS FFPQ 418  
 89 G14 194 PQPQ PQPQ SFPQ QPIS LIQP 419  
 90 G15A 194 PQPQ PQPQ PFPQ QQQP LIQP 420  
 91 G15C 194 PQPQ PQPQ SFPQ QQQP LIQP 421  
 92 G11A 202 PQPQ PQQS FFPQ QPFF IQPS 422  
 93 G12A 202 PQPQ PQQS FFPQ QPFF IQPS 423  
 94 G13A 202 PQPQ PQQS FFPQ QPIS IQQS 424  
 POOL 55  
 95 G11A 210 FFPQ QPFF IQPS LQQQ VNPC 425  
 96 G12A 210 FFPQ QPFF IQPS LQQQ LNPC 426  
 97 G13A 210 FFPQ QPIS IQQS LQQQ LNPC 427  
 98 G15A 210 FFPQ QPPL IQPQ LQQQ MNPC 428  
 99 G16A 210 FFPQ QPPL IQSF LQQQ MNPC 429  
 100 G11A 218 IQPS LQQQ VNPC KNFL LQQC 430  
 101 G12A 218 IQPS LQQQ LNPC KNIL LQQS 431  
 102 G13A 218 IQQS LQQQ LNPC KNFL LQQC 432  
 POOL 56  
 103 G15A 218 IQPQ LQQQ MNPC KNYL LQQC 433  
 104 G16A 218 IQSF LQQQ MNPC KNFL LQQC 434  
 105 G11A 226 VNPC KNFL LQQC KPVS LVSS 435  
 106 G12A 226 LNPC KNIL LQQC KPVS LVSS 436  
 107 G13A 226 LNPC KNFL LQQC KPVS LVSS 437  
 108 G15A 226 MNPC KNYL LQQC NPVS LVSS 438  
 109 G16A 226 MNPC KNFL LQQC NPVS LVSS 439  
 110 G11A 234 LQQC KPVS LVSS LWSM IWPQ 440  
 POOL 57  
 111 G12A 234 LQQS KPVS LVSS LWSI IWPQ 441  
 112 G13A 234 LQQC KPVS LVSS LWSM ILPR 442  
 113 G15A 234 LQQC NPVS LVSS LVSM ILPR 443  
 114 G16A 234 LQQC NPVS LVSS LVSI ILPR 444  
 115 G11A 242 LVSS LWSM IWPQ SDCQ VMRQ 445  
 116 G12A 242 LVSS LWSI IWPQ SDCQ VMRQ 446  
 117 G13A 242 LVSS LWSM ILPR SDCQ VMRQ 447  
 118 G14 242 LVSS LWSI ILPR SDCQ VMRQ 448  
 POOL 58  
 119 G15A 242 LVSS LVSM ILPR SDCK VMRQ 449  
 120 G15C 242 LVSS LVSM ILPR SDCQ VMQ 450  
 121 G16A 242 LVSS LVSI ILPR SDCQ VMQ 451  
 122 G11A 250 IWPQ SDCQ VMRQ QCCQ QLAQ 452  
 123 G13A 250 ILPR SDCQ VMRQ QCCQ QLAQ 453  
 124 G14 250 ILPR SDCQ VMRQ QCCQ QLAQ 454  
 125 G15A 250 ILPR SDCK VMRQ QCCQ QLAQ 455

A2A1 138 QQQQ QQQQ QQKQ QQQQ QQQI  
 POOL 17  
 A4B 139 AQQQ QQQQ QQQQ QQQQ TLQQ  
 A1A1 146 QQQQ QQQQ ILQQ ILQQ QLIP  
 A1A6 146 QQQQ QEQQ ILQQ ILQQ QLIP  
 A1B6 146 QQQQ QEQQ ILQQ MLQQ QLIP  
 A1B10 146 QQQQ QEQQ ILQQ ILQQ QLTP  
 A1B11 146 QQQQ QQQQ ILQQ ILQQ QLIP  
 A2A1 146 QQKQ QQQQ QQQI LQQI LQQQ  
 A3A2 146 QQQQ QQQQ ILPQ ILQQ QLIP  
 POOL 18  
 A4A 146 QQQQ QQQQ TLQQ ILQQ QLIP  
 A1A1 163 ILQQ ILQQ QLIP CMDV VLQQ  
 A1B6 163 ILQQ MLQQ QLIP CMDV VLQQ  
 A1B10 163 ILQQ ILQQ QLTP CMDV VLQQ  
 A2B1 163 ILQQ ILQQ QLIP CRDV VLQQ  
 A3A2 163 ILPQ ILQQ QLIP CRDV VLQQ  
 A4A 163 TLQQ ILQQ QLIP CRDV VLQQ  
 A1A1 171 QLIP CMDV VLQQ HNIA HGRS  
 POOL 19  
 A1A3 171 QLIP CMDV VLQQ HNKA HGRS  
 A1B2 171 QLIP CMDV VLQQ HNLA HGRS  
 A1B7 171 QLIP CMDV VLQQ HNIV HGRS  
 A1B10 171 QLTP CMDV VLQQ HNIA HGRS  
 A1B11 171 QLIP CMDV VLQQ HNIV HGKS  
 A2A1 171 QLIP CRDV VLQQ HSIA YGSS  
 A2B1 171 QLIP CRDV VLQQ HSIA HGSS  
 A2B3 171 QLIP CRDV VLQQ HNIA HGSS  
 POOL 20  
 A3A1 171 QLIP CRDV VLQQ HNIA HARS  
 A3B1 171 QLIP CRDV VLQQ HNIA HASS  
 A1A1 179 VLQQ HNIA HGRS QVLQ QSTY  
 A1A3 179 VLQQ HNKA HGRS QVLQ QSTY  
 A1B2 179 VLQQ HNLA HGRS QVLQ QSTY  
 A1B7 179 VLQQ HNIV HGRS QVLQ QSTY  
 A1B10 179 VLQQ HNIA HGRS QVLQ QSTY  
 A1B11 179 VLQQ HNIV HGKS QVLQ QSTY  
 POOL 21  
 A2A1 179 VLQQ HSIA YGSS QVLQ QSTY  
 A2B1 179 VLQQ HSIA HGSS QVLQ QSTY  
 A2B3 179 VLQQ HNIA HGSS QVLQ ESTY  
 A3A1 179 VLQQ HNIA HARS QVLQ QSTY  
 A3B1 179 VLQQ HNIA HASS QVLQ QSTY  
 A4A 179 VLQQ HNIA HASS QVLQ QSSY  
 A1A1 187 HGRS QVLQ QSTY QLLQ ELCC  
 A1A3 187 HGRS QVLQ QSTY QLLR ELCC  
 POOL 22  
 A1B8 187 HGRS QVLQ QSTY QLLR ELCC  
 A1B11 187 HGKS QVLQ QSTY QLLQ ELCC  
 A2A1 187 YGSS QVLQ QSTY QLVQ QLCC  
 A2B1 187 HGSS QVLQ QSTY QLVQ QFCC  
 A2B3 187 HGSS QVLQ ESTY QLVQ QLCC  
 A3A1 187 HARS QVLQ QSTY QPLQ QLCC  
 A3B1 187 HASS QVLQ QSTY QLLQ QLCC  
 A4A 187 HASS QVLQ QSSY QQLQ QLCC  
 POOL 23  
 A1A1 195 QSTY QLLQ ELCC QHLW QIPE  
 A1A3 195 QSTY QLLR ELCC QHLW QIPE  
 A1B8 195 QSTY QLLR ELCC QHLW QIPE  
 A2A1 195 QSTY QLVQ QLCC QQLW QIPE  
 A2B1 195 QSTY QLVQ QFCC QQLW QIPE  
 A3A1 195 QSTY QPLQ QLCC QQLW QIPE  
 A3B1 195 QSTY QLLQ QLCC QQLL QIPE  
 A4A 195 QSSY QQLQ QLCC QQLF QIPE  
 POOL 24  
 A1A1 203 ELCC QHLW QIPE QSQC QAIH  
 A1B6 203 ELCC QHLW QIPE QSQC QAIH  
 A1B10 203 ELCC QHLW QIPE KLQC QAIH  
 A2A1 203 QLCC QQLW QIPE QSRC QAIH  
 A2B1 203 QFCC QQLW QIPE QSRC QAIH  
 A3B1 203 QLCC QQLL QIPE QSRC QAIH  
 POOL 25

126 G15C 250 ILPR SDCQ VMQQ QCCQ QLAQ  
 POOL 59  
 127 G11A 258 VMRQ QCCQ QLAQ IPQQ LQCA  
 128 G15A 258 VMRQ QCCQ QLAR IPQQ LQCA  
 129 G15C 258 VMRQ QCCQ QLAQ IPQQ LQCA  
 130 G16A 258 VMRQ QCCQ QLAQ IPQQ LQCA  
 131 G11A 266 QLAQ IPQQ LQCA AIHT IHS  
 132 G11B 266 QLAQ IPQQ LQCA AIHT VIHS  
 133 G12A 266 QLAQ IPQQ LQCA AIHS VVHS  
 134 G13A 266 QLAQ IPQQ LQCA AIHS IVHS  
 POOL 60  
 135 G15A 266 QLAR IPQQ LQCA AIHG IVHS  
 136 G15C 266 QLAQ IPQQ LQCA AIHS VVHS  
 137 G16A 266 QLAQ IPQQ LQCA AIHS VAHS  
 138 G11A 274 LQCA AIHT IHS IIMQ QEQQ  
 139 G11B 274 LQCA AIHT VIHS IIMQ QEQQ  
 140 G12A 274 LQCA AIHS VVHS IIMQ QQQQ  
 141 POOL 61  
 142 G13A 274 LQCA AIHS IVHS IIMQ QEQQ  
 G14 274 LQCA AIHS VVHS IIMQ QEQQ  
 143 G15A 274 LQCA AIHG IVHS IIMQ QEQQ  
 144 G16A 274 LQCA AIHS VAHS IIMQ QEQQ  
 145 G11A 282 IHS IIMQ QEQQ EQQQ GMHI  
 146 G11B 282 VIHS IIMQ QEQQ QGMH ILLP  
 147 G12A 282 VVHS IIMQ QQQQ QQQQ QGID  
 148 G13A 282 IVHS IIMQ QEQQ EQQQ GVQI  
 149 POOL 62  
 150 G14 282 VVHS IIMQ QEQQ EQQQ GVQI  
 G15A 282 IVHS IIMQ QEQQ QQQQ QQQQ  
 151 G15C 282 VVHS IIMQ QEQQ QGII ILRP  
 152 G16A 282 VAHS IIMQ QEQQ QGVP ILRP  
 153 G11A 290 QEQQ EQQQ GMHI LLPL YQQQ  
 154 G12A 290 QQQQ QQQQ QGID IFLP LSQH  
 155 G12B 290 QQQQ QQQQ QGMH IFLP LSQQ  
 156 G13A 290 QEQQ EQQQ GVQI LVPL SQQQ  
 157 POOL 63  
 158 G14 290 QEQQ EQQQ GVQI LVPL SQQQ  
 G15A 290 QEQQ QQQQ QQQQ QQQQ IQIM  
 159 G15C 290 QEQQ QGII ILRP LFQL VQQQ  
 160 G16A 290 QEQQ QGVP ILRP LFQL AQQL  
 161 G15A 298 QQQQ QQQQ IQIM RPLF QLVQ  
 162 G11A 305 GMHI LLPL YQQQ QVGG GTLV  
 163 G12A 305 GIDI FLPL SQHE QVGG GSLV  
 164 G12B 305 GMHI FLPL SQQQ QVGG GSLV  
 165 POOL 64  
 166 G13A 305 GVQI LVPL SQQQ QVGG GTLV  
 G14 305 GVQI LVPL SQQQ QVGG GILV  
 167 G15A 305 GIIQ MRPL FQLV QGQG IIQP  
 168 G15C 305 GIIQ LRPL FQLV QGQG IIQP  
 169 G16A 305 GVPI LRPL FQLA QGLG IIQP  
 170 G11A 313 YQQQ QVGG GTLV QGQG IIQP  
 171 G12A 313 SQHE QVGG GSLV QGQG IIQP  
 172 G12B 313 SQQQ QVGG GSLV QGQG IIQP  
 173 POOL 65  
 174 G13A 313 SQQQ QVGG GTLV QGQG IIQP  
 G14 313 SQQQ QVGG GILV QGQG IIQP  
 175 G11A 321 GTLV QGQG IIQP QQPA QLEA  
 176 G12A 321 GSLV QGQG IIQP QQPA QLEA  
 177 G15A 321 FQLV QGQG IIQP QQPA QLEV  
 178 G16A 321 FQLA QGLG IIQP QQPA QLEG  
 179 G11A 329 IIQP QQPA QLEA IRSI VLQT  
 180 G13A 329 IIQP QQPA QLEV IRSI VLQT  
 181 POOL 66  
 182 G13C 329 IIQP QQPA QLEV IRSS VLQT  
 G15C 329 IIQP QQPA QYEV IRSI VLRT  
 183 G16A 329 IIQP QQPA QLEG IRSI VLKT  
 184 G11A 337 QLEA IRSI VLQT LPTM CNVY  
 185 G12A 337 QLEA IRSI VLQT LPSM CNVY  
 186 G13A 337 QLEV IRSI VLQT LATM CNVY  
 187 G13C 337 QLEV IRSS VLQT LATM CNVY  
 188 G15A 337 QLEV IRSI VLGT LPTM CNVY  
 POOL 67

456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518

A3B3 203 GLCC QQLL QIPE QSQC QAIH  
 A4A 203 QLCC QQLF QIPE QSRC QAIH  
 A1A1 211 QIPE QSQC QAIH NVVH AAIL  
 A1B3 211 QIPE QSQC QAIQ NVVH AAIL  
 A1B6 211 QILE QSQC QAIH NVVH AAIL  
 A1B9 211 QIPE QSQC QAIH KVVH AAIL  
 A1B10 211 QIPE KLQC QAIH NVVH AAIL  
 A2A1 211 QIPE QSRC QAIH NVVH AAIL  
 POOL 26  
 A3B3 211 QIPE QSQC QAIH NVAH AAIM  
 A4A 211 QIPE QSRC QAIH NVVH AAIL  
 A1A1 219 QAIH NVVH AAIL HQQQ KQQQ  
 A1A6 219 QAIH NVVH AAIL HQQQ KQQQ  
 A1B3 219 QAIQ NVVH AAIL HQQQ KQQQ  
 A1B9 219 QAIH KVVH AAIL HQQQ KQQQ  
 A1B13 219 QAIH NVVH AAIL HQQQ QQQQ  
 A2B3 219 QAIH NVVH AAIL HQQH HHHQ  
 POOL 27  
 A3A1 219 QAIH NVVH AAIL HQQQ RQQQ  
 A3B1 219 QAIH NVVH AAIM HQQE QQQQ  
 A3B3 219 QAIH NVAH AAIM HQQQ QQQQ  
 A4A 219 QAIH NVVH AAIL HHHQ QQQQ  
 A1A1 227 AAIL HQQQ KQQQ QPSS QVSF  
 A1A6 227 AAIL HQQQ KQQQ QPSS QVSF  
 A1B2 227 AAIL HQQQ KQQQ QLSS QVSF  
 A1B10 227 AAIL HQQQ KQQQ PSSQ VSFQ  
 POOL 28  
 A1B13 227 AAIL HQQQ QQQQ EQKQ QLQQ  
 A2A1 227 AAIL HQQQ QQQQ QQQQ QPLS  
 A2B3 227 AAIL HQQH HHHQ QQQQ QQQQ  
 A2B4 227 AAIL HQQH HHHQ EQKQ QLQQ  
 A3A1 227 AAIL HQQQ RQQQ PSSQ VSLQ  
 A3B1 227 AAIM HQQE QQQQ LQQQ QQQQ  
 A3B3 227 AAIM HQQQ QQQQ EQKQ QLQQ  
 A4A 227 AAIL HHHQ QQQQ QPSS QVSF  
 POOL 29  
 A1A1 235 KQQQ QPSS QVSF QQPL QQYP  
 A1A6 235 KQQQ QPSS QVSF QQPL QQYP  
 A1B2 235 KQQQ QLSS QVSF QQPQ QQYP  
 A1B10 235 KQQQ PSSQ VSFQ QPQQ QYPL  
 A1B13 235 QQQQ EQKQ QLQQ QQQQ QQQQ  
 A2B4 235 HHHQ EQKQ QLQQ QQQQ QQQQ  
 A3A1 235 RQQQ PSSQ VSLQ QPQQ QYPS  
 A3B1 235 QQQQ LQQQ QQQQ LQQQ QQQQ  
 POOL 30  
 A4A 235 QQQQ QPSS QVSF QQPQ EQYP  
 A1B13 243 QLQQ QQQQ QQQQ QQQQ KQQQ  
 A1B13 251 QQQQ QQQQ KQQQ QPSS QVSF  
 A2A1 260 QQQQ QQQQ QPLS QVSF QPQQ  
 A2B1 260 QQQQ QQQQ QPLS QVSF QPQQ  
 A2B3 260 HHHQ QQQQ QQQQ QPLS QVSF  
 A3B1 260 QQQQ QQQQ QPSS QVSF QPQQ  
 A2A1 289 QPLS QVSF QQPQ QQYP SGQG  
 POOL 31  
 A2B1 289 QPLS QVSF QPQQ QQYP SGQG  
 A3B1 289 QPSS QVSF QQPQ QQYP SSQV  
 A1A1 293 QVSF QQPL QQYP LQQG SFRP  
 A1A6 293 QVSF QQPL QQYP LQQG SFRP  
 A1B2 293 QVSF QQPQ QQYP LQQG SFRP  
 A2A1 293 QVSF QQPQ QQYP SGQG SFQP  
 A2B1 293 QVSF QPQQ QQYP SGQG SFQP  
 A2B3 293 QVSF QQPQ QQYP SGQG FFQP  
 POOL 32  
 A2B5 293 QVSF QQPQ QQYP SGQG FFQP  
 A3A1 293 QVSL QQPQ QQYP SGQG FFQP  
 A3B1 293 QVSF QQPQ QQYP SSQV SFQP  
 A3B2 293 QVSF QQPQ QQYP SSQV SFQP  
 A4A 293 QVSF QQPQ EQYP SGQV SFQS  
 A1A1 301 QQYP LQQG SFRP SQQN PQAQ  
 A1B2 301 QQYP LQQG SFRP SQQN PQAQ  
 A2A1 301 QQYP SGQG SFQP SQQN PQAQ  
 POOL 33

189 GISC 337 QYEV IRSI VLRT LPNM CNVY 519  
 190 G16A 337 QLEG IRSI VLKT LPTM CNVY 520  
 191 G11A 345 VLQT LPTM CNVY VPPE CSII 521  
 192 G12A 345 VLQT LPSM CNVY VPPE CSIM 522  
 193 G13A 345 VLQT LATM CNVY VPPY CSTI 523  
 194 G15A 345 VLGT LPTM CNVY VPPE CSTT 524  
 195 G15C 345 VLRT LPNM CNVY VRPD CSTI 525  
 196 G16A 345 VLKT LPTM CNVY VPPD CSTI 526  
 POOL 68  
 197 G11A 353 CNVY VPPE CSII KAPF SSVV 527  
 198 G12A 353 CNVY VPPE CSIM RAPF ASIV 528  
 199 G13A 353 CNVY VPPY CSTI RAPF ASIV 529  
 200 G15A 353 CNVY VPPE CSTT KAPF ASIV 530  
 201 G15C 353 CNVY VRPD CSTI NAPF ASIV 531  
 202 G16A 353 CNVY VPPD CSTI NVPY ANID 532  
 203 G11A 361 CSII KAPF SSVV AGIG GQ 533  
 204 G12A 361 CSIM RAPF ASIV AGIG GQ 534  
 POOL 69  
 205 G13A 361 CSTI RAPF ASIV AGIG GQYR 535  
 206 G14 361 CSTI RAPF ASIV ASIG GQ 536  
 207 G15A 361 CSTT KAPF ASIV ADIG GQ 537  
 208 G15C 361 CSTI NAPF ASIV AGIS GQ 538  
 209 G16A 361 CSTI NVPY ANID AGIG GQ 539  
 210 G11 1 PQQP FPLQ PQQS FLWQ SQQP 540  
 211 G11 9 PQQS FLWQ SQQP FLQQ PQQP 541  
 212 G11 17 SQQP FLQQ PQQP SPQP QQVV 542  
 POOL 70  
 213 G11 25 PQQP SPQP QQVV QIIS PATP 543  
 214 G11 33 QQVV QIIS PATP TTIP SAGK 544  
 215 G11 41 PATP TTIP SAGK PTSA PFPQ 545  
 216 G11 49 SAGK PTSA PFPQ QQQQ HQQL 546  
 217 G11 57 PFPQ QQQQ HQQL AQQQ IPVV 547  
 218 G11 65 HQQL AQQQ IPVV QPSI LQQL 548  
 219 G11 73 IPVV QPSI LQQL NPCK VFLQ 549  
 220 G11 81 LQQL NPCK VFLQ QPCS PVAM 550  
 POOL 71  
 221 G11 89 VFLQ QPCS PVAM PQLR ARSQ 551  
 222 G11 97 PVAM PQLR ARSQ MLQQ SSCH 552  
 223 G11 105 ARSQ MLQQ SSCH VMQQ QCCQ 553  
 224 G11 113 SSCH VMQQ QCCQ QLPQ IPQQ 554  
 225 G11 121 QCCQ QLPQ IPQQ SRYQ AIRA 555  
 226 G11 127B PQIP QQSR YEAI RAIT YSII 556  
 227 G11 129 IPQQ SRYQ AIRA IYIS IILQ 557  
 228 G11 137 AIRA IYIS IILQ EQQQ VQGS 558  
 POOL 72  
 229 G11 145 IILQ EQQQ VQGS IQSQ QQQP 559  
 230 G11 153 VQGS IQSQ QQQP QQLG QCVS 560  
 231 G11 161 QQQP QQLG QCVS QPQQ QSQQ 561  
 232 G11 169 QCVS QPQQ QSQQ QLGQ QPQQ 562  
 233 G11 177 QSQQ QLGQ QPQQ QQLA QGTF 563  
 234 G11 185 QPQQ QQLA QGTF LQPH QIAQ 564  
 POOL 73  
 235 G11 193 QGTF LQPH QIAQ LEVM TSIA 565  
 236 G11 201 QIAQ LEVM TSIA LRIL PTMC 566  
 237 G11 209 TSIA LRIL PTMC SVNV PLYR 567  
 238 G11 217 PTMC SVNV PLYR TTTS VPFG 568  
 239 G11 225 PLYR TTTS VPFG VGTG VGAY 569  
 240 G111 1A 1 TTTR TFFI PTIS SNNN HHFR 570  
 241 G111 1A 9 PTIS SNNN HHFR SNNN HHFR 571  
 242 G111 1A 17 HHFR SNNN HHFR SNNN QFYR 572  
 POOL 74  
 243 G111 1A 25 HHFR SNNN QFYR NNNS PGHN 573  
 244 G111 1A 33 QFYR NNNS PGHN NPLN NNNS 574  
 245 G111 1A 41 PGHN NPLN NNNS PNNN SPSN 575  
 246 G111 1A 49 NNNS PNNN SPSN HHNN SPNN 576  
 247 G111 1A 57 SPSN HHNN SPNN NFQY HTHP 577  
 248 G111 1A 65 SPNN NFQY HTHP SNHK NLPH 578  
 249 G111 1A 73 HTHP SNHK NLPH TNNI QQQQ 579  
 250 G111 1A 81 NLPH TNNI QQQQ PPFS QQQQ 580  
 POOL 75  
 251 G111 1A 89 QQQQ PPFS QQQQ PPFS QQQQ 581  
 252 G111 1A 97 QQQQ PPFS QQQQ PVLP QQQP 582

A2B3 301 QQYP SGQG FFQP SQQN PQAQ  
 A2B5 301 QQYP SGQG FFQP FQON PQAQ  
 A3A1 301 QQYP SGQG FFQP SQQN PQAQ  
 A3B1 301 QQYP SSQV SFQP SQLN PQAQ  
 A3B2 301 QQYP SSQG SFQP SQQN PQAQ  
 A4A 301 EQYP SGQV SFQS SQQN PQAQ  
 A1B1 309 SFRP SQQN PLAQ GSVQ PQQL  
 A1A1 309 SFRP SQQN PQAQ GSVQ PQQL  
 POOL 34  
 A1A3 309 SFRP SQQN PQTQ GSVQ PQQL  
 A1B2 309 SFRP SQQN SQAQ GSVQ PQQL  
 A1B3 309 SFRP SQQN PQDQ GSVQ PQQL  
 A1B4 309 SFRP SQQN PRAQ GSVQ PQQL  
 A2A1 309 SFQP SQQN PQAQ GSVQ PQQL  
 A2B3 309 FFQP SQQN PQAQ GSFQ PQQL  
 A2B5 309 FFQP FQON PQAQ GSFQ PQQL  
 A3A1 309 FFQP SQQN PQAQ GSVQ PQQL

## Pool 35

A3B1 309 SFQP SQLN PQAQ GSVQ PQQL  
 A3B1 309 SFQP SQLN PQAQ GSVQ PQQL  
 A3B2 309 SFQP SQQN PQAQ GSVQ PQQL  
 A4A 309 SFQS SQQN PQAQ GSVQ PQQL  
 A1A1 317 PQAQ GSVQ PQQL PQFE EIRN  
 A1A3 317 PQTQ GSVQ PQQL PQFE EIRN  
 A1A6 317 PQAQ GSVQ PQQL PQFE EIRN  
 A1B1 317 PLAQ GSVQ PQQL PQFE EIRN  
 POOL 36  
 A1B3 317 PQDQ GSVQ PQQL PQFE EIRN  
 A1B4 317 PRAQ GSVQ PQQL PQFE EIRN  
 A2B3 317 PQAQ GSFQ PQQL PQFE EIRN  
 A2B5 317 PQAQ GSFQ PQQL PQFE EIRN  
 A3B1 317 PQAQ GSVQ PQQL PQFA EIRN  
 A4A 317 PQAQ GSVQ PQQL PQFQ EIRN

## Pool 37

A1A1 325 PQQL PQFE EIRN LALQ TLPA  
 A1A6 325 PQQL PQFE EIRN ALQT LPAM  
 A1B12 325 PQQL PQFE EIRN LARK  
 A2A1 325 PQQL PQFE EIRN LALQ TLPA  
 A2B5 325 PQQL PQFE EIRN LALQ TLPA  
 A3B1 325 PQQL PQFA EIRN LALQ TLPA  
 A4A 325 PQQL PQFQ EIRN LALQ TLPA  
 A1A1 333 EIRN LALQ TLPA MCNV YIPP  
 POOL 38  
 A1A3 333 EIRN LALQ TLPS MCNV YIPP  
 A2A1 333 EIRN LALQ TLPA MCNV YIPP  
 A3A1 333 EIRN LALQ TLPR MCNV YIPP  
 A1A1 341 TLPA MCNV YIPP YCTI APFG  
 A1A3 341 TLPS MCNV YIPP YCTI APFG  
 A1B1 341 TLPA MCNV YIPP YCTI VPFQ  
 A1B4 341 TLPA MCNV YIPP YCAM APFG  
 A1B9 341 TLPA MCNV YIPP YCTI TPFQ

## Pool 39

A2A1 341 TLPA MCNV YIPP YCTI APVG  
 A2B2 341 TLPA MCNV YIPP YCST TIAP  
 A3A1 341 TLPR MCNV YIPP YCST TIAP  
 A3A2 341 TLPR MCNV YIPP YCST TIAP  
 A3B1 341 TLPA MCNV YIPP HCST TIAP  
 A1A1 349 YIPP YCTI APFG IFGT NYR  
 A1B1 349 YIPP YCTI VPFQ IFGT NYR  
 A1B4 349 YIPP YCAM APFG IFGT NYR

## Pool 40

A1B5 349 YIPP YCTM APFG IFGT NYR  
 A1B9 349 YIPP YCTI TPFQ IFGT NYR  
 A2A1 349 YIPP YCTI APVG IFGT NYR  
 A2B2 349 YIPP YCST TIAP VGIF GTN  
 A3A2 349 YIPP YCST TIAP FGIF GTN  
 A3B1 349 YIPP HCST TIAP FGIF GTN  
 A3B3 349 YIPP HCST TIAP FGIS GTN  
 A4D 350 IPY CSTT IAPF GIGF TNYR

## Pool 41

GI1A 17 GTAN MQVD PSSQ VQWP QQQP  
 GI2A 17 GTAN IQVD PSGQ VQWL QQQL

253 GIII 1A 105 QQQQ PVLP QQSP FSQQ QQLV 583  
 254 GIII 1A 113 QQSP FSQQ QQLV LPPQ QQQQ 584  
 255 GIII 1A 121 QQLV LPPQ QQQQ QLVQ QQIP 585  
 256 GIII 1A 129 QQQQ QLVQ QQIP IVQP SVLQ 586  
 257 GIII 1A 137 QQIP IVQP SVLQ QLNP CKVF 587  
 258 GIII 1A 145 SVLQ QLNP CKVF LQQQ CSPV 588  
 259 POOL 76  
 260 GIII 1A 153 CKVF LQQQ CSPV AMPQ RLAR 589  
 GIII 1A 161 CSPV AMPQ RLAR SQMW QQSS 590  
 261 GIII 1A 169 RLAR SQMW QQSS CHVM QQQQ 591  
 262 GIII 1A 177 QQSS CHVM QQQC CQQL QQIP 592  
 263 GIII 1A 185 QQQC CQQL QQIP EQSR YEAI 593  
 264 GIII 1A 193 QQIP EQSR YEAI RAII YSII 594  
 265 GIII 1A 201 YEAI RAII YSII LQEQ QQGF 595  
 266 GIII 1A 209 YSII LQEQ QQGF VQPQ QQQP 596  
 267 POOL 77  
 268 GIII 1A 217 QQGF VQPQ QQQP QQSG QGVS 597  
 GIII 1A 225 QQQP QQSG QGVS QSQQ QSQQ 598  
 269 GIII 1A 233 QGVS QSQQ QSQQ QLQV CSFQ 599  
 270 GIII 1A 241 QSQQ QLQV CSFQ QPQQ QLQV 600  
 271 GIII 1A 249 CSFQ QPQQ QLQV QPQQ QQQQ 601  
 272 GIII 1A 257 QLQV QPQQ QQQQ QVLQ GTFL 602  
 273 GIII 1A 263 QQQQ QVLQ GTFL QPHQ IAH 603  
 274 GIII 1A 271 GTFL QPHQ IAH EAVT SIAL 604  
 275 POOL 78  
 276 GIII 1A 279 IAH EAVT SIAL RTLP TMCS 605  
 GIII 1A 287 SIAL RTLP TMCS VNVP LYSA 606  
 277 GIII 1A 295 TMCS VNVP LYSA TTSV PFGV 607  
 278 GIII 1A 303 LYSA TTSV PFGV GTGV GAY 608  
 279 GIII 1B 26 SCIS GLER FWQQ QPLP PQQS 609  
 280 GIII 1B 34 PWQQ QPLP PQQS FSQQ PFFS 610  
 281 GIII 1B 42 PQQS FSQQ PFFS QQQQ QPLP 611  
 282 GIII 1B 50 PFFS QQQQ QPLP PQPS FSQQ 612

## Pool 79

283 GIII 1B 58 QPLP PQPS FSQQ QPFF SQQQ 613  
 284 GIII 1B 66 FSQQ QPFF SQQQ PILS QQQP 614  
 285 GIII 1B 74 SQQQ PILS QQQP FSQQ QQQV 615  
 286 O 1A 17 ATAA RELN PSNK ELQS PQQS 616  
 287 O 1A 25 PSNK ELQS PQQS FSYQ QQQP 617  
 288 O 1A 33 PQQS FSYQ QQQP PQQP YPQQ 618  
 289 O 1A 41 QQQP PQQP YPQQ PYPS QQQY 619  
 290 O 1A 49 YPQQ PYPS QQQY PSQQ PFPT 620  
 POOL 80  
 291 O 1A 57 QQQY PSQQ PFPT PQQQ FPEQ 621  
 292 O 1A 65 PFPT PQQQ FPEQ SQQP FTQP 622  
 293 O 1A 73 FPEQ SQQP FTQP QPPT PIQP 623  
 294 O 1A 81 FTQP QPPT PIQP QQQP PQQP 624  
 295 O 1A 89 PIQP QQQP PQQP QQQP QQQP 625  
 296 O 1A 97 PQQP QQQP QQQP QQQP PFPW 626  
 297 O 1A 105 QQQP QQQP PFPW QQQP PFPQ 627  
 298 O 1A 113 PFPW QQQP PFPQ TQQS FPLQ 628

## POOL 81

299 O 1A 121 PFPQ TQQS FPLQ PQQP FPQQ 629  
 300 O 1A 129 FPLQ PQQP FPQQ PQQP FPQP 630  
 301 O 1A 137 FPQQ PQQP FPQP QLPP PQQS 631  
 302 O 1A 145 FPQP QLPP PQQS EQII PQQL 632  
 303 O 1A 153 PQQS EQII PQQL QQQP PLQP 633  
 304 O 1A 161 PQQL QQQP PLQP QQQP PQQP 634  
 305 O 1A 169 PLQP QQQP PQQP QQQP PQQP 635  
 306 O 1A 177 PQQP QQQP PQQP QPQP VQPQ 636

## Pool 82

307 O 1A 185 PQQP QPQP VQPQ QQQP QQQQ 637  
 308 O 1A 193 VQPQ QQQP QQQQ QQQQ PFAQ 638  
 309 O 1A 201 QQQQ QQQQ PFAQ PQQL FPFL 639  
 310 O 1A 209 PFAQ PQQL FPFL QQQP PQQP 640  
 311 O 1A 217 FPFL QQQP PQQP QQQP PLQP 641  
 312 O 1A 225 PQQP QQQP PLQP QQQP PQQP 642  
 313 O 1A 233 PLQP QQQP PQQP QQQP PQQP 643  
 314 O 1A 241 PQQP QQQP PQQP QQQP PQQP 644  
 POOL 83  
 315 O 1A 249 PQQP QQQP PQQP QQQP PQQP 645  
 316 O 1A 257 PQQP QQQP PQQP PYGS SLTS 646

104

G13A 17 ATAN MQVD PSGQ VPWP QQQP	317 O 1A 265 PQQQ PYGS SLTS IGGQ	647
G13B 19 MN IQVD PSGQ VPWP QQQP FP	318 O 1B 1 ARQL NPSD QELQ SPQQ LYPQ	648
G14 17 ATAN MQAD PSGQ VQWP QQQP	319 O 1B 9 QELQ SPQQ LYPQ QPYP QQPY	649
G15A 17 TTAN IQVD PSGQ VQWP QQQQ	320 O 1C 1 SRLL SPRG KELH TPQE QFPQ	650
G15C 17 ATAN MQVD PSGQ VQWP QQQP	321 O 1C 9 KELH TPQE QFPQ QQQF PQPQ	651
G17 20 QIVF PSGQ VQWP QQQQ PFP	322 O 1C 17 QFPQ QQQF PQPQ QFPQ	652
Pool 42		
G11A 25 PSSQ VQWP QQQP VPQP HQPF	323	
G12A 25 PSGQ VQWL QQQL VPQL QQPL	324	
G13A 25 PSGQ VPWP QQQP FPQP HQPF	325	
G14 25 PSGQ VQWP QQQP FLQP HQPF	326	
G15A 25 PSGQ VQWP QQQQ FFPQ PQQP	327	
G15C 25 PSGQ VQWP QQQP FRQP QQPF	328	
G16A 25 PSGQ VQWP QQQP FPQP QQPF	329	
G11A 33 QQQP VPQP HQPF SQQP QQTF	330	

---

\*Position of N-terminal residue in  $\alpha$ -,  $\gamma$ 1-,  $\gamma$ 2-,  $\gamma$ 3-, or  $\omega$  consensus sequence





[illegible]

[illegible]

[illegible]







[illegible]







[illegible]

[illegible]



## CLAIMS

1. A method of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from:
  - 5 (a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs:18-22, 31-36, 39-44, and 46, and equivalents thereof; and
  - (b) an analogue of (a) which is capable of being recognised by a T cell receptor that recognises the peptide of (a) and which is not more than 50 amino acids
  - 10 in length; and
  - (c) optionally, in addition to the agent selected from (a) and (b), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NO:1 and SEQ ID NO:2.
- 15 2. A method of claim 1 wherein the agent is HLA-DQ2-restricted.
3. A method of claim 1 wherein the agent is HLA-DQ8-restricted.
4. A method of claim 1 wherein one agent is HLA-DQ2-restricted and a second
- 20 agent is HLA-DQ8-restricted.
5. A method of claim 1 wherein the agent comprises a wheat epitope.
6. A method of claim 1 wherein one agent comprises a wheat epitope and one
- 25 agent comprises a rye epitope.
7. A method of claim 1 wherein one agent comprises a wheat epitope and one agent comprises a barley epitope.
- 30 8. A method of claim 1 wherein one agent comprises a rye epitope and one agent comprises a barley epitope.

9. A method of claim 1 wherein one agent comprises a wheat epitope, one agent comprises a barley epitope, and one agent comprises a rye epitope.

10. A method of claim 1 wherein a single agent comprises a wheat epitope, a  
5 barley epitope, and a rye epitope.

11. A method of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an agent as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.

10

12. A method of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined in claim 1, and a pharmaceutically acceptable carrier or diluent.

15

13. A method of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1, which composition comprises an agent as defined in claim 1.

20

14. A method of preventing or treating coeliac disease comprising:  
diagnosing coeliac disease in an individual by either:

a) contacting a sample from the host with at least one agent selected from:

25

i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof;  
and

30

ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and

- iii) optionally, in addition to the agent selected from i) and ii),  
a peptide comprising at least one epitope comprising a  
sequence selected from SEQ ID NOS:1 and 2; and  
determining *in vitro* whether T cells in the sample recognise the agent;  
5 recognition by the T cells indicating that the individual has, or is  
susceptible to, coeliac disease; or  
b) administering an agent as defined in claim 1 and determining *in*  
*vivo* whether T cells in the individual recognise the agent, recognition of the  
agent indicating that the individual has or is susceptible to coeliac disease;  
10 and  
administering to an individual diagnosed as having, or being susceptible to,  
coeliac disease a therapeutic agent for preventing or treating coeliac disease.

15. Use of an agent for the preparation of a medicament for treating or preventing  
15 coeliac disease, wherein the agent comprises:

(a) a peptide comprising at least one epitope comprising a sequence selected  
from the group consisting of SEQ ID NOs:18-22, 31-36, 39-44, and 46, and  
equivalents thereof; and

- (b) an analogue of (a) which is capable of being recognised by a T cell  
20 receptor that recognises the peptide of (a) and which is not more than 50 amino acids  
in length; and

(c) optionally, in addition to the agent selected from (a) and (b), a peptide  
comprising at least one epitope comprising a sequence selected from SEQ ID NO:1  
and SEQ ID NO:2.

25

16. A use of claim 15 wherein the agent is HLA-DQ2-restricted.

17. A use of claim 15 wherein the agent is HLA-DQ8-restricted.

- 30 18. A use of claim 15 wherein one agent is HLA-DQ2-restricted and a second  
agent is HLA-DQ8-restricted.

19. A use of claim 15 wherein the agent comprises a wheat epitope.
20. A use of claim 15 wherein one agent comprises a wheat epitope and one agent comprises a rye epitope.
- 5 21. A use of claim 15 wherein one agent comprises a wheat epitope and one agent comprises a barley epitope.
22. A use of claim 15 wherein one agent comprises a rye epitope and one agent  
10 comprises a barley epitope.
23. A use of claim 15 wherein one agent comprises a wheat epitope, one agent comprises a barley epitope, and one agent comprises a rye epitope.
- 15 24. A use of claim 15 wherein a single agent comprises a wheat epitope, a barley epitope, and a rye epitope.
25. A use of claim 15 wherein the agent is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent.
- 20 26. A use of claim 15 wherein the agent is present within a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined in claim 15, and a pharmaceutically acceptable carrier or diluent.
- 25 27. A use of claim 15 wherein the agent is present within a composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1.
- 30 28. An agent as defined in claim 1, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.



29. An antagonist of a T cell which has a T cell receptor as defined in claim 1, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.
- 5 30. An agent as defined in claim 1 or an analogue that binds an antibody that binds to an epitope of an agent as defined in claim 1 for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.
- 10 31. A protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined in claim 1, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.
32. An agent as defined in claim 1 or an antagonist as defined in claim 12.
- 15 33. A pharmaceutical composition comprising an agent as defined in claim 1 or an antagonist as defined in claim 12 and a pharmaceutically acceptable carrier or diluent.
- 20 34. A composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1, which composition comprises an agent as defined in claim 1.
35. A composition for antagonising a T cell response to an agent as defined in claim 1, which composition comprises an antagonist as defined in claim 12.
- 25 36. A mutant gliadin protein whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined in claim 1, which mutant gliadin protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined in claim 1; or a fragment of such a mutant gliadin protein which is at least 15 amino acids long and which comprises the mutation.
- 30

37. A polynucleotide that comprises a coding sequence that encodes a protein or fragment as defined in claim 36 or 31.

38. A polynucleotide according to claim 37 that additionally comprises one or  
5 more regulatory sequences operably linked to the coding sequence, which regulatory sequences are capable of securing the expression of the coding sequence in a cell.

39. A polynucleotide according to claim 38 wherein the regulatory sequence(s) allow expression of the coding sequence in a prokaryotic or mammalian cell.

10

40. A polynucleotide according to any one of claims 37 to 39 which is a vector or which is in the form of a vector.

41. A cell comprising a polynucleotide as defined in any one of claims 37 to 40  
15 or which has been transformed with such a polynucleotide.

42. A cell according to claim 41 which is a prokaryotic cell or a mammalian cell.

43. A mammal that expresses a T cell receptor as defined in claim 1.

20

44. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:

(a) contacting a sample from the host with at least one agent selected from

25

(i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof; and

(ii) an analogue of (i) which is capable of being recognised by a T cell receptor that recognises (i) and which is not more than 50 amino acids in length; and

30

(iii) optionally, in addition to the agent selected from (i) and (ii), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NOS:1 and 2; and

(b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

- 5    45.    Use of an agent as defined in claim 44 for the preparation of a diagnostic means for use in a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.
- 10    46.    A method or use according to claim 44 or 45 wherein the agent is an analogue (iii) which comprises (i) or (ii) bound to (a) an HLA molecule, or (b) a fragment of an HLA molecule capable of binding (i) or (ii).
- 15    47.    A method or use according to claim 46 wherein the HLA molecule or fragment is in a complex comprising four HLA molecules or fragments of HLA molecules.
- 20    48.    Use according to claim 45, 46 or 47 wherein the method comprises administering the agent to the skin of an individual and detecting the presence of inflammation at the site of administration, the detection of inflammation indicating that the T cells of the individual recognise the agent.
- 25    49.    A method according to claim 44, 46 or 47 wherein the sample is blood sample.
50.    A method according to claim 44, 46, 47 or 49 wherein the T cells are not restimulated in antigen specific manner *in vitro* before the said determining.
- 30    51.    A method or use according to any one claims 44-50 in which the recognition of the agent by the T cells is determined by detecting the secretion of a cytokine from the T cells.

52. A method or use according to claim 51 in which the cytokine is IFN- $\gamma$ .
53. A method or use according to claim 51 or claim 52 in which the cytokine is detected by allowing the cytokine to bind to an immobilised antibody specific to the cytokine and then detecting the presence of the antibody/cytokine complex.
54. A method or use according to any one of claims 44 to 50 wherein said determining is done by measuring whether the agent binds the T cell receptor.
55. A method for identifying an analogue as defined in a claim 44, 46 or 47 comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope comprising sequence as defined in claim 44, recognition of the substance indicating that the substance is an analogue.
56. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to an epitope of an epitope comprising sequence as defined in claim 44 in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.
57. A method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined in claim 44 is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.
58. A method according to claim 57 wherein the said determining is done by contacting the composition with an antibody specific for the sequence which is capable of being modified to the oligopeptide sequence, binding of the antibody to a protein in the composition indicating the composition is capable of causing coeliac disease.

59. A method of identifying an antagonist of a T cell, which T cell recognises an agent as defined in claim 1, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the detecting of any such decrease in said ability indicating that the substance is an antagonist.

5

60. A kit for carrying out a method or use according to any one of claims 44 to 54 comprising an agent as defined in claim 44, 46 or 47 and a means to detect the recognition of the peptide by the T cell.

10

61. A kit according to claim 60 wherein the means to detect recognition comprises an antibody to IFN- $\gamma$ .

15

62. A kit according to claim 61 wherein the antibody is immobilised on a solid support and optionally the kit also comprises a means to detect the antibody/IFN- $\gamma$  complex.

20

63. Use of an agent or antagonist as defined in claim 62 or a wild type sequence as defined in claim 36 to produce an antibody specific to the agent, antagonist or wild type sequence.

25

64. Use of a mutation in an epitope of a gliadin protein, which epitope is as defined in claim 44, to decrease the ability of the gliadin protein to cause coeliac disease.

30

65. Method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined in claim 43 which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

66. A therapeutic product as identified in the method of claim 65 for use in a method of preventing or treating coeliac disease.
67. A method of diagnosing coeliac disease, or susceptibility to coeliac disease in  
5 an individual comprising administering an agent as defined in claim 44 and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease.
68. A cell according to claim 41 which is a cell of a graminaceous  
10 monocotyledonous species.
69. A cell according to claim 68 which is a cell of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane.
70. A process for the production of a protein encoded by a coding sequence as  
15 defined in claim 37 which process comprises:  
(a) cultivating a cell according to any one of claims 41, 42, 68 or 69 under conditions that allow the expression of the protein; and optionally  
(b) recovering the expressed protein.  
20
71. A method of obtaining a transgenic plant cell comprising:  
(a) transforming a plant cell with a vector according to claim 40 to give a transgenic plant cell.
72. A method of obtaining a first-generation transgenic plant comprising:  
25 (b) regenerating a transgenic plant cell transformed with a vector according to claim 40 to give a transgenic plant.
73. A method of obtaining a transgenic plant seed comprising:  
30 (c) obtaining a transgenic seed from a transgenic plant obtainable by step (b) of claim 72.

74. A method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method according to claim 72, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

75. A method according to claim 74 comprising:

(d) obtaining a transgenic seed from a first-generation transgenic plant obtainable by the method according to claim 73, then obtaining a second-generation transgenic progeny plant from the transgenic seed;

and/or

(e) propagating clonally a first-generation transgenic plant obtainable by the method according to claim 72 to give a second-generation progeny plant;

and/or

(f) crossing a first-generation transgenic plant obtainable by a method according to claim 72 with another plant to give a second-generation progeny plant; and optionally

(g) obtaining transgenic progeny plants of one or more further generations from the second-generation progeny plant thus obtained.

76. A transgenic plant cell, plant, plant seed or progeny plant obtainable by a method according to any one of claims 71 to 75.

77. A transgenic plant or plant seed comprising plant cells according to claim 68 or 69.

78. A transgenic plant cell callus comprising plant cells according to claim 68 or 69 obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny as defined in any one of claims 68, 69, or 71 to 75.

79. A plant or callus according to any one of claims claim 76 to 78 which is of a species as defined in claim 68 or 69.

80. A method of obtaining a crop product comprising harvesting a crop product from a plant according to any one of claims 76 to 79 and optionally further processing the harvested product.

5 81. A method according to claim 80 wherein the plant is a wheat plant and the harvested crop product is grain; optionally further processed into flour or another grain product.

82. A crop product obtainable by a method according to claim 80 or 81.

10

83. A food that comprises a protein as defined in any claim 31 or 36.

84. A food according to claim 83 in which a protein as defined in claim 31 or 36 is used instead of wild-type gliadin.


15




1 / 47

Fig.1a.

Peptide pool 3




Gliadin digest



2 /47

Fig.1b.



3 /47

Fig.2a.






Fig.2b.





5 / 47

Fig.4a.





Fig.4b.



6/47

Fig.5.





Fig.6.



7/47

Fig.7a.





Fig.7b.









Fig.9.



10/47

Fig.10.





Fig.11.




Fig.12a.

Dose response to A-gliadin 57-73 QE65:  
QLQPFPQPELPYPQPQS.




Fig.12b.

Dose response to GDA4\_WHEAT P04724 84-100 QE92:  
PQLPYPQPELPYPQPQP.




Fig.12c.

Dose response to A-gliadin 57-73:  
QLQPFPPQPQLPYQPQS (2.5, 25 & 250 mcg/ml),  
and A-gliadin 57-73 (25 mcg/ml) + tTG treatment.




Fig.12d.

Dose response to GDA4\_WHEAT P04724 84-100:  
PQLPYQPQLPYQPQP (2.5, 25 & 250 mcg/ml),  
and P04724 84-100 (25 mcg/ml) + tTG treatment.




Fig.12e.

Dose response to the DQ2-restricted  $\alpha$  gliadin T cell epitope A-gliadin 57-68 QE65: QLQPFQPELPY (E65) (2.5, 25 & 250 mcg/ml), and A-gliadin 57-68: QLQPFQPQLPY (Q65) (25 mcg/ml) +/- tTG treatment.




Fig.12f.

Dose response to the DQ2-restricted  $\alpha$  gliadin T cell epitope  $\alpha$ -2 62-75 QE65 & QE72: PQPELPYPQPELPY (E65) (2.5, 25 & 250 mcg/ml), and  $\alpha$ -2 62-75: PQPQLPYPQPQLPY (Q65) (25 mcg/ml) +/- tTG treatment.




Fig.12g.

Dose response to the DQ8-restricted  $\alpha$  gliadin T cell epitope GDA9 202-219: QE208 & 216: QQYPSGEGSFQPSQENPQ (E) (25 & 250 mcg/ml), and to GDA9 202-219 QQYPSGQGSFQPSQQNPQ (Q) (25 mcg/ml) +/- tTG treatment.







Fig.12h.

Dose response to the DQ2-restricted  $\gamma$  gliadin T cell epitope GDB2 134-153 QE140, 148,150: QQLPQPEQPQQSFPEQERPF (E) (25 & 250 mcg/ml), and to GDB2 134-153: QQLPQPQQPQQSFPQQRRPF (Q) (25 mcg/ml) +/- tTG treatment.



18 / 47

Fig.13a.

Dose response to gliadin digest by  
chymotrysin.





Fig.13b.


Dose response to gliadin digested by  
chymotrysin then treated with tTG.



**Fig.13c.**

Total ELISpot responses to A-gliadin 57-73 QE65 (25mcg/ml) versus A-gliadin 57-73 QE65 responses as percent of tTG gliadin (500mcg/ml) responses.


Responses to dominant epitope and complete antigen (A-gliadin 57-73 QE65 and tTG-treated gliadin)



(Fig.14.)

Bioactivity of gliadin polymorphisms of A-gliadin 57-73  
(A) in coeliac subjects 6/7 days after gluten challenge  
(Gamma-Interferon Elispot) (n=4).

Fig.14a.




A QLQPFPPQPQLPYPQPQS  
B QLQPFPPQPQLPYPQPQP  
C QLQPFPPQPQLPYPQPQL  
D QLQPFPPQPQLPYLQPQS  
E QLQPFPPQPQLPYPQPQP  
F QLQPFPPQPQLPYSQPQP  
G QLQPFLLQPQLPYSQPQP  
H QLQPFSSQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP  
J QPQPFPPQPQLPYPQTQP  
K PQLPYPQPQLPYPQPQP  
L PQLPYPQPQLPYPQPQL  
M PQPQPFLLPQLPYPQPQS  
N PQPQPFPPQPQLPYPQPQS  
O PQPQPFPPQPQLPYPQIQP  
P PQPQPFPPQPQLPYPQPQP

21 / 47


Fig.14b.



A QLQPFPPQPQLPYQPQSQS  
 B QLQPFPPQPQLPYQPQPQ  
 C QLQPFPPQPQLPYQPQQL  
 D QLQPFPPQPQLPYLQPQSQS  
 E QLQPFPPQPQLPYQPQPQ  
 F QLQPFPPQPQLPYSQPQP  
 G QLQPFLLQPQLPYSQPQP  
 H QLQPFSSQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP  
 J QPQPFPFPQLPYQPQIQP  
 K PQLPYQPQLPYQPQPQ  
 L PQLPYQPQLPYQPQQL  
 M PQQPFFLPQLPYQPQSQS  
 N PQQPFFPPQLPYQPQSQS  
 O PQQPFFPPQLPYQPQIQP  
 P PQQPFFPPQLPYQPQPP

Fig.14c.



A QLQPFPQPQLPYPQPQS  
 B QLQPFPQPQLPYPQPQP  
 C QLQPFPQPQLPYPQPQL  
 D QLQPFPQPQLPYLQPQS  
 E QLQPFPQPQLPYPQPQP  
 F QLQPFPQPQLPYSQPQP  
 G QLQPFLQPQLPYSQPQP  
 H QLQPF<sup>S</sup>QPQLPYSQPQP

I QLQPFPQPQLSYSQPQP  
 J QPQPFPQPQLPYPQIQP  
 K PQLPYPQPQLPYPQPQP  
 L PQLPYPQPQLPYPQPQL  
 M PQPQFPLPQLPYPQPQS  
 N PQPQFPQPQLPYPQPQS  
 O PQPQFPQPQLPYPQIQP  
 P PQPQFPQPQLPYPQPPP

Fig. 14d. QE65-substituted (2.5 mcg/ml): Means (error bars: 1 SEM)





Fig. 14e. QE65-substituted (250 mcg/ml): Means (error bars: 1 SEM)



A QLQPFPPQPQLPYQPQS  
 B QLQPFPPQPQLPYQPQP  
 C QLQPFPPQPQLPYQPQL  
 D QLQPFPPQPQLPYLQPQS  
 E QLQPFPPRPQLPYQPQP  
 F QLQPFPPQPQLPYSQPQP  
 G QLQPFLLQPQLPYSQPQP  
 H QLQPFSSQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP  
 J QPQPFPPQPQLPYPQTQP  
 K PQLPYQPQLPYQPQP  
 L PQLPYQPQLPYQPQL  
 M PQQPFLLPQLPYQPQS  
 N PQQPFPPQPQLPYQPQS  
 O PQQPFPPQPQLPYPQTQP  
 P PQQPFPPQPQLPYQPQP

Fig.15.

Alanine scan: Means (error bars: 95% CI for mean)





Fig.16.

Lysine scan: Means (error bars: 95% CI for mean)





25 / 47

Fig.17.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70





Fig.18.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>PQPELPYPQPQS

60.....70



27 / 47

Fig.19.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>FPQPELPYPQPQS

60.....70





Fig.20.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70



29 /47

Fig.21.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70

P64 Means (error bars: 95% CI for mean)




Fig.22.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>PQPELPYPQPQS<sup>70</sup>

60.....70




Fig.23.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




Fig.24.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70






Fig.25.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




Fig.26.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70





Fig.27.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>PQPELPYPQPQS<sup>70</sup>


60.....70



(Fig.28.)

Interferon gamma ELISpot responses in newly diagnosed and treated coeliac subjects, before and after gluten challenge.

Fig.28a. Untreated, newly diagnosed coeliacs (Mean+SEM, n=9)



37 / 47

Fig.28b.




Fig.28c.




Fig.28d.




Fig.28e.




Fig.28f.




Fig.28g.






Figure 29. Bioactivity of prolamin homologues of A-gliadin 57-73 (IFNg-ELISpot, mean+SEM, n=6)



Omega: AAG17702 (141-157), Gamma: P21292 (96-112), SEC1: Q43639 (335-351), C-HOR: Q40055 (166-182). E-substituted peptides were synthesized with E for Q at position 9.



Figure 30. Healthy HLA-DQ2 Subjects: Change in IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools (median change Day 6 vs Day 0, n=10)



42 / 47

Figure 31. Coeliac HLA-DQ2 Subjects: Change in IFNgamma ELISpot  
Responses to tTG-deamidated Gliadin Peptide Pools  
(median change Day 6 vs Day 0, n=6)




Figure 32. Individual Peptide Contributions to "Summed"  
Gliadin Peptide Response




Figure 33. Coeliac HLA-DQ2/8 Subject C08: Gluten challenge induced IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools




Figure 34. Coeliac HLA-DQ2/8 Subject C07: Change in IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools




Figure 35. Coeliac HLA-DQ8/7 Subject C12: Gluten challenge induced IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools





Figure 36. Coeliac HLA-DQ6/8 Subject C11: Change in IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools



CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
**WO 2003/104273 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/415**,  
A61K 39/35, G01N 33/68, C12N 15/82, A01H 5/10,  
A23L 1/025

(21) International Application Number:  
PCT/GB2003/002450

(22) International Filing Date: 5 June 2003 (05.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0212885.8 5 June 2002 (05.06.2002) GB

(71) Applicant (*for all designated States except US*): **ISIS IN-  
NOVATION LIMITED** [GB/GB]; Ewert House, Ewert  
Place, Summertown, Oxford OX2 7SG (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ANDERSON,**  
**Robert, Paul** [GB/AU]; Autoimmunity and Transplan-  
tation Division, Walter & Eliza Hall Institute, c/o Royal  
Melbourne Hospital PO, Grattan Street, Parkville, VIC  
3050 (AU). **HILL, Adrian, Vivian, Sinton** [IE/GB];  
Wellcome Trust Centre for Human Genetics, University  
of Oxford, Roosevelt Drive, Oxford OX3 7BN (GB).  
**JEWELL, Derek, Parry** [GB/GB]; Gastroenterology  
Unit, Gibson Building, Radcliffe Infirmary, Woodstock  
Road, Oxford OX2 6HE (GB).

(74) Agent: **MARSHALL, Cameron, John**; Carpmals and  
Ransford, 43 Bloomsbury Square, London WC1A 2RA  
(GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report*

(88) Date of publication of the international search report:  
23 September 2004

(48) Date of publication of this corrected version:  
13 January 2005

(15) Information about Correction:  
see PCT Gazette No. 02/2005 of 13 January 2005, Sec-  
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: THERAPEUTIC EPITOPES AND USES THEREOF

(57) Abstract: The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.



## THERAPEUTIC EPITOPES AND USES THEREOF

The invention relates to epitopes useful in the diagnosis and therapy of coeliac disease, including diagnostics, therapeutics, kits, and methods of using the foregoing.

5           An immune reaction to gliadin (a component of gluten) in the diet causes coeliac disease. It is known that immune responses in the intestinal tissue preferentially respond to gliadin which has been modified by an intestinal transglutaminase. Coeliac disease is diagnosed by detection of anti-endomysial antibodies, but this requires confirmation by the finding of a lymphocytic  
10   inflammation in intestinal biopsies. The taking of such a biopsy is inconvenient for the patient.

Investigators have previously assumed that only intestinal T cell responses provide an accurate indication of the immune response against gliadins. Therefore they have concentrated on the investigation of T cell responses in intestinal tissue<sup>1</sup>.  
15   Gliadin epitopes which require transglutaminase modification (before they are recognised by the immune system) are known<sup>2</sup>.

The inventors have found the immunodominant T cell A-gliadin epitope recognised by the immune system in coeliac disease, and have shown that this is recognised by T cells in the peripheral blood of individuals with coeliac disease (see  
20   WO 01/25793). Such T cells were found to be present at high enough frequencies to be detectable without restimulation (i.e. a 'fresh response' detection system could be used). The epitope was identified using a non-T cell cloning based method which provided a more accurate reflection of the epitopes being recognised. The immunodominant epitope requires transglutaminase modification (causing  
25   substitution of a particular glutamine to glutamate) before immune system recognition.

Based on this work the inventors have developed a test which can be used to diagnose coeliac disease at an early stage. The test may be carried out on a sample from peripheral blood and therefore an intestinal biopsy is not required. The test is  
30   more sensitive than the antibody tests which are currently being used.

The invention thus provides a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:

(a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO:1 (PQPELPY) or SEQ ID NO:2 (QLQFPQPPELPYPQPQS), or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3, (ii) an epitope comprising  
5 sequence comprising: SEQ ID NO:1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3 (shown in Table 1), which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50  
10 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining *in vitro* whether T cells in the sample recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

Through comprehensive mapping of wheat gliadin T cell epitopes (see  
15 Example 13), the inventors have also found epitopes bioactive in coeliac disease in HLA-DQ2+ patients in other wheat gliadins, having similar core sequences (e.g., SEQ ID NOS:18-22) and similar full length sequences (e.g., SEQ ID NOS:31-36), as well as in rye secalins and barley hordeins (e.g., SEQ ID NOS:39-41); see also Tables 20 and 21. Additionally, several epitopes bioactive in coeliac disease in  
20 HLA-DQ8+ patients have been identified (e.g., SEQ ID NOS:42-44, 46). This comprehensive mapping thus provides the dominant epitopes recognized by T cells in coeliac patients. Thus, the above-described method and other methods of the invention described herein may be performed using any of these additional identified epitopes, and analogues and equivalents thereof; (i) and (ii) herein include these  
25 additional epitopes. That is, the agents of the invention also include these novel epitopes.

The invention also provides use of the agent for the preparation of a diagnostic means for use in a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T  
30 cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The finding of an immunodominant epitope which is modified by transglutaminase (as well as the additional other epitopes defined herein) also allows diagnosis of coeliac disease based on determining whether other types of immune response to this epitope are present. Thus the invention also provides a method of  
5 diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to the epitope in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.

The invention additionally provides the agent, optionally in association with a  
10 carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent. Also provided is an antagonist of a T cell which has a T cell receptor that recognises (i) or (ii), optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells. Additionally provided is the agent or an analogue that binds an antibody (that  
15 binds the agent) for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.

The invention provides a method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined  
20 above is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

The invention also provides a mutant gliadin protein whose wild-type sequence can be modified by a transglutaminase to a sequence that comprises an epitope comprising sequence as defined above, but which mutant gliadin protein has  
25 been modified in such a way that it does not contain sequence which can be modified by a transglutaminase to a sequence that comprises such an epitope comprising sequence; or a fragment of such a mutant gliadin protein which is at least 15 amino acids long and which comprises sequence which has been modified in said way.

The invention also provides a protein that comprises a sequence which is able  
30 to bind to a T cell receptor, which T cell receptor recognises the agent, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

Additionally the invention provides a food that comprises the proteins defined above.

#### SUMMARY OF THE INVENTION

5 The present invention provides methods of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from: a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs:18-22, 31-36, 39-44, and 46, and equivalents thereof; and b) an analogue of a) which is capable of being recognised by a T cell  
10 receptor that recognises the peptide of a) and which is not more than 50 amino acids in length; and c) optionally, in addition to the agent selected from a) and b), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NO:1 and SEQ ID NO:2. In some embodiments, the agent is HLA-DQ2-restricted, HLA-DQ8-restricted or one agent is HLA-DQ2-restricted and a second agent is HLA-  
15 DQ8-restricted. In some embodiments, the agent comprises a wheat epitope, a rye epitope, a barley epitope or any combination thereof either as a single agent or as multiple agents.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition  
20 comprising an agent above and pharmaceutically acceptable carrier or diluent.

The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined above, and a pharmaceutically acceptable carrier or diluent.

25 The present invention also provides methods of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

30 The present invention also provides methods of preventing or treating coeliac disease by 1) diagnosing coeliac disease in an individual by either: a) contacting a sample from the host with at least one agent selected from: i) a peptide comprising at

least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and iii) optionally, in addition to the agent selected from i) and ii), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NOS:1 and 2; and determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease; or b) administering an agent as defined above and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease; and 2) administering to an individual diagnosed as having, or being susceptible to, coeliac disease a therapeutic agent for preventing or treating coeliac disease.

The present invention also provides agents as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.

The present invention also provides antagonists of a T cell which has a T cell receptor as defined above, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.

The present invention also provides proteins that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined above, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

The present invention also provides pharmaceutical compositions comprising an agent or antagonist as defined and a pharmaceutically acceptable carrier or diluent.

The present invention also provides compositions for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined above, which composition comprises an agent as defined above.

The present invention also provides compositions for antagonising a T cell response to an agent as defined above, which composition comprises an antagonist as defined above.

The present invention also provides mutant gliadin proteins whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined in claim 1, which mutant gliadin protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined above; or a fragment of such a mutant gliadin protein which is at least 15 amino acids long and which comprises the mutation.

The present invention also provides polynucleotides that comprises a coding sequence that encodes a protein or fragment as defined above.

The present invention also provides cells comprising a polynucleotide as defined above or which has been transformed with such a polynucleotide.

The present invention also provides mammals that expresses a T cell receptor as defined above.

The present invention also provides methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: a) contacting a sample from the host with at least one agent selected from i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof; and ii) an analogue of i) which is capable of being recognised by a T cell receptor that recognises i) and which is not more than 50 amino acids in length; and iii) optionally, in addition to the agent selected from i) and ii), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NOS:1 and 2; and b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

The present invention also provides methods of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence is present in the composition, the presence of the protein indicating that the composition is capable of causing coeliac disease.

The present invention also provides methods of identifying an antagonist of a T cell, which T cell recognises an agent as defined above, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the

detecting of any such decrease in said ability indicating that the substance is an antagonist.

The present invention also provides kits for carrying out any of the method described above comprising an agent as defined above and a means to detect the  
5 recognition of the peptide by the T cell.

The present invention also provides methods of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined above which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the  
10 prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

The present invention also provides processes for the production of a protein encoded by a coding sequence as defined above which process comprises: a)  
cultivating a cell described above under conditions that allow the expression of the  
15 protein; and optionally b) recovering the expressed protein.

The present invention also provides methods of obtaining a transgenic plant cell comprising transforming a plant cell with a vector as described above to give a transgenic plant cell.

The present invention also provides methods of obtaining a first-generation  
20 transgenic plant comprising regenerating a transgenic plant cell transformed with a vector as described above to give a transgenic plant.

The present invention also provides methods of obtaining a transgenic plant seed comprising obtaining a transgenic seed from a transgenic plant obtainable as described above.

25 The present invention also provides methods of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method as described above, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

30 The present invention also provides transgenic plant cells; plants, plant seeds or progeny plants obtainable by any of the methods described above.

The present invention also provides transgenic plants or plant seeds comprising plant cells as described above.

The present invention also provides transgenic plant cell calluses comprising plant cells as described above obtainable from a transgenic plant cell, first-generation  
5 plant, plant seed or progeny as defined above.

The present invention also provides methods of obtaining a crop product comprising harvesting a crop product from a plant according to any method described above and optionally further processing the harvested product.

The present invention also provides food that comprises a protein as defined  
10 above.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The invention is illustrated by the accompanying drawings in which:

Figure 1 shows freshly isolated PBMC (peripheral blood mononuclear cell)  
15 IFN $\gamma$  ELISPOT responses (vertical axis shows spot forming cells per 10<sup>6</sup> PBMC) to transglutaminase (tTG)-treated and untreated peptide pool 3 (each peptide 10  $\mu$ g/ml) including five overlapping 15mers spanning A-gliadin 51-85 (see Table 1) and a-chymotrypsin-digested gliadin (40  $\mu$ g/ml) in coeliac disease Subject 1, initially in remission following a gluten free diet then challenged with 200g bread daily for three  
20 days from day 1 (a). PBMC IFN $\gamma$  ELISPOT responses by Subject 2 to tTG-treated A-gliadin peptide pools 1-10 spanning the complete A-gliadin protein during ten day bread challenge (b). The horizontal axis shows days after commencing bread.

Figure 2 shows PBMC IFN $\gamma$  ELISPOT responses to tTG-treated peptide pool 3 (spanning A-gliadin 51-85) in 7 individual coeliac disease subjects (vertical axis  
25 shows spot forming cells per 10<sup>6</sup> PBMC), initially in remission on gluten free diet, challenged with bread for three days (days 1 to 3). The horizontal axis shows days after commencing bread. (a). PBMC IFN $\gamma$  Elispot responses to tTG-treated overlapping 15mer peptides included in pool 3; bars represent the mean ( $\pm$  SEM) response to individual peptides (10  $\mu$ g/ml) in 6 Coeliac disease subjects on day 6 or  
30 7(b). (In individual subjects, ELISPOT responses to peptides were calculated as a % of response elicited by peptide 12 - as shown by the vertical axis.)



Figure 3 shows PBMC IFN $\gamma$  ELISPOT responses to tTG-treated truncations of A-gliadin 56-75 (0.1  $\mu$ M). Bars represent the mean ( $\pm$  SEM) in 5 Coeliac disease subjects. (In individual subjects, responses were calculated as the % of the maximal response elicited by any of the peptides tested.)

5 Figure 4 shows how the minimal structure of the dominant A-gliadin epitope was mapped using tTG-treated 7-17mer A-gliadin peptides (0.1  $\mu$ M) including the sequence, PQQQLPY (SEQ ID NO:4) (A-gliadin 62-68) (a), and the same peptides without tTG treatment but with the substitution Q $\rightarrow$ E65 (b). Each line represents PBMC IFN $\gamma$  ELISPOT responses in each of three Coeliac disease subjects on day 6  
10 or 7 after bread was ingested on days 1-3. (In individual subjects, ELISPOT responses were calculated as a % of the response elicited by the 17mer, A-gliadin 57-73.)

Figure 5 shows the amino acids that were deamidated by tTG. A-gliadin 56-75 LQLQFPQPQLPYQPQSFP (SEQ ID NO:5) (0.1  $\mu$ M) was incubated with tTG  
15 (50  $\mu$ g/ml) at 37°C for 2 hours. A single product was identified and purified by reverse phase HPLC. Amino acid analysis allowed % deamidation (Q $\rightarrow$ E) of each Gln residue in A-gliadin 56-75 attributable to tTG to be calculated (vertical axis).

Figure 6 shows the effect of substituting Q $\rightarrow$ E in A-gliadin 57-73 at other positions in addition to Q65 using the 17mers: ELQFPQPQELPYQPQS (SEQ ID  
20 NO:6) (E57,65), QLQFPQPELPYQPPES (SEQ ID NO:7) (E65,72),  
ELQFPQPELPYQPPES (SEQ ID NO:8) (E57, 65, 72), and  
QLQFPQPELPYQPQS (SEQ ID NO:2) (E65) in three Coeliac disease subjects on day 6 or 7 after bread was ingested on days 1-3. Vertical axis shows % of the E65 response.

25 Figure 7 shows that tTG treated A-gliadin 56-75 (0.1  $\mu$ M) elicited IFN-g ELISPOT responses in (a) CD4 and CD8 magnetic bead depleted PBMC. (Bars represent CD4 depleted PBMC responses as a % of CD8 depleted PBMC responses; spot forming cells per million CD8 depleted PBMC were: Subject 4: 29, and Subject 6: 535). (b) PBMC IFN $\gamma$  ELISPOT responses (spot forming cells/million PBMC)  
30 after incubation with monoclonal antibodies to HLA-DR (L243), -DQ (L2) and -DP (B7.21) (10  $\mu$ g/ml) 1h prior to tTG-treated 56-75 (0.1  $\mu$ M) in two coeliac disease subjects homozygous for HLA-DQ a1\*0501, b1\*0201.

Figure 8 shows the effect of substituting Glu at position 65 for other amino acids in the immunodominant epitope. The vertical axis shows the % response in the 3 subjects in relation to the immunodominant epitope.

Figure 9 shows the immunoreactivity of naturally occurring gliadin peptides (measuring responses from 3 subjects) which contain the sequence PQLPY (SEQ ID NO:12) with (shaded) and without (clear) transglutaminase treatment.

Figure 10 shows CD8, CD4,  $\beta_7$ , and  $\alpha^E$ -specific immunomagnetic bead depletion of peripheral blood mononuclear cells from two coeliac subjects 6 days after commencing gluten challenge followed by interferon gamma ELISpot. A-gliadin 57-73 QE65 (25mcg/ml), tTG-treated chymotrypsin-digested gliadin (100 mcg/ml) or PPD (10 mcg/ml) were used as antigen.

Figure 11 shows the optimal T cell epitope length.

Figure 12 shows a comparison of A-gliadin 57-73 QE65 with other peptides in a dose response study.

Figure 13 shows a comparison of gliadin and A-gliadin 57-73 QE65 specific responses.

Figure 14 shows the bioactivity of gliadin polymorphisms in coeliac subjects.

Figures 15 and 16 show the defining of the core epitope sequence.

Figures 17 to 27 show the agonist activity of A-gliadin 57-73 QE65 variants.

Figure 28 shows responses in different patient groups.

Figure 29 shows bioactivity of prolamins homologues of A-gliadin 57-73.

Figure 30 shows, for healthy HLA-DQ2 subjects, the change in IFN-gamma ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 31 shows, for coeliac HLA-DQ2 subjects, the change in IFN-gamma ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 32 shows individual peptide contributions to "summed" gliadin peptide response.

Figure 33 shows, for coeliac HLA-DQ2/8 subject C08, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 34 shows, for coeliac HLA-DQ2/8 subject C07, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 35 shows, for coeliac HLA-DQ8/7 subject C12, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

Figure 36 shows, for coeliac HLA-DQ6/8 subject C11, gluten challenge induced IFN $\gamma$  ELISpot responses to tTG-deamidated gliadin peptide pools.

5

### Detailed Description of the Invention

The term "coeliac disease" encompasses a spectrum of conditions caused by varying degrees of gluten sensitivity, including a severe form characterised by a flat small intestinal mucosa (hyperplastic villous atrophy) and other forms characterised by milder symptoms.

The individual mentioned above (in the context of diagnosis or therapy) is human. They may have coeliac disease (symptomatic or asymptomatic) or be suspected of having it. They may be on a gluten free diet. They may be in an acute phase response (for example they may have coeliac disease, but have only ingested gluten in the last 24 hours before which they had been on a gluten free diet for 14 to 28 days).

The individual may be susceptible to coeliac disease, such as a genetic susceptibility (determined for example by the individual having relatives with coeliac disease or possessing genes which cause predisposition to coeliac disease).

20

### The agent

The agent is typically a peptide, for example of length 7 to 50 amino acids, such as 10 to 40, or 15 to 30 amino acids in length.

SEQ ID NO:1 is PQPELPY. SEQ ID NO:2 is QLQPFPPQPELPYPQPQS. SEQ ID NO:3 is shown in Table 1 and is the sequence of a whole A-gliadin. The glutamate at position 4 of SEQ ID NO:1 (equivalent to position 9 of SEQ ID NO:2) is generated by transglutaminase treatment of A-gliadin.

The agent may be the peptide represented by SEQ ID NO:1 or 2 or an epitope comprising sequence that comprises SEQ ID NO:1 which is an isolated oligopeptide derived from a gliadin protein; or an equivalent of these sequences from a naturally occurring gliadin protein which is a homologue of SEQ ID NO:3. Thus the epitope may be a derivative of the protein represented by SEQ ID NO:3. Such a derivative is

30

typically a fragment of the gliadin, or a mutated derivative of the whole protein or fragment. Therefore the epitope of the invention does not include this naturally occurring whole gliadin protein, and does not include other whole naturally occurring gliadins.

5       The epitope may thus be a fragment of A-gliadin (e.g. SEQ ID NO:3), which comprises the sequence of SEQ ID NO:1, obtainable by treating (fully or partially) with transglutaminase, i.e. with 1, 2, 3 or more glutamines substituted to glutamates (including the substitution within SEQ ID NO:1).

Such fragments may be or may include the sequences represented by  
10       positions 55 to 70, 58 to 73, 61 to 77 of SEQ ID NO:3 shown in Table 1. Typically such fragments will be recognised by T cells to at least the same extent that the peptides represented by SEQ ID NO:1 or 2 are recognised in any of the assays described herein using samples from coeliac disease patients.

Additionally, the agent may be the peptide represented by any of SEQ ID  
15       NOS:18-22, 31-36, 39-44, and 46 or a protein comprising a sequence corresponding to any of SEQ ID NOS:18-22, 31-36, 39-44, and 46 (such as fragments of a gliadin comprising any of SEQ ID NOS:18-22, 31-36, 39-44, and 46, for example after the gliadin has been treated with transglutaminase). Bioactive fragments of such sequences are also agents of the invention. Sequences equivalent to any of SEQ ID  
20       NOS:18-22, 31-36, 39-44, and 46 or analogues of these sequences are also agents of the invention.

In the case where the epitope comprises a sequence equivalent to the above epitopes (including fragments) from another gliadin protein (e.g. any of the gliadin proteins mentioned herein or any gliadins which cause coeliac disease), such  
25       equivalent sequences will correspond to a fragment of a gliadin protein typically treated (partially or fully) with transglutaminase. Such equivalent peptides can be determined by aligning the sequences of other gliadin proteins with the gliadin from which the original epitope derives, such as with SEQ ID NO:3 (for example using any of the programs mentioned herein). Transglutaminase is commercially available  
30       (e.g. Sigma T-5398). Table 4 provides a few examples of suitable equivalent sequences.

The agent which is an analogue is capable of being recognised by a TCR which recognises (i) or (ii). Therefore generally when the analogue is added to T cells in the presence of (i) or (ii), typically also in the presence of an antigen presenting cell (APC) (such as any of the APCs mentioned herein), the analogue  
5 inhibits the recognition of (i) or (ii), i.e. the analogue is able to compete with (i) or (ii) in such a system.

The analogue may be one which is capable of binding the TCR which recognises (i) or (ii). Such binding can be tested by standard techniques. Such TCRs can be isolated from T cells which have been shown to recognise (i) or (ii) (e.g. using  
10 the method of the invention). Demonstration of the binding of the analogue to the TCRs can then shown by determining whether the TCRs inhibit the binding of the analogue to a substance that binds the analogue, e.g. an antibody to the analogue. Typically the analogue is bound to a class II MHC molecule (e.g. HLA-DQ2) in such an inhibition of binding assay.

15 Typically the analogue inhibits the binding of (i) or (ii) to a TCR. In this case the amount of (i) or (ii) which can bind the TCR in the presence of the analogue is decreased. This is because the analogue is able to bind the TCR and therefore competes with (i) or (ii) for binding to the TCR.

T cells for use in the above binding experiments can be isolated from patients  
20 with coeliac disease, for example with the aid of the method of the invention.

Other binding characteristics of the analogue may also be the same as (i) or (ii), and thus typically the analogue binds to the same MHC class II molecule to which the peptide binds (HLA-DQ2 or -DQ8). The analogue typically binds to antibodies specific for (i) or (ii), and thus inhibits binding of (i) or (ii) to such  
25 antibodies.

The analogue is typically a peptide. It may have homology with (i) or (ii), typically at least 70% homology, preferably at least 80, 90%, 95%, 97% or 99% homology with (i) or (ii), for example over a region of at least 15 more (such as the entire length of the analogue and/or (i) or (ii), or across the region which contacts the  
30 TCR or binds the MHC molecule) contiguous amino acids. Methods of measuring protein homology are well known in the art and it will be understood by those of skill

in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings)

5 (Devereux *et al* (1984) *Nucleic Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically on their default settings), for example as described in Altschul S. F. (1993) *J Mol Evol* 36:290-300; Altschul, S, F *et al* (1990) *J Mol Biol* 215:403-10.

Software for performing BLAST analyses is publicly available through the  
10 National Center for Biotechnology Information on the world wide web through the internet at, for example, "www.ncbi.nlm.nih.gov/". This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is  
15 referred to as the neighbourhood word score threshold (Altschul *et al*, supra). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off  
20 by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the BLOSUM62 scoring  
25 matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci.*  
30 *USA* 90: 5873-5787. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences

would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

5 The homologous peptide analogues typically differ from (i) or (ii) by 1, 2, 3, 4, 5, 6, 7, 8 or more mutations (which may be substitutions, deletions or insertions). These mutations may be measured across any of the regions mentioned above in relation to calculating homology. The substitutions are preferably 'conservative'. These are defined according to the following Table. Amino acids in the same block  
10 in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar – uncharged	C S T M
		N Q
	Polar – charged	D E
		K R
		H F W Y
AROMATIC		

Typically the amino acids in the analogue at the equivalent positions to amino  
15 acids in (i) or (ii) that contribute to binding the MHC molecule or are responsible for the recognition by the TCR, are the same or are conserved.

Typically the analogue peptide comprises one or more modifications, which may be natural post-translation modifications or artificial modifications. The modification may provide a chemical moiety (typically by substitution of a  
20 hydrogen, e.g. of a C-H bond), such as an amino, acetyl, hydroxy or halogen (e.g. fluorine) group or carbohydrate group. Typically the modification is present on the N or C terminus.

The analogue may comprise one or more non-natural amino acids, for example amino acids with a side chain different from natural amino acids.

Generally, the non-natural amino acid will have an N terminus and/or a C terminus. The non-natural amino acid may be an L- or a D- amino acid.

The analogue typically has a shape, size, flexibility or electronic configuration that is substantially similar to (i) or (ii). It is typically a derivative of (i) or (ii). In one embodiment the analogue is a fusion protein comprising the sequence of SEQ ID NO:1 or 2, or any of the other peptides mentioned herein; and non-gliadin sequence.

In one embodiment the analogue is or mimics (i) or (ii) bound to a MHC class II molecule. 2, 3, 4 or more of such complexes may be associated or bound to each other, for example using a biotin/streptavidin based system, in which typically 2, 3 or 4 biotin labelled MHC molecules bind to a streptavidin moiety. This analogue typically inhibits the binding of the (i) or (ii)/MHC Class II complex to a TCR or antibody which is specific for the complex.

The analogue is typically an antibody or a fragment of an antibody, such as a Fab or (Fab)<sub>2</sub> fragment. The analogue may be immobilised on a solid support, particularly an analogue that mimics peptide bound to a MHC molecule.

The analogue is typically designed by computational means and then synthesised using methods known in the art. Alternatively the analogue can be selected from a library of compounds. The library may be a combinatorial library or a display library, such as a phage display library. The library of compounds may be expressed in the display library in the form of being bound to a MHC class II molecule, such as HLA-DQ2 or -DQ8. Analogues are generally selected from the library based on their ability to mimic the binding characteristics (i) or (ii). Thus they may be selected based on ability to bind a TCR or antibody which recognises (i) or (ii).

Typically analogues will be recognised by T cells to at least the same extent as any of the agents (i) or (ii), for example at least to the same extent as the equivalent epitope and preferably to the same extent as the peptide represented by SEQ ID NO:2, is recognised in any of the assays described herein, typically using T cells from coeliac disease patients. Analogues may be recognised to these extents *in vivo* and thus may be able to induce coeliac disease symptoms to at least the same



extent as any of the agents mentioned herein (e.g. in a human patient or animal model).

Analogues may be identified in a method comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope of the invention, recognition of the substance indicating that the substance is an analogue. Such TCRs may be any of the TCRs mentioned herein, and may be present on T cells. Any suitable assay mentioned herein can be used to identify the analogue. In one embodiment this method is carried out *in vivo*. As mentioned above preferred analogues are recognised to at least the same extent as the peptide SEQ ID NO:2, and so the method may be used to identify analogues which are recognised to this extent.

In one embodiment the method comprises determining whether a candidate substance is able to inhibit the recognition of an epitope of the invention, inhibition of recognition indicating that the substance is an analogue.

The agent may be a product comprising at least 2, 5, 10 or 20 agents as defined by (i), (ii) or (iii). Typically the composition comprises epitopes of the invention (or equivalent analogues) from different gliadins, such as any of the species or variety of or types of gliadin mentioned herein. Preferred compositions comprise at least one epitope of the invention, or equivalent analogue, from all of the gliadins present in any of the species or variety mentioned herein, or from 2, 3, 4 or more of the species mentioned herein (such as from the panel of species consisting of wheat, rye, barley, oats and triticale). Thus, the agent may be monovalent or multivalent.

## 25 **Diagnosis**

As mentioned above the method of diagnosis of the invention may be based on the detection of T cells that bind the agent or on the detection of antibodies that recognise the agent.

The T cells that recognise the agent in the method (which includes the use mentioned above) are generally T cells that have been pre-sensitised *in vivo* to gliadin. As mentioned above such antigen-experienced T cells have been found to be present in the peripheral blood.

In the method the T cells can be contacted with the agent *in vitro* or *in vivo*, and determining whether the T cells recognise the agent can be performed *in vitro* or *in vivo*. Thus the invention provides the agent for use in a method of diagnosis practiced on the human body. Different agents are provided for simultaneous,  
5 separate or sequential use in such a method.

The *in vitro* method is typically carried out in aqueous solution into which the agent is added. The solution will also comprise the T cells (and in certain embodiments the APCs discussed below). The term 'contacting' as used herein includes adding the particular substance to the solution.

10 Determination of whether the T cells recognise the agent is generally accomplished by detecting a change in the state of the T cells in the presence of the agent or determining whether the T cells bind the agent. The change in state is generally caused by antigen specific functional activity of the T cell after the TCR binds the agent. The change of state may be measured inside (e.g. change in  
15 intracellular expression of proteins) or outside (e.g. detection of secreted substances) the T cells.

The change in state of the T cell may be the start of or increase in secretion of a substance from the T cell, such as a cytokine, especially IFN- $\gamma$ , IL-2 or TNF- $\alpha$ . Determination of IFN- $\gamma$  secretion is particularly preferred. The substance can  
20 typically be detected by allowing it to bind to a specific binding agent and then measuring the presence of the specific binding agent/substance complex. The specific binding agent is typically an antibody, such as polyclonal or monoclonal antibodies. Antibodies to cytokines are commercially available, or can be made using standard techniques.

25 Typically the specific binding agent is immobilised on a solid support. After the substance is allowed to bind the solid support can optionally be washed to remove material which is not specifically bound to the agent. The agent/substance complex may be detected by using a second binding agent that will bind the complex. Typically the second agent binds the substance at a site which is different  
30 from the site which binds the first agent. The second agent is preferably an antibody and is labelled directly or indirectly by a detectable label.

Thus the second agent may be detected by a third agent that is typically labelled directly or indirectly by a detectable label. For example the second agent may comprise a biotin moiety, allowing detection by a third agent which comprises a streptavidin moiety and typically alkaline phosphatase as a detectable label.

5 In one embodiment the detection system which is used is the *ex-vivo* ELISPOT assay described in WO 98/23960. In that assay IFN- $\gamma$  secreted from the T cell is bound by a first IFN- $\gamma$  specific antibody that is immobilised on a solid support. The bound IFN- $\gamma$  is then detected using a second IFN- $\gamma$  specific antibody which is labelled with a detectable label. Such a labelled antibody can be obtained from  
10 MABTECH (Stockholm, Sweden). Other detectable labels which can be used are discussed below.

The change in state of the T cell that can be measured may be the increase in the uptake of substances by the T cell, such as the uptake of thymidine. The change in state may be an increase in the size of the T cells, or proliferation of the T cells, or  
15 a change in cell surface markers on the T cell.

In one embodiment the change of state is detected by measuring the change in the intracellular expression of proteins, for example the increase in intracellular expression of any of the cytokines mentioned above. Such intracellular changes may be detected by contacting the inside of the T cell with a moiety that binds the  
20 expressed proteins in a specific manner and which allows sorting of the T cells by flow cytometry.

In one embodiment when binding the TCR the agent is bound to an MHC class II molecule (typically HLA-DQ2 or -DQ8), which is typically present on the surface of an antigen presenting cell (APC). However as mentioned herein other  
25 agents can bind a TCR without the need to also bind an MHC molecule.

Generally the T cells which are contacted in the method are taken from the individual in a blood sample, although other types of samples which contain T cells can be used. The sample may be added directly to the assay or may be processed first. Typically the processing may comprise diluting of the sample, for example  
30 with water or buffer. Typically the sample is diluted from 1.5 to 100 fold, for example 2 to 50 or 5 to 10 fold.

The processing may comprise separation of components of the sample. Typically mononuclear cells (MCs) are separated from the samples. The MCs will comprise the T cells and APCs. Thus in the method the APCs present in the separated MCs can present the peptide to the T cells. In another embodiment only T  
5 cells, such as only CD4 T cells, can be purified from the sample. PBMCs, MCs and T cells can be separated from the sample using techniques known in the art, such as those described in Lalvani *et al* (1997) *J. Exp. Med.* 186, p859-865.

In one embodiment, the T cells used in the assay are in the form of unprocessed or diluted samples, or are freshly isolated T cells (such as in the form of  
10 freshly isolated MCs or PBMCs) which are used directly *ex vivo*, i.e. they are not cultured before being used in the method. Thus the T cells have not been restimulated in an antigen specific manner *in vitro*. However the T cells can be cultured before use, for example in the presence of one or more of the agents, and generally also exogenous growth promoting cytokines. During culturing the agent(s)  
15 are typically present on the surface of APCs, such as the APC used in the method. Pre-culturing of the T cells may lead to an increase in the sensitivity of the method. Thus the T cells can be converted into cell lines, such as short term cell lines (for example as described in Ota *et al* (1990) *Nature* 346, p183-187).

The APC that is typically present in the method may be from the same  
20 individual as the T cell or from a different host. The APC may be a naturally occurring APC or an artificial APC. The APC is a cell that is capable of presenting the peptide to a T cell. It is typically a B cell, dendritic cell or macrophage. It is typically separated from the same sample as the T cell and is typically co-purified with the T cell. Thus the APC may be present in MCs or PBMCs. The APC is  
25 typically a freshly isolated *ex vivo* cell or a cultured cell. It may be in the form of a cell line, such as a short term or immortalised cell line. The APC may express empty MHC class II molecules on its surface.

In the method one or more (different) agents may be used. Typically the T  
cells derived from the sample can be placed into an assay with all the agents which it  
30 is intended to test or the T cells can be divided and placed into separate assays each of which contain one or more of the agents.

The invention also provides the agents such as two or more of any of the agents mentioned herein (e.g. the combinations of agents which are present in the composition agent discussed above) for simultaneous separate or sequential use (eg. for *in vivo* use).

5        In one embodiment agent *per se* is added directly to an assay comprising T cells and APCs. As discussed above the T cells and APCs in such an assay could be in the form of MCs. When agents that can be recognised by the T cell without the need for presentation by APCs are used then APCs are not required. Analogues which mimic the original (i) or (ii) bound to a MHC molecule are an example of such  
10        an agent.

      In one embodiment the agent is provided to the APC in the absence of the T cell. The APC is then provided to the T cell; typically after being allowed to present the agent on its surface. The peptide may have been taken up inside the APC and presented; or simply be taken up onto the surface without entering inside the APC.

15        The duration for which the agent is contacted with the T cells will vary depending on the method used for determining recognition of the peptide. Typically  $10^5$  to  $10^7$ , preferably  $5 \times 10^5$  to  $10^6$  PBMCs are added to each assay. In the case where agent is added directly to the assay its concentration is from  $10^{-1}$  to  $10^3 \mu\text{g/ml}$ , preferably 0.5 to  $50 \mu\text{g/ml}$  or 1 to  $10 \mu\text{g/ml}$ .

20        Typically the length of time for which the T cells are incubated with the agent is from 4 to 24 hours, preferably 6 to 16 hours. When using *ex vivo* PBMCs it has been found that  $0.3 \times 10^6$  PBMCs can be incubated in  $10 \mu\text{g/ml}$  of peptide for 12 hours at  $37^\circ\text{C}$ .

      The determination of the recognition of the agent by the T cells may be done  
25        by measuring the binding of the agent to the T cells (this can be carried out using any suitable binding assay format discussed herein). Typically T cells which bind the agent can be sorted based on this binding, for example using a FACS machine. The presence of T cells that recognise the agent will be deemed to occur if the frequency of cells sorted using the agent is above a "control" value. The frequency of antigen-experienced T cells is generally 1 in  $10^6$  to 1 in  $10^3$ , and therefore whether or not the  
30        sorted cells are antigen-experienced T cells can be determined.

The determination of the recognition of the agent by the T cells may be measured *in vivo*. Typically the agent is administered to the host and then a response which indicates recognition of the agent may be measured. The agent is typically administered intradermally or epidermally. The agent is typically administered by contacting with the outside of the skin, and may be retained at the site with the aid of a plaster or dressing. Alternatively the agent may be administered by needle, such as by injection, but can also be administered by other methods such as ballistics (e.g. the ballistics techniques which have been used to deliver nucleic acids). EP-A-0693119 describes techniques that can typically be used to administer the agent. Typically from 0.001 to 1000 µg, for example from 0.01 to 100 µg or 0.1 to 10 µg of agent is administered.

In one embodiment a product can be administered which is capable of providing the agent *in vivo*. Thus a polynucleotide capable of expressing the agent can be administered, typically in any of the ways described above for the administration of the agent. The polynucleotide typically has any of the characteristics of the polynucleotide provided by the invention which is discussed below. The agent is expressed from the polynucleotide *in vivo*. Typically from 0.001 to 1000 µg, for example from 0.01 to 100 µg or 0.1 to 10 µg of polynucleotide is administered.

Recognition of the agent administered to the skin is typically indicated by the occurrence of inflammation (e.g. induration, erythema or oedema) at the site of administration. This is generally measured by visual examination of the site.

The method of diagnosis based on the detection of an antibody that binds the agent is typically carried out by contacting a sample from the individual (such as any of the samples mentioned here, optionally processed in any manner mentioned herein) with the agent and determining whether an antibody in the sample binds the agent, such a binding indicating that the individual has, or is susceptible to coeliac disease. Any suitable format of binding assay may be used, such as any such format mentioned herein.

30

## Therapy

The identification of the immunodominant epitope and other epitopes described herein allows therapeutic products to be made which target the T cells which recognise this epitope (such T cells being ones which participate in the immune response against gliadin). These findings also allow the prevention or  
5 treatment of coeliac disease by suppressing (by tolerisation) an antibody or T cell response to the epitope(s).

Certain agents of the invention bind the TCR that recognises the epitope of the invention (as measured using any of the binding assays discussed above) and cause tolerisation of the T cell that carries the TCR. Such agents, optionally in  
10 association with a carrier, can therefore be used to prevent or treat coeliac disease.

Generally tolerisation can be caused by the same peptides which can (after being recognised by the TCR) cause antigen specific functional activity of the T cell (such as any such activity mentioned herein, e.g. secretion of cytokines). Such agents cause tolerisation when they are presented to the immune system in a  
15 'tolerising' context.

Tolerisation leads to a decrease in the recognition of a T cell or antibody epitope by the immune system. In the case of a T cell epitope this can be caused by the deletion or anergising of T cells that recognise the epitope. Thus T cell activity (for example as measured in suitable assays mentioned herein) in response to the  
20 epitope is decreased. Tolerisation of an antibody response means that a decreased amount of specific antibody to the epitope is produced when the epitope is administered.

Methods of presenting antigens to the immune system in such a context are known and are described for example in Yoshida et al. Clin. Immunol.  
25 Immunopathol. 82, 207-215 (1997), Thureau et al. Clin. Exp. Immunol. 109, 370-6 (1997), and Weiner et al. Res. Immunol. 148, 528-33 (1997). In particular certain routes of administration can cause tolerisation, such as oral, nasal or intraperitoneal. Tolerisation may also be accomplished via dendritic cells and tetramers presenting peptide. Particular products which cause tolerisation may be administered (e.g. in a  
30 composition that also comprises the agent) to the individual. Such products include cytokines, such as cytokines that favour a Th2 response (e.g. IL-4, TGF- $\beta$  or IL-10). Products or agent may be administered at a dose that causes tolerisation.

The invention provides a protein that comprises a sequence able to act as an antagonist of the T cell (which T cell recognises the agent). Such proteins and such antagonists can also be used to prevent or treat coeliac disease. The antagonist will cause a decrease in the T cell response. In one embodiment, the antagonist binds the TCR of the T cell (generally in the form of a complex with HLA-DQ2 or -DQ8) but instead of causing normal functional activation causing an abnormal signal to be passed through the TCR intracellular signalling cascade, which causes the T cell to have decreased function activity (e.g. in response to recognition of an epitope, typically as measured by any suitable assay mentioned herein).

In one embodiment the antagonist competes with epitope to bind a component of MHC processing and presentation pathway, such as an MHC molecule (typically HLA-DQ2 or -DQ8). Thus the antagonist may bind HLA-DQ2 or -DQ8 (and thus be a peptide presented by this MHC molecule), such as peptide TP (Table 10) or a homologue thereof.

Methods of causing antagonism are known in the art. In one embodiment the antagonist is a homologue of the epitopes mentioned above and may have any of the sequence, binding or other properties of the agent (particularly analogues). The antagonists typically differ from any of the above epitopes (which are capable of causing a normal antigen specific function in the T cell) by 1, 2, 3, 4 or more mutations (each of which may be a substitution, insertion or deletion). Such antagonists are termed "altered peptide ligands" or "APL" in the art. The mutations are typically at the amino acid positions that contact the TCR.

The antagonist may differ from the epitope by a substitution within the sequence that is equivalent to the sequence represented by amino acids 65 to 67 of A-gliadin (such antagonists are shown in Table 9). Thus preferably the antagonist has a substitution at the equivalent of position 64, 65 or 67. Preferably the substitution is 64W, 67W, 67M or 65T.

Since the T cell immune response to the epitope of the invention in an individual is polyclonal, more than one antagonist may need to be administered to cause antagonism of T cells of the response which have different TCRs. Therefore the antagonists may be administered in a composition which comprises at least 2, 4, 6 or more different antagonists, which each antagonise different T cells.



The invention also provides a method of identifying an antagonist of a T cell (which recognises the agent), comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response (e.g. using any suitable assay mentioned  
5 herein), the detecting of any such decrease in said ability indicating that the substance is an antagonist.

In one embodiment, the antagonists (including combinations of antagonists to a particular epitope) or tolerising (T cell and antibody tolerising) agents are present in a composition comprising at least 2, 4, 6 or more antagonists or agents which  
10 antagonise or tolerate to different epitopes of the invention, for example to the combinations of epitopes discussed above in relation to the agents which are a product comprising more than one substance.

#### **Testing whether a composition is capable of causing coeliac disease**

As mentioned above the invention provides a method of determining whether  
15 a composition is capable of causing coeliac disease comprising detecting the presence of a protein sequence which is capable of being modified by a transglutaminase to a sequence comprising the agent or epitope of the invention (such transglutaminase activity may be a human intestinal transglutaminase activity).  
20 Typically this is performed by using a binding assay in which a moiety which binds to the sequence in a specific manner is contacted with the composition and the formation of sequence/moiety complex is detected and used to ascertain the presence of the agent. Such a moiety may be any suitable substance (or type of substance) mentioned herein, and is typically a specific antibody. Any suitable format of  
25 binding assay can be used (such as those mentioned herein).

In one embodiment, the composition is contacted with at least 2, 5, 10 or more antibodies which are specific for epitopes of the invention from different gliadins, for example a panel of antibodies capable of recognising the combinations of epitopes discussed above in relation to agents of the invention which are a product  
30 comprising more than one substance.

The composition typically comprises material from a plant that expresses a gliadin which is capable of causing coeliac disease (for example any of the gliadins

or plants mentioned herein). Such material may be a plant part, such as a harvested product (e.g. seed). The material may be processed products of the plant material (e.g. any such product mentioned herein), such as a flour or food that comprises the gliadin. The processing of food material and testing in suitable binding assays is  
5 routine, for example as mentioned in Kricka LJ, J. Biolumin. Chemilumin. 13, 189-93 (1998).

### **Binding assays**

The determination of binding between any two substances mentioned herein  
10 may be done by measuring a characteristic of either or both substances that changes upon binding, such as a spectroscopic change.

The binding assay format may be a 'band shift' system. This involves determining whether the presence of one substance (such as a candidate substance) advances or retards the progress of the other substance during gel electrophoresis.

15 The format may be a competitive binding method which determines whether the one substance is able to inhibit the binding of the other substance to an agent which is known to bind the other substance, such as a specific antibody.

### **Mutant gliadin proteins**

20 The invention provides a gliadin protein in which an epitope sequence of the invention, or sequence which can be modified by a transglutaminase to provide such a sequence has been mutated so that it no longer causes, or is recognised by, a T cell response that recognises the epitope. In this context the term recognition refers to the TCR binding the epitope in such a way that normal (not antagonistic) antigen-  
25 specific functional activity of the T cell occurs.

Methods of identifying equivalent epitopes in other gliadins are discussed above. The wild type of the mutated gliadin is one which causes coeliac disease. Such a gliadin may have homology with SEQ ID NO:3, for example to the degree mentioned above (in relation to the analogue) across all of SEQ ID NO:3 or across  
30 15, 30, 60, 100 or 200 contiguous amino acids of SEQ ID NO:3. Likewise, for other non-A-gliadins, homology will be present between the mutant and the native form of that gliadin. The sequences of other natural gliadin proteins are known in the art.

The mutated gliadin will not cause coeliac disease or will cause decreased symptoms of coeliac disease. Typically the mutation decreases the ability of the epitope to induce a T cell response. The mutated epitope may have a decreased binding to HLA-DQ2 or -DQ8, a decreased ability to be presented by an APC or a decreased ability to bind to or to be recognised (i.e. cause antigen-specific functional activity) by T cells that recognise the agent. The mutated gliadin or epitope will therefore show no or reduced recognition in any of the assays mentioned herein in relation to the diagnostic aspects of the invention.

The mutation may be one or more deletions, additions or substitutions of length 1 to 3, 4 to 6, 6 to 10, 11 to 15 or more in the epitope, for example across sequence SEQ ID NO:2 or across any of SEQ ID NOS: 18-22, 31-36, 39-44, and 46; or across equivalents thereof. Preferably the mutant gliadin has at least one mutation in the sequence SEQ ID NO:1. A preferred mutation is at position 65 in A-gliadin (or in an equivalent position in other gliadins). Typically the naturally occurring glutamine at this position is substituted to any of the amino acids shown in Table 3, preferably to histidine, tyrosine, tryptophan, lysine, proline, or arginine.

The invention thus also provides use of a mutation (such any of the mutations in any of the sequences discussed herein) in an epitope of a gliadin protein, which epitope is an epitope of the invention, to decrease the ability of the gliadin protein to cause coeliac disease.

In one embodiment the mutated sequence is able to act as an antagonist. Thus the invention provides a protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent of the invention, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.

The invention also provides proteins which are fragments of the above mutant gliadin proteins, which are at least 15 amino acids long (e.g. at least 30, 60, 100, 150, 200, or 250 amino acids long) and which comprise the mutations discussed above which decrease the ability of the gliadin to be recognised. Any of the mutant proteins (including fragments) mentioned herein may also be present in the form of fusion proteins, for example with other gliadins or with non-gliadin proteins.

The equivalent wild type protein to the mutated gliadin protein is typically from a graminaceous monocotyledon, such as a plant of genus *Triticum*, e.g. wheat, rye, barley, oats or triticale. The protein is typically an  $\alpha$ ,  $\alpha\beta$ ,  $\beta$ ,  $\gamma$  or  $\omega$  gliadin. The gliadin may be an A-gliadin.

5

#### Kits

The invention also provides a kit for carrying out the method comprising one or more agents and optionally a means to detect the recognition of the agent by the T cell. Typically the different agents are provided for simultaneous, separate or sequential use. Typically the means to detect recognition allows or aids detection based on the techniques discussed above.

Thus the means may allow detection of a substance secreted by the T cells after recognition. The kit may thus additionally include a specific binding moiety for the substance, such as an antibody. The moiety is typically specific for IFN- $\gamma$ . The moiety is typically immobilised on a solid support. This means that after binding the moiety the substance will remain in the vicinity of the T cell which secreted it. Thus "spots" of substance/moiety complex are formed on the support, each spot representing a T cell which is secreting the substance. Quantifying the spots, and typically comparing against a control, allows determination of recognition of the agent.

The kit may also comprise a means to detect the substance/moiety complex. A detectable change may occur in the moiety itself after binding the substance, such as a colour change. Alternatively a second moiety directly or indirectly labelled for detection may be allowed to bind the substance/moiety complex to allow the determination of the spots. As discussed above the second moiety may be specific for the substance, but binds a different site on the substance than the first moiety.

The immobilised support may be a plate with wells, such as a microtitre plate. Each assay can therefore be carried out in a separate well in the plate.

The kit may additionally comprise medium for the T cells, detection moieties or washing buffers to be used in the detection steps. The kit may additionally comprise reagents suitable for the separation from the sample, such as the separation of PBMCs or T cells from the sample. The kit may be designed to allow detection of

30

the T cells directly in the sample without requiring any separation of the components of the sample.

The kit may comprise an instrument which allows administration of the agent, such as intradermal or epidermal administration. Typically such an instrument comprises plaster, dressing or one or more needles. The instrument may allow  
5 ballistic delivery of the agent. The agent in the kit may be in the form of a pharmaceutical composition.

The kit may also comprise controls, such as positive or negative controls. The positive control may allow the detection system to be tested. Thus the positive  
10 control typically mimics recognition of the agent in any of the above methods. Typically in the kits designed to determine recognition *in vitro* the positive control is a cytokine. In the kit designed to detect *in vivo* recognition of the agent the positive control may be antigen to which most individuals should response.

The kit may also comprise a means to take a sample containing T cells from  
15 the host, such as a blood sample. The kit may comprise a means to separate mononuclear cells or T cells from a sample from the host.

#### **Polynucleotides, cells, transgenic mammals and antibodies**

The invention also provides a polynucleotide which is capable of expression  
20 to provide the agent or mutant gliadin proteins. Typically the polynucleotide is DNA or RNA, and is single or double stranded. The polynucleotide will preferably comprise at least 50 bases or base pairs, for example 50 to 100, 100 to 500, 500 to 1000 or 1000 to 2000 or more bases or base pairs. The polynucleotide therefore comprises a sequence which encodes the sequence of SEQ ID NO: 1 or 2 or any of  
25 the other agents mentioned herein. To the 5' and 3' of this coding sequence the polynucleotide of the invention has sequence or codons which are different from the sequence or codons 5' and 3' to these sequences in the corresponding gliadin gene.

5' and/or 3' to the sequence encoding the peptide the polynucleotide has coding or non-coding sequence. Sequence 5' and/or 3' to the coding sequence may  
30 comprise sequences which aid expression, such as transcription and/or translation, of the sequence encoding the agent. The polynucleotide may be capable of expressing the agent prokaryotic or eukaryotic cell. In one embodiment the polynucleotide is

capable of expressing the agent in a mammalian cell, such as a human, primate or rodent (e.g. mouse or rat) cell.

A polynucleotide of the invention may hybridise selectively to a polynucleotide that encodes SEQ ID NO:3 at a level significantly above background.

5 Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C). However, such hybridisation may be carried out under any suitable conditions known in the art (see Sambrook *et al* (1989), Molecular Cloning: A Laboratory Manual). For example, if high stringency is required, suitable  
10 conditions include 0.2 x SSC at 60°C. If lower stringency is required, suitable conditions include 2 x SSC at 60°C.

Agents or proteins of the invention may be encoded by the polynucleotides described herein.

The polynucleotide may form or be incorporated into a replicable vector.

15 Such a vector is able to replicate in a suitable cell. The vector may be an expression vector. In such a vector the polynucleotide of the invention is operably linked to a control sequence which is capable of providing for the expression of the polynucleotide. The vector may contain a selectable marker, such as the ampicillin resistance gene.

20 The polynucleotide or vector may be present in a cell. Such a cell may have been transformed by the polynucleotide or vector. The cell may express the agent. The cell will be chosen to be compatible with the said vector and may for example be a prokaryotic (bacterial), yeast, insect or mammalian cell. The polynucleotide or vector may be introduced into host cells using conventional techniques including  
25 calcium phosphate precipitation, DEAE-dextran transfection, or electroporation.

The invention provides processes for the production of the proteins of the invention by recombinant means. This may comprise (a) cultivating a transformed cell as defined above under conditions that allow the expression of the protein; and preferably (b) recovering the expressed polypeptide. Optionally, the polypeptide  
30 may be isolated and/or purified, by techniques known in the art.

The invention also provides TCRs which recognise (or bind) the agent, or fragments thereof which are capable of such recognition (or binding). These can be

present in the any form mentioned herein (e.g. purity) discussed herein in relation to the protein of the invention. The invention also provides T cells which express such TCRs which can be present in any form (e.g. purity) discussed herein for the cells of the invention.

5           The invention also provides monoclonal or polyclonal antibodies which specifically recognise the agents (such as any of the epitopes of the invention) and which recognise the mutant gliadin proteins (and typically which do not recognise the equivalent wild-type gliadins) of the invention, and methods of making such antibodies. Antibodies of the invention bind specifically to these substances of the  
10 invention.

For the purposes of this invention, the term "antibody" includes antibody fragments such as Fv, F(ab) and F(ab)<sub>2</sub> fragments, as well as single-chain antibodies.

A method for producing a polyclonal antibody comprises immunising a suitable host animal, for example an experimental animal, with the immunogen and  
15 isolating immunoglobulins from the serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified. A method for producing a monoclonal antibody comprises immortalising cells which produce the desired antibody. Hybridoma cells may be produced by fusing spleen cells from an inoculated experimental animal with tumour  
20 cells (Kohler and Milstein (1975) *Nature* 256, 495-497).

An immortalized cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally for formation of ascites fluid or into the blood stream of an allogenic host or immunocompromised host. Human antibody may be prepared by *in*  
25 *vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus.

For the production of both monoclonal and polyclonal antibodies, the experimental animal is suitably a goat, rabbit, rat or mouse. If desired, the immunogen may be administered as a conjugate in which the immunogen is coupled,  
30 for example via a side chain of one of the amino acid residues, to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier. The antibody obtained may be isolated and, if desired, purified.

The polynucleotide, agent, protein or antibody of the invention, may carry a detectable label. Detectable labels which allow detection of the secreted substance by visual inspection, optionally with the aid of an optical magnifying means, are preferred. Such a system is typically based on an enzyme label which causes colour change in a substrate, for example alkaline phosphatase causing a colour change in a substrate. Such substrates are commercially available, e.g. from BioRad. Other suitable labels include other enzymes such as peroxidase, or protein labels, such as biotin; or radioisotopes, such as  $^{32}\text{P}$  or  $^{35}\text{S}$ . The above labels may be detected using known techniques.

Polynucleotides, agents, proteins, antibodies or cells of the invention may be in substantially purified form. They may be in substantially isolated form, in which case they will generally comprise at least 80% e.g. at least 90, 95, 97 or 99% of the polynucleotide, peptide, antibody, cells or dry mass in the preparation. The polynucleotide, agent, protein or antibody is typically substantially free of other cellular components. The polynucleotide, agent, protein or antibody may be used in such a substantially isolated, purified or free form in the method or be present in such forms in the kit.

The invention also provides a transgenic non-human mammal which expresses a TCR of the invention. This may be any of the mammals discussed herein (e.g. in relation to the production of the antibody). Preferably the mammal has, or is susceptible, to coeliac disease. The mammal may also express HLA-DQ2 or -DQ8 or HLA-DR3-DQ2 and/or may be given a diet comprising a gliadin which cause coeliac disease (e.g. any of the gliadin proteins mentioned herein). Thus the mammal may act as an animal model for coeliac disease.

The invention also provides a method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal of the invention which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product. Such a product may be used to treat or prevent coeliac disease.

The invention provides therapeutic (including prophylactic) agents or diagnostic substances (the agents, proteins and polynucleotides of the invention).



These substances are formulated for clinical administration by mixing them with a pharmaceutically acceptable carrier or diluent. For example they can be formulated for topical, parenteral, intravenous, intramuscular, subcutaneous, intraocular, intradermal, epidermal or transdermal administration. The substances may be mixed  
5 with any vehicle which is pharmaceutically acceptable and appropriate for the desired route of administration. The pharmaceutically carrier or diluent for injection may be, for example, a sterile or isotonic solution such as Water for Injection or physiological saline, or a carrier particle for ballistic delivery.

The dose of the substances may be adjusted according to various parameters,  
10 especially according to the agent used; the age, weight and condition of the patient to be treated; the mode of administration used; the severity of the condition to be treated; and the required clinical regimen. As a guide, the amount of substance administered by injection is suitably from 0.01 mg/kg to 30 mg/kg, preferably from 0.1 mg/kg to 10 mg/kg.

15 The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The substances of the invention may thus be used in a method of treatment of the human or animal body, or in a diagnostic method practised on the human body.  
20 In particular they may be used in a method of treating or preventing coeliac disease. The invention also provide the agents for use in a method of manufacture of a medicament for treating or preventing coeliac disease. Thus the invention provides a method of preventing or treating coeliac disease comprising administering to a human in need thereof a substance of the invention (typically a non-toxic effective  
25 amount thereof).

The agent of the invention can be made using standard synthetic chemistry techniques, such as by use of an automated synthesizer. The agent may be made from a longer polypeptide e.g. a fusion protein, which polypeptide typically comprises the sequence of the peptide. The peptide may be derived from the  
30 polypeptide by for example hydrolysing the polypeptide, such as using a protease; or by physically breaking the polypeptide. The polynucleotide of the invention can be made using standard techniques, such as by using a synthesiser.

**Plant cells and plants that express mutant gliadin proteins or express proteins comprising sequences which can act as antagonists**

The cell of the invention may be a plant cell, such as a cell of a graminaceous monocotyledonous species. The species may be one whose wild-type form expresses gliadins, such as any of the gliadin proteins mentioned herein (including gliadins with any degree of homology to SEQ ID NO:3 mentioned herein). Such a gliadin may cause coeliac disease in humans. The cell may be of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane. Typically the cell is of the *Triticum* genus, such as *aestivum*, *spelta*, *polonicum* or *monococcum*.

The plant cell of the invention is typically one which does not express a wild-type gliadin (such as any of the gliadins mentioned herein which may cause coeliac disease), or one which does not express a gliadin comprising a sequence that can be recognised by a T cell that recognises the agent. Thus if the wild-type plant cell did express such a gliadin then it may be engineered to prevent or reduce the expression of such a gliadin or to change the amino acid sequence of the gliadin so that it no longer causes coeliac disease (typically by no longer expressing the epitope of the invention).

This can be done for example by introducing mutations into 1, 2, 3 or more or all of such gliadin genes in the cell, for example into coding or non-coding (e.g. promoter regions). Such mutations can be any of the type or length of mutations discussed herein (e.g., in relation to homologous proteins). The mutations can be introduced in a directed manner (e.g., using site directed mutagenesis or homologous recombination techniques) or in a random manner (e.g. using a mutagen, and then typically selecting for mutagenised cells which no longer express the gliadin (or a gliadin sequence which causes coeliac disease)).

In the case of plants or plant cells that express a protein that comprises a sequence able to act as an antagonist such a plant or plant cell may express a wild-type gliadin protein (e.g. one which causes coeliac disease). Preferably though the presence of the antagonist sequence will cause reduced coeliac disease symptoms (such as no symptoms) in an individual who ingests a food comprising protein from the plant or plant cell.

The polynucleotide which is present in (or which was transformed into) the plant cell will generally comprise promoter capable of expressing the mutant gliadin protein the plant cell. Depending on the pattern of expression desired, the promoter may be constitutive, tissue- or stage-specific; and/or inducible. For example, strong  
5 constitutive expression in plants can be obtained with the CAMV 35S, Rubisco ssu, or histone promoters. Also, tissue-specific or stage-specific promoters may be used to target expression of protein of the invention to particular tissues in a transgenic plant or to particular stages in its development. Thus, for example seed-specific, root-specific, leaf-specific, flower-specific etc promoters may be used. Seed-specific  
10 promoters include those described by Dalta *et al* (Biotechnology Ann. Rev. (1997), 3, pp.269-296). Particular examples of seed-specific promoters are napin promoters (EP-A-0 255, 378), phaseolin promoters, glutenine promoters, helianthene promoters (WO92/17580), albumin promoters (WO98/45460), oleosin promoters (WO98/45461) and ATS1 and ATS3 promoters (PCT/US98/06798).

15 The cell may be in any form. For example, it may be an isolated cell, e.g. a protoplast, or it may be part of a plant tissue, e.g. a callus, or a tissue excised from a plant, or it may be part of a whole plant. The cell may be of any type (e.g. of any type of plant part). For example, an undifferentiated cell, such as a callus cell; or a differentiated cell, such as a cell of a type found in embryos, pollen, roots, shoots or  
20 leaves. Plant parts include roots; shoots; leaves; and parts involved in reproduction, such as pollen, ova, stamens, anthers, petals, sepals and other flower parts.

The invention provides a method of obtaining a transgenic plant cell comprising transforming a plant cell with a polynucleotide or vector of the invention to give a transgenic plant cell. Any suitable transformation method may be used (in  
25 the case of wheat the techniques disclosed in Vasil V et al, Biotechnology 10, 667-674 (1992) may be used). Preferred transformation techniques include electroporation of plant protoplasts and particle bombardment. Transformation may thus give rise to a chimeric tissue or plant in which some cells are transgenic and some are not.

30 The cell of the invention or thus obtained cell may be regenerated into a transgenic plant by techniques known in the art. These may involve the use of plant growth substances such as auxins, giberellins and/or cytokinins to stimulate the

growth and/or division of the transgenic cell. Similarly, techniques such as somatic embryogenesis and meristem culture may be used. Regeneration techniques are well known in the art and examples can be found in, e.g. US 4,459,355, US 4,536,475, US 5,464,763, US 5,177,010, US 5,187,073, EP 267,159, EP 604,662, EP 672,752, 5 US 4,945,050, US 5,036,006, US 5,100,792, US 5,371,014, US 5,478,744, US 5,179,022, US 5,565,346, US 5,484,956, US 5,508,468, US 5,538,877, US 5,554,798, US 5,489,520, US 5,510,318, US 5,204,253, US 5,405,765, EP 442,174, EP 486,233, EP 486,234, EP 539,563, EP 674,725, WO91/02071 and WO 95/06128.

In many such techniques, one step is the formation of a callus, i.e. a plant 10 tissue comprising expanding and/or dividing cells. Such calli are a further aspect of the invention as are other types of plant cell cultures and plant parts. Thus, for example, the invention provides transgenic plant tissues and parts, including embryos, meristems, seeds, shoots, roots, stems, leaves and flower parts. These may be chimeric in the sense that some of their cells are cells of the invention and some 15 are not. Transgenic plant parts and tissues, plants and seeds of the invention may be of any of the plant species mentioned herein.

Regeneration procedures will typically involve the selection of transformed cells by means of marker genes.

The regeneration step gives rise to a first generation transgenic plant. The 20 invention also provides methods of obtaining transgenic plants of further generations from this first generation plant. These are known as progeny transgenic plants. Progeny plants of second, third, fourth, fifth, sixth and further generations may be obtained from the first generation transgenic plant by any means known in the art.

Thus, the invention provides a method of obtaining a transgenic progeny 25 plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant of the invention, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

Progeny plants may be produced from their predecessors of earlier 30 generations by any known technique. In particular, progeny plants may be produced by:

obtaining a transgenic seed from a transgenic plant of the invention belonging to a previous generation, then obtaining a transgenic progeny plant of the invention belonging to a new generation by growing up the transgenic seed; and/or

propagating clonally a transgenic plant of the invention belonging to a previous generation to give a transgenic progeny plant of the invention belonging to a new generation; and/or

crossing a first-generation transgenic plant of the invention belonging to a previous generation with another compatible plant to give a transgenic progeny plant of the invention belonging to a new generation; and optionally

obtaining transgenic progeny plants of one or more further generations from the progeny plant thus obtained.

These techniques may be used in any combination. For example, clonal propagation and sexual propagation may be used at different points in a process that gives rise to a transgenic plant suitable for cultivation. In particular, repetitive back-crossing with a plant taxon with agronomically desirable characteristics may be undertaken. Further steps of removing cells from a plant and regenerating new plants therefrom may also be carried out.

Also, further desirable characteristics may be introduced by transforming the cells, plant tissues, plants or seeds, at any suitable stage in the above process, to introduce desirable coding sequences other than the polynucleotides of the invention. This may be carried out by the techniques described herein for the introduction of polynucleotides of the invention.

For example, further transgenes may be selected from those coding for other herbicide resistance traits, e.g. tolerance to: Glyphosate (e.g. using an EPSP synthase gene (e.g. EP-A-0 293,358) or a glyphosate oxidoreductase (WO 92/000377) gene); or tolerance to fosametin; a dihalobenzonitrile; glufosinate, e.g. using a phosphinothrycin acetyl transferase (PAT) or glutamine synthase gene (cf. EP-A-0 242,236); asulam, e.g. using a dihydropteroate synthase gene (EP-A-0 369,367); or a sulphonylurea, e.g. using an ALS gene); diphenyl ethers such as acifluorfen or oxyfluorfen, e.g. using a protoporphyrinogen oxidase gene); an oxadiazole such as oxadiazon; a cyclic imide such as chlorophthalim; a phenyl pyrazole such as TNP, or a phenopylate or carbamate analogue thereof.

Similarly, genes for beneficial properties other than herbicide tolerance may be introduced. For example, genes for insect resistance may be introduced, notably genes encoding *Bacillus thuringiensis* (*Bt*) toxins. Likewise, genes for disease resistance may be introduced, e.g. as in WO91/02701 or WO95/06128.

5 Typically, a protein of the invention is expressed in a plant of the invention. Depending on the promoter used, this expression may be constitutive or inducible. Similarly, it may be tissue- or stage-specific, i.e. directed towards a particular plant tissue (such as any of the tissues mentioned herein) or stage in plant development.

The invention also provides methods of obtaining crop products by  
10 harvesting, and optionally processing further, transgenic plants of the invention. By crop product is meant any useful product obtainable from a crop plant.

**15 Products that contain mutant gliadin proteins or proteins that comprise sequence capable of acting as an antagonist**

The invention provides a product that comprises the mutant gliadin proteins or protein that comprises sequence capable of acting as an antagonist. This is typically derived from or comprise plant parts from plants mentioned herein which express such proteins. Such a product may be obtainable directly by harvesting or  
20 indirectly, by harvesting and further processing the plant of the invention. Directly obtainable products include grains. Alternatively, such a product may be obtainable indirectly, by harvesting and further processing. Examples of products obtainable by further processing are flour or distilled alcoholic beverages; food products made from directly obtained or further processed material, e.g. baked products (e.g. bread)  
25 made from flour. Typically such food products, which are ingestible and digestible (i.e. non-toxic and of nutrient value) by human individuals.

In the case of food products that comprise the protein which comprises an antagonist sequence the food product may also comprise wild-type gliadin, but preferably the antagonist is able to cause a reduction (e.g. completely) in the coeliac  
30 disease symptoms after such food is ingested.

The invention is illustrated by the following nonlimiting Examples:

**Example 1**

We carried out epitope mapping in Coeliac disease by using a set of 51 synthetic 15-mer peptides that span the complete sequence of a fully characterized a-gliadin, "A-gliadin" (see Table 1). A-Gliadin peptides were also individually treated with tTG to generate products that might mimic those produced in-vivo<sup>3</sup>. We also  
5 sought to study Coeliac disease patients at the point of initiation of disease relapse to avoid the possibility that epitope "spreading" or "exhaustion" may have occurred, as described in experimental infectious and autoimmune diseases.

*Clinical and A-gliadin specific T-cell responses with 3 and 10 day bread challenge*

10 In a pilot study, two subjects with Coeliac disease in remission, defined by absence of serum anti-endomysial antibody (EMA), on a gluten free diet were fed four slices of standard gluten-containing white bread daily in addition to their usual gluten free diet. Subject 1 ceased bread because of abdominal pain, mouth ulcers and mild diarrhoea after three days, but Subject 2 continued for 10 days with only  
15 mild nausea at one week. The EMA became positive in Subject 2 one week after the bread challenge, indicating the bread used had caused a relapse of Coeliac disease. But in Subject 1, EMA remained negative up to two months after bread challenge. In both subjects, symptoms that appeared with bread challenge resolved within two days after returning to gluten free diet.

20 PBMC responses in IFN $\gamma$  ELISPOT assays to A-gliadin peptides were not found before or during bread challenge. But from the day after bread withdrawal (Day 4) in Subject 1 a single pool of 5 overlapping peptides spanning A-gliadin 51-85 (Pool 3) treated with tTG showed potent IFN $\gamma$  responses (see Figure 1a). In Subject 1, the PBMC IFN $\gamma$  response to A-gliadin peptide remained targeted to Pool 3  
25 alone and was maximal on Day 8. The dynamics and magnitude of the response to Pool 3 was similar to that elicited by  $\alpha$ -chymotrypsin digested gliadin. PBMC IFN $\gamma$  responses to tTG-treated Pool 3 were consistently 5 to 12-fold greater than Pool 3 not treated with tTG, and responses to  $\alpha$ -chymotrypsin digested gliadin were 3 to 10-fold greater if treated with tTG. In Subject 2, Pool 3 treated with tTG was also the only  
30 immunogenic set of A-gliadin peptides on Day 8, but this response was weaker than Subject 1, was not seen on Day 4 and by Day 11 the response to Pool 3 had diminished and other tTG-treated pools of A-gliadin peptides elicited stronger IFN $\alpha$

responses (see Figure 1b).

The pilot study indicated that the initial T cell response in these Coeliac disease subjects was against a single tTG-treated A-gliadin pool of five peptides and was readily measured in peripheral blood. But if antigen exposure is continued for ten days instead of three, T cell responses to other A-gliadin peptides appear, consistent with epitope spreading.

*Coeliac disease-specific IFN- $\gamma$  induction by tTG-treated A-gliadin peptides*

In five out of six further Coeliac disease subjects on gluten free diet (see Table 1), bread challenge for three days identified tTG-treated peptides in Pool 3, and in particular, peptides corresponding to 56-70 (12) and 60-75 (13) as the sole A-gliadin components eliciting IFN $\gamma$  from PBMC (see Figure 2). IL-10 ELISPOT assays run in parallel to IFN $\gamma$  ELISPOT showed no IL-10 response to tTG-treated peptides 12 or 13. In one subject, there were no IFN $\gamma$  responses to any A-gliadin peptide or  $\alpha$ -chymotrypsin digested gliadin before, during or up to four days after bread challenge. In none of these Coeliac disease subjects did EMA status change from baseline when measured for up to two months after bread challenge.

PBMC from four healthy, EMA-negative subjects with the HLA-DQ alleles  $\alpha 1^*0501$ ,  $\beta 1^*0201$  (ages 28-52, 2 females) who had been challenged for three days with bread after following a gluten free diet for one month, showed no IFN $\gamma$  responses above the negative control to any of the A-gliadin peptides with or without tTG treatment. Thus, induction of IFN $\gamma$  in PBMC to tTG-treated Pool 3 and A-gliadin peptides 56-70 (12) and 60-75 (13) were Coeliac disease specific (7/8 vs. 0/4,  $p < 0.01$  by Chi-squared analysis).

*Fine mapping of the minimal A-gliadin T cell epitope*

tTG-treated peptides representing truncations of A-gliadin 56-75 revealed that the same core peptide sequence QPQLP (SEQ ID NO:9) was essential for antigenicity in all of the five Coeliac disease subjects assessed (see Figure 3). PBMC IFN $\gamma$  responses to tTG-treated peptides spanning this core sequence beginning with the 7-mer PQPQLPY (SEQ ID NO:4) and increasing in length, indicated that the tTG-treated 17-mer QLQPFQPQLPYQPQS (SEQ ID NO:10) (A-gliadin 57-73)



possessed optimal activity in the IFN $\gamma$  ELISPOT (see Figure 4).

*Deamidation of Q65 by tTG generates the immunodominant T cell epitope in A-gliadin*

5 HPLC analysis demonstrated that tTG treatment of A-gliadin 56-75 generated a single product that eluted marginally later than the parent peptide. Amino acid sequencing indicated that out of the six glutamine (Q) residues contained in A-gliadin 56-75, Q65 was preferentially deamidated by tTG (see Figure 5). Bioactivity of peptides corresponding to serial expansions from the core A-gliadin 62-68  
10 sequence in which glutamate (E) replaced Q65, was equivalent to the same peptides with Q65 after tTG-treatment (see Figure 4a). Replacement of Q57 and Q72 by E together or alone, with E65 did not enhance antigenicity of the 17-mer in the three Coeliac disease subjects studied (see Figure 6). Q57 and Q72 were investigated because glutamine residues followed by proline in gliadin peptides are not  
15 deamidated by tTG in vitro (W. Vader et al, Proceedings 8th International Symposium Coeliac Disease). Therefore, the immunodominant T cell epitope was defined as QLQPFQPELPYPQPQS (SEQ ID NO:2).

*Immunodominant T cell epitope response is DQ2-restricted and CD4 dependent*

20 In two Coeliac disease subjects homozygous for HLA-DQ  $\alpha$ 1\*0501,  $\beta$ 1\*0201, anti-DQ monoclonal antibody blocked the ELISPOT IFN $\gamma$  response to tTG-treated A-gliadin 56-75, but anti-DP and -DR antibody did not (see Figure 7). Anti-CD4 and anti-CD8 magnetic bead depletion of PBMC from two Coeliac disease subjects indicated the IFN $\gamma$  response to tTG-treated A-gliadin 56-75 is CD4 T cell-  
25 mediated.

*Discussion*

In this study we describe a rather simple dietary antigen challenge using standard white bread to elicit a transient population of CD4 T cells in peripheral  
30 blood of Coeliac disease subjects responsive to a tTG-treated A-gliadin 17-mer with the sequence: QLQPFQPELPYPQPQS (SEQ ID NO:2) (residues 57-73). The immune response to A-gliadin 56-75 (Q $\rightarrow$ E65) is restricted to the Coeliac disease-

associated HLA allele, DQ  $\alpha 1^*0501$ ,  $\beta 1^*0201$ . Tissue transglutaminase action in vitro selectively deamidates Q65. Elicited peripheral blood IFN $\gamma$  responses to synthetic A-gliadin peptides with the substitution Q $\rightarrow$ E65 is equivalent to tTG-treated Q65 A-gliadin peptides; both stimulate up to 10-fold more T cells in the IFN $\gamma$  ELISPOT than unmodified Q65 A-gliadin peptides.

We have deliberately defined this Coeliac disease-specific T cell epitope using in vivo antigen challenge and short-term ex vivo immune assays to avoid the possibility of methodological artifacts that may occur with the use of T cell clones in epitope mapping. Our findings indicate that peripheral blood T cell responses to ingestion of gluten are rapid but short-lived and can be utilized for epitope mapping. In vivo antigen challenge has also shown there is a temporal hierarchy of immune responses to A-gliadin peptides; A-gliadin 57-73 modified by tTG not only elicits the strongest IFN $\gamma$  response in PBMC but it is also the first IFN $\gamma$  response to appear.

Because we have assessed only peptides spanning A-gliadin, there may be other epitopes in other gliadins of equal or greater importance in the pathogenesis of Coeliac disease. Indeed, the peptide sequence at the core of the epitope in A-gliadin that we have identified PQQQLPY (SEQ ID NO:4) is shared by several other gliadins (SwissProt and TrEMBL accession numbers: P02863, Q41528, Q41531, Q41533, Q9ZP09, P04722, P04724, P18573). However, A-gliadin peptides that have previously been shown to possess bioactivity in biopsy challenge and in vivo studies (for example: 31-43, 44-55, and 206-217)<sup>4,5</sup> did not elicit IFN $\gamma$  responses in PBMC following three day bread challenge in Coeliac disease subjects. These peptides may be "secondary" T cell epitopes that arise with spreading of the immune response.

## Example 2

### *The effect on T cell recognition of substitutions in the immunodominant epitope*

The effect of substituting the glutamate at position 65 in the 57-73 A-gliadin epitope was determined by measuring peripheral blood responses against the substituted epitopes in an IFN $\gamma$  ELISPOT assay using synthetic peptides (at 50  $\mu$ g/ml). The responses were measured in 3 Coeliac disease subjects 6 days after commencing gluten challenge (4 slices bread daily for 3 days). Results are shown in table 3 and Figure 8. As can be seen substitution of the glutamate to histidine,

tyrosine, tryptophan, lysine, proline or arginine stimulated a response whose magnitude was less than 10% of the magnitude of the response to the immunodominant epitope. Thus mutation of A-gliadin at this position could be used to produce a mutant gliadin with reduce or absent immunoreactivity.

5

### Example 3

#### *Testing the immunoreactivity of equivalent peptides from other naturally occurring gliadins*

The immunoreactivity of equivalent peptides from other naturally occurring wheat gliadins was assessed using synthetic peptides corresponding to the naturally occurring sequences which were then treated with transglutaminase. These peptides were tested in an ELISPOT in the same manner and with PBMCs from the same subjects as described in Example 2. At least five of the peptides show immunoreactivity comparable to the A-gliadin 57-73 E65 peptide (after  
15 transglutaminase treatment) indicating that other gliadin proteins in wheat are also likely to induce this Coeliac disease-specific immune response (Table 4 and Figure 9).

### Methods

20 *Subjects:* Patients used in the study attended a Coeliac Clinic in Oxford, United Kingdom. Coeliac disease was diagnosed on the basis of typical small intestinal histology, and normalization of symptoms and small intestinal histology with gluten free diet.

25 *Tissue typing:* Tissue typing was performed using DNA extracted from EDTA-anticoagulated peripheral blood. HLA-DQA and DQB genotyping was performed by PCR using sequence-specific primer mixes<sup>6-8</sup>.

*Anti-endomysial antibody assay:* EMA were detected by indirect  
30 immunofluorescence using patient serum diluted 1:5 with monkey oesophagus, followed by FITC-conjugated goat anti-human IgA. IgA was quantitated prior to EMA, none of the subjects were IgA deficient.

*Antigen Challenge:* Coeliac disease subjects following a gluten free diet, consumed 4 slices of gluten-containing bread (50g/slice, Sainsbury's "standard white sandwich bread") daily for 3 or 10 days. EMA was assessed the week before and up to two months after commencing the bread challenge. Healthy subjects who had followed a gluten free diet for four weeks, consumed their usual diet including four slices of gluten-containing bread for three days, then returned to gluten free diet for a further six days.

*IFN $\gamma$  and IL-10 ELISPOT:* PBMC were prepared from 50-100 ml of venous blood by Ficoll-Hypaque density centrifugation. After three washes, PBMC were resuspended in complete RPMI containing 10% heat inactivated human AB serum. ELISPOT assays for single cell secretion of IFN $\gamma$  and IL-10 were performed using commercial kits (Mabtech; Stockholm, Sweden) with 96-well plates (MAIP-S-45; Millipore, Bedford, MA) according to the manufacturers instructions (as described elsewhere<sup>9</sup>) with  $2.5 \times 10^5$  (IFN $\gamma$ ) or  $0.4-1 \times 10^5$  (IL-10) PBMC in each well. Peptides were assessed in duplicate wells, and Mycobacterium tuberculosis purified protein derivative (PPD RT49) (Serum Institute; Copenhagen, Denmark) (20  $\mu$ g/ml) was included as a positive control in all assays.

*Peptides:* Synthetic peptides were purchased from Research Genetics (Huntsville, Alabama) Mass-spectroscopy and HPLC verified peptides' authenticity and >70% purity. Digestion of gliadin (Sigma; G-3375) (100 mg/ml) with  $\alpha$ -chymotrypsin (Sigma; C-3142) 200:1 (w/w) was performed at room temperature in 0.1 M  $\text{NH}_4\text{HCO}_3$  with 2M urea and was halted after 24 h by heating to 98°C for 10 minutes. After centrifugation (13,000g, 10 minutes), the gliadin digest supernatant was filter-sterilized (0.2  $\mu$ m). Digestion of gliadin was verified by SDS-PAGE and protein concentration assessed.  $\alpha$ -Chymotrypsin-digested gliadin (640  $\mu$ g/ml) and synthetic gliadin peptides (15-mers: 160  $\mu$ g/ml, other peptides: 0.1 mM) were individually treated with tTG (Sigma; T-5398) (50  $\mu$ g/ml) in PBS +  $\text{CaCl}_2$  1 mM for 2 h at 37°C. Peptides and peptide pools were aliquotted into sterile 96-well plates and stored frozen at -20°C until use.

*Amino acid sequencing of peptides:* Reverse phase HPLC was used to purify the peptide resulting from tTG treatment of A-gliadin 56-75. A single product was identified and subjected to amino acid sequencing (automated sequencer Model 5 494A, Applied Biosystems, Foster City, California). The sequence of unmodified G56-75 was confirmed as: LQLQPFPPQLPYPQPQSFP (SEQ ID NO:5), and tTG treated G56-75 was identified as: LQLQPFPPQPELPYPQPQSFP (SEQ ID NO:11). Deamidation of glutamyl residues was defined as the amount (pmol) of glutamate recovered expressed as a percent of the combined amount of glutamine and 10 glutamate recovered in cycles 2, 4, 8, 10, 15 and 17 of the amino acid sequencing. Deamidation attributable to tTG was defined as (% deamidation of glutamine in the tTG treated peptide - % deamidation in the untreated peptide) / (100 - % deamidation in the untreated peptide).

*CD4/CD8 and HLA Class II Restriction:* Anti-CD4 or anti-CD8 coated magnetic 15 beads (Dynal, Oslo, Norway) were washed four times with RPMI then incubated with PBMC in complete RPMI containing 10% heat inactivated human AB serum ( $5 \times 10^6$  cells/ml) for 30 minutes on ice. Beads were removed using a magnet and cells remaining counted. In vivo HLA-class II restriction of the immune response to tTG-treated A-gliadin 56-75 was established by incubating PBMC ( $5 \times 10^6$  cells/ml) 20 with anti-HLA-DR (L243), -DQ (L2), and -DP (B7.21) monoclonal antibodies (10  $\mu$ g/ml) at room temperature for one hour prior to the addition of peptide.

#### Example 4

##### *Mucosal integrin expression by gliadin -specific peripheral blood lymphocytes*

25 Interaction between endothelial and lymphocyte adreessins facilitates homing of organ-specific lymphocytes. Many adreessins are known. The heterodimer  $\alpha_4\beta_7$  is specific for lamina propria gut and other mucosal lymphocytes, and  $\alpha^E\beta_7$  is specific and intra-epithelial lymphocytes in the gut and skin. Approximately 30% of peripheral blood CD4 T cells express  $\alpha_4\beta_7$  and are presumed to be in transit to a 30 mucosal site, while 5% of peripheral blood T cells express  $\alpha^E\beta_7$ . Immunomagnetic beads coated with antibody specific for  $\alpha^E$  or  $\beta_7$  deplete PBMC of cells expressing  $\alpha^E\beta_7$  or  $\alpha^E\beta_7$  and  $\alpha_4\beta_7$ , respectively. In combination with ELISpot assay,

immunomagnetic bead depletion allows determination of gliadin-specific T cell addressin expression that may identify these cells as homing to a mucosal surface. Interestingly, gluten challenge in vivo is associated with rapid influx of CD4 T cells to the small intestinal lamina propria (not intra-epithelial sites), where over 90% lymphocytes express  $\alpha_4\beta_7$ .

Immunomagnetic beads were prepared and used to deplete PBMC from coeliac subjects on day 6 or 7 after commencing 3 day gluten challenge. FACS analysis demonstrated  $\alpha^E$  beads depleted approximately 50% of positive CD4 T cells, while  $\beta_7$  beads depleted all  $\beta_7$  positive CD4 T cells. Depletion of PBMC using CD4- or  $\beta_7$ -beads, but not CD8- or  $\alpha^E$ -beads, abolished responses in the interferon gamma ELISpot. tTG gliadin and PPD responses were abolished by CD4 depletion, but consistently affected by integrin-specific bead depletion.

Thus A-gliadin 57-73 QE65-specific T cells induced after gluten challenge in coeliac disease express the integrin,  $\alpha_4\beta_7$ , present on lamina propria CD4 T cells in the small intestine.

### Example 5

#### *Optimal T cell Epitope Length*

Previous data testing peptides from 7 to 17 amino acids in length spanning the core of the dominant T cell epitope in A-gliadin indicated that the 17mer, A-gliadin 57-73 QE65 (SEQ ID NO:2) induced maximal responses in the interferon gamma Elispot using peripheral blood mononuclear cells (PBMC) from coeliac volunteers 6 days after commencing a 3-day gluten challenge.

Peptides representing expansions form the core sequence of the dominant T cell epitope in A-gliadin were assessed in the IFN gamma ELISPOT using peripheral blood mononuclear cells (PBMC) from coeliac volunteers in 6 days after commencing a 3-day gluten challenge (n=4). Peptide 13: A-gliadin 59-71 QE65 (13mer), peptide 15: 58-72 QE65 (15mer), ..., peptide 27: 52-78 SE65 (27mer).

As shown in Figure 11 expansion of the A-gliadin 57-73 QE65 sequence does not substantially enhance response in the IFNgamma Elispot. Subsequent Examples

characterise the agonist and antagonist activity of A-gliadin 57-73 QE65 using 17mer peptides.

#### Example 6

##### 5 *Comparison of A-gliadin 57-73 QE65 with other DQ2-restricted T cell epitopes in coeliac disease*

Dose response studies were performed using peptides corresponding to unmodified and transglutaminase-treated peptides corresponding to T cell epitopes of gluten-specific T cell clones and lines from intestinal biopsies of coeliac subjects.

10 Responses to peptides were expressed as percent of response to A-gliadin 57-73 QE65. All subjects were HLA-DQ2+ (none were DQ8+).

The studies indicate that A-gliadin 57-73 QE65 is the most potent gliadin peptide for induction of interferon gamma in the ELISpot assay using coeliac PBMC after gluten challenge (see Figure 12a-h, and Tables 5 and 6). The second and third  
15 epitopes are suboptimal fragments of larger peptides i.e. A-gliadin 57-73 QE65 and GDA4\_WHEAT P04724-84-100 QE92. The epitope is only modestly bioactive (approximately 1/20<sup>th</sup> as active as A-gliadin 57-73 QE65 after blank is subtracted).

A-gliadin 57-73 QE65 is more potent than other known T cell epitopes in coeliac disease. There are 16 polymorphisms of A-gliadin 57-73 (including the  
20 sequence PQLPY (SEQ ID NO:12)) amongst sequenced gliadin genes, their bioactivity is assessed next.

#### Example 7

##### 25 *Comparison of gliadin- and A-gliadin 57-73 QE65-specific responses in peripheral blood*

The relative contribution of the dominant epitope, A-gliadin 57-73 QE65, to the total T cell response to gliadin in coeliac disease is a critical issue. Pepsin-trypsin and chymotrypsin-digested gliadin have been traditionally used as antigen for development of T cell lines and clones in coeliac disease. However, it is possible  
30 that these proteases may cleave through certain peptide epitopes. Indeed, chymotrypsin digestion of recombinant  $\alpha$ 9-gliadin generates the peptide QLQPFQPELPY (SEQ ID NO:13), that is a truncation of the optimal epitope

sequence QLQPFQPELPYPQPQS (SEQ ID NO:2) (see above).

Transglutaminase-treatment substantially increases the potency of chymotrypsin-digested gliadin in proliferation assays of gliadin-specific T cell clones and lines. Hence, transglutaminase-treated chymotrypsin-digested gliadin (tTG gliadin) may not be an ideal antigen, but responses against this mixture may approximate the “total” number of peripheral blood lymphocyte specific for gliadin. Comparison of responses against A-gliadin 57-73 QE65 and tTG gliadin in the ELISpot assay gives an indication of the contribution of this dominant epitope to the overall immune response to gliadin in coeliac disease, and also be a measure of epitope spreading.

PBMC collected on day 6 or 7 after commencing gluten challenge in 4 coeliac subjects were assessed in dose response studies using chymotrypsin-digested gliadin +/- tTG treatment and compared with ELISpot responses to an optimal concentration of A-gliadin 57-73 QE65 (25mcg/ml). TTG treatment of gliadin enhanced PBMC responses in the ELISpot approximately 10-fold (tTG was comparable to blank when assessed alone) (see Figure 13a-c). In the four coeliac subjects studied, A-gliadin 57-73 QE65 (25 mcg/ml) elicited responses between 14 and 115% those of tTG gliadin (500 mcg/ml), and the greater the response to A-gliadin 57-73 QE65 the greater proportion it represented of the tTG gliadin response.

Relatively limited data suggest that A-gliadin 57-73 QE65 responses are comparable to tTG gliadin in some subjects. Epitope spreading associated with more evolved anti-gliadin T cell responses may account for the smaller contribution of A-gliadin 57-73 QE65 to “total” gliadin responses in peripheral blood in some individuals. Epitope spreading may be maintained in individuals with less strictly gluten free diets.

### Example 8

*Definition of gliadin peptides bioactive in coeliac disease: polymorphisms of A-gliadin 57-73*

Overlapping 15mer peptides spanning the complete sequence of A-gliadin were assessed in order to identify the immunodominant sequence in coeliac disease. A-gliadin was the first fully sequenced alpha gliadin protein and gene, but is one of approximately 30-50 related alpha gliadin proteins in wheat. Twenty five distinct



alpha-gliadin genes have been identified by searching protein data bases, Swiss-Prot and TREMBL describing a further 8 alpha-gliadins. Contained within these 25 alpha-gliadins, there are 16 distinct polymorphisms of the sequence corresponding to A-gliadin 57-73 (see Table 7).

5 Synthetic peptides corresponding to these 16 polymorphisms, in an unmodified form, after treatment with transglutaminase in vitro, as well as with glutamate substituted at position 10 (equivalent to QE65 in A-gliadin 57-73) were assessed using PBMC from coeliac subjects, normally following a gluten free diet, day 6 or 7 after gluten challenge in interferon gamma ELISpot assays. Glutamate-  
10 substituted peptides were compared at three concentrations (2.5, 25 and 250 mcg/ml), unmodified peptide and transglutaminase-treated peptides were assessed at 25 mcg/ml only. Bioactivity was expressed as % of response associated with A-gliadin 57-73 QE65 25 mcg/ml in individual subjects (n=4). (See Fig 14).

Bioactivity of "wild-type" peptides was substantially increased (>5-fold) by  
15 treatment with transglutaminase. Transglutaminase treatment of wild-type peptides resulted in bioactivity similar to that of the same peptides substituted with glutamate at position 10. Bioactivities of five glutamate-substituted peptides (B, C, K, L, M), were >70% that of A-gliadin 57-73 QE65 (A), but none was significantly more bioactive than A-gliadin 57-73 QE65. PBMC responses to glutamate-substituted  
20 peptides at concentrations of 2.5 and 250 mcg/ml were comparable to those at 25 mcg/ml. Six glutamate-substituted gliadin peptides (H, I, J, N, O, P) were <15% as bioactive as A-gliadin 57-73 QE65. Other peptides were intermediate in bioactivity.

At least six gliadin-derived peptides are equivalent in potency to A-gliadin 57-73 QE65 after modification by transglutaminase. Relatively non-bioactive  
25 polymorphisms of A-gliadin 57-73 also exist. These data indicate that transglutaminase modification of peptides from several gliadins of *Triticum aestivum*, *T. uarzu* and *T. spelta* may be capable of generating the immunodominant T cell epitope in coeliac disease.

Genetic modification of wheat to generate non-coeliac-toxic wheat may likely  
30 require removal or modification of multiple gliadin genes. Generation of wheat containing gliadins or other proteins or peptides incorporating sequences defining altered peptide ligand antagonists of A-gliadin 57-73 is an alternative strategy to

generate genetically modified wheat that is therapeutic rather than "non-toxic" in coeliac disease.

### Example 9

#### 5 *Definition of Core Epitope Sequence:*

Comparison of peptides corresponding to truncations of A-gliadin 56-75 from the N- and C-terminal indicated that the core sequence of the T cell epitope is PELPY (A-gliadin 64-68). Attempts to define non-agonists and antagonists will focus on variants of A-gliadin that are substituted at residues that substantially  
10 contribute to its bioactivity.

Peptides corresponding to A-gliadin 57-73 QE65 with alanine (Figure 15) or lysine (Figure 16) substituted for residues 57 to 73 were compared in the IFN gamma ELISPOT using peripheral blood mononuclear cells (PBMC) from coeliac volunteers 6 days after commencing a 3-day gluten challenge (n=8). (BL is blank, E is A-  
15 gliadin 57-73 QE65: QLQPFQPELPYPQPQS (SEQ ID NO:2)).

It was found that residues corresponding to A-gliadin 60-70 QE65 (PFPQPELPYPQ (SEQ ID NO:14)) contribute substantially to the bioactivity in A-gliadin 57-73 QE65. Variants of A-gliadin 57-73 QE65 substituted at positions 60-70 are assessed in a 2-step procedure. Initially, A-gliadin 57-73 QE65 substituted at  
20 positions 60-70 using 10 different amino acids with contrasting properties are assessed. A second group of A-gliadin 57-73 QE65 variants (substituted with all other naturally occurring amino acids except cysteine at positions that prove are sensitive to modification) are assessed in a second round.

### 25 **Example 10**

#### *Agonist activity of substituted variants of A-gliadin 57-73 QE65*

A-gliadin 60-70 QE65 is the core sequence of the dominant T cell epitope in A-gliadin. Antagonist and non-agonist peptide variants of this epitope are most likely generated by modification of this core sequence. Initially, A-gliadin 57-73  
30 QE65 substituted at positions 60-70 using 10 different amino acids with contrasting properties will be assessed in the IFNgamma ELISPOT using PBMC from coeliac subjects 6 days after starting 3 day gluten challenge. A second group of A-gliadin

57-73 QE65 variants (substituted with all other naturally occurring amino acids except cysteine) at positions 61-70 were also assessed. Both groups of peptides (all at 50 mcg/ml, in duplicate) were assessed using PBMC from 8 subjects and compared to the unmodified peptide (20 replicates per assay). Previous studies  
5 indicate that the optimal concentration for A-gliadin 57-73 QE65 in this assay is between 10 and 100 mcg/ml.

Results are expressed as mean response in spot forming cells (95% confidence interval) as % A-G 57-73 QE65 mean response in each individual. Unpaired t-tests will be used to compare ELISPOT responses of modified peptides  
10 with A-G 57-73 QE65. Super-agonists were defined as having a greater response than A-G 57-73 QE65 at a level of significance of  $p < 0.01$ ; partial agonists as having a response less than A-G 57-73 QE65 at a level of significance of  $p < 0.01$ , and non-agonists as being not significantly different ( $p > 0.01$ ) from blank (buffer without peptide). Peptides with agonist activity 30% or less that of A-gliadin 57-73 QE65  
15 were considered "suitable" partial or non-agonists to assess for antagonistic activity (see Table 8 and Figures 17-27).

The IFN $\gamma$  ELISPOT response of PBMC to A-gliadin 57-73 QE65 is highly specific at a molecular level. Proline at position 64 (P64), glutamate at 65 (E65) and leucine at position 66 (L66), and to a lesser extent Q63, P67, Y68 and P69  
20 are particularly sensitive to modification. The substitutions Y61 and Y70 both generate super-agonists with 30% greater bioactivity than the parent peptide, probably by enhancing binding to HLA-DQ2 since the motif for this HLA molecule indicates a preference for bulky hydrophobic residues at positions 1 and 9. Eighteen non-agonist peptides were identified. Bioactivities of the variants (50 mcg/ml): P65,  
25 K64, K65 and Y65 (bioactivity 7-8%) were comparable to blank (7%). In total, 57 mutated variants of A-gliadin 57-73 QE65 were 30% or less bioactive than A-gliadin 57-73 QE65.

The molecular specificity of the peripheral blood lymphocyte (PBL) T cell response to the dominant epitope, A-gliadin 57-73 QE65, is consistently reproducible  
30 amongst HLA-DQ2+ coeliac subjects, and is highly specific to a restricted number of amino acids in the core 7 amino acids. Certain single-amino acid variants of A-gliadin 57-73 QE65 are consistently non-agonists in all HLA-DQ2+ coeliac subjects.

**Example 11***Antagonist activity of substituted variants*

The homogeneity of the PBL T cell response to A-gliadin 57-73 QE65 in HLA-DQ2+ coeliac disease suggests that altered peptide ligands (APL) capable of antagonism in PBMC ex vivo may exist, even though the PBL T cell response is likely to be poly- or oligo-clonal. APL antagonists are generally weak agonists. Fifty-seven single amino acid-substituted variants of A-gliadin 57-73 QE65 with agonist activity 30% or less have been identified and are suitable candidates as APL antagonists. In addition, certain weakly bioactive naturally occurring polymorphisms of A-gliadin 57-73 QE65 have also been identified (see below) and may be “naturally occurring” APL antagonists. It has also been suggested that competition for binding MHC may also antagonise antigen-specific T cell immune. Hence, non-gliadin peptides that do not induce IFN $\gamma$  responses in coeliac PBMC after gluten challenge but are known to bind to HLA-DQ2 may be capable of reducing T cell responses elicited by A-gliadin 57-73 QE65. Two peptides that bind avidly to HLA-DQ2 are HLA class 1  $\alpha$  46-60 (HLA 1a) (PRAPWIEQEGPEYW (SEQ ID NO:15)) and thyroid peroxidase (tp) 632-645Y (IDVWLGGLLAENFLPY (SEQ ID NO:16)).

Simultaneous addition of peptide (50 $\mu$ g/ml) or buffer and A-gliadin 57-73 QE65 (10 $\mu$ g/ml) in IFN $\gamma$  ELISPOT using PBMC from coeliac volunteers 6 days after commencing 3 day gluten challenge (n=5). Results were expressed as response with peptide plus A-G 57-73 QE65 (mean of duplicates) as % response with buffer plus A-G 57-73 QE65 (mean of 20 replicates). (See Table 9).

Four single amino acid-substituted variants of A-gliadin 57-73 QE65 reduce the interferon gamma PBMC ELISPOT response to A-gliadin 57-73 QE65 ( $p < 0.01$ ) by between 25% and 28%, 13 other peptide variants reduce the ELISPOT response by between 18% and 24% ( $p < 0.06$ ). The HLA-DQ2 binder, thyroid peroxidase (tp) 632-645Y reduces PBMC interferon gamma responses to A-gliadin 57-73 QE65 by 31% ( $p < 0.0001$ ) but the other HLA-DQ2 binder, HLA class 1  $\alpha$  46-60, does not alter responses (see Tables 9 and 10). The peptide corresponding to a transglutaminase-modified polymorphism of A-gliadin 57-73, SwissProt accession no.: P04725 82-98

QE90 (PQPQFPPELPYPQPQS (SEQ ID NO:17)) reduces responses to A-gliadin 57-73 QE65 by 19% ( $p < 0.009$ ) (see Table 11).

Interferon gamma responses of PBMC to A-gliadin 57-73 QE65 in ELISPOT assays are reduced by co-administration of certain single-amino acid A-gliadin 57-73 QE65 variants, a polymorphism of A-gliadin 57-73 QE65, and an unrelated peptide known to bind HLA-DQ2 in five-fold excess. These findings suggest that altered peptide ligand antagonists of A-gliadin 57-73 QE65 exist. Not only putative APL antagonists but also certain peptides that bind HLA-DQ2 effectively reduce PBL T cell responses to A-gliadin 57-73 QE65.

These findings support two strategies to interrupt the T cell response to the dominant A-gliadin epitope in HLA-DQ2+ coeliac disease.

1. Optimisation of APL antagonists by substituting amino acids at more than one position (64-67) for use as "traditional" peptide pharmaceuticals or for specific genetic modification of gliadin genes in wheat.
2. Use of high affinity HLA-DQ2 binding peptides to competitively inhibit presentation of A-gliadin 57-73 QE65 in association with HLA-DQ2.

These two approaches may be mutually compatible. Super-agonists were generated by replacing F61 and Q70 with tyrosine residues. It is likely these super-agonists resulted from improved binding to HLA-DQ2 rather than enhanced contact with the T cell receptor. By combining these modifications with other substitutions that generate modestly effective APL antagonists might substantially enhance the inhibitory effect of substituted A-gliadin 57-73 QE65 variants.

## Example 12

*Development of interferon gamma ELISpot using PBMC and A-gliadin 57-73 QE65 and P04724 84-100 QE92 as a diagnostic for coeliac disease: Definition of immune-responsiveness in newly diagnosed coeliac disease*

Induction of responsiveness to the dominant A-gliadin T cell epitope in PBMC measured in the interferon gamma ELISpot follows gluten challenge in almost all DQ2+ coeliac subjects following a long term strict gluten free diet (GFD) but not in healthy DQ2+ subjects after 4 weeks following a strict GFD. A-gliadin

57-73 QE65 responses are not measurable in PBMC of coeliac subjects before gluten challenge and pilot data have suggested these responses could not be measured in PBMC of untreated coeliacs. These data suggest that in coeliac disease immune-responsiveness to A-gliadin 57-73 QE65 is restored following antigen exclusion (GFD). If a diagnostic test is to be developed using the ELISpot assay and PBMC, it is desirable to define the duration of GFD required before gluten challenge is capable of inducing responses to A-gliadin 57-73 QE65 and other immunoreactive gliadin peptides in blood.

Newly diagnosed DQ2+ coeliac subjects were recruited from the gastroenterology outpatient service. PBMC were prepared and tested in interferon gamma ELISpot assays before subjects commenced GFD, and at one or two weeks after commencing GFD. In addition, gluten challenge (3 days consuming 4 slices standard white bread, 200g/day) was performed at one or two weeks after starting GFD. PBMC were prepared and assayed on day six after commencing gluten challenge. A-gliadin 57-73 QE65 (A), P04724 84-100 QE92 (B) (alone and combined) and A-gliadin 57-73 QP65 (P65) (non-bioactive variant, see above) (all 25 mcg/ml) were assessed.

All but one newly diagnosed coeliac patient was DQ2+ (one was DQ8+) (n=11). PBMC from newly diagnosed coeliacs that were untreated, or after 1 or 2 weeks following GFD did not show responses to A-gliadin 57-73 QE65 and P04724 84-100 QE92 (alone or combined) that were not significantly different from blank or A-gliadin 57-73 QP65 (n=9) (see Figure 28). Gluten challenge in coeliacs who had followed GFD for only one week did not substantially enhance responses to A-gliadin 57-73 QE65 or P04724 84-100 QE92 (alone or combined). But gluten challenge 2 weeks after commencing GFD did induce responses to A-gliadin 57-73 QE65 and P04724 84-100 QE92 (alone or combined) that were significantly greater than the non-bioactive variant A-gliadin 57-73 QP65 and blank. Although these responses after gluten challenge at 2 weeks were substantial they appear to be less than in subjects >2 months after commencing GFD. Responses to A-gliadin 57-73 QE65 alone were equivalent or greater than responses to P04724 84-100 QE92 alone or when mixed with A-gliadin 57-73 QE65. None of the subjects experienced troubling symptoms with gluten challenge.

Immune responsiveness (as measured in PBMC after gluten challenge) to A-gliadin is partially restored 2 weeks after commencing GFD, implying that "immune unresponsiveness" to this dominant T cell epitope prevails in untreated coeliac disease and for at least one week after starting GFD. The optimal timing of a  
5 diagnostic test for coeliac disease using gluten challenge and measurement of responses to A-gliadin 57-73 QE65 in the ELISpot assay is at least 2 weeks after commencing a GFD.

Interferon gamma-secreting T cells specific to A-gliadin 57-73 QE65 cannot be measured in the peripheral blood in untreated coeliacs, and can only be induced  
10 by gluten challenge after at least 2 weeks GFD (antigen exclusion). Therefore, timing of a diagnostic test using this methodology is crucial and further studies are needed for its optimization. These findings are consistent with functional anergy of T cells specific for the dominant epitope, A-gliadin 57-73 QE65, reversed by antigen exclusion (GFD). This phenomenon has not been previously demonstrated in a  
15 human disease, and supports the possibility that T cell anergy may be inducible with peptide therapy in coeliac disease.

### Example 13

#### *Comprehensive Mapping of Wheat Gliadin T Cell Epitopes*

20 Antigen challenge induces antigen-specific T cells in peripheral blood. In coeliac disease, gluten is the antigen that maintains this immune-mediated disease. Gluten challenge in coeliac disease being treated with a gluten free diet leads to the appearance of gluten-specific T cells in peripheral blood, so enabling determination of the molecular specificity of gluten T cell epitopes. As described above, we have  
25 identified a single dominant T cell epitope in a model gluten protein, A-gliadin (57-73 deamidated at Q65). In this Example, gluten challenge in coeliac patients was used to test all potential 12 amino acid sequences in every known wheat gliadin protein derived from 111 entries in Genbank. In total, 652 20mer peptides were tested in HLA-DQ2 and HLA-DQ8 associated coeliac disease. Seven of the 9  
30 coeliac subjects with the classical HLA-DQ2 complex (HLA-DQA1\*05, HLA-DQB1\*02) present in over 90% of coeliacs had an inducible A-gliadin 57-73 QE65- and gliadin-specific T cell response in peripheral blood. A-gliadin 57-73 was the

only significant  $\alpha$ -gliadin T cell epitope, as well as the most potent gliadin T cell epitope, in HLA-DQ2-associated coeliac disease. In addition, there were as many as 5 families of structurally related peptides that were between 10 and 70% as potent as A-gliadin 57-73 in the interferon- $\gamma$  ELISpot assay. These new T cell epitopes were  
5 derived from  $\gamma$ - and  $\omega$ -gliadins and included common sequences that were structurally very similar, but not identical to the core sequence of A-gliadin 57-73 (core sequence: FPQPQLPYP (SEQ ID NO:18)), for example: FPQPQQPFP (SEQ ID NO:19) and PQQPQQPFP (SEQ ID NO:20). Although no homologues of A-gliadin 57-73 have been found in rye or barley, the other two cereals toxic in coeliac  
10 disease, the newly defined T cell epitopes in  $\gamma$ - and  $\omega$ -gliadins have exact matches in rye and barley storage proteins (secalins and hordeins, respectively).

Coeliac disease not associated with HLA-DQ2 is almost always associated with HLA-DQ8. None of the seven HLA-DQ8+ coeliac subjects had inducible A-gliadin 57-73-specific T cell responses following gluten challenge, unless they also  
15 possessed the complete HLA-DQ2 complex. Two of 4 HLA-DQ8+ coeliac subjects who did not possess the complete HLA-DQ2 complex, had inducible gliadin peptide-specific T cell responses following gluten challenge. In one HLA-DQ8 subject, a novel dominant T cell epitope was identified with the core sequence LQPQNPSQQQPQ (SEQ ID NO:21). The transglutaminase-deamidated version of  
20 this peptide was more potent than the non-deamidated peptide. Previous studies suggest that the transglutaminase-deamidated peptide would have the sequence LQPENPSQEQPE (SEQ ID NO:22); but further studies are required to confirm this sequence. Amongst the healthy HLA-DQ2 (10) and HLA-DQ8 (1) subjects who followed a gluten free diet for a month, gliadin peptide-specific T cell responses  
25 were uncommon, seldom changed with gluten challenge, and were never potent T cell epitopes revealed with gluten challenge in coeliac subjects. In conclusion, there are unlikely to be more than six important T cell epitopes in HLA-DQ2-associated coeliac disease, of which A-gliadin 57-73 is the most potent. HLA-DQ2- and HLA-DQ8-associated coeliac disease do not share the same T cell specificity.

30 We have shown that short-term gluten challenge of individuals with coeliac disease following a gluten free diet induces gliadin-specific T cells in peripheral blood. The frequency of these T cells is maximal in peripheral blood on day 6 and



then rapidly wanes over the following week. Peripheral blood gliadin-specific T cells express the integrin  $\alpha 4 \beta 7$  that is associated with homing to the gut lamina propria. We exploited this human antigen-challenge design to map T cell epitopes relevant to coeliac disease in the archetypal gluten  $\alpha$ -gliadin protein, A-gliadin.

- 5 Using 15mer peptides overlapping by 10 amino acids with and without deamidation by transglutaminase (tTG), we demonstrated that T cells induced in peripheral blood initially target only one A-gliadin peptide, residues 57-73 in which glutamine at position 65 is deamidated. The epitope is HLA-DQ2-restricted, consistent with the intimate association of coeliac disease with HLA-DQ2.

- 10 Coeliac disease is reactivated by wheat, rye and barley exposure. The  $\alpha/\beta$ -gliadin fraction of wheat gluten is consistently toxic in coeliac disease, and most studies have focused on these proteins. The gene cluster coding for  $\alpha/\beta$ -gliadins is located on wheat chromosome 6C. There are no homologues of  $\alpha/\beta$ -gliadins in rye or barley. However, all three of the wheat gliadin subtypes ( $\alpha/\beta$ ,  $\gamma$ , and  $\omega$ ) are toxic  
15 in coeliac disease. The  $\gamma$ - and  $\omega$ -gliadin genes are located on chromosome 1A in wheat, and are homologous to the secalins and hordeins in rye and barley.

- There are now genes identified for 61  $\alpha$ -gliadins in wheat (*Triticum aestivum*). The  $\alpha$ -gliadin sequences are closely homologous, but the dominant epitope in A-gliadin derives from the most polymorphic region in the  $\alpha$ -gliadin  
20 sequence. Anderson et al (1997) have estimated that there are a total of about 150 distinct  $\alpha$ -gliadin genes in *T. aestivum*, but many are pseudogenes. Hence, it is unlikely that T-cell epitopes relevant to coeliac disease are not included within known  $\alpha$ -gliadin sequences.

- Our work has identified a group of deamidated  $\alpha$ -gliadin peptides almost  
25 identical to A-gliadin 57-73 as potent T cell epitopes specific to coeliac disease. Over 90% of coeliac patients are HLA-DQ2+, and so far, we have only assessed HLA-DQ2+ coeliac subjects after gluten challenge. However, coeliac patients who do not express HLA-DQ2 nearly all carry HLA-DQ8. Hence, it is critical to know whether A-gliadin 57-73 and its homologues in other wheat, rye and barley gluten  
30 proteins are the only T-cell epitopes recognized by T cells induced by gluten challenge in both HLA-DQ2+ and HLA-DQ8+ coeliac disease. If this were the case, design of peptide therapeutics for coeliac disease might only require one peptide.

*Homologues of A-gliadin 57-73 as T-cell epitopes*

Initial searches of SwissProt and Trembl gene databases for cereal genes coding for the core sequence of A-gliadin 57-73 (PQLPY <SEQ ID NO:12>) only revealed  $\alpha/\beta$ -gliadins. However, our fine-mapping studies of the A-gliadin 57-73 QE65 epitope revealed a limited number of permissive point substitutions in the core region (PQLP) (note Q65 is actually deamidated in the epitope). Hence, we extended our search to genes in SwissProt or Trembl databases encoding for peptides with the sequence XXXXXXXXPQ[ILMP][PST]XXXXXX (SEQ ID NO:23). Homologues were identified amongst  $\gamma$ -gliadins, glutenins, hordeins and secalins (see Table 12). A further homologue was identified in  $\omega$ -gliadin by visual search of the three  $\omega$ -gliadin entries in Genbank.

These homologues of A-gliadin 57-73 were assessed after deamidation by tTG (or synthesis of the glutamate(QE)-substituted variant in four close homologues) using the IFN $\gamma$  ELISpot assay with peripheral blood mononuclear cells after gluten challenge in coeliac subjects. The  $\omega$ -gliadin sequence (AAG17702 141-157) was the only bioactive peptide, approximately half as potent as A-gliadin 57-73 (see Table 12, and Figure 29). Hence, searches for homologues of the dominant A-gliadin epitope failed to account for the toxicity of  $\gamma$ -gliadin, secalins, and hordeins.

*Methods**Design of a set of peptides spanning all possible wheat gliadin T-cell epitopes*

In order to identify all possible T cell epitopes coded by the known wheat (*Triticum aestivum*) gliadin genes or gene fragments (61  $\alpha/\beta$ -, 47  $\gamma$ -, and 3  $\omega$ -gliadin entries in Genbank), gene-derived protein sequences were aligned using the CustalW software (MegAlign) and arranged into phylogenetic groupings (see Table 22). Many entries represented truncations of longer sequences, and many gene segments were identical except for the length of polyglutamine repeats or rare substitutions. Hence, it was possible to rationalize all potential unique 12 amino acid sequences encoded by known wheat genes to be included in a set of 652 20mer peptides. (Signal peptide sequences were not included). Peptide sequences are listed in Table 23.

*Comprehensive epitope mapping*

Healthy controls (HLA-DQ2+ n=10, and HLA-DQ8+ n=1) who had followed a gluten free diet for 4 weeks, and coeliac subjects (six HLA-DQ2, four complex heterozygotes HLA-DQ2/8, and three HLA-DQ8/X) (see Table 13) following long-term gluten free diet were studied before and on day 6 and 7 after 3-day gluten  
5 challenge (four 50g slices of standard white bread – Sainsbury's sandwich bread, each day). Peripheral blood (a total of 300ml over seven days) was collected and peripheral blood mononuclear cells (PBMC) were separated by Lymphoprep density gradient. PBMC were incubated with pools of 6 or 8 20mer peptides, or single  
10 peptides with or without deamidation by tTG in overnight interferon gamma (IFN $\gamma$ ) ELISpot assays.

Peptides were synthesized in batches of 96 as Pepsets (Mimotopes Inc., Melbourne Australia). Approximately 0.6 micromole of each of 652 20mers was provided. Two marker 20mer peptides were included in each set of 96 (VLQQHNI AHGSSQVLQESTY – peptide 161 (SEQ ID NO:24), and  
15 IKDFHVYFRESRDALWKGPG (SEQ ID NO:25)) and were characterized by reverse phase-HPLC and amino acid sequence analysis. Average purities of these marker peptides were 50% and 19%, respectively. Peptides were initially dissolved in acetonitrile (10%) and Hepes 100mM to 10mg/ml.

The final concentration of individual peptides in pools (or alone) incubated  
20 with PBMC for the IFN $\gamma$  ELISpot assays was 20  $\mu$ g/ml. Five-times concentrated solutions of peptides and pools in PBS with calcium chloride 1mM were aliquotted and stored in 96-well plates according to the template later used in ELISpot assays. Deamidated peptides and pools of peptides were prepared by incubation with guinea pig tissue tTG (Sigma T5398) in the ratio 100:32  $\mu$ g/ml for two hours at 37°C.  
25 Peptides solutions were stored at -20°C and freshly thawed prior to use.

Gliadin (Sigma G3375) (100 mg/ml) in endotoxin-free water and 2M urea was boiled for 10 minutes, cooled to room temperature and incubated with filter (0.2  $\mu$ m)-sterilised pepsin (Sigma P6887) (2 mg/ml) in HCl 0.02M or chymotrypsin (C3142) (4mg/ml) in ammonium bicarbonate (0.2M). After incubation for 4 hours,  
30 pepsin-digested gliadin was neutralized with sodium hydroxide, and then both pepsin- and chymotrypsin-digested gliadin were boiled for 15 minutes. Identical incubations with protease in which gliadin was omitted were also performed.

Samples were centrifuged at 15 000g, then protein concentrations were estimated in supernatants by the BCA method (Pierce, USA). Before final use in IFN $\gamma$  ELISpot assays, aliquots of gliadin-protease were incubated with tTG in the ratio 2500:64  $\mu$ g/ml.

5 IFN $\gamma$  ELISpot assays (Mabtech, Sweden) were performed in 96-well plates (MAIP S-45, Millipore) in which each well contained 25 $\mu$ l of peptide solution and 100 $\mu$ l of PBMC ( $2-8 \times 10^5$ /well) in RPMI containing 10% heat inactivated human AB serum. Deamidated peptide pools were assessed in one 96-well ELISpot plate, and peptides pools without deamidation in a second plate (with an identical layout) on  
10 both day 0 and day 6. All wells in the plate containing deamidated peptides included tTG (64  $\mu$ g/ml). In each ELISpot plate there were 83 wells with peptide pools (one unique pool in each well), and a series of wells for "control" peptides (peptides all >90% purity, characterized by MS and HPLC, Research Genetics): P04722 77-93 (QLQFPQPQLPYQPQP (SEQ ID NO:26)), P04722 77-93 QE85 (in duplicate)  
15 (QLQFPQPQLPYQPQP (SEQ ID NO:27)), P02863 77-93 (QLQFPQPQLPYSQPQP (SEQ ID NO:28)), P02863 77-93 QE85 (QLQFPQPQLPYSQPQP (SEQ ID NO:29)), and chymotrypsin-digested gliadin (500  $\mu$ g/ml), pepsin-digested gliadin (500  $\mu$ g/ml), chymotrypsin (20  $\mu$ g/ml) alone, pepsin (10  $\mu$ g/ml) alone, and blank (PBS+/-tTG) (in triplicate).

20 After development and drying, IFN $\gamma$  ELISpot plates were assessed using the MAIP automated ELISpot plate counter. In HLA-DQ2 healthy and coeliac subjects, induction of spot forming cells (sfc) by peptide pools in the IFN $\gamma$  ELISpot assay was tested using a one-tailed Wilcoxon Matched-Pairs Signed-Ranks test (using SPSS software) applied to spot forming cells (sfc) per million PBMC minus blank on day 6  
25 versus day 0 ("net response"). Significant induction of an IFN $\gamma$  response to peptide pools in PBMC by *in vivo* gluten challenge was defined as a median "net response" of at least 10 sfc/million PBMC and  $p < 0.05$  level of significance. Significant response to a particular pool of peptides on day 6 was followed by assessment of individual peptides within each pool using PBMC drawn the same day or on day 7.

30 For IFN $\gamma$  ELISpot assays of individual peptides, bioactivity was expressed as a percent of response to P04722 77-93 QE85 assessed in the same ELISpot plate. Median response to blank (PBS alone) was 0.2 (range 0-5) sfc per well, and the

positive control (P04722 77-93 QE85) 76.5 (range: 25-282) sfc per well using a median of 0.36 million (range: 0.3-0.72) PBMC. Hence, median response to blank expressed as a percentage of P04722 77-93 QE65 was 0.2% (range: 0-6.7).

Individual peptides with mean bioactivity greater than 10% that of P04722 QE85 were analyzed for common structural motifs.

## Results

### *Healthy HLA-DQ2 subjects*

None of the healthy HLA-DQ2+ subjects following a gluten free diet for a month had IFN $\gamma$  ELISpot responses to homologues of A-gliadin 57-73 before or after gluten challenge. However, in 9/10 healthy subjects, gluten challenge was associated with a significant increase in IFN $\gamma$  responses to both peptic- and chymotryptic-digests of gliadin, from a median of 0-4 sfc/million on day 0 to a median of 16-29 sfc/million (see Table 14). Gliadin responses in healthy subjects were unaffected by deamidation (see Table 15). Amongst healthy subjects, there was no consistent induction of IFN $\gamma$  responses to specific gliadin peptide pools with gluten challenge (see Figure 30, and Table 16). IFN $\gamma$  ELISpot responses were occasionally found, but these were weak, and not altered by deamidation. Many of the strongest responses to pools were also present on day 0 (see Table 17, subjects H2, H8 and H9). Four healthy subjects did show definite responses to pool 50, and the two with strongest responses on day 6 also had responses on day 0. In both subjects, the post-challenge responses to pool 50 responses were due to peptide 390 (QQTYPQRPQQPFPQTQQPQQ (SEQ ID NO:30)).

### *HLA-DQ2 coeliac subjects*

Following gluten challenge in HLA-DQ2+ coeliac subjects, median IFN $\gamma$  ELISpot responses to P04722 77-93 E85 rose from a median of 0 to 133 sfc/million (see Table 4). One of the six coeliac subjects (C06) did not respond to P04722 77-93 QE85 (2 sfc/million) and had only weak responses to gliadin peptide pools (maximum: Pool 50+tTG 27 sfc/million). Consistent with earlier work, bioactivity of wild-type P04722 increased 6.5 times with deamidation by tTG (see Table 15). Interferon-gamma responses to gliadin-digests were present at baseline, but were substantially increased by gluten challenge from a median of 20 up to 92 sfc/million for chymotryptic-gliadin, and from 44 up to 176 sfc/million for peptide-gliadin.

Deamidation of gliadin increased bioactivity by a median of 3.2 times for chymotryptic-gliadin and 1.9 times for peptic-gliadin (see Table 15). (Note that the acidity required for digestion by pepsin is likely to result in partial deamidation of gliadin.)

5 In contrast to healthy subjects, gluten challenge induced IFN $\gamma$  ELISpot responses to 22 of the 83 tTG-treated pools including peptides from  $\alpha$ -,  $\gamma$ - and  $\omega$ -gliadins (see Figure 31, and Table 17). Bioactivity of pools was highly consistent between subjects (see Table 18). IFN $\gamma$  ELISpot responses elicited by peptide pools were almost always increased by deamidation (see Table 17). But enhancement of  
10 bioactivity of pools by deamidation was not as marked as for P04722 77-73 Q85, even for pools including homologues of A-gliadin 57-73. This suggests that Pepset peptides were partially deamidated during synthesis or in preparation, for example the Pepset peptides are delivered as salts of trifluoroacetic acid (TFA) after lyophilisation from a TFA solution.

15 One hundred and seventy individual tTG-deamidated peptides from 21 of the most bioactive pools were separately assessed. Seventy-two deamidated peptides were greater than 10% as bioactive as P04722 77-93 QE85 at an equivalent concentration (20  $\mu$ g/ml) (see Table 19). The five most potent peptides (85-94% bioactivity of P04722 QE85) were previously identified  $\alpha$ -gliadin homologues A-  
20 gliadin 57-73. Fifty of the bioactive peptides were not homologues of A-gliadin 57-73, but could be divided into six families of structurally related sequences (see Table 20). The most bioactive sequence of each of the peptide families were:  
PQQPQQPQQPFPOPQQPFPW (SEQ ID NO:31) (peptide 626, median 72%  
bioactivity of P04722 QE85), QQPQQPFPPOPQQPQLPFPQQ (SEQ ID NO:32)  
25 (343, 34%), QAFPOPQOTFPHOPQQQFPQ (SEQ ID NO:33) (355, 27%),  
TQQPQQPFPQQPQQPFPQTQ (SEQ ID NO:34) (396, 23%),  
PIQPQQPFPQQPQQPQQPFP (SEQ ID NO:35) (625, 22%),  
PQQSFSYQQQPFPQQPYPPQQ (SEQ ID NO:36) (618, 18%) (core sequences are  
underlined). All of these sequences include glutamine residues predicted to be  
30 susceptible to deamidation by transglutaminase (e.g. QXP, QXPF (SEQ ID NO:37),  
QXX[FY] (SEQ ID NO:38)) (see Vader et al 2002). Some bioactive peptides contain two core sequences from different families.

Consistent with the possibility that different T-cell populations respond to peptides with distinct core sequences, bioactivity of peptides from different families appear to be additive. For example, median bioactivity of tTG-treated Pool 81 was 141% of P04722 QE85, while bioactivity of individual peptides was in rank order:

5 Peptide 631 (homologue of A-gliadin 57-73) 61%, 636 (homologue of 626) 51%, and 635 19%, 629 16%, and 634 13% (all homologues of 396).

Although likely to be an oversimplification, the contribution of each "peptide family" to the summed IFN $\gamma$  ELISpot response to gliadin peptides was compared in the HLA-DQ2+ coeliac subjects (see Figure 32). Accordingly, the contribution of

10 P04722 77-73 E85 to the summed response to gliadin peptides is between 1/5 and 2/3.

Using the peptide homology search programme, WWW PepPepSearch, which can be accessed through the world wide web of the internet at, for example, "cbrg.inf.ethz.ch/subsection3\_1\_5.html.", and by direct comparison with Genbank

15 sequences for rye secalins, exact matches were found for the core sequences QQPFPPQQPFPP (SEQ ID NO:39) in barley hordeins (HOR8) and rye secalins (A23277, CAA26449, AAG35598), QQPFPPQQPFPP (SEQ ID NO:40) in barley hordeins (HOG1 and HOR8), and for PIQPQQPFPPQP (SEQ ID NO:41) also in barley hordeins (HOR8).

20

#### *HLA-DQ8-associated coeliac disease*

Seven HLA-DQ8+ coeliac subjects were studied before and after gluten challenge. Five of these HLA-DQ8+ (HLA-DQA0\*0301-3, HLA-DQB0\*0302) subjects also carried one or both of the coeliac disease-associated HLA-DQ2

25 complex (DQA0\*05, DQB0\*02). Two of the three subjects with both coeliac-associated HLA-DQ complexes had potent responses to gliadin peptide pools (and individual peptides including P04722 77-93 E85) that were qualitatively and quantitatively identical to HLA-DQ2 coeliac subjects (see Figures 33 and 34, and Table 18). Deamidated peptide pool 74 was bioactive in both HLA-DQ2/8 subjects,

30 but only in one of the 6 HLA-DQ2/X subjects. Pretreatment of pool 74 with tTG enhances bioactivity between 3.8 and 22-times, and bioactivity of tTG-treated pool 74 in the three responders is equivalent to between 78% and 350% the bioactivity of

P04722 77-93 E85. Currently, it is not known which peptides are bioactive in Pool 74 in subject C02, C07, and C08.

Two of the four HLA-DQ8 coeliac subjects that lacked both or one of the HLA-DQ2 alleles associated with coeliac disease showed very weak IFN $\gamma$  ELISpot responses to gliadin peptide pools, but the other two did respond to both protease-digested gliadin and specific peptide pools. Subject C12 (HLA-DQ7/8) responded vigorously to deamidated Pools 1-3 (see Figure 35). Assessment of individual peptides in these pools identified a series of closely related bioactive peptides including the core sequence LQPQNPSQQQPQ (SEQ ID NO:42) (see Table 20). Previous work (by us) has demonstrated that three glutamine residues in this sequence are susceptible to tTG-mediated deamidation (underlined). Homology searches using WWW PepPepSearch have identified close matches to LQPQNPSQQQPQ (SEQ ID NO:43) only in wheat  $\alpha$ -gliadins.

The fourth HLA-DQ8 subject (C11) had inducible IFN $\gamma$  ELISpot responses to tTG-treated Pool 33 (see Figure 36). Pools 32 and 33 include polymorphisms of a previously defined HLA-DQ8 restricted gliadin epitope (QQYPSGQGSFQPSQQNPQ (SEQ ID NO:44)) active after deamidation by tTG (underlined Gln are deamidated and convey bioactivity) (van der Wal et al 1998). Currently, it is not known which peptides are bioactive in Pool 33 in subject C11.

Comprehensive T cell epitope mapping in HLA-DQ2-associated coeliac disease using in vivo gluten challenge and a set of 652 peptides spanning all known 12 amino acid sequences in wheat gliadin has thus identified at least 72 peptides at 10% as bioactive as the known  $\alpha$ -gliadin epitope, A-gliadin 57-73 E65. However, these bioactive peptides can be reduced to a set of perhaps as few as 5 distinct but closely related families of peptides. Almost all these peptides are rich in proline, glutamine, phenylalanine, and/or tyrosine and include the sequence PQ(QL)P(FY)P (SEQ ID NO:45). This sequence facilitates deamidation of Q in position 2 by tTG. By analogy with deamidation of A-gliadin 57-68 (Arentz-Hansen 2000), the enhanced bioactivity of these peptides generally found with deamidation by tTG may be due to increased affinity of binding for HLA-DQ2.

Cross-reactivity amongst T cells in vivo recognizing more than one of these bioactive gliadin peptides is possible. However, if each set of related peptides does



activate a distinct T cell population in vivo, the epitope corresponding to A-gliadin 57-73 E65 is the most potent and is generally recognized by at least 40% of the peripheral blood T cells that secrete IFN $\gamma$  in response to gliadin after gluten challenge.

5. No gliadin-peptide specific responses were found in HLA-DQ2/8 coeliac disease that differed qualitatively from those in HLA-DQ2/X-associated coeliac disease. However, peripheral blood T cells in HLA-DQ8+ coeliac subjects without both HLA-DQ2 alleles did not recognize A-gliadin 57-73 E65 homologues. Two different epitopes were dominant in two HLA-DQ8+ coeliacs. The dominant epitope  
10 in one of these HLA-DQ8+ individuals has not been identified previously (LQPQNPSQQQPQ (SEQ ID NO:46)).

Given the teaching herein, design of an immunotherapy for coeliac disease utilizing all the commonly recognised T cell epitopes is practical and may include fewer than six distinct peptides. Epitopes in wheat  $\gamma$ - and  $\omega$ -gliadins are also present  
15 in barley hordeins and rye secalins.

#### Example 14

Several ELISpot assays were performed as previously described and yielded the following results and/or conclusions:

##### 20 *Examination of multiple $\alpha$ -gliadin polymorphisms with PQLPY*

Potent agonists of A-gliadin 57-73QE (G01) include QLQPFPPQELPYPQPQS (G01), PQL-Y-----P (G10), and PQPQPFL----- (G12). Less potent include -----L-----P (G04), -----R-----P (G05), and -----S-----P (G06). Less potent yet  
25 include -----L-----S-----P (G07), -----S-----S-----P (G08), -----S--S-----P (G09), and PQPQPFP----- (G13). Dashes indicate identity with the G01 sequence in the particular position.

##### 30 *Gluten challenge induces A-gliadin 57-73 QE65 T cells only after two weeks of gluten-free diet in newly diagnosed coeliac disease*

Additional analyses indicated that tTG-deamidated gliadin responses change after two weeks of gluten-free diet in newly diagnosed coeliac disease. Other

analyses indicated that deamidated gliadin-specific T cells are CD4<sup>+</sup>α<sub>4</sub>β<sub>7</sub><sup>+</sup> HLA-DQ2 restricted.

*Optimal epitope (clones versus gluten challenge)*

- 5 A "dominant" epitope is defined by γIFN ELISpot after gluten challenge. QLQPFQPELPYPQPQS (100% ELISpot response). Epitopes defined by intestinal T cell clones: QLQPFQPELPY (27%), PQPELPYPQPELPY (52%), and QQLPQPEQPQQSFPEQERPF (9%).

10

*Dominance among individual peptide responses*

- Dominance depends on wheat or rye. For wheat, dominant peptides include peptide numbers 89, 90 and 91 (referring to sequence numbers in Table 23). For rye,  
15 dominant peptides include peptide numbers 368, 369, 370, 371, and 372 (referring to sequence numbers in Table 23). Some peptides, including 635 and 636 (referring to sequence numbers in Table 23) showed activity in both rye and wheat.

20 *In vivo gluten challenge allows T cell epitope hierarchy to be defined for coeliac disease*

- The epitope hierarchy is consistent among HLA-DQ2<sup>+</sup> coeliacs but different for HLA-DQ8<sup>+</sup> coeliacs. The hierarchy depends on what cereal is consumed. Deamidation generates almost all gliadin epitopes. HLA-DQ2, DQ8, and DR4 present deamidated peptides. HLA-DQ2/8-associated coeliac disease preferentially  
25 present DQ2-associated gliadin epitopes. Gliadin epitopes are sufficiently restricted to justify development of epitope-based therapeutics.

Other analyses indicated the following: HLA-DR3-DQ2 (85-95%) and HLA-DR4-DQ8 (5-15%).

Other analyses indicated the following:

- 30
- |        |          |          |           |        |          |
|--------|----------|----------|-----------|--------|----------|
| HLA-DQ | HLA-DQA1 | HLA-DQB1 | Duodenal  | Gluten | EMA on   |
|        | allele   | allele   | histology | free   | gluten   |
|        |          |          |           |        | (on GFD) |

	C01	2,6	102/6, 501	201, 602	SVA	1 yr	+(-)
	C02	2,2	501	201	SVA	1 yr	+(-)
	C03	2,5	101/4/5, 501	201, 501	PVA	1 yr	+(-)
	C04	2,5	101/4/5, 501	201, 501	SVA	7 yr	+(-)
5	C05	2,2	201, 501	201, 202	SVA	4 mo	+(ND)
	C06	2,2	201, 501	201, 202	SVA	2 yr	+(-)
	C07	2,8	301-3, 501	201, 302	SVA	1 yr	+(-)
	C08	2,8	301-3, 501	201,302/8	SVA	11 yr	ND (-)
	C09	2,8	301-3, 501	201, 302	SVA	29 yr	+(-)
10	C10	2,8	201, 301-3	202, 302	IEL	1 yr	+(-)
	C11	6,8	102/6, 301-3	602/15, 302/8	IEL	9 mo	-(ND)
	C12	8,7	301-3, 505	302, 301/9-10	SVA	2 yr	- (-)
	C13	8,8	301	302	SVA	1 yr	+(+)

15 Another analysis was carried out to determine the bioactivity of individual tTG-deamidated peptides in pools 1-3 in subject C12. The results are as follows (sequence numbers refer to the peptides listed in Table 23): Sequence 8 (100%), Sequence 5 (85%), Sequence 6 (82%), Sequence 3 (77%), Sequence 1 (67%), Sequence 2 (59%), Sequence 9 (49%), Sequence 7 (49%), Sequence 10 (33%),

20 Sequence 4 (15%), Sequence 12 (8%), Sequence 11 (0%), Sequence 23 (26%), Sequence 14 (18%), Sequence 15 (18%), Sequence 17 (18%), Sequence 16 (13%), Sequence 14 (8%), Sequence 22 (5%), Sequence 18 (3%), Sequence 19 (3%), Sequence 20 (0%), Sequence 21 (0%). The predicted deamidated sequence is LQPENPSQEQPE.

25

*Individual ELISpot responses by PBMC (Spot forming cells determined by ELISpot Reader)*

Peptide (see Table 23)	C01	C02	C03	C04	C05
65	16	2	1	2	3
30 66	32	6	13	0	6
67	16	3	4	0	4
68	25	8	4	2	2

68

	69	4	0	0	0	0
	70	2	1	0	0	0
	71	1	1	0	0	1
	72	0	0	0	0	0
5	73	95	21	42	31	31
	74	122	15	29	21	28
	75	5	1	2	2	5
	76	108	13	28	16	22
	77	3	0	1	0	1
10	78	21	2	3	5	3
	79	20	0	2	0	2
	80	5	2	0	0	3
	81	4	1	2	3	1
	82	3	3	5	2	2
15	83	14	2	0	0	1
	84	3	0	0	0	0
	85	14	1	2	1	2
	86	11	0	2	0	2

## 20 *Cross-reactivity*

To deal with data from 652 peptides in 29 subjects, or to determine when a particular response is a true positive peptide-specific T-cell response, or to determine when a response to a peptide is due to cross-reactivity with another structurally related peptide, expression of a particular peptide response can be as a percentage of a "dominant" peptide response. Alternately, the expression can be a "relatedness" as correlation coefficients between peptide responses, or via bioinformatics.

## *Additional epitopes*

30 A representative result is as follows:

Combination of peptides with P04722E (all 20mcg/ml) (n=4)

Alone

P04722E+

69

Pep 626	60	135
P04722E	100	110
HLAa	0	85

(expressed as percent P04722E)

- 5 626+tT: PQQPQQPQQPFPQPQQPFPW  
P04724E: QLQFPQPPELPYPQPQL

TTG-deamidation of peptide 626 (n=12)

- 10 No tTG = 100%  
TTG = 170%

*Substitution at particular positions*

Substitution of Peptide 626 PQQP[Q1]QP[Q2]QFPQP[Q3]QFPFW(n=12)

15		Glu	Arg
	Q1	95	90
	Q2	145	80
	Q3	155	10

(expressed as percent wild-type peptide)

20

Bioactivity of tTG-treated 15mers spanning Peptide 626/627  
(PQQPQQPQQPFPQPQQPFPWQP) (n=8)

	P1-15	5
	P2-16	4
25	P3-17	3
	P4-18	38
	P5-19	65
	P6-20	95
	P7-21	65
30	P8-22	90

(expressed as percent of maximal 15mer response)

*Multiple epitopes:*

P04724E: QLQFFPQPQLPYPQPQL

626+ $\alpha$ TG: PQQPQQPQQPFPQQPFPW

Minimal epitope: QPQQPFPQPQQPFPW

5 Immunomagnetic depletion of PBMC by beads coated with anti-CD4 and by anti-integrin  $\beta_7$  depleted IFN $\gamma$  ELISpot responses, while immunomagnetic depletion of PBMC by beads coated with anti-CD8 or anti- $\alpha$ E integrin. Thus, the PBMC secreting IFN $\gamma$  are CD4+ and  $\alpha_4\beta_7$ +, associated with homing to the lamina propria in the gut.

10 Blocked by anti-DQ antibody but not by anti-DR antibody in heterozygotes and homozygotes for HLA-DQ2. This may imply multiple epitopes within one sequence.

*T cell epitopes in coeliac disease*

15 Other investigators have characterized certain intestinal T cell clone epitopes. See, e.g., Vader et al., Gastroenterology 2002, 122:1729-37; Arentz-Hansen et al., Gastroenterology 2002, 123:803-809. These are examples of epitopes whose relevance is at best unclear because of the in vitro techniques used to clone T cells.

*Intestinal versus peripheral blood clones*

Intestinal: 1) intestinal biopsies, 2) T cell clones raised against peptic-tryptic digest of gluten, 3) all HLA-DQ2 restricted, 4) clones respond to gliadin deamidated by transglutaminase.

Peripheral blood: 1) T cell clones raised against gluten are HLA-DR, DQ and DP  
25 restricted. Result: Intestinal T cell clones can be exclusively used to map coeliac disease associated epitopes

GDA\_9Wheat 307 aa Definition Alpha/Beta-Gliadin MM1 Precursor (Prolamin)

Accession P18573 -- Genbank (which is incorporated herein by reference in its

30 entirety)

*Intestinal T cell clone epitopes*

A definition of intestinal T cell clone epitopes can be found in, for example, Arentz-Hansen et al., J Exp Med. 2000, 191:603-12. Also disclosed therein are gliadin epitopes for intestinal T cell clones. Deamidated QLQPFQPQLPY is an epitope, with a deamidated sequence of QLQPFQPPELPY. There is an HLA-DQ2 restriction. A homology search shows other bioactive  $\alpha$ -gliadins include PQPQLPY singly or duplicated. A majority of T cell clones respond to either/or DQ2- $\alpha$ I: QLQPFQPPELPY DQ2- $\alpha$ II: PQPELPYPQPELPY

*Dominant gliadin T cell epitopes*

10 All deamidated by transglutaminase.

Peripheral blood day 6 after gluten challenge: A-gliadin 57-73:

QLQPFQPPELPYPQPQS

Intestinal T cell clones: DQ2- $\alpha$ I: QLQPFQPPELPY DQ2- $\alpha$ II: PQPELPYPQPELPY

15 *Intestinal T-cell Clone Epitope Mapping*

	$\alpha$ -Gliadins	A1	PFPQPQLPY
		A2	PQPQLPYPQ
		A3	PYPQPQLPY
		Glia-20	PQQPYPQPQPQ
20	$\Gamma$ -Gliadins	G1	PQQSFPQQQ
		G2	IIPQQPAQ
		G3	FPQQPQQPYPQQP
		G4	FSQPQQQFPQPQ
		G5	LQPQQPFPQQPQQPYPQQPQ
25		Glu-21	QSEQSQQPFPQQF
		Glu-5	Q(IL)PQQPQQF
	Glutenin	Glt-156	PFSQQQQSPF
		Glt-17	PFSQQQQQ

*Gluten exposure and induction of IFN $\gamma$ -secreting A-Gliadin 57-73QE65-specific T cells in peripheral blood*

Untreated coeliac disease, followed by gluten free diet for 1, 2, or 8 weeks, followed by gluten exposure (3 days bread 200g/day), followed by gluten free diet

5      Result 1: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: A-gliadin 57-73 QE65 (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (5), 1 week (1), 2 weeks (2), 8 weeks (1)

Day 6: none (0), 1 week (4), 2 weeks (28), 8 weeks (48)

10      Result 2: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: tTG-gliadin (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (45), 1 week (62), 2 weeks (5), 8 weeks (5)

Day 6: none (0), 1 week (67), 2 weeks (40), 8 weeks (60)

15      Result 3: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: A-gliadin 57-73 P65 (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (1), 1 week (2), 2 weeks (1), 8 weeks (1)

Day 6: none (0), 1 week (0), 2 weeks (0), 8 weeks (0)

20      Result 4: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: PPD (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (90), 1 week (88), 2 weeks (210), 8 weeks (150)

Day 6: none (0), 1 week (100), 2 weeks (210), 8 weeks (100)

25      Result 5: Duration of gluten free diet and IFN $\gamma$  ELISpot responses on day 0 and day 6 of gluten challenge: tTG (results expressed as IFN $\gamma$  specific spots/million PPBMC)

Day 0: none (5), 1 week (4), 2 weeks (3), 8 weeks (2)

Day 6: none (0), 1 week (4), 2 weeks (1), 8 weeks (2)

30

*Gluten challenge in HLA-DQ2 coeliac disease on long term gluten*



Characterization of anti-gliadin T cell response was carried out in peripheral blood on day 6-8 after 3-day gluten challenge.

Result 1: PBMC Day 6 Long-term gluten free diet (preincubation with anti-HLA-DR and -DQ antibody) (expressed as % inhibition)

5 DR-: tTG-gliadin 100 mcg/ml (105), A-gliadin 57-73 QE65 50 mcg/ml (90), PPD 5 mcg/ml (30)

DQ-: tTG-gliadin 100 mcg/ml (5), A-gliadin 57-73 QE65 50 mcg/ml (22), PPD 5 mcg/ml (78).

Result 2: PBMC Day 6 Long-term gluten free diet (expressed as % CD8-  
10 depleted PBMC response)

B7 depletion: tTG-gliadin n=6 (7), A-gliadin 57-73 n=9 (6), PPD n=8 (62)

AE depletion: tTG-gliadin n=6 (120), A-gliadin 57-73 n=9 (80), PPD n=8  
(110).

CD4 depletion: tTG-gliadin n=6 (10), A-gliadin 57-73 n=9 (9), PPD n=8  
15 (10).

*Therapeutic peptides include, but are not limited to*

QLQFPFPQQLPYPQPQS (AG01)

QLQFPFPQQLPYPQPQP (AG02)

20 QLQFPFPQQLPYPQPQL (AG03)

QLQFPFPQQLPYLQPQP (AG04)

QLQFPFRPQLPYPQPQP (AG05)

QLQFPFPQQLPYSQPQP (AG06)

QLQPFLLPQLPYSQPQP (AG07)

25 QLQFFSQPQLPYSQPQP (AG08)

QLQFPFPQLSYSQPQP (AG09)

PQLPYPQPQLPYPQPQP (AG10)

PQLPYPQPQLPYPQPQL (AG11)

PQPQFLLPQLPYPQPQS (AG12)

30 PQPQFPFPQLPYPQPQS (AG13)

PQPQFPFPQLPYPQYQP (AG14)

PQPQFPFPQLPYPQPPP (AG015)

Briefly after oral antigen challenge, specificities of peripheral blood T cells reflect those of intestinal T cell clones. In peripheral blood, epitopes of intestinal T cell clones are sub-optimal compared to A-gliadin 57-73 QE65, which is an optimal  $\alpha$ -gliadin epitope.

### Example 15

ELISpot assays were also carried out for mapping purposes as follows.

#### *Fine-mapping the dominant DQ-8 associated epitope*

Sequence / sfc	tTG-treated sequence / sfc
VPQLQPQNPSQQQPQEQV / 76	RWPVPQLQPQNPSQQ / 60
	WPVPQLQPQNPSQQQ / 90
VPQLQPENPSQQQPQEQV / 3	PVPQLQPQNPSQQQP / 130
VPQLQPRNPSQQQPQEQV / 76	VPQLQPQNPSQQQPQ / 140
	PQLQPQNPSQQQPQE / 59
VPQLQPQNPSQEQPQEQV / 100	QLQPQNPSQQQPQEQ / 95
VPQLQPQNPSQRQPQEQV / 1	LQPQNPSQQQPQEQV / 30
	QPQNPSQQQPQEQVP / 4
VPQLQPQNPSQQQPPEEQV / 71	
VPQLQPQNPSQQQPPEEQV / 27	DQ8 Gliadin Epitope
	GDA09 202Q / 6
VPQLQPQNPSQEQPPEEQV / 81	GDA09 202E / 83
VPQLQPENPSQQQPPEEQV / 2	GDA09 202Q+tTG / 17
VPQLQPENPSQEQPQEQV / 6	BI + tTG / 0
VPQLQPENPSQEQPPEEQV / 5	BI / 0

#### *Fine-mapping dominant epitope (2)*

Pool 33 (deamidated) / sfc

A2b3 301 qqyp sgqg ffqp sqqn pqaq / 2
A2b5 301 qqyp sgqg ffqp fqqn pqaq / 1
A3a1 301 qqyp sgqg ffqp sqqn pqaq / 0
A3b1 301 qqyp ssqv sfqp sqln pqaq / 0

A3b2 301 qqyp ssqg sfqp sqqn pqaq / 2

A4a 301 eqyp sgqv sfqs sqqn pqaq / 28

A1b1 309 sfrp sqqn plaq gsvq pqq1 / 2

A1a1 309 sfrp sqqn pqaq gsvq pqq1 / 2

5

#### Example 16

*Bioactivity of gliadin epitopes in IFN $\gamma$ -ELISpot (25 mcg/ml, n=6) (expressed as % A-gliadin 57-73 QE65 response)*

DQ2-AII: wild type (WT) (4), WT + tTG (52), Glu-substituted (52)

10 DQ2-AI: wild type (WT) (2), WT + tTG (22), Glu-substituted (28)

GDA09: wild type (WT) (1), WT + tTG (7), Glu-substituted (8)

A-G31-49: wild type (WT) (2), WT + tTG (3), Glu-substituted (0)

*Dose response of A-Gliadin 57-73 QE65 (G01E) (n=8) (expressed as %G01E maximal response)*

15

0.025 mcg/ml (1), 0.05 mcg/ml (8), 0.1 mcg/ml (10), 0.25 mcg/ml (22), 0.5 mcg/ml (38), 1 mcg/ml (43), 2.5 mcg/ml (52), 5 mcg/ml (70), 10 mcg/ml (81), 25 mcg/ml (95), 50 mcg/ml (90), 100 mcg/ml (85).

IFN $\gamma$  ELISpot response to gliadin epitopes alone or mixed with A-gliadin

20 57-75 (G01E) (all 50 mcg/ml, tTG-gliadin 100 mcg/ml, PPD 5 mcg/ml; n=9)  
(expressed as % G01E response)

Alone: DQ2-A1 (20), DQ2-A2 (55), Omega G1 (50), tTG Gliadin (80), PPD (220), DQ2 binder (0)

25 G01E+: DQ2-A1 (90), DQ2-A2 (95), Omega G1 (100), tTG Gliadin (120),  
PPD (280), DQ2 binder (80)

*Effect of alanine and lysine substitution of A-gliadin 57-73 QE65 on IFN $\gamma$  ELISpot responses in individual coeliac subjects (n=8)*

Epitope sequence: QLQPFQPELPYPQPQS

30 Alanine substitution at positions 57-59 and 72-73 showed little to no decrease in % A-gliadin 57-73 QE65 response. Alanine substitution at positions 60-62 and 68-71 showed moderate decrease in % A-gliadin 57-73 QE65 response.

Alanine substitution at positions 63-67 showed most decrease in % A-gliadin 57-73 QE65 response.

Effect of lysine substitution of A-gliadin 57-73 QE65 on IFN $\gamma$  ELISpot responses in individual coeliac subjects (n=8);

5 Epitope sequence: QLQPFQPELPYPQPQS

Lysine substitution at positions 57-59 and 71-73 showed little to no decrease in % A-gliadin 57-73 QE65 response. Lysine substitution at positions 60-61 and 69-70 showed moderate decrease in % A-gliadin 57-73 QE65 response. Lysine substitution at positions 62-68 showed most decrease in % A-gliadin 57-73 QE65 response.

#### Example 17

Table 24 shows the results of analyses examining the 652 peptides with several patients challenged with wheat or rye.

15

#### References

1. Molberg O, et al. Nature Med. 4, 713-717 (1998).
2. Quarsten H, et al. Eur. J. Immunol. 29, 2506-2514 (1999).
- 20 3. Greenberg CS et al. FASEB 5, 3071-3077 (1991).
4. Mantzaris G, Jewell D. Scand. J. Gastroenterol. 26, 392-398 (1991).
5. Mauri L, et al. Scand. J. Gastroenterol. 31, 247-253 (1996).
6. Bunce M, et al. Tissue Antigens 46, 355-367 (1995).
7. Olerup O, et al. Tissue antigens 41, 119-134 (1993).
- 25 8. Mullighan CG, et al. Tissue-Antigens. 50, 688-92 (1997).
9. Plebanski M et al. Eur. J. Immunol. 28, 4345-4355 (1998).
10. Anderson DO, Greene FC. The alpha-gliadin gene family. II. DNA and protein sequence variation, subfamily structure, and origins of pseudogenes. Theor Appl Genet (1997) 95:59-65.
- 30 11. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Van der Wal Y, Kooy YMC, Lundin KEA, Koning F, Roepstorff P, Sollid LM, McAdam SN. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a

- single deamidated glutamine targeted by tissue transglutaminase. *J Exp Med.* 2000; 191:603-12.
12. Vader LW, de Ru A, van der Wal, Kooy YMC, Benckhuijsen W, Mearin ML,  
5 Drijfhout JW, van Veelen P, Koning F. Specificity of tissue transglutaminase  
explains cereal toxicity in celiac disease. *J Exp Med* 2002; 195:643-649.
13. van der Wal Y, Kooy Y, van Veelan P, Pena S, Mearin L, Papadopoulos G,  
Koning F. Selective deamidation by tissue transglutaminase strongly enhances  
10 gliadin-specific T cell reactivity. *J Immunol.* 1998; 161:1585-8.
14. van der Wal Y, Kooy Y, van Veelan P, Pena S, Mearin L, Molberg O, Lundin  
KEA, Sollid L, Mutis T, Benckhuijsen WE, Drijfhout JW, Koning F. *Proc Natl*  
*Acad Sci USA* 1998; 95:10050-10054.
- 15 15. Vader W, Kooy Y, Van Veelen P et al. The gluten response in children  
with celiac disease is directed toward multiple gliadin and glutenin  
peptides. *Gastroenterology* 2002, 122:1729-37
- 20 16. Arentz-Hansen H, McAdam SN, Molberg O, et al. Celiac lesion T cells  
recognize epitopes that cluster in regions of gliadin rich in proline  
residues. *Gastroenterology* 2002, 123:803-809.
- 25 Each of the PCT publications, U.S. patents, other patents, journal references, and  
any other publications cited or referred to herein is incorporated herein by reference  
in their entirety.

**Table 1. A-Gliadin protein sequence (based on amino acid sequencing)**

5	VRVPVPQLQP QNPSQQQPQE QVPLVQQQF PGQQQQFPPQ QPYPQPQFPF SQQPYLQLQP FPQPQLPYPQ
	1 11 21 31 41 51 61
10	PQSFPQQPY PQPQPYSQP QQPISQQQAQ QQQQQQQQQQ QQQILQQILQ QQLPCMDVV LQQHNIAHAR
	71 81 91 101 111 121 131
	SQVLQQSTYQ LLQELCCQHL WQIPEQSQCQ AIHNVVHAIL LHQQQKQQQ PSSQVSFQQP LQQYP LGQGS
	141 151 161 171 181 191 201
	FRPSQQNPQA QGSVQPQQLP QFEEIRNLAL QTLPAMCNVY IAPYCTIAPF GIFGTN
	211 221 231 241 251 261

**Table 2. Coeliac disease subjects studied**

	Age Sex	Gluten free diet	HLA-DQ2	Bread. challenge	Symptoms with bread
1	64 f	14 yr	Homozygote	3 days	Abdominal pain, lethargy, mouth ulcers, diarrhoea
2	57 m	1 yr	Heterozygote	10 days	Lethargy, nausea
3	35 f	7 yr	Heterozygote	3 days	Nausea
4	36 m	6 wk	Homozygote	3 days	Abdominal pain, mouth ulcers, diarrhoea
5	26 m	19 yr	Heterozygote	3 days	None
6	58 m	35 yr	Heterozygote	3 days	None
7	55 m	1 yr	Heterozygote	3 days	Diarrhoea
8	48 f	15 yr	Homozygote	3 days	Abdominal pain, diarrhoea

Aminoacid at position 65	Range	Mean
Glutamate	(100)	100%
Asparagine	(50-84)	70%
Aspartate	(50-94)	65%
Alanine	(44-76)	64%
Cysteine	(45-83)	62%
Serine	(45-75)	62%
Valine	(24-79)	56%
Threonine	(46-66)	55%
Glycine	(34-47)	40%
Leucine	(8-46)	33%
Glutamine	(16-21)	19%
Isoleucine	(3-25)	14%
Methionine	(3-32)	14%
Phenylalanine	(0-33)	12%
Histidine	(0-13)	8%
Tyrosine	(0-17)	8%
Tryptophan	(0-17)	8%
Lysine	(0-11)	4%
Proline	(0-4)	2%
Arginine	(0-2)	1%

Table 3

Isotop response to TG	TG	Peptide sequence	Corresponding residues in gliadin protein sequences (Accession no.)
(1-13)	100 (100)	QLQPFQPQLPYQPQS	57-73 $\alpha$ -Gliadin (T. aestivum) Q41545
(1-7)	53 (44-67)	QLQPFQPQLPYQPQS	57-73 $\alpha$ -Gliadin (T. aestivum) Q41545
		QLQPFQPQLPYSQPQP	77-93 $\alpha/\beta$ -Gliadin precursor (Triticum. aestivum) P02863
			76-92 $\alpha$ -Gliadin (T. aestivum) Q41528
			77-93 $\alpha$ -Gliadin storage protein (T. aestivum) Q41531
			57-73 $\alpha$ -Gliadin mature peptide (T. aestivum) Q41533
			77-93 $\alpha$ -Gliadin precursor (T. spelta) Q9ZP09
2 (0-20)	83 (61-113)	QLQPFQPQLPYQPQP	77-93 $\alpha/\beta$ -Gliadin A-II precursor (T. aestivum) P0472
9 (0-33)	83 (74-97)	QLQPFQPQLPYQPQL	77-93 $\alpha/\beta$ -Gliadin A-IV precursor (T. aestivum) P04724
			77-93 $\alpha/\beta$ -Gliadin MM1 precursor (T. aestivum) P18573
(0-7)	109 (41-152)	PQLPYQPQLPYQPQP	84-100 $\alpha/\beta$ -Gliadin A-IV precursor (T. aestivum) P04724
ID		PQLPYQPQLPYQPQL	84-100 $\alpha/\beta$ -Gliadin MM1 precursor (T. aestivum) P18573
(0-1)	3 (0-7)	QLQPFQPQLPYSQPQP	77-93 $\alpha/\beta$ -Gliadin A-I precursor (T. aestivum) P04721
			77-93 $\alpha$ -Gliadin (T. aestivum) Q41509
(0-0)	2 (0-7)	QLQPFQPQLPYSQPQP	77-93 $\alpha$ -Gliadin storage protein (T. aestivum) Q41530
ID		PQPQFPQPQLPYQTQP	77-93 $\alpha/\beta$ -Gliadin A-III precursor (T. aestivum) P04723
7 (0-40)	24 (11-43)	PQPQFPQPQLPYQPQS	82-98 $\alpha/\beta$ -Gliadin A-V precursor (T. aestivum) P04725
0 (0-30)	19 (11-33)	PQPQFPQPQLPYQPPP	82-98 $\alpha/\beta$ -Gliadin clone PW1215 precursor (T. aestivum) P04726
			82-98 $\alpha/\beta$ -Gliadin (T. urartu) Q41632
0 (0-30)	21 (11-33)	PQPQFPLPQLPYQPQS	79-95 $\alpha/\beta$ -Gliadin clone PW8142 precursor (T. aestivum) P04726
			79-95 $\alpha$ -Gliadin (T. aestivum) Q41529
			79-95 $\alpha/\beta$ -Gliadin precursor (T. aestivum) Q41546

Table 4

**Table 5. T cell epitopes described in coeliac disease**

Source	Restriction	Frequency	Sequence*
Gamma -gliadin	DQ2	3/NS (iTCC)	QQLPQPEQPQQSFPEQERPF
Alpha-gliadin	DQ2	12/17 (iTCL)	QLQPFQPELPY
Alpha-gliadin	DQ2	11/17 (iTCL)	PQPELPYPQPELPY
Alpha-gliadin	DQ2	1/23 (bTCC)	LGQQQPFPFPQYPYPQPPF
Alpha-gliadin	DQ8	3/NS (iTCC)	QQYPSGEGSFQPSQENPQ
Glutenin	DQ8	1/1 (iTCC)	GQQGYPTSPQQSGQ
Alpha-gliadin	DQ2	11/12 in vivo	QLQPFQPELPYPQPQS

NS not stated in original publication, iTCC intestinal T cell clone, iTCL intestinal polyclonal T cell line, bTCC peripheral blood T cell clone

\*All peptides are the products of transglutaminase modifying wild type gluten peptides except the fourth and sixth peptides

**Table 6. Relative bioactivity of gliadin T cell epitopes in coeliac PBMC after gluten challenge**

Sequence*	ELISpot response as % A-gliadin 57-73 QE65 (all 25mcg/ml)		
	Wild type	Wildtype+tTG	E-substituted
QQLPQPEQPQQSFPEQERPF	9 (3)	18 (7)	10 (5)
QLQPFQPELPY	6 (2)	19 (1)	8 (3)
PQPELPYPQPELPY	13 (6)	53 (8)	48 (9)
QQYPSGEGSFQPSQENPQ	10 (3)	9 (3)	14 (3)
QLQPFQPELPYPQPQS	18 (7)	87 (7)	100
PQLPYFQPELPYPQPQP	14 (4)	80 (17)	69 (20)

\* sequence refers that of transglutaminase (tTG) modified peptide and the T cell epitope. Wild type is the unmodified gliadin peptide. Data from 4 subjects. Blank was 5 (1) %.



**Table 7. Polymorphisms of A-gliadin 57-73****A. Sequences derived from Nordic autumn wheat strain Mjoelner**

Alpha-gliadin protein (single letter code refers to Fig. 14 peptides)	Polymorphism
Q41545 A-gliadin (from sequenced protein) 57-73 (A)	QLQPFPPQQLPYQPQPS
Gli alpha 1,6: (EMBL: AJ133605 & AJ133602 58-74) (J)	QPQPFPPQQLPYPQTQP
Gli alpha 3,4,5: (EMBL: AJ133606, AJ133607, AJ133608 57-73) (I)	QLQPFPPQQLSYSQPQP
Gli alpha 7: (EMBL: AJ133604 57-73) (E)	QLQPFPPQQLPYQPQQP
Gli alpha 8, 9, 11: (EMBL: ) (F)	QLQPFPPQQLPYSQPQP
Gli alpha 10: (EMBL: AJ133610 57-73) (D)	QLQPFPPQQLPYLQPQS

5 **B. SWISSPROT and TREMBL scan (10.12.99) for gliadins containing the sequence: XXXXXXXXPQLPYXXXXX**

Wheat ( <i>Triticum aestivum</i> unless stated) gliadin accession number	Polymorphism
Q41545 A-gliadin (from sequenced protein) 57-73 (A)	QLQPFPPQQLPYQPQPS
SWISSPROT:	
GDA0_WHEAT P02863 77-93 (F)	QLQPFPPQQLPYSQPQP
GDA1_WHEAT P04721 77-93 (G)	QLQPFLLQQLPYSQPQP
GDA2_WHEAT P04722 77-93 (B)	QLQPFPPQQLPYQPQQP
GDA3_WHEAT P04723 77-93 (O)	POQPFPPQQLPYPQTQP
GDA4_WHEAT P04724 77-93 (C)	QLQPFPPQQLPYQPQQL
GDA4_WHEAT P04724 84-100 (K)	PQLPYQPQLPYQPQQP
GDA5_WHEAT P04725 82-98 (N)	POQPFPPQQLPYQPQPS
GDA6_WHEAT P04726 82-98 (P)	POQPFPPQQLPYQPQPP
GDA7_WHEAT P04727 79-95 (M)	POQPFLLQQLPYQPQPS
GDA9_WHEAT P18573 77-93 (C)	QLQPFPPQQLPYQPQQL
GDA9_WHEAT P18573 84-100 (L)	PQLPYQPQLPYQPQQL
GDA9_WHEAT P18573 91-107 (K)	PQLPYQPQLPYQPQQP
TREMBL	
Q41509 ALPHA-GLIADIN 77-93 (G)	QLQPFLLQQLPYSQPQP
Q41528 ALPHA-GLIADIN 76-92 (F)	QLQPFPPQQLPYSQPQP
Q41529 ALPHA-GLIADIN 79-95 (M)	POQPFLLQQLPYQPQPS
Q41530 ALPHA-GLIADIN 77-93 (H)	QLQPFSSQQLPYSQPQP
Q41531 ALPHA-GLIADIN 77-93 (F)	QLQPFPPQQLPYSQPQP
Q41533 ALPHA-GLIADIN 57-73 (F)	QLQPFPPQQLPYSQPQP
Q41546 ALPHA/BETA-GLIADIN 79-95 (M)	POQPFLLQQLPYQPQPS
Q41632 ALPHA/BETA-TYPE GLIADIN. <i>Triticum urartu</i> 82-98 (P)	POQPFPPQQLPYQPQPP
Q9ZP09 ALPHA-GLIADIN <i>Triticum spelta</i> 77-93 (F)	QLQPFPPQQLPYSQPQP

Table 8. Bioactivity of substituted variants of A-gliadin 57-73 QE65 (Subst) compared to unmodified A-gliadin 57-73 QE65 (G) (mean 100%, 95% CI 97-104) and blank (no peptide, bl) (mean 7.1%, 95% CI: 5.7-8.5)

Subst	%	P vs G	Subst	%	P vs G	Subst	%	P vs G	Subst	%	P vs G	P vs bl
Super-agonists			F62	71	0.001	H62	47	<0.0001	N66	24	<0.0001	
Y61	129	<0.0001	V63	70	<0.0001	G69	47	<0.0001	R64	24	<0.0001	
Agonists			H63	70	<0.0001	H68	47	<0.0001	V65	23	<0.0001	
Y70	129	0.0006	S69	70	<0.0001	N63	47	<0.0001	K63	23	<0.0001	
W70	119	0.017	F63	70	0.008	M68	46	<0.0001	H66	23	<0.0001	
K57	118	0.02	P70	69	<0.0001	D68	46	<0.0001	H67	22	<0.0001	
Y59	117	0.04	T62	69	<0.0001	V69	46	<0.0001	L64	22	<0.0001	
A57	116	0.046	L61	69	<0.0001	G63	45	<0.0001	S66	22	<0.0001	
S70	116	0.045	S61	69	<0.0001	V64	45	<0.0001	F67	21	<0.0001	
K58	114	0.08	T61	69	<0.0001	E61	45	<0.0001	W66	21	<0.0001	
W59	110	0.21	T63	69	<0.0001	A69	43	<0.0001	G64	21	<0.0001	
A73	109	0.24	M66	68	<0.0001	R62	42	<0.0001	G65	21	<0.0001	
I59	108	0.37	T69	67	<0.0001	G68	42	<0.0001	D64	21	<0.0001	
G59	108	0.34	K60	66	<0.0001	A64	42	<0.0001	I65	21	<0.0001	
A58	108	0.35	S62	66	<0.0001	C65	42	<0.0001	M64	20	<0.0001	<0.0001
W60	105	0.62	M61	66	<0.0001	N67	41	<0.0001	G67	19	<0.0001	<0.0001
A59	104	0.61	P61	65	<0.0001	W63	41	<0.0001	T65	19	<0.0001	0.003
K72	104	0.65	M62	64	<0.0001	F69	41	<0.0001	A66	19	<0.0001	<0.0001
S59	103	0.76	Q61	64	<0.0001	N68	40	<0.0001	I64	19	<0.0001	0.0003
K73	102	0.8	G61	64	<0.0001	V66	40	<0.0001	R63	19	<0.0001	<0.0001
A70	102	0.81	A63	64	<0.0001	H69	40	<0.0001	W67	19	<0.0001	<0.0001
Y60	101	0.96	L62	60	<0.0001	M69	40	<0.0001	K68	18	<0.0001	<0.0001
A72	100	0.94	I68	60	<0.0001	R69	40	<0.0001	H64	18	<0.0001	<0.0001
S63	98	0.67	S67	59	<0.0001	W69	40	<0.0001	W64	18	<0.0001	0.0001
K59	96	0.46	N61	59	<0.0001	Q69	39	<0.0001	Q65	18	<0.0001	0.0002
I60	96	0.5	I69	59	<0.0001	L67	38	<0.0001	F64	16	<0.0001	0.0008
G70	95	0.41	V61	58	<0.0001	K69	38	<0.0001	L65	16	<0.0001	0.0022
D65	95	0.44	D61	58	<0.0001	K62	38	<0.0001	N64	16	<0.0001	<0.0001
E70	93	0.27	E60	57	<0.0001	E67	37	<0.0001	F65	16	<0.0001	0.12
I63	92	0.19	A61	57	<0.0001	L69	37	<0.0001	Q67	15	<0.0001	0.0012
S60	92	0.23	Q62	56	<0.0001	S64	36	<0.0001	M65	14	<0.0001	0.015
P59	88	0.08	F68	56	<0.0001	G62	36	<0.0001	D66	14	<0.0001	0.013
M63	87	0.03	N65	56	<0.0001	E69	36	<0.0001	R67	14	<0.0001	0.002
K71	85	0.047	A62	56	<0.0001	E68	36	<0.0001	Non-agonists			
V62	84	0.04	A68	53	<0.0001	V67	35	<0.0001	P63	13	<0.0001	0.012
I70	84	0.04	P66	53	<0.0001	D62	35	<0.0001	E64	12	<0.0001	0.053
I61	83	0.01	R61	53	<0.0001	R68	34	<0.0001	W65	11	<0.0001	0.24
V68	82	0.0045	S68	53	<0.0001	Q66	34	<0.0001	Q64	11	<0.0001	0.15
E59	81	0.01	Y63	52	<0.0001	A67	33	<0.0001	G66	11	<0.0001	0.07
Partial agonists			N69	51	<0.0001	N62	32	<0.0001	R65	11	<0.0001	0.26
W61	79	0.002	E63	51	<0.0001	F66	31	<0.0001	Y67	10	<0.0001	0.13
A60	78	0.002	T64	51	<0.0001	E62	31	<0.0001	E66	10	<0.0001	0.17
Y62	78	0.006	T67	51	<0.0001	D69	31	<0.0001	K66	10	<0.0001	0.21
G60	77	0.003	Y69	50	<0.0001	D67	30	<0.0001	R66	10	<0.0001	0.23
A71	77	0.003	D63	50	<0.0001	M67	29	<0.0001	K67	10	<0.0001	0.11
W62	76	0.0009	A65	49	<0.0001	Y66	28	<0.0001	P65	8	<0.0001	0.57
Q60	76	0.001	K61	49	<0.0001	I67	28	<0.0001	K64	8	<0.0001	0.82
L63	74	0.0002	I66	49	<0.0001	H65	26	<0.0001	K65	8	<0.0001	0.63
I62	74	0.0005	T68	48	<0.0001	P68	26	<0.0001	Y65	7	<0.0001	0.9
K70	74	0.001	S65	48	<0.0001	Y64	25	<0.0001				
H61	72	<0.0001	L68	48	<0.0001	EK65	25	<0.0001				
W68	72	<0.0001	Q68	48	<0.0001	T66	25	<0.0001				

5 Table 9. Antagonism of A-gliadin 57-73 QE65 interferon gamma ELISPOT response by substituted variants of A-gliadin 57-73 QE65 (Subst) (P is significance level in unpaired t-test). Agonist activity (% agonist) of peptides compared to A-gliadin 57-73 QE65 is also shown.

Subst	% Inhibit.	P	% agonist.	Subst	% Inhibit.	P	% agonist.
Antagonists							
65T	28	0.004	19	65M	13	0.16	14
67M	27	0.0052	29	68P	13	0.16	26
64W	26	0.007	18	63R	13	0.19	19
67W	25	0.0088	19	66G	12	0.19	11
Potential antagonists				65Q	12	0.2	18
67I	24	0.013	10	65Y	12	0.22	7
67Y	24	0.013	21	66S	12	0.22	22
64G	21	0.03	21	67F	11	0.25	21
64D	21	0.029	16	66R	10	0.29	10
65L	20	0.046	26	67K	10	0.29	10
66N	20	0.037	24	64F	10	0.29	16
65H	20	0.038	16	65F	9	0.41	16
64N	19	0.05	16	63P	8	0.42	13
64Y	19	0.06	25	65EK	8	0.39	25
66Y	19	0.048	28	64Q	7	0.49	11
64E	19	0.049	12	64I	5	0.6	21
67A	18	0.058	30	68K	5	0.56	19
67H	18	0.052	22	67Q	5	0.61	18
Non-antagonists				65G	5	0.62	15
65V	17	0.07	23	64M	4	0.7	20
65I	17	0.086	21	66H	4	0.66	23
66T	17	0.069	25	66E	3	0.76	10
65W	15	0.11	11	66D	1	0.9	14
67R	15	0.13	14	63K	1	0.88	23
65P	15	0.13	8	64H	1	0.93	18
65K	15	0.11	8	66K	0	0.98	10
66W	15	0.12	21	64K	-2	0.88	8
67G	14	0.14	19	64L	-11	0.26	22
66A	14	0.14	19				

Table 10. Inhibition of A-gliadin 57-73 QE65 interferon gamma ELISPOT response by peptides known to bind HLA-DQ2 (P is significance level in unpaired t-test).

20

Peptide	% Inhibit.	P
TP	31	<0.0001
HLA1a	0	0.95

Table 11. Antagonism of A-gliadin 57-73 QE65 interferon gamma ELISpot response by naturally occurring polymorphisms of A-gliadin 57-73 QE65 (P is significance level in unpaired t-test).

A-gliadin 57-73 QE65 polymorphism	% Inhibit.	P
P04725 82-98 QE90 <u>POQOPFPPELPYPQPQS</u>	19	0.009
Q41509 77-93 QE85 <u>QLQPFLLQPELPYSQFQP</u>	11	0.15
Gli $\alpha$ 1,6 58-74 QE66 <u>QPQPFPPPELPYPQTQP</u>	11	0.11
P04723 77-93 QE85 <u>POQOPFPPELPYPQTQP</u>	10	0.14
Gli $\alpha$ 3-5 57-73 QE65 <u>QLQPFPPQPELSYSQFQP</u>	7	0.34
P02863 77-93 QE85 <u>QLQPFPPQPELPYSQFQP</u>	6	0.35
Q41509 77-93 QE85 <u>QLQPFLLQPELPYSQFQP</u>	6	0.41
P04727 79-95 QE65 <u>POQOPFLLPELPYPQPQS</u>	6	0.39
P04726 82-98 QE90 <u>POQOPFPPELPYPQPPP</u>	5	0.43

**Table 12. Prolamin homologues of A-gliadin 57-73 (excluding alpha/beta-gliadins)**

Prolamin	Accession number	Sequence	% Bioactivity*
Wheat: $\alpha$ -gliadin	A-gliadin (57-73)	QLQPFPPQLPYPPQPS	100 (0)
Wheat: $\omega$ -gliadin	AAG17702 (141-157)	PQ.....F.....QSE	32 (6.4)
Barley: C-hordein	Q40055 (166-182)	...QPFP...F.....Q	2.3 (2.0)
Wheat $\gamma$ -gliadin	P21292 (96-112)	...QTFPQ.....F.....QPQ	2.1 (4.2)
Rye: secalin	Q43639 (335-351)	...QPSPQ.....F.....Q	1.6 (1.4)
Barley: $\gamma$ -hordein	P80198 (52-68)	...QPFPQ.....HQQHFP	-1.0 (1.8)
Wheat: LMW glutenin	P16315 (67-83)	LQ...QPIL.....FS...Q...Q	-0.9 (1.0)
Wheat: HMW glutenin	P08489 (718-734)	HGYYPTS.....SGQGQRP	6.4 (4.0)
Wheat $\gamma$ -gliadin	P04730 (120-136)	...QCCQQL.....I...QPSRYQ	0.7 (0.9)
Wheat: LMW glutenin	P10386 (183-199)	...QCCQQL.....I...QPSRYE	-0.7 (0.5)
Wheat: LMW glutenin	O49958 (214-230)	...QCCRQL.....I...EQSRYD	-1.1 (0.3)
Barley: B1-hordein	P06470 (176-192)	...QCCQQL.....I...EQFRHE	1.8 (1.4)
Barley: B-hordein	Q40026 (176-192)	...QCCQQL.....ISEQFRHE	0.5 (0.9)

\*Bioactivity is expressed as 100x(spot forming cells with peptide 25mcg/ml plus tTG 8mcg/ml minus blank)/(spot forming cells with A-gliadin 57-73 25mcg/ml plus tTG 8mcg/ml minus blank) (mean (SEM), n=5).

Peptides were preincubated with tTG for 2h 37°C. Note, Q is deamidated in A-gliadin 57-73 by tTG.

**Table 13. Clinical details of coeliac subjects.**

	HLA-DQ	HLA-DQA1 alleles	HLA-DQB1 alleles	Duodenal histology	Gluten free	EMA on gluten (on GFD)
C01	2, 6	102/6, 501	201, 602	SVA	1 yr	+ (-)
C02	2, 2	501	201	SVA	1 yr	+ (-)
C03	2, 5	101/4/5, 501	201, 501	PVA	1 yr	+ (-)
C04	2, 5	101/4-5, 501	201, 501	SVA	7 yr	+ (-)
C05	2, 2	201, 501	201, 202	SVA	4 mo	+ (ND)
C06	2, 2	201, 501	201, 202	SVA	2 yr	+ (-)
C07	2, 8	301-3, 501	201, 302	SVA	1 yr	+ (-)
C08	2, 8	301-3, 501	201, 302/8	SVA	11 yr	ND (-)
C09	2, 8	301-3, 501	201, 302	SVA	29 yr	+ (-)
C10	2, 8	201, 301-3	202, 302	IEL	1 yr	+ (-)
C11	6, 8	102/6, 301-3	602/15, 302/8	IEL	9 mo	- (ND)
C12	8, 7	301-3, 505	302, 301/9-10	SVA	2 yr	- (-)
C13	8, 8	301	302	SVA	1 yr	+ (+)

SVA subtotal villous atrophy, PVA partial villous atrophy, IEL increased intra-epithelial atrophy, GFD gluten-free diet, ND not done.

**Table 14. HLA-DQ2+ Coeliac (C01-6) and healthy control (H01-10) IFN $\gamma$  ELISpot responses to control peptides (20  $\mu$ g/ml) and gliadin (500  $\mu$ g/ml) before and after gluten challenge (sfc/million PBMC minus response to PBS alone)**

Peptide	Healthy Day 0	Healthy Day 6	Coeliac Day 0	Coeliac Day 6
P04722 77-93	0 (-4 to 17)	0 (-5 to 9)	-2 (-3 to 0)	27 (0-100)*
P04722 77-93 + tTG	0 (-5 to 4)	0 (-9 to 3)	0 (-4 to 11)	141 (8 to 290)**
P04722 77-93 QE85	0 (-5 to 5)	0 (-3 to 4)	0 (-6 to 14)	133 (10 to 297)*
P02863 77-93	0 (-4 to 13)	2 (-3 to 5)	-2 (-3 to 2)	8 (-2 to 42)**
P02863 77-93 + tTG	-1 (-5 to 4)	-1 (-4 to 11)	1 (-4 to 6)	65 (8-164)**
P02863 77-93 QE85	0 (-4 to 13)	0 (-4 to 14)	-1 (-4 to 6)	42 (-2 to 176)*
Gliadin chymotrypsin	2 (-5 to 20)	18 (0 to 185)*	20 (11 to 145)	92 (50 to 154)
Gliadin chymotrypsin + tTG	0 (-1 to 28)	16 (-9 to 171)*	55 (29 to 248)	269 (206 to 384)**
Chymotrypsin	0 (-4 to 5)	1 (-4 to 11)	-2 (-5 to 5)	1 (-4 to 8)
Chymotrypsin + tTG	0 (-5 to 8)	6 (0 to 29)	-2 (-3 to 11)	2 (-3 to 18)*
Gliadin pepsin	4 (-4 to 28)	29 (0 to 189)***	44 (10 to 221)	176 (54 to 265)**
Gliadin pepsin + tTG	2 (-3 to 80)	27 (-4 to 241)***	61 (8 to 172)	280 (207 to 406)**
Pepsin	0 (-4 to 10)	0 (-3 to 12)	0 (-2 to 3)	2 (-2 to 8)
Pepsin + tTG	0 (-3 to 8)	0 (-5 to 9)	1 (-6 to 3)	0 (-3 to 14)
PBS alone	4 (0 to 6)	2 (0 to 6)	4 (1 to 12)	4 (0 to 4)
PBS + tTG	3 (0 to 8)	3 (0 to 11)	4 (2 to 10)	4 (2 to 11)

5 Day 6 vs. Day 0: \*P<0.05 \*\*P<0.02, \*\*\*P<0.01 by one-tailed Wilcoxon Matched-Pairs Signed-Ranks test

**Table 15. Effect of deamidation by tTG to gliadin (0.5 mg/ml) and A-gliadin 57-73 homologues on IFN $\gamma$  ELISpot responses in HLA-DQ2+ coeliac (C01-6) and healthy control subjects (H01-10) (median ratio tTG:no tTG pretreatment, range)**

Peptide	Healthy Day 6	Coeliac Day 0	Coeliac Day 6
Gliadin chymotrypsin	0.94 (0.4-9.0)	2.1 (0.8-6.8)*	3.2 (1.8-4.2)**
Gliadin pepsin	1.4 (0.5-1.4)	1.4 (0.8-4.0)*	1.9 (1.1-4.4)**
P04722 77-93 Q85			6.5 (2.3-12)**
P04722 77-93 E85			0.7 (0.6-1.1)
P02863 77-93 Q85			7.5 (3.9-19.9)**
P02863 77-93 E85			1.0 (0.8-1.2)

tTG>no tTG: \*P<0.05 \*\*P,0.02, \*\*\*P<0.01 by one-tailed Wilcoxon Matched-Pairs Signed-Ranks test





43	.	.	.	.	.	.	.	.	11	.	.
44	.	14	.	.	.	.	.	.	.	.	.
45	.	11	.	.	.	.	.	.	.	.	.
46	.	.	.	.	.	.	.	.	.	.	.
47	.	.	.	.	.	.	.	.	.	.	.
48	.	.	.	.	.	.	.	.	.	.	.
49	.	.	.	.	.	.	.	.	.	.	.
50	.	14	.	.	12	.	.	22	.	14	.
51	.	.	.	.	.	.	.	.	.	.	.
52	.	14	.	.	.	.	.	.	.	.	.
53	.	26	.	.	.	.	.	.	.	.	.
54	.	.	.	.	.	.	.	12	.	.	.
55	.	.	.	.	.	.	.	.	.	.	.
56	.	.	.	.	.	.	.	.	.	.	.
57	.	23	.	.	.	.	12	.	.	.	.
58	.	14	.	.	.	.	.	.	.	.	.
59	.	.	.	.	.	.	.	.	.	.	.
60	.	.	.	.	.	.	.	.	.	.	.
61	.	23	.	.	.	.	.	11	11	.	.
62	.	.	.	.	.	.	.	.	.	.	.
63	.	.	.	.	.	.	.	.	.	.	.
64	.	20	.	.	.	.	.	.	.	.	.
65	.	.	.	.	.	.	.	.	.	.	.
66	.	14	.	.	.	.	.	.	.	.	.
67	.	11	.	.	.	.	.	.	.	.	.
68	.	20	.	.	.	.	.	20	.	.	.
69	.	20	.	.	.	.	.	.	.	.	.
70	.	.	.	.	.	.	.	.	.	.	.
71	.	.	.	.	.	.	.	.	.	.	.
72	.	11	.	.	.	.	.	.	.	.	.
73	.	14	.	.	.	.	.	.	.	.	.
74	.	.	.	.	.	.	.	.	.	.	.
75	.	.	.	.	.	.	.	.	.	.	.
76	.	14	.	.	.	.	.	.	.	.	.
77	.	.	.	.	.	.	.	.	.	.	.
78	.	11	.	.	.	.	.	.	.	.	.
79	.	11	.	.	19	.	.	.	.	.	.
80	.	.	.	.	.	.	.	.	.	.	.
81	.	.	.	.	.	.	.	.	.	.	.
82	.	.	.	.	.	.	.	.	.	.	.
83	.	.	.	.	.	.	.	.	.	.	.
P04722 77-93	.	.	.	.	.	.	.	.	.	.	.
P04722 77-93 E	.	.	.	.	.	.	.	.	.	.	.
P04722 77-93 E	.	.	.	.	.	.	.	.	.	.	.
P02863 77-93	.	.	.	.	.	.	.	11	.	.	.
P02863 77-93 E	.	.	.	.	.	.	.	.	.	.	.
Gliadin+C	171	40	25	16	10	.	18	14	.	17	.
Chymotrypsin	29	26	18	.	.	.	.	.	22	.	.
Gliadin+Pepsin	241	151	29	24	48	.	16	45	.	19	.
Pepsin	.	.	.	.	.	.	.	.	.	.	.

16

90

35

Table 17: tTG-deamidated gliadin peptide pools showing significant increase in IFN gamma responses between Day 0 and Day 6 of gluten challenge in HLA-DQ2 coeliac subjects C01-6 (Day 6 –Day 0 response, and ratio of responses to tTG-deamidated pool and same pool without tTG treatment)

IFN $\gamma$ ELISpot			IFN $\gamma$ ELISpot		
Pool	(Median sfc/million)	tTG: no tTG (Median)	Pool	(Median sfc/million)	tTG: no tTG (Median)
9	59***	1.0	49	46***	1.4
10	116**	1.7	50	50***	4.6
11	24***	2.5	51	40***	1.7
12	133***	1.1	52	30***	3.1
13	26**	2.1	53	27**	1.4
42	30**	1.2	76	17***	1.1
43	32***	1.3	79	20***	0.9
44	24***	1.5	80	83***	1
45	10***	1.1	81	141***	1.1
46	12***	2.1	82	22***	1.5
48	17***	1.4	83	16**	1.8

Day 6 vs. Day 0 \*\*P<0.02, \*\*\*P<0.01 by one-tailed Wilcoxon Matched-Pairs Signed-Ranks test

**Table 18. Coeliac subjects: IFN $\gamma$  ELISpot Responses >10 sfc/million PBMC and >4 x buffer only to tTG-treated Pepset Pools on Day 6 of gluten challenge (sfc/million PBMC) (*italic*: response also present on Day 0):**

**Group 1 – HLA-DQ2 (DQA1\*0501-5, DQB1\*0201/2),**

**5 Group 2 – HLA-DQ2/8 (DQA1\*0501-5, \*0301, and DQB1\*0201/2, \*0302), and**

**Group 3 – HLA-DQ8 (DQA1\*0301, DQB1\*0302) and absent or “incomplete”**

**DQ2 (only DQA1\*0501-5 or DQB1\*0201/2)**

Group 1:							Group 2:			Group 3			
Subject	C01	C02	C03	C04	C05	C06	C07	C08	C09	C10	C11	C12	C13
<b>HLA-DQ</b>	2, 6	2, 2	2, 5	2, 5	2, 2	2, 2	2, 8	2, 8	2, 8	2, 8	6, 8	7, 8	8, 8
<b>Pool 1</b>	.	.	.	.	.	.	23	.	.	.	.	223	.
2	.	.	.	.	.	.	.	.	.	.	.	155	.
3	.	.	.	.	.	.	.	.	.	.	.	41	.
4	11	.	.	.	.	.	.	.	.	22	.	.	.
5	.	.	.	.	.	.	.	.	.	.	.	.	.
6	18	.	.	21	.	.	20	17	.	.	.	.	.
7	.	.	.	.	.	.	353	.	.	.	.	.	.
8	11	64	.	.	.	14	20	480	.	.	.	.	13
9	93	127	.	92	25	.	32	460	.	.	.	.	18
10	175	491	58	200	48	.	84	787	.	.	.	.	.
11	32	118	.	33	14	.	26	27	.	12	.	.	.
12	204	379	54	225	61	.	129	587	.	12	.	.	.
13	93	142	.	29	18	.	60	.	.	.	.	.	11
14	.	45	.	21	.	.	17	.	.	.	.	.	.
15	18	30	.	.	.	.	38	43	.	.	.	.	.
16	.	.	.	.	.	.	37	.	.	.	.	.	.
17	.	.	.	.	.	.	.	.	.	.	.	.	.
18	.	.	.	.	.	.	.	.	.	.	.	.	.
19	11	.	.	.	.	.	.	.	.	.	.	.	.
20	11	215	.	.	.	.	51	167	.	.	.	.	.
21	.	.	.	.	.	.	.	.	11	.	.	.	.
22	.	21	.	.	.	.	.	.	.	.	.	.	.
23	.	18	.	21	.	.	.	.	.	12	.	.	.
24	.	15	.	.	.	.	.	10	.	.	.	.	.
25	.	15	.	.	.	.	.	.	.	12	.	.	.
26	.	18	.	.	.	.	.	13	.	12	.	.	.
27	.	15	.	.	.	.	.	.	.	.	.	.	.
28	.	.	.	.	.	.	.	.	.	.	.	.	11
29	.	.	.	.	.	.	11	.	.	.	.	.	.
30	11	.	.	.	.	.	11	.	.	.	.	.	.
31	.	70	.	.	.	.	.	.	.	.	.	.	.
32	.	18	.	.	.	.	20	.	.	.	.	.	.
33	11	.	.	10	.	.	14	.	11	.	40	.	11
34	.	.	.	.	.	.	.	.	11	.	.	.	.
35	.	.	.	.	.	.	.	.	.	.	.	.	.
36	.	.	.	.	.	.	.	.	.	.	.	.	.
37	.	.	.	23	.	14	.	.	.	.	.	.	.
38	.	24	.	19	.	.	20	.	.	.	.	.	.
39	.	49	.	15	.	.	.	.	11	.	.	.	.
40	.	.	.	.	.	.	14	.	.	.	.	.	.

41		21				
42	39	42		44	21	
43	50	91	13	75	14	
44	32	97	17	96	13	
45		21	10	100	11	
46	14	55		102	18	
47	14	58		38		
48	21	106		60	14	
49	75	170	17	142	30	
50	57	245	23	140	61	27
51	68	106	10	127		
52	43	121		79	13	16
53	36	94		92	29	
54	36			35	11	
55						
56	29					
57		36				
58						
59			10			
60		18		15		
61						
62	14	18		13		
63			10			14
64		15				
65		36		25	23	
66				31	11	10
67				17		
68			19	127		14
69		15		10		
70		12	31		13	10
71	11	21	13			
72						16
73				13		14
74		239				
75						
76	18	21	19	15		
77		88				10
78		18	17	69		
79	11	85		44	29	12
80	132	133	33	240	39	12
81	171	318	113	367	104	12
82	18	300	17	125	32	16
83	14	164		31	21	
P04722 77-93	211	291	75	281	66	
P04722 77-93 E	164	297	108	221	64	10
P04722 77-93 E	161	182	98	256	73	16
P02863 77-93	139	164	35	94	36	
P02863 77-93 E	46	176	19	88	41	
Gliadin+C	214	273	265	360	384	206
Chymotrypsin						18
Gliadin+Pepsin	239	315	269	406	207	292
Pepsin						14

11	63	
190	113	
87	107	
38	110	
63	163	
223	97	
144	353	
202	293	
248	143	
220	267	
175	180	
69	53	
166	27	
		11
20	13	
	53	
11	53	
20		
60		
35	27	
17		
17		
20	20	
14		
11		
254	447	
	13	
44	43	
208	467	
211	530	
241	723	
163	277	
78	740	
84	653	
63	500	
29	603	
23	520	
278	543	17
357	557	

[illegible]

**Table 19. Deamidated peptides with mean bioactivity > 10% of P04722 E85 (20  $\mu$ g/ml) in HLA-DQ2 coeliac subjects C01-5**

Rank	No.	Sequence	Mean (SEM)	Rank	No.	Sequence	Mean (SEM)
	89	PQLPYPQQLPYPQQLRYP	94 (18)	37	413	SKQPQQFFPQQPQQSHQ	18 (4)
*2	91	PQFFPQLPYPQQLPYPQP	89 (12)	38	380	QPQQPQQFFPQQPQLPFP	18 (6)
*3	74	MLQPFPPQQLPYPQQLPY	88 (14)	39	618	PQQSFSYQQPFFQPPYQQ	18 (7)
*4	90	PQLPYPQQLPYPQPQFR	87 (16)	*40	78	LQLQFFRPQLPYPQPQFR	17 (8)
*5	76	LQLQFFRPQLPYPQPQFR	85 (15)	41	390	QQTYPQRQPFFQTQQPQQ	17 (9)
6	626	PQQPQQPQQPQQPQQPFW	72 (23)	42	348	QQTFFPQQTFPHQPQQFP	16 (10)
7	627	QFFPQQPQQPQQPQQPFR	66 (30)	43	409	QPQQPQLQQPQQPLPQP	16 (2)
*8	631	FPQQPQQPQQPQLPQQS	61 (12)	44	382	QQPFPQQPQQPQTQQPQQ	16 (6)
9	636	PQQPQQPQQPQQPQQPQ	51 (10)	45	629	PPFTQSQSFLQPQQPQQ	16 (5)
*10	73	LQLQFFPQLPYPQQLPY	49 (11)	46	643	PLQQPQQPQQPQQPQQP	16 (6)
11	412	SQQPQQPQQPQQPQQPQQ	34 (19)	47	389	QQPFPQTQQPQQPQQPQQ	16 (6)
12	343	QQPQQPQQPQQPQLPQQ	34 (11)	48	350	QQPFPQQTFPHQPQQFP	15 (8)
*13	68	LQLQFFPQLPYLQPQFR	33 (10)	49	65	PPFSQQPYPQPQQPQQP	15 (5)
*14	66	LQLQFFPQLPYSQPQFR	32 (7)	50	349	QQPFPQQTFPHQPQQFP	15 (9)
*15	96	PQFFPQLPYPQPQSFQQ	28 (6)	51	610	PWQQQLPQQSQSQPQS	15 (11)
16	393	QLFFPQQPQQPQQPQQ	27 (8)	*52	81	PQPQFFPQLPYPQTQFP	15 (5)
17	355	QAFFPQQTFPHQPQQFP	27 (15)	*53	75	MLQFPFPQFPFPQLYPQ	14 (5)
*18	67	LQLQFFPQLPYSQPQFR	26 (6)	54	368	QQPFPQQPQQPQQPQQ	14 (7)
19	335	QQQQPQQPQQPQQPQQ	25 (11)	*55	82	PQPFPFPQFPFPQLYPQ	14 (3)
*20	95	PQFFLPQLPYPQPQSFQQ	24 (6)	*56	80	LQLQFFPQPFPQLYPQ	14 (4)
21	396	TQQPQQPQQPQQPQQTQ	23 (9)	57	624	FTQPQQPQQPQQPQQP	14 (6)
22	609	SCISGLERPQQQLPQQS	23 (18)	58	407	QPQQPQQPQQPQQPQQ	14 (5)
23	385	QQPFPQQPQLPFPQQPQQ	23 (7)	59	337	QQQPFPQQPQQPQQPQT	13 (4)
24	375	PQQPFPQQPQQPQQPQQ	23 (10)	60	634	PQQLQPPFLQPQQPQQP	13 (3)
25	406	QPQQPQLQQPQQPQQPQ	22 (8)	61	388	QQPYPQQPQQPQTQQPQQ	13 (3)
26	625	PIQPQQPQQPQQPQQPFP	22 (9)	62	641	FPQLQPFPQQPQQPQLQ	13 (7)
27	378	QQPQQPFPQQPQQPQQPQQ	22 (10)	63	399	QQPFPQTQQPQQPQLQQP	13 (5)
28	371	PQQQFPQQPQQPQQPQTY	22 (10)	64	387	QQTFFPQQPQLPFPQQPFP	13 (4)
29	642	PQQPQQPFLQPQQPQQP	20 (8)	65	628	PPFWQPQQPQTQQSFLQ	12 (4)
30	635	PLQPQQPQQPQQPQQPQ	19 (5)	*66	88	PQFFPQLPYSQPQFPQQ	12 (3)
*31	93	PQFFPQLPYPQPQFPQQ	19 (5)	67	408	QPQQPFPQSKQPQQPQQP	12 (5)
32	377	PQQQFPQQPQQPQQPQQ	19 (9)	*68	77	LQLQFPFPQPFPQLPYPQ	11 (4)
33	411	LQQPQQPFPQQPQQPQQ	19 (4)	69	370	PQQQFLQPQQPQQPQQPY	11 (5)
34	415	SQQPQQPFPQQPQQSQS	18 (5)	*70	79	LQLQFPFPQPFPQLPYPQ	11 (5)
*35	94	PQFFPQLPYPQPFPFPQQ	18 (3)	71	379	QQPQQPFPQQPQQPQQP	11 (5)
36	329	PSGQVQWPQQPQQPQQP	18 (4)	72	397	PQQPQQPQTQQPQQPFP	11 (3)

\* Indicates homologue of A-gliadin 57-73 with the core sequence PQLP(Y/F)

Table 20. Peptides &gt;10% as bioactive as P04722 QE65 grouped by structure.

Rank	Peptide no. (Pool) Gliadin-subtype	Sequence	IFNg ELISpot response compared to P04722 77-93 QE85: mean (SEM)
<b>Group 1: Homologues of A-gliadin 57-73</b>			
	P04722 77-93	QLQPFPPQQLPYPPQPP	
1	89 (12) $\alpha$	PQL...Y.....LPYP	94 (18)
2	91 (12) $\alpha$	PQPFPPQL...Y.....	89 (12)
3	74 (10) $\alpha$	M.....LPY	88 (14)
4	90 (12) $\alpha$	PQL...Y.....PFRP	87 (16)
5	76 (10) $\alpha$	L.....PFR	85 (15)
8	631 (81) $\omega$	FPQQPQ.....F.....QS	61 (12)
10	73 (10) $\alpha$	L.....LPY	49 (11)
13	68 (9) $\alpha$	L.....PFR	33 (10)
14	66 (9) $\alpha$	L.....S.....PFR	32 (7)
18	67 (9) $\alpha$	L.....S.....QFR	26 (6)
20	95 (13) $\alpha$	PQPF.....PFPQQ	24 (6)
31	93 (12) $\alpha$	PQPF.....PFRPQQ	19 (5)
35	94 (12) $\alpha$	PQPF.....PFFSPQQ	18 (3)
40	78 (10) $\alpha$	L.....R.....PFR	17 (8)
52	81 (11) $\alpha$	PQPQPF.....T...PFPF	15 (5)
53	75 (10) $\alpha$	MQLPFPQPQPF.....	14 (5)
55	82 (11) $\alpha$	PQPQPFQPQPF.....	14 (3)
56	80 (10) $\alpha$	LQLQPFQPQPF.....	14 (4)
66	88 (11) $\alpha$	PQPF.....S.....PFRPQQ	12 (3)
68	77 (10) $\alpha$	LQLQPFQPQPF.....	11 (4)
70	79 (10) $\alpha$	LQLQPFQPQPF.....	11 (5)
<b>Group 2: Homologues of peptide 626</b>			
		QQPFPPQPPFP	
6	626(80) $\omega$	PQQPQQP.....W	72 (23)
7	627(80) $\omega$	.....WQPQQPFPQ	66 (30)
9	636(81) $\omega$	PQQP.....I...VQPQ	51 (10)
11	412(53) $\gamma$	SQQP.....Q.....PQQ	34 (19)
33	411(53) $\gamma$	LQQP.....Q.....PQQ	19 (4)
36	329(42) $\gamma$	PSGQVQWPQ.....	18 (4)
41	390(50) $\gamma$	QQTYPQRP.....T.....QQ	17 (9)
59	337(43) $\gamma$	Q.....CQQPQRTI	13 (4)
61	388(50) $\gamma$	QQPYPQQP.....T.....QQ	13 (3)
<b>Group 3: Homologues of peptide 355</b>			
		FPQPQQTFPHQPQQFP	
17	355(46) $\gamma$	QA.....Q	27 (15)
42	348(45) $\gamma$	QQT.....	16 (10)
48	350(45) $\gamma$	QQL.....A.....	15 (8)
50	349(45) $\gamma$	QQL.....	15 (9)
<b>Group 4: Homologues of Peptide 396</b>			
		QQPFPPQPPFP	
21	396(51) $\gamma$	TQQP.....QTQ	23 (9)
27	378(49) $\gamma$	QQP.....QPQQ	22 (10)
28	371(48) $\gamma$	PQQQFIQP.....TY	22 (10)
29	642(82) $\omega$	PQQP.....L.....QQP	20 (8)
30	635(81) $\omega$	PLQP.....QPQ	19 (5)
44	382(49) $\gamma$	.....QTQQPQQ	16 (6)
45	629(81) $\omega$	PFPQT.....S.....L.....QQ	16 (5)
46	643(82) $\omega$	PLQP.....QQP	16 (6)
60	634(81) $\omega$	PQQL.....L.....QQP	13 (3)
64	387(50) $\gamma$	.....T.....L.....QQPQQPF	13 (4)
62	641(82) $\omega$	FPQL.....L.....LQP	13 (7)

Group 5: Homologues of Peptide 343 (overlap Groups 2 and 4)			
QQPFPQPQQPQLPFPQ			
12	343(44) $\gamma$	QQP.....Q	34 (11)
16	393(51) $\gamma$	QLPFPQP.....	27 (8)
19	335(43) $\gamma$	QQ.....Q.....PQ	25 (11)
23	385(50) $\gamma$	.....QPQQ	23 (7)
24	375(48) $\gamma$	P.....Q.....PQQ	23 (10)
25	406(52) $\gamma$	QP.....L.....Q.....PQ	22 (8)
32	377(49) $\gamma$	P.....Q.....Q.....QPQ	19 (9)
34	415(53) $\gamma$	SQQP.....QS.....	18 (5)
37	413(53) $\gamma$	SKQP.....QS.....	18 (4)
38	380(49) $\gamma$	QPQQP.....	18 (6)
43	409(53) $\gamma$	QP.....L.....Q...L.....PQ	16 (2)
47	389(50) $\gamma$	.....T.....Q.....QPQQ	16 (6)
58	407(52) $\gamma$	QP.....S.....Q.....PQ	14 (5)
63	399(51) $\gamma$	.....T.....Q.....LQQP	13 (5)
67	408(52) $\gamma$	QP.....SK.....Q.....PQ	12 (5)
71	379(49) $\gamma$	QQP.....Q.....Q.....P	11 (5)
72	397(51) $\gamma$	PQQP.....T.....Q.....	11 (3)
Group 6: Peptide 625			
PIQPQQPFPQQP			
26	625(80) $\omega$	.....QQPQQPFP	22 (9)
57	624(80) $\omega$	FTQPQQPT.....	14 (6)
65	628(80) $\omega$	PF...W.....TQQSFPLQ	12 (4)
Group 7: Peptide 618			
39	618(79) $\omega$	PQQSFSYQQPFPQQPYPQQ	18 (7)



**Table 21. Bioactivity of individual tTG-deamidated Pools 1-3 peptides in Subject C12:**

No.	Sequence	%	No.	Sequence	%
8	AVRWPVPQ <u>LOPONPSOOQPO</u>	100	23	<u>LOPONPSOOQPO</u> EQVPLMQQ	26
		85			18
5	MVRVTVPQ.....	82	14	.....EQVPLVQQ	18
6	AVRVSVPQ.....	77	15	.....H.....EQVPLVQQ	18
3	MVRVPVPQ.....H.....	67	17	.....KQVPLVQQ	13
1	AVRFPVPQ.....L.....	59	16	.....D.....EQVPLVQQ	8
2	MVRVPVPQ.....	49	13	.....EQVPLVQQ	5
9	AVRVPVPQ.....L.....	49	22	.....K.....EQVPLVQQ	3
7	AVRVPVPQ.....	33	18	.....L.....EQVPLVQE	3
10	MVRVPVPQ.....L.....		19	.....L.....EQVPLVQE	
4	MVRVPMPQ.....D.....	15	20	P.....P.....GQVPLVQQ	0
12	AVRVPVPQ.....K.....	8	21	P.....P.....RQVPLVQQ	0
11	AVRVPVPQP.....P.....	0			
Core sequence of epitope is underlined. Predicted deamidated sequence is: LQPENPSQEQPE					

Table 22: Phylogenetic groupings of wheat (*Triticum aestivum*) gliadins

Alpha/beta-gliadins (n=61)			
A1a1	AAA96525, EEWTA, P02863	A1b13	B22364, P04271
A1a2	CAB76963	A2a1	AAB23109, CAA35238, P18573, S10015
A1a3	AAA96276	A2a2	CAB76964
A1a4	CAA26384, S07923	A2b1	P04724, T06500, AAA348282
A1a5	AAA34280	A2b2	D22364
A1a6	P04728	A2b3	P04722, T06498, AAA34276
A1b1	CAB76962	A2b4	C22364
A1b2	CAB76961	A2b5	CAB76956
A1b3	BAA12318	A3a1	AAA34277, CAA26383, P04726, S07361
A1b4	CAB76960	A3a2	I307187B, A27319, S13333
A1b5	CAB76958	A3b1	AAA96522
A1b6	CAB76959	A3b2i	AAA34279, P04727,
A1b7	CAB76955	A3b2ii	CAA26385, S07924
A1b8	AAA96524	A3b3	A22364, AAA34278, AAB23108, C61218, P04725
A1b9	CAA10257	A4a	P04723, AAA34283, T06504
A1b10	AAA96523, T06282	A4b	E22364
A1b11	AAA17741, S52124	A4c	CAB76957
A1b12	AAA34281	A4d	CAB76954
Gamma-gliadins (n=47)		Gamma-gliadins	
GI1a	P08079, AAA34288, PS0094, CAC11079, AAD30556, CAC11057, CAC11065, CAC11056	GI5a	AAK84774, AAK84772
GI1b	CAC11089, CAC11064, CAC11080, CAC11078, AAD30440	GI5b	AAK84773
GI1c	CAC11087	GI5c	AAK84776
GI1d	CAC11088	GI6a	JA0153, P21292, AAA34272, I507333A
GI1e	CAC11055	GI6b	AAK84777
GI2a	JS0402, P08453, AAA34289	GI6c	1802407A, AAK84775, AAK84780
GI2b	AAF42989, AAK84779, AAK84779	GI7	AAB31090
GI3a	AAK84778	GI1a	AAA34287, P04730, S07398
GI3b	CAB75404	GI1b	I209306A
GI3c	BAA11251	GI11a	P04729
GI4	EEWTG, P06659, AAA34274	GI11b	AAA34286
Omega-gliadins (n=3)			
O1a	AAG17702		
O1b	P02865		
O1c	A59156		

Table 23. Synthetic peptides spanning all known wheat gliadin 12mers

Protein	Position*	Sequence	No.	Protein	Position*	Sequence	No.
<b>POOL 1</b>				<b>POOL 43</b>			
A1A1	20	AVRF PVPQ LQPQ NPSQ QLPQ		1	G12A 33	QQQL VPQL QQPL SQQP QQTF	331
A1A2	20	MVRV PVPQ LQPQ NPSQ QQPQ		2	G13A 33	QQQP FPQP HQPF SQQP QQTF	332
A1B1	20	MVRV PVPQ LQPQ NPSQ QHPQ		3	G14 33	QQQP FLQP HQPF SQQP QQIF	333
A1B2	20	MVRV PMPQ LQPQ DPSQ QQPQ		4	G15A 33	QQQQ PFPQ PQQP FSOQ PQQI	334
A1B7	20	MVRV TVPQ LQPQ NPSQ QQPQ		5	G15B 33	QQQQ PFPQ PQQP QQPF PQPQ	335
A1B8	20	AVRV SVTPQ LQPQ NPSQ QQPQ		6	G15C 33	QQQP FRQP QQPF YQQP QHTF	336
A1B8	20	AVRV PVPQ LQPQ NPSQ QQPQ		7	G16A 33	QQQP FPQP QQPF CQQP QRTI	337
A1B10	20	AVRW PVPQ LQPQ NPSQ QQPQ		8	G16C 42	QQQP FPQP QQPF CEQP QRTI	338
<b>POOL 2</b>				<b>POOL 44</b>			
A2B3	20	AVRV PVPQ LQLQ NPSQ QQPQ		9	G11A 42	HQPF SQQP QQTF PQPQ QTFF	339
A2B5	20	MVRV PVPQ LQLQ NPSQ QQPQ		10	G12A 42	QQPL SQQP QQTF PQPQ QTFF	340
A3A1	20	AVRV PVPQ PQPQ NPSQ PQPQ		11	G14 42	HQPF SQQP QQIF PQPQ QTFF	341
A3B1	20	AVRV PVPQ LQPK NPSQ QQPQ		12	G15A 42	QQPF SQQP QQIF PQPQ QTFF	342
A1A1	28	LQPQ NPSQ QLPQ EQVP LVQQ		13	G15B 42	QQQP QFPF PQQP PQLP FPQQ	343
A1A2	28	LQPQ NPSQ QQPQ EQVP LVQQ		14	G15C 42	QQPF YQQP QHTF PQPQ QTCP	344
A1B1	28	LQPQ NPSQ QHPQ EQVP LVQQ		15	G16A 42	QQPF CQQP QRTI PQPH QTFF	345
A1B2	28	LQPQ DPSQ QQPQ EQVP LVQQ		16	G16B 42	QQPF CQQP QRTI PQPH QTFF	346
<b>POOL 3</b>				<b>POOL 45</b>			
A2B1	28	LQPQ NPSQ QQPQ KQVP LVQQ		17	G16C 42	QQPF CEQP QRTI PQPH QTFF	347
A2B3	28	LQLQ NPSQ QQPQ EQVP LVQE		18	G11A 50	QQTF PQPQ QTFF HQPQ QQFF	348
A2B5	28	LQLQ NPSQ QQPQ EQVP LVQE		19	G14 50	QQIF PQPQ QTFF HQPQ QQFF	349
A3A1	28	PQPQ NPSQ PQPQ GQVP LVQQ		20	G15A 50	QQIF PQPQ QTFF HQPQ QAFF	350
A3A2	28	PQPQ NPSQ PQPQ RQVP LVQQ		21	G16A 50	QRTI PQPH QTFF HQPQ QTFF	351
A3B1	28	LQPK NPSQ QQPQ EQVP LVQQ		22	G15A 58	QTFF HQPQ QAFF PQQP TFFH	352
A4A	28	LQPQ NPSQ QQPQ EQVP LMQQ		23	G16A 58	QTFF HQPQ QTFF PQQP TYPH	353
A1A1	36	QLPQ EQVP LVQQ QQFL GQQQ		24	G16C 58	QTFF HQPQ QTFF PQEP TYPH	354
<b>POOL 4</b>				<b>POOL 46</b>			
A1B1	36	QHPQ EQVP LVQQ QQFL GQQQ		25	G15A 66	QAFF PQQP TFFH PQQP QFPQ	355
A1B2	36	QQPQ EQVP LVQQ QQFL GQQQ		26	G15C 66	QHTF PQPQ QTCP HQPQ QQFF	356
A1B12	36	QQPQ EQVP LVQQ QQFL GQQQ		27	G16A 66	QTFF PQQP TYPH PQQP QFPQ	357
A2A1	36	QQPQ EQVP LVQQ QQFF GQQQ		28	G16C 66	QTFF PQEP TYPH PQQP QFPQ	358
A2B1	36	QQPQ KQVP LVQQ QQFF GQQQ		29	G11A 73	QTFF HQPQ QQFF PQQP PQQP	359
A2B3	36	QQPQ EQVP LVQE QQFQ GQQQ		30	G12A 73	QTFF HQPQ QQVP PQQP PQQP	360
A3A1	36	PQPQ GQVP LVQQ QQFF GQQQ		31	G13A 73	QTFF HQPQ QQFS PQQP PQQP	361
A3A2	36	PQPQ RQVP LVQQ QQFF GQQQ		32	G15C 73	QTCP HQPQ QQFF PQQP PQQP	362
<b>POOL 5</b>				<b>POOL 47</b>			
A4A	36	QQPQ EQVP LMQQ QQQF PGQQ		33	G16A 73	QTFP HQPQ QQFF QTQP PQQP	363
A1A1	44	LVQQ QQFL GQQQ PFPF QQPY		34	G11A 81	QQFF PQQP PQQP FLQP QQPF	364
A1B1	44	LVQQ QQFL GQQQ SFPP QQPY		35	G12A 81	QQVP PQQP PQQP FLQP QQPF	365
A1B12	44	LVQQ QQFL GQQQ PFPF QQPY		36	G13A 81	QQFS PQQP PQQP FIQP QQPF	366
A2A1	44	LVQQ QQFF GQQQ PFPF QQPY		37	G14 81	QQFF PQQP PQQP FLQP RQPF	367
A2B3	44	LVQE QQFQ GQQQ PFPF QQPY		38	G15A 81	QQFF PQQP PQQP FPQP PQQP	368
A3A1	44	LVQQ QQFF GQQQ QFPF QQPY		39	G16A 81	QQFF QTQP PQQP FPQP QQTF	369
A4A	44	LMQQ QQQF PGQQ EQFP PQQP		40	G11A 89	PQQQ FLQP QQPF PQQP QQPY	370
<b>POOL 6</b>				<b>POOL 48</b>			
A4D	44	LMQQ QQQF PGQQ ERFP PQQP		41	G13A 89	PQQQ FIQP QQPF PQQP QQTY	371
A1A1	53	GQQQ PFPF QQPY PQPQ PFPF		42	G13B 89	PQQQ FIQP QQQP QTFP QRPQ	372
A1A3	53	GQQQ PFPF QQPY PQPQ PFPF		43	G14 89	PQQQ FLQP RQPF PQQP QQPY	373
A1B1	53	GQQQ SFPP QQPY PQPQ PFPF		44	G15A 89	PQQP FPQP PQQP FPQP QQQP	374
A2B1	53	GQQQ PFPF QQPY PQQP PFPF		45	G15C 89	PQQP FPQP QQQP QFPF PQQP	375
A3A1	53	GQQQ QFPF QQPY PQPQ PFPF		46	G16A 89	PQQP FPQP QQTF PQQP QLFF	376
A4A	53	GQQE QFPF QQPY PHQQ PFPF		<b>POOL 49</b>			
A4D	53	GQQE RFPP QQPY PHQQ PFPF		47			
<b>POOL 7</b>				48	G15A 97	PQQQ FPQP QQPF QQPF QQPF	377
A1A1	61	QQPY PQPQ PFPF QLPY LQLQ		49	G15A 105	QQQP QFPF QQQP QQPF PQQP	378
A1A3	61	QQPY PQPQ PFPF QLPY LQLQ		50	G15A 113	QQQP QQFF PQQP PQQP FPQP	379
A1B1	61	QQPY PQPQ PFPF QQPY LQLQ		51	G11A 126	QQPF PQQP QQPY PQQP QQPF	380
A2B1	61	QQPY PQQP PFPF QQPY MQLQ		52	G12A 126	QQPF PQQP QQPF PQTP PQQP	381
A4A	61	QQPY PHQQ PFPF QQPY PQPQ		53	G13A 126	QQPF PQQP QQTY PQRP QQPF	382
A1A1	69	PFPF QLPY LQLQ PFPQ PQLP		54	G14 126	RQPF PQQP QQPY PQQP QQPF	383
A1B1	69	PFPF QQPY LQLQ PFPQ PQLP		55			
A1B10	69	PFPF QQPY LQLQ PFSQ PQLP		56	G15A 126	QQPF PQQP QPQL PFPQ PQQP	385
<b>POOL 8</b>				57	G15C 126	QQPF PQQP QAQL PFPQ PQQP	386
A1B11	69	PFPF QQPY LQLQ PFLQ PQLP		58	G16A 126	QQTF PQQP QLFF PQQP QQPF	387
A1B12	69	PFPF QQPY LQLQ PFLQ PQPF		59	G11A 134	QQPY PQQP QQPF PQTP PQQP	388
A2A1	69	PFPF QQPY LQLQ PFPQ PQLP		60	G12A 134	QQPF PQTP PQQP PFPQ PQQP	389
A2B1	69	PFPF QQPY MQLQ PFPQ PQLP		61	G13A 134	QQTY PQRP QQPF PQTP PQQP	390
A2B2	69	PFPF QQPY MQLQ PFPQ PQPF		61	G15A 134	QPQL PFPQ PQQP PQQP PFPQ	391

A2B4 69 PFPS QQPY LQLQ PFPQ PQPF  
 A2B5 69 PFPS QQPY LQLQ PFFR PQLP  
 A4A 69 PFPS QQPY PQPQ PFFP QLPY  
 POOL 9  
 A4B 69 PFPS QQPY PQPQ PFPQ PQPF  
 A1A1 77 LQLQ PFPQ PQLP YSQP QPFR  
 A1A4 77 LQLQ PFPQ PQLP YSQP QQFR  
 A1B1 77 LQLQ PFPQ PQLP YLQP QPFR  
 A1B4 77 LQLQ PFPQ PQLS YSQP QPFR  
 A1B10 77 LQLQ PFSQ PQLP YSQP QPFR  
 A1B11 77 LQLQ PFLQ PQLP YSQP QPFR  
 A1B12 77 LQLQ PFLQ PQPF PPQL PYSQ  
 POOL 10  
 A2A1 77 LQLQ PFPQ PQLP YPQP QLPY  
 A2B1 77 MQLQ PFPQ PQLP YPQP QLPY  
 A2B2 77 MQLQ PFPQ PQPF PPQL PYPQ  
 A2B3 77 LQLQ PFPQ PQLP YPQP QPFR  
 A2B4 77 LQLQ PFPQ PQPF PPQL PYPQ  
 A2B5 77 LQLQ PFFR PQLP YPQP QPFR  
 A3B1 77 LQLQ PFPQ PQPF LPQL PYPQ  
 A3B3 77 LQLQ PFPQ PQPF PPQL PYPQ  
 POOL 11  
 A4A 77 PQPQ PFFP QLPY PQTQ PFFP  
 A4B 77 PQPQ PFPQ PQPF PPQL PYPQ  
 A1A1 85 PQLP YSQP QPFR PQQP YPQP  
 A1A6 85 PQLP YSQP QQFR PQQP YPQP  
 A1B1 85 PQLP YLQP QPFR PQQP YPQP  
 A1B4 85 PQLS YSQP QPFR PQQP YPQP  
 A1B6 85 PQLS YSQP QPFR PQQL YPQP  
 A1B12 85 PQPF PPQL PYSQ PQPF RPQQ  
 POOL 12  
 A2A1 85 PQLP YPQP QLPY PQPQ LPYP  
 A2B1 85 PQLP YPQP QLPY PQPQ PFRP  
 A2B2 85 PQPF PPQL PYPQ PQLP YPQP  
 A2B3 85 PQLP YPQP QPFR PQQP YPQP  
 A2B4 85 PQPF PPQL PYPQ PQPF RPQQ  
 A3A1 85 PQPF PPQL PYPQ PPF SPQQ  
 POOL 13  
 A3B1 85 PQPF LPQL PYPQ PQSF PPQQ  
 A3B3 85 PQPF PPQL PYPQ PQSF PPQQ  
 A4A 85 QLPY PQTQ PFFP QQPY PQPQ  
 A4B 85 PQPF PPQL PYPQ TQPF PPQQ  
 A2A1 106 LPYP QPQP FRPQ QPYP QSQP  
 A2B1 106 LPYP QPQP FRPQ QSYF QPQP  
 A3A1 106 LPYP QPPP FSPQ QPYP QPQP  
 A3B1 106 LPQL PYPQ PQSF PPQQ PYPQ  
 POOL 14  
 A4A 106 PPQL PYPQ TQPF PPQQ PYPQ  
 A1A1 112 QPFR PQQP YPQP QPQY SQPQ  
 A1B6 112 QPFR PQQL YPQP QPQY SQPQ  
 A2A1 112 QPFR PQQP YPQS QPQY SQPQ  
 A2B1 112 QPFR PQQS YPQP QPQY SQPQ  
 A3A1 112 PFFS PQQP YPQP QPQY PQPQ  
 A3B1 112 QSFQ PQQP YPQQ RPKY LQPQ  
 A3B2 112 QSFQ PQQP YPQQ RPYM LQPQ  
 POOL 15  
 A3B3 112 QSFQ PQQP YPQQ QPQY LQPQ  
 A4A 112 QPFP PQQP YPQP QPQY PQPQ  
 A1A1 120 YPQP QPQY SQPQ QPIS QQQQ  
 A1B3 120 YPQP QPQY SQPQ EPIS QQQQ  
 A2A1 120 YPQS QPQY SQPQ QPIS QQQQ  
 A3A1 120 YPQP QPQY PQPQ QPIS QQQQ  
 A3B1 120 YPQP RPKY LQPQ QPIS QQQQ  
 A3B2 120 YPQQ RPYM LQPQ QPIS QQQQ  
 POOL 16  
 A3B3 120 YPQQ QPQY LQPQ QPIS QQQQ  
 A1A1 128 SQPQ QPIS QQQQ QQQQ QQQQ  
 A1B3 128 SQPQ EPIS QQQQ QQQQ QQQQ  
 A3A1 128 PQPQ QPIS QQQQ QQQQ QQQQ  
 A1A1 138 QQQQ QQQQ QQQQ QQQQ ILQQ  
 A1A6 138 QQQQ QQQQ QQQQ QQQQ ILQQ  
 A1B11 138 QQQQ QQQQ QQQQ QQQQ IQQQ

62 G15C 134 QAQL PFPQ QPQQ PLPQ PQQP 392  
 63 POOL 51  
 64 G16A 134 QLPF PQQP QQPF PQPQ QPQQ 393  
 G12A 142 QPQQ PFPQ QPQQ PFPQ TQQP 394  
 65 G12A 150 QPQQ PFPQ TQQP QQPF PQQP 395  
 66 G12A 158 TQQP QQPF PQQP QQPF PQTQ 396  
 67 G12A 166 PQQP QQPF PQTQ QPQQ PFPQ 397  
 68 G11A 170 QQPF PQTQ QPQQ LFPQ SQQP 398  
 69 G12A 170 QQPF PQTQ QPQQ PFPQ LQQP 399  
 70 G13A 170 QQPF PQTQ QPQQ PFPQ SQQP 400  
 71 POOL 52  
 72 G14 170 QQPF PQTQ QPQQ PFPQ SKQP 401  
 G15A 170 QQPF PQPQ QPQQ PFPQ LQQP 402  
 73 G15C 170 QPPL PQPQ QPQQ PFPQ SQQP 403  
 74 G16A 170 QQPF PQPQ QPQQ PFPQ SQQP 404  
 75 G11A 178 QPQQ LFPQ SQQP QQQF SQPQ 405  
 76 G12A 178 QPQQ PFPQ LQQP QQPF PQPQ 406  
 77 G13A 178 QPQQ PFPQ SQQP QQPF PQPQ 407  
 78 G14 178 QPQQ PFPQ SKQP QQFF PQPQ 408  
 79 POOL 53  
 80 G15A 178 QPQQ PFPQ LQQP QQPL PQPQ 409  
 G11A 186 SQQP QQQF SQPQ QQFF QPQQ 410  
 81 G12A 186 LQQP QQPF PQPQ QQLP QPQQ 411  
 82 G13A 186 SQQP QQPF PQPQ QQFF QPQQ 412  
 83 G14 186 SKQP QQPF PQPQ QPQQ SFPQ 413  
 84 G15A 186 LQQP QQPL PQPQ QPQQ PFPQ 414  
 85 G15C 186 SQQP QQPF PQPQ QPQQ SFPQ 415  
 86 G11A 194 SQPQ QQFF QPQQ PQQS FPQQ 416  
 87 POOL 54  
 88 G12A 194 PQPQ QQLP QPQQ PQQS FPQQ 417  
 G13A 194 PQPQ QQFF QPQQ PQQS FPQQ 418  
 89 G14 194 PQPQ QPQQ SFPQ QPQS LIQP 419  
 90 G15A 194 PQPQ QPQQ PFPQ QQQP LIQP 420  
 91 G15C 194 PQPQ QPQQ SFPQ QQQP LIQP 421  
 92 G11A 202 QPQQ PQQS FPQQ QPFF IQPS 422  
 93 G12A 202 QPQQ PQQS FPQQ QRPF IQPS 423  
 94 G13A 202 QPQQ PQQS FPQQ QPQL IQQS 424  
 POOL 55  
 95 G11A 210 FPQQ QPFF IQPS LQQQ VNPC 425  
 96 G12A 210 FPQQ QRPF IQPS LQQQ LNPC 426  
 97 G13A 210 FPQQ QPQL IQQS LQQQ LNPC 427  
 98 G15A 210 FPQQ QQPL IQPY LQQQ MNPC 428  
 99 G16A 210 FPQQ QQPA IQSF LQQQ MNPC 429  
 100 G11A 218 IQPS LQQQ VNPC KNFL LQQC 430  
 101 G12A 218 IQPS LQQQ LNPC KNIL LQQS 431  
 102 G13A 218 IQQS LQQQ LNPC KNFL LQQC 432  
 POOL 56  
 103 G15A 218 IQPY LQQQ MNPC KNYL LQQC 433  
 104 G16A 218 IQSF LQQQ MNPC KNFL LQQC 434  
 105 G11A 226 VNPC KNFL LQQC KPVS LVSS 435  
 106 G12A 226 LNPC KNIL LQQS KPVS LVSS 436  
 107 G13A 226 LNPC KNFL LQQC KPVS LVSS 437  
 108 G15A 226 MNPC KNYL LQQC NPVS LVSS 438  
 109 G16A 226 MNPC KNFL LQQC NHVS LVSS 439  
 110 G11A 234 LQQC KPVS LVSS LWSM IWPQ 440  
 POOL 57  
 111 G12A 234 LQQS KPVS LVSS LWSI IWPQ 441  
 112 G13A 234 LQQC KPVS LVSS LWSM ILPR 442  
 113 G15A 234 LQQC NPVS LVSS LVSM ILPR 443  
 114 G16A 234 LQQC NHVS LVSS LVSI ILPR 444  
 115 G11A 242 LVSS LWSM IWPQ SDCQ VMRQ 445  
 116 G12A 242 LVSS LWSI IWPQ SDCQ VMRQ 446  
 117 G13A 242 LVSS LWSM ILPR SDCQ VMRQ 447  
 118 G14 242 LVSS LWSI ILPP SDCQ VMRQ 448  
 POOL 58  
 119 G15A 242 LVSS LVSM ILPR SDCQ VMRQ 449  
 120 G15C 242 LVSS LVSM ILPR SDCQ VMQQ 450  
 121 G16A 242 LVSS LVSI ILPR SDCQ VMQQ 451  
 122 G11A 250 IWPQ SDCQ VMRQ QCCQ QLAQ 452  
 123 G13A 250 ILPR SDCQ VMRQ QCCQ QLAQ 453  
 124 G14 250 ILPP SDCQ VMRQ QCCQ QLAQ 454  
 125 G15A 250 ILPR SDCQ VMRQ QCCQ QLAR 455

A2A1 138 QQQQ QQQQ QQQQ QQQQ QQQI  
 POOL 17  
 A4B 139 AQQQ QQQQ QQQQ QQQQ TLQQ  
 A1A1 146 QQQQ QQQQ ILQQ ILQQ QLIP  
 A1A6 146 QQQQ QQQQ ILQQ ILQQ QLIP  
 A1B6 146 QQQQ QQQQ ILQQ MLQQ QLIP  
 A1B10 146 QQQQ QQQQ ILQQ ILQQ QLTP  
 A1B11 146 QQQQ QQQQ ILQQ ILQQ QLIP  
 A2A1 146 QQQQ QQQQ QQQI LQQI LQQQ  
 A3A2 146 QQQQ QQQQ ILPP ILQQ QLIP  
 POOL 18  
 A4A 146 QQQQ QQQQ TLQQ ILQQ QLIP  
 A1A1 163 ILQQ ILQQ QLIP CMDV VLQQ  
 A1B6 163 ILQQ MLQQ QLIP CMDV VLQQ  
 A1B10 163 ILQQ ILQQ QLTP CMDV VLQQ  
 A2B1 163 ILQQ ILQQ QLIP CRDV VLQQ  
 A3A2 163 ILPP ILQQ QLIP CRDV VLQQ  
 A4A 163 TLQQ ILQQ QLIP CRDV VLQQ  
 A1A1 171 QLIP CMDV VLQQ HNIA HGRS  
 POOL 19  
 A1A3 171 QLIP CMDV VLQQ HNIA HGRS  
 A1B2 171 QLIP CMDV VLQQ HNIA HGRS  
 A1B7 171 QLIP CMDV VLQQ HNIV HGRS  
 A1B10 171 QLTP CMDV VLQQ HNIA HGRS  
 A1B11 171 QLIP CMDV VLQQ HNIV HGKS  
 A2A1 171 QLIP CRDV VLQQ HSIA YGSS  
 A2B1 171 QLIP CRDV VLQQ HSIA HGSS  
 A2B3 171 QLIP CRDV VLQQ HNIA HGSS  
 POOL 20  
 A3A1 171 QLIP CRDV VLQQ HNIA HARS  
 A3B1 171 QLIP CRDV VLQQ HNIA HARS  
 A1A1 179 VLQQ HNIA HGRS QVLQ QSTY  
 A1A3 179 VLQQ HNIA HGRS QVLQ QSTY  
 A1B2 179 VLQQ HNIA HGRS QVLQ QSTY  
 A1B7 179 VLQQ HNIV HGRS QVLQ QSTY  
 A1B10 179 VLQQ HNIA HGRS QVLQ QSTY  
 A1B11 179 VLQQ HNIV HGKS QVLQ QSTY  
 POOL 21  
 A2A1 179 VLQQ HSIA YGSS QVLQ QSTY  
 A2B1 179 VLQQ HSIA HGSS QVLQ QSTY  
 A2B3 179 VLQQ HNIA HGSS QVLQ QSTY  
 A3A1 179 VLQQ HNIA HARS QVLQ QSTY  
 A3B1 179 VLQQ HNIA HARS QVLQ QSTY  
 A4A 179 VLQQ HNIA HARS QVLQ QSTY  
 A1A1 187 HGRS QVLQ QSTY QLLQ ELCC  
 A1A3 187 HGRS QVLQ QSTY QLLR ELCC  
 POOL 22  
 A1B8 187 HGRS QVLQ QSTY QLLR ELCC  
 A1B11 187 HGKS QVLQ QSTY QLLQ ELCC  
 A2A1 187 YGSS QVLQ QSTY QLVQ QLCC  
 A2B1 187 HGSS QVLQ QSTY QLVQ QFCC  
 A2B3 187 HGSS QVLQ QSTY QLVQ QLCC  
 A3A1 187 HARS QVLQ QSTY QPLQ QLCC  
 A3B1 187 HARS QVLQ QSTY QLLQ QLCC  
 A4A 187 HARS QVLQ QSSY QLLQ QLCC  
 POOL 23  
 A1A1 195 QSTY QLLQ ELCC QHLW QIPE  
 A1A3 195 QSTY QLLR ELCC QHLW QIPE  
 A1B8 195 QSTY QLLR ELCC QHLW QIPE  
 A2A1 195 QSTY QLVQ QLCC QQLW QIPE  
 A2B1 195 QSTY QLVQ QFCC QQLW QIPE  
 A3A1 195 QSTY QPLQ QLCC QQLW QIPE  
 A3B1 195 QSTY QLLQ QLCC QQLL QIPE  
 A4A 195 QSSY QQLQ QLCC QQLF QIPE  
 POOL 24  
 A1A1 203 ELCC QHLW QIPE QSQC QAIH  
 A1B6 203 ELCC QHLW QILE QSQC QAIH  
 A1B10 203 ELCC QHLW QIPE KLQC QAIH  
 A2A1 203 QLCC QQLW QIPE QSRC QAIH  
 A2B1 203 QFCC QQLW QIPE QSRC QAIH  
 A3B1 203 QLCC QQLL QIPE QSRC QAIH  
 POOL 25

126 G15C 250 ILPR SDCQ VMQQ QCCQ QLAQ 456  
 POOL 59  
 127 G11A 258 VMRQ QCCQ QLAQ IPQQ LQCA 457  
 128 G15A 258 VMRQ QCCQ QLAR IPQQ LQCA 458  
 129 G15C 258 VMQQ QCCQ QLAQ IPQQ LQCA 459  
 130 G16A 258 VMQQ QCCQ QLAQ IPQQ LQCA 460  
 131 G11A 266 QLAQ IPQQ LQCA AIHT IIHS 461  
 132 G11B 266 QLAQ IPQQ LQCA AIHT VIHS 462  
 133 G12A 266 QLAQ IPQQ LQCA AIHS VVHS 463  
 134 G13A 266 QLAQ IPQQ LQCA AIHS IVHS 464  
 POOL 60  
 135 G15A 266 QLAR IPQQ LQCA AIHG IVHS 465  
 136 G15C 266 QLAQ IPQQ LQCA AIHS VVHS 466  
 137 G16A 266 QLAQ IPQQ LQCA AIHS VAHS 467  
 138 G11A 274 LQCA AIHT IIHS IIMQ QEQQ 468  
 139 G11B 274 LQCA AIHT VIHS IIMQ QEQQ 469  
 140 G12A 274 LQCA AIHS VVHS IIMQ QQQQ 470  
 141 POOL 61  
 142 G13A 274 LQCA AIHS IVHS IIMQ QEQQ 471  
 G14 274 LQCA AIHS VVHS IIMQ QEQQ 472  
 143 G15A 274 LQCA AIHG IVHS IIMQ QEQQ 473  
 144 G16A 274 LQCA AIHS VAHS IIMQ QEQQ 474  
 145 G11A 282 IIHS IIMQ QEQQ EQQQ GMHI 475  
 146 G11B 282 VIHS IIMQ QEQQ QGMH ILLP 476  
 147 G12A 282 VVHS IIMQ QQQQ QQQQ QGID 477  
 148 G13A 282 IVHS IIMQ QEQQ EQQQ GVQI 478  
 149 POOL 62  
 150 G14 282 VVHS IIMQ QEQQ EQQQ GVQI 479  
 G15A 282 IVHS IIMQ QEQQ QQQQ QQQQ 480  
 151 G15C 282 VVHS IIMQ QEQQ QQQQ QQQQ 481  
 152 G16A 282 VAHS IIMQ QEQQ QGVV ILRP 482  
 153 G11A 290 QEQQ EQQQ GMHI LLPL YQQQ 483  
 154 G12A 290 QQQQ QQQQ QGID IFLL LSQH 484  
 155 G12B 290 QQQQ QQQQ QGMH IFLL LSQH 485  
 156 G13A 290 QEQQ EQQQ GVQI LVPL SQQQ 486  
 157 POOL 63  
 158 G14 290 QEQQ EQQQ GVQI LVPL SQQQ 487  
 G15A 290 QEQQ QQQQ QQQQ QQQQ IQIM 488  
 159 G15C 290 QEQQ QQQQ QQQQ QQQQ ILRP 489  
 160 G16A 290 QEQQ QGVV ILRP LFLL AQGL 490  
 161 G15A 298 QQQQ QQQQ IQIM RPLF QLVQ 491  
 162 G11A 305 GMHI LLPL YQQQ QVGG GTLV 492  
 163 G12A 305 GIDI FLPL SQHE QVGG GSVL 493  
 164 G12B 305 GMHI FLPL SQQQ QVGG GSVL 494  
 165 POOL 64  
 166 G13A 305 GVQI LVPL SQQQ QVGG GTLV 495  
 G14 305 GVQI LVPL SQQQ QVGG GILV 496  
 167 G15A 305 GIQI MRPL FQLV QGQG IIQP 497  
 168 G15C 305 GIQI LRPL FQLV QGQG IIQP 498  
 169 G16A 305 GVPI LRPL FQLV QGLG IIQP 499  
 170 G11A 313 YQQQ QVGG GTLV QGQG IIQP 500  
 171 G12A 313 SQHE QVGG GSVL QGQG IIQP 501  
 172 G12B 313 SQQQ QVGG GSVL QGQG IIQP 502  
 173 POOL 65  
 174 G13A 313 SQQQ QVGG GTLV QGQG IIQP 503  
 G14 313 SQQQ QVGG GILV QGQG IIQP 504  
 175 G11A 321 GTLV QGQG IIQP QQPA QLEA 505  
 176 G12A 321 GSVL QGQG IIQP QQPA QLEA 506  
 177 G15A 321 FQLV QGQG IIQP QQPA QLEV 507  
 178 G16A 321 FQLA QGLG IIQP QQPA QLEG 508  
 179 G11A 329 IIQP QQPA QLEA IRSI VLQT 509  
 180 G13A 329 IIQP QQPA QLEV IRSI VLQT 510  
 181 POOL 66  
 182 G13C 329 IIQP QQPA QLEV IRSS VLQT 511  
 G15C 329 IIQP QQPA QYEV IRSI VLRT 512  
 183 G16A 329 IIQP QQPA QLEG IRSI VLKT 513  
 184 G11A 337 QLEA IRSI VLQT LPTM CNVY 514  
 185 G12A 337 QLEA IRSI VLQT LPSM CNVY 515  
 186 G13A 337 QLEV IRSI VLQT LATM CNVY 516  
 187 G13C 337 QLEV IRSS VLQT LATM CNVY 517  
 188 G15A 337 QLEV IRSI VLGT LPTM CNVY 518  
 POOL 67

A3B3 203 GLCC QQLL QIPE QSQC QAIH  
 A4A 203 QLCC QQLF QIPE QSRC QAIH  
 A1A1 211 QIPE QSQC QAIH NVVH AAIL  
 A1B3 211 QIPE QSQC QAIQ NVVH AAIL  
 A1B6 211 QILE QSQC QAIH NVVH AAIL  
 A1B9 211 QIPE QSQC QAIH KVVH AAIL  
 A1B10 211 QIPE KLQC QAIH NVVH AAIL  
 A2A1 211 QIPE QSRC QAIH NVVH AAIL  
 POOL 26  
 A3B3 211 QIPE QSQC QAIH NVAH AIIM  
 A4A 211 QIPE QSRC QAIH NVVH AAIL  
 A1A1 219 QAIH NVVH AAIL HQQQ KQQQ  
 A1A6 219 QAIH NVVH AAIL HQQQ KQQQ  
 A1B3 219 QAIQ NVVH AAIL HQQQ KQQQ  
 A1B9 219 QAIH KVVH AAIL HQQQ KQQQ  
 A1B13 219 QAIH NVVH AAIL HQQQ KQQQ  
 A2B3 219 QAIH NVVH AAIL HQQH HHHQ  
 POOL 27  
 A3A1 219 QAIH NVVH AAIL HQQQ RQQQ  
 A3B1 219 QAIH NVVH AIIM HQQE QQQQ  
 A3B3 219 QAIH NVAH AIIM HQQQ QQQQ  
 A4A 219 QAIH NVVH AAIL HHHQ QQQQ  
 A1A1 227 AAIL HQQQ KQQQ QPSS QVSF  
 A1A6 227 AAIL HQQQ KQQQ QPSS QVSF  
 A1B2 227 AAIL HQQQ KQQQ QPSS QVSF  
 A1B10 227 AAIL HQQQ KQQQ PSSQ VSFQ  
 POOL 28  
 A1B13 227 AAIL HQQQ QQQQ EQKQ QLQQ  
 A2A1 227 AAIL HQQQ QQQQ QQQQ QPLS  
 A2B3 227 AAIL HQQH HHHQ QQQQ QQQQ  
 A2B4 227 AAIL HQQH HHHQ EQKQ QLQQ  
 A3A1 227 AAIL HQQQ RQQQ PSSQ VSLQ  
 A3B1 227 AIIM HQQE QQQQ LQQQ QQQQ  
 A3B3 227 AIIM HQQQ QQQQ EQKQ QLQQ  
 A4A 227 AAIL HHHQ QQQQ QPSS QVSF  
 POOL 29  
 A1A1 235 KQQQ QPSS QVSF QQPL QQYP  
 A1A6 235 KQQQ QPSS QVSF QQPL QQYP  
 A1B2 235 KQQQ QLSS QVSF QPQ QQQP  
 A1B10 235 KQQQ PSSQ VSFQ QPQ QYPL  
 A1B13 235 QQQQ EQKQ QLQQ QQQQ QQQQ  
 A2B4 235 HHHQ EQKQ QLQQ QQQQ QQQQ  
 A3A1 235 RQQQ PSSQ VSLQ QPQ QYPS  
 A3B1 235 QQQQ LQQQ QQQQ LQQQ QQQQ  
 POOL 30  
 A4A 235 QQQQ QPSS QVSF QQQP EQYP  
 A1B13 243 QLQQ QQQQ QQQQ QQQQ QQQQ  
 A1B13 251 QQQQ QQQQ KQQQ QQQQ QQQQ  
 A2A1 260 QQQQ QQQQ QPLS QVSF QQQP  
 A2B1 260 QQQQ QQQQ QPLS QVCF QQQQ  
 A2B3 260 HHHQ QQQQ QQQQ QPLS QVSF  
 A3B1 260 QQQQ QQQQ QPSS QVSF QQQP  
 A2A1 289 QPLS QVSF QQQP QQYP SGQG  
 POOL 31  
 A2B1 289 QPLS QVCF QQQQ QQYP SGQG  
 A3B1 289 QPSS QVSF QQQP QQYP SSQV  
 A1A1 293 QVSF QQPL QQYP LGQG SFRP  
 A1A6 293 QVSF QQPL QQYP LGQG SFRP  
 A1B2 293 QVSF QQQP QQYP LGQG SFRP  
 A2A1 293 QVSF QQQP QQYP SGQG SFQP  
 A2B1 293 QVCF QQQQ QQYP SGQG SFQP  
 A2B3 293 QVSF QQQP QQYP SGQG FFQP  
 POOL 32  
 A2B5 293 QVSF QQQP QQYP SGQG FFQP  
 A3A1 293 QVSL QQQP QQYP SGQG FFQP  
 A3B1 293 QVSF QQQP QQYP SSQV SFQP  
 A3B2 293 QVSF QQQP QQYP SSQG SFQP  
 A4A 293 QVSF QQQP EQYP SGQV SFQS  
 A1A1 301 QQQP LGQG SFRP SQQN PQAQ  
 A1B2 301 QQQP LGQG SFRP SQQN PQAQ  
 A2A1 301 QQQP SGQG SFQP SQQN PQAQ  
 POOL 33

189 G15C 337 QYEV IRSI VLRT LPNM CNVY 519  
 190 G16A 337 QLEG IRSI VLKT LPTM CNVY 520  
 191 G11A 345 VLQT LPTM CNVY VPPE CSII 521  
 192 G12A 345 VLQT LPSM CNVY VPPE CSIM 522  
 193 G13A 345 VLQT LATM CNVY VPPY CSTI 523  
 194 G15A 345 VLGT LPTM CNVY VPPE CSTT 524  
 195 G15C 345 VLRT LPNM CNVY VRPD CSTI 525  
 196 G16A 345 VLKT LPTM CNVY VPPD CSTI 526  
 POOL 68  
 197 G11A 353 CNVY VPPE CSII KAPF SSVV 527  
 198 G12A 353 CNVY VPPE CSIM RAPF ASIV 528  
 199 G13A 353 CNVY VPPY CSTI RAPF ASIV 529  
 200 G15A 353 CNVY VPPE CSTT KAPF ASIV 530  
 201 G15C 353 CNVY VRPD CSTI NAPF ASIV 531  
 202 G16A 353 CNVY VPPD CSTI NVPY ANID 532  
 203 G11A 361 CSII KAPF SSVV AGIG GQ 533  
 204 G12A 361 CSIM RAPF ASIV AGIG GQ 534  
 POOL 69  
 205 G13A 361 CSTI RAPF ASIV AGIG GQYR 535  
 206 G14 361 CSTI RAPF ASIV ASIG GQ 536  
 207 G15A 361 CSTT KAPF ASIV ADIG GQ 537  
 208 G15C 361 CSTI NAPF ASIV AGIS GQ 538  
 209 G16A 361 CSTI NVPY ANID AGIG GQ 539  
 210 GII 1 PQQP FPLQ PQQS FLWQ SQQP 540  
 211 GII 9 PQQS FLWQ SQQP FLQQ PQQP 541  
 212 GII 17 SQQP FLQQ PQQP SPQP QQQV 542  
 POOL 70  
 213 GII 25 PQQP SPQP QQQV QIIS PATP 543  
 214 GII 33 QQQV QIIS PATP TTIP SAGK 544  
 215 GII 41 PATP TTIP SAGK PTSA PFPQ 545  
 216 GII 49 SAGK PTSA PFPQ QQQQ HQQL 546  
 217 GII 57 PFPQ QQQQ HQQL AQQQ IPVV 547  
 218 GII 65 HQQL AQQQ IPVV QPSI LQQL 548  
 219 GII 73 IPVV QPSI LQQL NPCK VFLQ 549  
 220 GII 81 LQQL NPCK VFLQ QQCS PVAM 550  
 POOL 71  
 221 GII 89 VFLQ QQCS PVAM PQRL ARSQ 551  
 222 GII 97 PVAM PQRL ARSQ MLQQ SSCH 552  
 223 GII 105 ARSQ MLQQ SSCH VMQQ QCCQ 553  
 224 GII 113 SSCH VMQQ QCCQ QLPQ IPQQ 554  
 225 GII 121 QCCQ QLPQ IPQQ SRYQ AIRA 555  
 226 GII 127B PQIP QQSR YEAI RAII YSII 556  
 227 GII 129 IPQQ SRYQ AIRA IYYS IILQ 557  
 228 GII 137 AIRA IYYS IILQ EQQQ VQGS 558  
 POOL 72  
 229 GII 145 IILQ EQQQ VQGS IQSQ QQQP 559  
 230 GII 153 VQGS IQSQ QQQP QQLG QCVS 560  
 231 GII 161 QQQP QQLG QCVS QPQQ QSQQ 561  
 232 GII 169 QCVS QPQQ QSQQ QLGQ QPQQ 562  
 233 GII 177 QSQQ QLGQ QPQQ QQLA QGTF 563  
 234 GII 185 QPQQ QQLA QGTF LQPH QIAQ 564  
 235 POOL 73  
 236 GII 193 QGTF LQPH QIAQ LEVM TSIA 565  
 237 GII 201 QIAQ LEVM TSIA LRIL PTMC 566  
 238 GII 209 TSIA LRIL PTMC SVNV PLYR 567  
 239 GII 217 PTMC SVNV PLYR TTTS VPFQ 568  
 240 GII 225 PLYR TTTS VPFQ VGTG VGAY 569  
 241 GIII 1A 1 TTTR TFPI PTIS SNNN HHFR 570  
 242 GIII 1A 9 PTIS SNNN HHFR SNSN HHFH 571  
 243 GIII 1A 17 HHFR SNSN HHFH SNNN QFYR 572  
 244 POOL 74  
 245 GIII 1A 25 HHFH SNNN QFYR NNNS PGHN 573  
 246 GIII 1A 33 QFYR NNNS PGHN NPLN NNNS 574  
 247 GIII 1A 41 PGHN NPLN NNNS PNPN SPNN 575  
 248 GIII 1A 49 NNNS PNPN SPNN HHNN SPNN 576  
 249 GIII 1A 57 SPNN HHNN SPNN NFQY HTHP 577  
 250 GIII 1A 65 SPNN NFQY HTHP SNHK NLPH 578  
 251 GIII 1A 73 HTHP SNHK NLPH TNNI QQQQ 579  
 252 GIII 1A 81 NLPH TNNI QQQQ PPFS QQQQ 580  
 POOL 75  
 253 GIII 1A 89 QQQQ PPFS QQQQ PPFS QQQQ 581  
 254 GIII 1A 97 QQQQ PPFS QQQQ PVLQ QQQP 582

A2B3 301 QQYP SQQG FFQP SQQN PQAQ  
 A2B5 301 QQYP SQQG FFQP FQQN PQAQ  
 A3A1 301 QQYP SQQG FFQP SQQN PQAQ  
 A3B1 301 QQYP SSQV SFQP SQLN PQAQ  
 A3B2 301 QQYP SSQG SFQP SQQN PQAQ  
 A4A 301 EQYP SGQV SFQS SQQN PQAQ  
 A1B1 309 SFRP SQQN PLAQ GSVQ PQQL  
 A1A1 309 SFRP SQQN PQAQ GSVQ PQQL  
 POOL 34  
 A1A3 309 SFRP SQQN PQTQ GSVQ PQQL  
 A1B2 309 SFRP SQQN SQAQ GSVQ PQQL  
 A1B3 309 SFRP SQQN PQDQ GSVQ PQQL  
 A1B4 309 SFRP SQQN PRAQ GSVQ PQQL  
 A2A1 309 SFQP SQQN PQAQ GSVQ PQQL  
 A2B3 309 FFQP SQQN PQAQ GSFQ PQQL  
 A2B5 309 FFQP FQQN PQAQ GSFQ PQQL  
 A3A1 309 FFQP SQQN PQAQ GSVQ PQQL

## Pool 35

A3B1 309 SFQP SQLN PQAQ GSVQ PQQL  
 A3B1 309 SFQP SQQN SQAQ GSVQ PQQL  
 A3B2 309 SFQP SQQN PQAQ GSVQ PQQL  
 A4A 309 SFQS SQQN PQAQ GSVQ PQQL  
 A1A1 317 PQAQ GSVQ PQQL PQFE EIRN  
 A1A3 317 PQTQ GSVQ PQQL PQFE EIRN  
 A1A6 317 PQAQ GSVQ PQQL PQFE IRNL  
 A1B1 317 PLAQ GSVQ PQQL PQFE EIRN  
 POOL 36  
 A1B3 317 PQDQ GSVQ PQQL PQFE EIRN  
 A1B4 317 PRAQ GSVQ PQQL PQFE EIRN  
 A2B3 317 PQAQ GSFQ PQQL PQFE EIRN  
 A2B5 317 PQAQ GSFQ PQQL PQFE AIRN  
 A3B1 317 PQAQ GSVQ PQQL PQFA EIRN  
 A4A 317 PQAQ GSVQ PQQL PQFQ EIRN

## Pool 37

A1A1 325 PQQL PQFE EIRN LALQ TLPA  
 A1A6 325 PQQL PQFE IRNL ALQT LPAM  
 A1B12 325 PQQL PQFE EIRN LARK  
 A2A1 325 PQQL PQFE EIRN LALE TLPA  
 A2B3 325 PQQL PQFE AIRN LALQ TLPA  
 A3B1 325 PQQL PQFA EIRN LALQ TLPA  
 A4A 325 PQQL PQFQ EIRN LALQ TLPA  
 A1A1 333 EIRN LALQ TLPA MCNV YIPP  
 POOL 38  
 A1A3 333 EIRN LALQ TLPS MCNV YIPP  
 A2A1 333 EIRN LALE TLPA MCNV YIPP  
 A3A1 333 EIRN LALQ TLPR MCNV YIPP  
 A1A1 341 TLPA MCNV YIPP YCTI APFG  
 A1A3 341 TLPS MCNV YIPP YCTI APFG  
 A1B1 341 TLPA MCNV YIPP YCTI VPFG  
 A1B4 341 TLPA MCNV YIPP YCAM APFG  
 A1B9 341 TLPA MCNV YIPP YCTI TPFG

## Pool 39

A2A1 341 TLPA MCNV YIPP YCTI APVG  
 A2B2 341 TLPA MCNV YIPP YCST TIAP  
 A3A1 341 TLPR MCNV YIPP YCST TIAP  
 A3A2 341 TLPR MCNV YIPP YCST TTAP  
 A3B1 341 TLPA MCNV YIPP HCST TIAP  
 A1A1 349 YIPP YCTI APFG IFGT NYR  
 A1B1 349 YIPP YCTI VPFG IFGT NYR  
 A1B4 349 YIPP YCAM APFG IFGT NYR

## Pool 40

A1B5 349 YIPP YCTM APFG IFGT NYR  
 A1B9 349 YIPP YCTI TPFG IFGT NYR  
 A2A1 349 YIPP YCTI APVG IFGT NYR  
 A2B2 349 YIPP YCST TIAP VGIF GTN  
 A3A2 349 YIPP YCST TTAP FGIF GTN  
 A3B1 349 YIPP HCST TIAP FGIF GTN  
 A3B3 349 YIPP HCST TIAP FGIS GTN  
 A4D 350 IPPY CSTT IAPF GIFG TNYR

## Pool 41

G11A 17 GTAN MQVD PSSQ VQWP QQQP  
 G12A 17 GTAN IQVD PSGQ VQWL QQQL

253 GIII 1A 105 QQQQ PVLP QQSF FSQQ QQLV 583  
 254 GIII 1A 113 QQSP FSQQ QQLV LPPQ QQQQ 584  
 255 GIII 1A 121 QQLV LPPQ QQQQ QLVQ QQIP 585  
 256 GIII 1A 129 QQQQ QLVQ QQIP IVQP SVLQ 586  
 257 GIII 1A 137 QQIP IVQP SVLQ QLNP CKVF 587  
 258 GIII 1A 145 SVLQ QLNP CKVF LQQQ CSPV 588  
 259 POOL 76  
 260 GIII 1A 153 CKVF LQQQ CSPV AMPQ RLAR 589  
 GIII 1A 161 CSPV AMPQ RLAR SQMW QQSS 590  
 261 GIII 1A 169 RLAR SQMW QQSS CHVM QQQC 591  
 262 GIII 1A 177 QQSS CHVM QQQC CQQL QQIP 592  
 263 GIII 1A 185 QQQC CQQL QQIP EQSR YEAI 593  
 264 GIII 1A 193 QQIP EQSR YEAI RAIH YSII 594  
 265 GIII 1A 201 YEAI RAIH YSII LQEQ QQGF 595  
 266 GIII 1A 209 YSII LQEQ QQGF VQPQ QQQP 596  
 267 POOL 77  
 268 GIII 1A 217 QQGF VQPQ QQQP QQSG QGVS 597  
 GIII 1A 225 QQQP QQSG QGVS QSQQ QSQQ 598  
 269 GIII 1A 233 QGVS QSQQ QSQQ QLGG CSFQ 599  
 270 GIII 1A 241 QSQQ QLGG CSFQ QPQQ QLGG 600  
 271 GIII 1A 249 CSFQ QPQQ QLGG QPQQ QQQQ 601  
 272 GIII 1A 257 QLGG QPQQ QQQQ QVLQ GTFL 602  
 273 GIII 1A 263 QQQQ QVLQ GTFL QPHQ IAHL 603  
 274 GIII 1A 271 GTFL QPHQ IAHL EAVT SIAL 604  
 275 POOL 78  
 276 GIII 1A 279 IAHL EAVT SIAL RTLP TMCS 605  
 GIII 1A 287 SIAL RTLP TMCS VNVP LYSA 606  
 277 GIII 1A 295 TMCS VNVP LYSA TTSV PFGV 607  
 278 GIII 1A 303 LYSA TTSV PFGV GTGV GAY 608  
 279 GIII 1B 26 SCIS GLER PWQQ QPLP PQQS 609  
 280 GIII 1B 34 PWQQ QPLP PQQS FSQQ PPF 610  
 281 GIII 1B 42 PQQS FSQQ PPF QQQ QPLP 611  
 282 GIII 1B 50 PPF QQQ QPLP PQQS FSQQ 612

## Pool 79

283 GIII 1B 58 QPLP PQQS FSQQ QPPF SQQQ 613  
 284 GIII 1B 66 FSQQ QPPF SQQQ PILS QQQP 614  
 285 GIII 1B 74 SQQQ PILS QPPF FSQQ QQPV 615  
 286 O 1A 17 ATAA RELN PSNK ELQS PQQS 616  
 287 O 1A 25 PSNK ELQS PQQS FSYQ QPPF 617  
 288 O 1A 33 PQQS FSYQ QPPF PQQP YPQQ 618  
 289 O 1A 41 QPPF PQQP YPQQ PYPS QQP 619  
 290 O 1A 49 YPQQ PYPS QQP YPQQ PFFT 620  
 POOL 80  
 291 O 1A 57 QQP YPQQ PFFT PQQQ FPEQ 621  
 292 O 1A 65 PFFT PQQQ FPEQ SQQP FTQP 622  
 293 O 1A 73 FPEQ SQQP FTQP QOPT PIQP 623  
 294 O 1A 81 FTQP QOPT PIQP QPPF PQQP 624  
 295 O 1A 89 PIQP QPPF PQQP QQP QPPF 625  
 296 O 1A 97 PQQP QQP QPPF PQQP PFPW 626  
 297 O 1A 105 QPPF PQQP PFPW PQQP PFPQ 627  
 298 O 1A 113 PFPW PQQP PFPQ TQQS FPLQ 628

## POOL 81

299 O 1A 121 PFPQ TQQS FPLQ PQQP FPQQ 629  
 300 O 1A 129 FPLQ PQQP FPQQ PQQP FPQP 630  
 301 O 1A 137 FPQQ PQQP FPQP QLPF PQQS 631  
 302 O 1A 145 FPQP QLPF PQQS EQII PQQL 632  
 303 O 1A 153 PQQS EQII PQQL QPPF PLQP 633  
 304 O 1A 161 PQQL QPPF PLQP QPPF PQQP 634  
 305 O 1A 169 PLQP QPPF PQQP QPPF PQQP 635  
 306 O 1A 177 PQQP QPPF PQQP QPQP VQPQ 636

## Pool 82

307 O 1A 185 PQQP QPIP VQPQ QSFP QSSQ 637  
 308 O 1A 193 VQPQ QSFP QSSQ QSQQ PFAQ 638  
 309 O 1A 201 QSSQ QSQQ PFAQ PQQL FPFL 639  
 310 O 1A 209 PFAQ PQQL FPFL QPQP PQQP 640  
 311 O 1A 217 FPFL QPQP PQQP QPPF PLQP 641  
 312 O 1A 225 PQQP QPPF PLQP QPPF PQQP 642  
 313 O 1A 233 PLQP QPPF PQQP QPPF PQQP 643  
 314 O 1A 241 PQQP QPPF PQQP QSSQ PQQP 644  
 POOL 83  
 315 O 1A 249 PQQP QSSQ PQQP QQP YPQQ 645  
 316 O 1A 257 PQQP QQP YPQQ PQQP PYGS SLTS 646

104

GI3A 17 ATAN MQVD PSGQ VPWP QQQP	317 O 1A 265 PQQQ PYGS SLTS IGGQ	647
GI3B 19 MN IQVD PSGQ VPWP QQQP FP	318 O 1B 1 ARQL NPSD QELQ SPQQ LYPQ	648
GI4 17 ATAN MQAD PSGQ VQWP QQQP	319 O 1B 9 QELQ SPQQ LYPQ QPYP QQPY	649
GI5A 17 TTAN IQVD PSGQ VQWP QQQQ	320 O 1C 1 SRLS SPRG KELH TPQE QFPQ	650
GI5C 17 ATAN MQVD PSGQ VQWP QQQP	321 O 1C 9 KELH TPQE QFPQ QQQF PQQP	651
GI7 20 QIVF PSGQ VQWP QQQQ PFP	322 O 1C 17 QFPQ QQQF PQQP QFPQ	652
Pool 42		
GI1A 25 PSSQ VQWP QQQP VPQP HQPF	323	
GI2A 25 PSGQ VQWL QQQL VPQL QQPL	324	
GI3A 25 PSGQ VPWP QQQP FPQP HQPF	325	
GI4 25 PSGQ VQWP QQQP FLQP HQPF	326	
GI5A 25 PSGQ VQWP QQQQ PFPQ PQQP	327	
GI5C 25 PSGQ VQWP QQQP FRQP QQQP	328	
GI6A 25 PSGQ VQWP QQQP FPQP QQQP	329	
GI1A 33 QQQP VPQP HQPF SQQP QQTF	330	

---

\*Position of N-terminal residue in  $\alpha$ -,  $\gamma 1$ -,  $\gamma 2$ -,  $\gamma 3$ -, or  $\omega$  consensus sequence





[illegible]

[illegible]



[illegible]





[illegible]



[illegible]

[illegible]

[illegible]



649	QELQSPQQLYPQQPYQQPY																		
650	SRLLSPRGKELHTPQEQQFPQ																		
651	KELHTPQEQQFPQQQQFPQPQ																		
652	QFPQQQQFPQPQQFPQ																		

	70.1 to 100
	40.1 to 70
	25.1 to 40
	10.1 to 25
	5.1 to 10
	<5

&gt;3 x B1

**CLAIMS**

1. A method of preventing or treating coeliac disease comprising administering to an individual at least one agent selected from:
  - 5 (a) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of SEQ ID NOs:18-22, 31-36, 39-44, and 46, and equivalents thereof; and
  - (b) an analogue of (a) which is capable of being recognised by a T cell receptor that recognises the peptide of (a) and which is not more than 50 amino acids
  - 10 in length; and
  - (c) optionally, in addition to the agent selected from (a) and (b), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NO:1 and SEQ ID NO:2.
- 15 2. A method of claim 1 wherein the agent is HLA-DQ2-restricted.
3. A method of claim 1 wherein the agent is HLA-DQ8-restricted.
4. A method of claim 1 wherein one agent is HLA-DQ2-restricted and a second
- 20 agent is HLA-DQ8-restricted.
5. A method of claim 1 wherein the agent comprises a wheat epitope.
6. A method of claim 1 wherein one agent comprises a wheat epitope and one
- 25 agent comprises a rye epitope.
7. A method of claim 1 wherein one agent comprises a wheat epitope and one agent comprises a barley epitope.
- 30 8. A method of claim 1 wherein one agent comprises a rye epitope and one agent comprises a barley epitope.

9. A method of claim 1 wherein one agent comprises a wheat epitope, one agent comprises a barley epitope, and one agent comprises a rye epitope.
10. A method of claim 1 wherein a single agent comprises a wheat epitope, a  
5 barley epitope, and a rye epitope.
11. A method of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an agent as defined in claim 1 and a pharmaceutically acceptable carrier or diluent.
- 10
12. A method of preventing or treating coeliac disease comprising administering to an individual a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined in claim 1, and a pharmaceutically acceptable carrier or diluent.
- 15
13. A method of preventing or treating coeliac disease comprising administering to an individual a composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1, which composition comprises an agent as defined in claim 1.
- 20
14. A method of preventing or treating coeliac disease comprising:  
diagnosing coeliac disease in an individual by either:  
a) contacting a sample from the host with at least one agent selected  
from:  
25 i) a peptide comprising at least one epitope comprising a  
sequence selected from the group consisting of: SEQ ID  
NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof;  
and  
ii) an analogue of i) which is capable of being recognised by a  
30 T cell receptor that recognises i) and which is not more than  
50 amino acids in length; and

- iii) optionally, in addition to the agent selected from i) and ii),  
a peptide comprising at least one epitope comprising a  
sequence selected from SEQ ID NOS:1 and 2; and  
determining *in vitro* whether T cells in the sample recognise the agent;  
5 recognition by the T cells indicating that the individual has, or is  
susceptible to, coeliac disease; or  
b) administering an agent as defined in claim 1 and determining *in*  
*vivo* whether T cells in the individual recognise the agent, recognition of the  
agent indicating that the individual has or is susceptible to coeliac disease;  
10 and  
administering to an individual diagnosed as having, or being susceptible to,  
coeliac disease a therapeutic agent for preventing or treating coeliac disease.

15. Use of an agent for the preparation of a medicament for treating or preventing  
15 coeliac disease, wherein the agent comprises:

- (a) a peptide comprising at least one epitope comprising a sequence selected  
from the group consisting of SEQ ID NOS:18-22, 31-36, 39-44, and 46, and  
equivalents thereof; and  
(b) an analogue of (a) which is capable of being recognised by a T cell  
20 receptor that recognises the peptide of (a) and which is not more than 50 amino acids  
in length; and  
(c) optionally, in addition to the agent selected from (a) and (b), a peptide  
comprising at least one epitope comprising a sequence selected from SEQ ID NO:1  
and SEQ ID NO:2.

25

16. A use of claim 15 wherein the agent is HLA-DQ2-restricted.

17. A use of claim 15 wherein the agent is HLA-DQ8-restricted.

- 30 18. A use of claim 15 wherein one agent is HLA-DQ2-restricted and a second  
agent is HLA-DQ8-restricted.



19. A use of claim 15 wherein the agent comprises a wheat epitope.
20. A use of claim 15 wherein one agent comprises a wheat epitope and one agent comprises a rye epitope.
- 5 21. A use of claim 15 wherein one agent comprises a wheat epitope and one agent comprises a barley epitope.
22. A use of claim 15 wherein one agent comprises a rye epitope and one agent  
10 comprises a barley epitope.
23. A use of claim 15 wherein one agent comprises a wheat epitope, one agent comprises a barley epitope, and one agent comprises a rye epitope.
- 15 24. A use of claim 15 wherein a single agent comprises a wheat epitope, a barley epitope, and a rye epitope.
25. A use of claim 15 wherein the agent is present within a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent.
- 20 26. A use of claim 15 wherein the agent is present within a pharmaceutical composition comprising an antagonist of a T cell which has a T cell receptor as defined in claim 15, and a pharmaceutically acceptable carrier or diluent.
- 25 27. A use of claim 15 wherein the agent is present within a composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1.
- 30 28. An agent as defined in claim 1, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by tolerising T cells which recognise the agent.

29. An antagonist of a T cell which has a T cell receptor as defined in claim 1, optionally in association with a carrier, for use in a method of treating or preventing coeliac disease by antagonising such T cells.
- 5 30. An agent as defined in claim 1 or an analogue that binds an antibody that binds to an epitope of an agent as defined in claim 1 for use in a method of treating or preventing coeliac disease in an individual by tolerising the individual to prevent the production of such an antibody.
- 10 31. A protein that comprises a sequence which is able to bind to a T cell receptor, which T cell receptor recognises an agent as defined in claim 1, and which sequence is able to cause antagonism of a T cell that carries such a T cell receptor.
32. An agent as defined in claim 1 or an antagonist as defined in claim 12.
- 15 33. A pharmaceutical composition comprising an agent as defined in claim 1 or an antagonist as defined in claim 12 and a pharmaceutically acceptable carrier or diluent.
- 20 34. A composition for tolerising an individual to a gliadin protein to suppress the production of a T cell or antibody response to an agent as defined in claim 1, which composition comprises an agent as defined in claim 1.
35. A composition for antagonising a T cell response to an agent as defined in claim 1, which composition comprises an antagonist as defined in claim 12.
- 25 36. A mutant gliadin protein whose wild-type sequence can be modified by a transglutaminase to a sequence which is an agent as defined in claim 1, which mutant gliadin protein comprises a mutation which prevents its modification by a transglutaminase to a sequence which is an agent as defined in claim 1; or a fragment of such a mutant gliadin protein which is at least 15 amino acids long and which comprises the mutation.
- 30

37. A polynucleotide that comprises a coding sequence that encodes a protein or fragment as defined in claim 36 or 31.

38. A polynucleotide according to claim 37 that additionally comprises one or  
5 more regulatory sequences operably linked to the coding sequence, which regulatory sequences are capable of securing the expression of the coding sequence in a cell.

39. A polynucleotide according to claim 38 wherein the regulatory sequence(s) allow expression of the coding sequence in a prokaryotic or mammalian cell.

10

40. A polynucleotide according to any one of claims 37 to 39 which is a vector or which is in the form of a vector.

15

41. A cell comprising a polynucleotide as defined in any one of claims 37 to 40 or which has been transformed with such a polynucleotide.

42. A cell according to claim 41 which is a prokaryotic cell or a mammalian cell.

20

43. A mammal that expresses a T cell receptor as defined in claim 1.

44. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:

(a) contacting a sample from the host with at least one agent selected from

25

(i) a peptide comprising at least one epitope comprising a sequence selected from the group consisting of: SEQ ID NOS:18-22, 31-36, 39-44, and 46, and equivalents thereof; and

(ii) an analogue of (i) which is capable of being recognised by a T cell receptor that recognises (i) and which is not more than 50 amino acids in length; and

30

(iii) optionally, in addition to the agent selected from (i) and (ii), a peptide comprising at least one epitope comprising a sequence selected from SEQ ID NOS:1 and 2; and

(b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.

- 5    45.    Use of an agent as defined in claim 44 for the preparation of a diagnostic means for use in a method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual, said method comprising determining whether T cells of the individual recognise the agent, recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease.
- 10    46.    A method or use according to claim 44 or 45 wherein the agent is an analogue (iii) which comprises (i) or (ii) bound to (a) an HLA molecule, or (b) a fragment of an HLA molecule capable of binding (i) or (ii).
- 15    47.    A method or use according to claim 46 wherein the HLA molecule or fragment is in a complex comprising four HLA molecules or fragments of HLA molecules.
- 20    48.    Use according to claim 45, 46 or 47 wherein the method comprises administering the agent to the skin of an individual and detecting the presence of inflammation at the site of administration, the detection of inflammation indicating that the T cells of the individual recognise the agent.
- 25    49.    A method according to claim 44, 46 or 47 wherein the sample is blood sample.
50.    A method according to claim 44, 46, 47 or 49 wherein the T cells are not restimulated in antigen specific manner *in vitro* before the said determining.
- 30    51.    A method or use according to any one claims 44-50 in which the recognition of the agent by the T cells is determined by detecting the secretion of a cytokine from the T cells.

52. A method or use according to claim 51 in which the cytokine is IFN- $\gamma$ .
53. A method or use according to claim 51 or claim 52 in which the cytokine is detected by allowing the cytokine to bind to an immobilised antibody specific to the  
5 cytokine and then detecting the presence of the antibody/cytokine complex.
54. A method or use according to any one of claims 44 to 50 wherein said determining is done by measuring whether the agent binds the T cell receptor.
- 10 55. A method for identifying an analogue as defined in a claim 44, 46 or 47 comprising determining whether a candidate substance is recognised by a T cell receptor that recognises an epitope comprising sequence as defined in claim 44, recognition of the substance indicating that the substance is an analogue.
- 15 56. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising determining the presence of an antibody that binds to an epitope of an epitope comprising sequence as defined in claim 44 in a sample from the individual, the presence of the antibody indicating that the individual has, or is susceptible to, coeliac disease.
- 20 57. A method of determining whether a composition is capable of causing coeliac disease comprising determining whether a protein capable of being modified by a transglutaminase to an oligopeptide sequence as defined in claim 44 is present in the composition, the presence of the protein indicating that the composition is capable of  
25 causing coeliac disease.
58. A method according to claim 57 wherein the said determining is done by contacting the composition with an antibody specific for the sequence which is capable of being modified to the oligopeptide sequence, binding of the antibody to a  
30 protein in the composition indicating the composition is capable of causing coeliac disease.

59. A method of identifying an antagonist of a T cell, which T cell recognises an agent as defined in claim 1, comprising contacting a candidate substance with the T cell and detecting whether the substance causes a decrease in the ability of the T cell to undergo an antigen specific response, the detecting of any such decrease in said  
5 ability indicating that the substance is an antagonist.

60. A kit for carrying out a method or use according to any one of claims 44 to 54 comprising an agent as defined in claim 44, 46 or 47 and a means to detect the recognition of the peptide by the T cell.

10

61. A kit according to claim 60 wherein the means to detect recognition comprises an antibody to IFN- $\gamma$ .

15

62. A kit according to claim 61 wherein the antibody is immobilised on a solid support and optionally the kit also comprises a means to detect the antibody/IFN- $\gamma$  complex.

20

63. Use of an agent or antagonist as defined in claim 62 or a wild type sequence as defined in claim 36 to produce an antibody specific to the agent, antagonist or wild type sequence.

25

64. Use of a mutation in an epitope of a gliadin protein, which epitope is as defined in claim 44, to decrease the ability of the gliadin protein to cause coeliac disease.

30

65. Method of identifying a product which is therapeutic for coeliac disease comprising administering a candidate substance to a mammal as defined in claim 43 which has, or which is susceptible to, coeliac disease and determining whether substance prevents or treats coeliac disease in the mammal, the prevention or treatment of coeliac disease indicating that the substance is a therapeutic product.

66. A therapeutic product as identified in the method of claim 65 for use in a method of preventing or treating coeliac disease.

5 67. A method of diagnosing coeliac disease, or susceptibility to coeliac disease in an individual comprising administering an agent as defined in claim 44 and determining *in vivo* whether T cells in the individual recognise the agent, recognition of the agent indicating that the individual has or is susceptible to coeliac disease.

10 68. A cell according to claim 41 which is a cell of a graminaceous monocotyledonous species.

69. A cell according to claim 68 which is a cell of wheat, maize, oats, rye, rice, barley, triticale, sorghum, or sugar cane.

15 70. A process for the production of a protein encoded by a coding sequence as defined in claim 37 which process comprises:

- (a) cultivating a cell according to any one of claims 41, 42, 68 or 69 under conditions that allow the expression of the protein; and optionally
- (b) recovering the expressed protein.

20

71. A method of obtaining a transgenic plant cell comprising:

- (a) transforming a plant cell with a vector according to claim 40 to give a transgenic plant cell.

25 72. A method of obtaining a first-generation transgenic plant comprising:

- (b) regenerating a transgenic plant cell transformed with a vector according to claim 40 to give a transgenic plant.

73. A method of obtaining a transgenic plant seed comprising:

- 30 (c) obtaining a transgenic seed from a transgenic plant obtainable by step (b) of claim 72.

74. A method of obtaining a transgenic progeny plant comprising obtaining a second-generation transgenic progeny plant from a first-generation transgenic plant obtainable by a method according to claim 72, and optionally obtaining transgenic plants of one or more further generations from the second-generation progeny plant thus obtained.

75. A method according to claim 74 comprising:

(d) obtaining a transgenic seed from a first-generation transgenic plant obtainable by the method according to claim 73, then obtaining a second-generation transgenic progeny plant from the transgenic seed;

and/or

(e) propagating clonally a first-generation transgenic plant obtainable by the method according to claim 72 to give a second-generation progeny plant;

and/or

(f) crossing a first-generation transgenic plant obtainable by a method according to claim 72 with another plant to give a second-generation progeny plant; and optionally

(g) obtaining transgenic progeny plants of one or more further generations from the second-generation progeny plant thus obtained.

76. A transgenic plant cell, plant, plant seed or progeny plant obtainable by a method according to any one of claims 71 to 75.

77. A transgenic plant or plant seed comprising plant cells according to claim 68 or 69.

78. A transgenic plant cell callus comprising plant cells according to claim 68 or 69 obtainable from a transgenic plant cell, first-generation plant, plant seed or progeny as defined in any one of claims 68, 69, or 71 to 75.

79. A plant or callus according to any one of claims claim 76 to 78 which is of a species as defined in claim 68 or 69.



80. A method of obtaining a crop product comprising harvesting a crop product from a plant according to any one of claims 76 to 79 and optionally further processing the harvested product.

5 81. A method according to claim 80 wherein the plant is a wheat plant and the harvested crop product is grain; optionally further processed into flour or another grain product.

82. A crop product obtainable by a method according to claim 80 or 81.

10


83. A food that comprises a protein as defined in any claim 31 or 36.

84. A food according to claim 83 in which a protein as defined in claim 31 or 36 is used instead of wild-type gliadin.

15

Fig.1a.

Peptide pool 3



Gliadin digest




Fig.1b.




Fig.2a.





Fig.2b.






Fig.4a.





Fig.4b.



6 / 47

Fig.5.





Fig.6.



7/47

Fig.7a.





Fig.7b.









Fig.9.



10/47

Fig.10.






Fig.11.

Peptide length and bioactivity: Means (n=4)  
A-gliadin 57-73 QE65 (17aa)=100%



12 / 47

Fig.12a.

Dose response to A-gliadin 57-73 QE65:  
QLQPFPPQPELPYPQPQS.





Fig.12b.

Dose response to GDA4\_WHEAT P04724 84-100 QE92:  
PQLPYPQPELPYPQPQP.



13 / 47

Fig.12c.

Dose response to A-gliadin 57-73:  
QLQFPQPQLPYQPQS (2.5, 25 & 250 mcg/ml),  
and A-gliadin 57-73 (25 mcg/ml) + tTG treatment.




Fig.12d.

Dose response to GDA4\_WHEAT P04724 84-100:  
PQLPYQPQLPYQPQP (2.5, 25 & 250 mcg/ml),  
and P04724 84-100 (25 mcg/ml) + tTG treatment.




Fig.12e.

Dose response to the DQ2-restricted  $\alpha$  gliadin T  
cell epitope A-gliadin 57-68 QE65:  
QLQPFPQPELPY (E65) (2.5, 25 & 250 mcg/ml),  
and A-gliadin 57-68: QLQPFPQPQLPY (Q65)  
(25 mcg/ml) +/- tTG treatment.




Fig. 12f.

Dose response to the DQ2-restricted  $\alpha$  gliadin T cell epitope  $\alpha$ -2 62-75 QE65 & QE72: PQPELPYPQPELPY (E65) (2.5, 25 & 250 mcg/ml), and  $\alpha$ -2 62-75: PQPQLPYPQPQLPY (Q65) (25 mcg/ml) +/- tTG treatment.







Fig.12g.

Dose response to the DQ8-restricted  $\alpha$  gliadin T cell epitope GDA9 202-219: QE208 & 216: QQYPSGEGSFQPSQENPQ (E) (25 & 250 mcg/ml), and to GDA9 202-219 QQYPSGQGSFQPSQQNPQ (Q) (25 mcg/ml) +/- tTG treatment.



# Fig.12h.

Dose response to the DQ2-restricted  $\gamma$  gliadin T cell epitope GDB2 134-153 QE140, 148,150: QQLPQPEQPQQSFPEQERPF (E) (25 & 250 mcg/ml), and to GDB2 134-153: QQLPQPQQPQQSFPPQQRRPF (Q) (25 mcg/ml) +/- tTG treatment.

GDB2 134-153 (mean+SEM,n=4)




Fig. 13a.

Dose response to gliadin digest by  
chymotrysin.




Fig. 13b.

Dose response to gliadin digested by  
chymotrysin then treated with tTG.





Fig. 13c.

Total ELISpot responses to A-gliadin 57-73 QE65 (25mcg/ml) versus A-gliadin 57-73 QE65 responses as percent of tTG gliadin (500mcg/ml) responses.


Responses to dominant epitope and complete antigen (A-gliadin 57-73 QE65 and tTG-treated gliadin)



(Fig.14.)

Bioactivity of gliadin polymorphisms of A-gliadin 57-73  
(A) in coeliac subjects 6/7 days after gluten challenge  
(Gamma-Interferon Elispot) (n=4).


Fig.14a.



A QLQPFPPQPQLPYPQPQS  
 B QLQPFPPQPQLPYPQPQP  
 C QLQPFPPQPQLPYPQPQL  
 D QLQPFPPQPQLPYLQPQS  
 E QLQPFPPQPQLPYPQPQP  
 F QLQPFPPQPQLPYSQPQP  
 G QLQPFLLQPQLPYSQPQP  
 H QLQPFLLQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP  
 J QPQPFPPPPQLPYPQTQP  
 K PQLPYPPQPQLPYPQPQP  
 L PQLPYPPQPQLPYPQPQL  
 M PQQQPFLPQLPYPQPQS  
 N PQQQPFPPQLPYPQPQS  
 O PQQQPFPPQLPYPQTQP  
 P PQQQPFPPQLPYPQPPP

Fig.14b.




A QLQPFPPQPQLPYPPQPQS  
 B QLQPFPPQPQLPYPPQPQ  
 C QLQPFPPQPQLPYPPQQL  
 D QLQPFPPQPQLPYLQPQS  
 E QLQPFPPQPQLPYPPQPQ  
 F QLQPFPPQPQLPYSQPQP  
 G QLQPFLLQPQLPYSQPQP  
 H QLQPFSSQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP  
 J QPQPFPPQPQLPYPPQTQP  
 K PQLPYPPQPQLPYPPQPQ  
 L PQLPYPPQPQLPYPPQQL  
 M PQQQPFLPQLPYPPQPQS  
 N PQQPFPPQPQLPYPPQPQS  
 O PQQPFPPQPQLPYPPQTQP  
 P PQQPFPPQPQLPYPPPPP

Fig.14c.

QE65 substituted (25 mcg/ml): Means (error bars: 1 SEM)



A	QLQPFPPQPQLPYPPQPQS	I	QLQPFPPQPQLSYSQPQP
B	QLQPFPPQPQLPYPPQPQP	J	QPQPFPFPQLPYPPQIQP
C	QLQPFPPQPQLPYPPQPQL	K	PQLPYPPQPQLPYPPQPQP
D	QLQPFPPQPQLPYLQPQS	L	PQLPYPPQPQLPYPPQPQL
E	QLQPFPPRPQLPYPPQPQP	M	PQPQPFLPQLPYPPQPQS
F	QLQPFPPQPQLPYSQPQP	N	PQPQPFPFPQLPYPPQPQS
G	QLQPFLQPQLPYSQPQP	O	PQPQPFPFPQLPYPPQIQP
H	QLQPFSQPQLPYSQPQP	P	PQPQPFPFPQLPYPPQPPP

Fig.14d. QE65-substituted (2.5 mcg/ml): Means (error bars: 1 SEM)





Fig.14e. QE65-substituted (250 mcg/ml): Means (error bars: 1 SEM)



A QLQPFPPQPQLPYPQPQS  
 B QLQPFPPQPQLPYPQPQP  
 C QLQPFPPQPQLPYPQPQL  
 D QLQPFPPQPQLPYLQPQS  
 E QLQPFPPQPQLPYPQPQP  
 F QLQPFPPQPQLPYSQPQP  
 G QLQPFLLQPQLPYSQPQP  
 H QLQPFSSQPQLPYSQPQP

I QLQPFPPQPQLSYSQPQP  
 J QPQPFPPQPQLPYPQIQP  
 K PQLPYPQPQLPYPQPQP  
 L PQLPYPQPQLPYPQPQL  
 M PQQPFLPQLPYPQPQS  
 N PQQPFPPQPQLPYPQPQS  
 O PQQPFPPQPQLPYPQIQP  
 P PQQPFPPQPQLPYPQPQP



24 / 47

Fig.15.

Alanine scan: Means (error bars: 95% CI for mean)




Fig.16.

Lysine scan: Means (error bars: 95% CI for mean)




Fig.17.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>PQPELPYPQPQS  
60.....70




Fig.18.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




Fig.19.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS  
60.....70




Fig.20.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>FPQPELPYPQPQS<sup>70</sup>




Fig.21.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS  
60.....70




Fig.22.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS  
60.....70




Fig.23.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>PQPELPYPQPQS

60.....70






Fig.24.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70




Fig.25.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS  
60.....70




Fig.26.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPFPPQPELPYPQPQS

60.....70





Fig.27.

Agonist activity of A-gliadin 57-73 QE65 variants according to position substituted (Mean of 8 coeliac subjects' PBMC responses in interferon gamma ELISPOT after gluten challenge)

QLQPF<sup>60</sup>PQPEL<sup>61</sup>PYPQ<sup>62</sup>PQS

60.....70



(Fig.28.)

Interferon gamma ELISpot responses in newly diagnosed and treated coeliac subjects, before and after gluten challenge.

Fig.28a. Untreated, newly diagnosed coeliacs (Mean+SEM, n=9)




Fig.28b.




Fig.28c.




Fig.28d.




Fig.28e.




Fig.28f.




Fig.28g.







Figure 29. Bioactivity of prolamin homologues of A-gliadin 57-73 (IFNg-ELISpot, mean+SEM, n=6)



Omega: AAG17702 (141-157), Gamma: P21292 (96-112), SEC1: Q43639 (335-351), C-HOR: Q40055 (166-182). E-substituted peptides were synthesized with E for Q at position 9.

Figure 30. Healthy HLA-DQ2 Subjects: Change in IFNgamma ELISpot  
Responses to tTG-deamidated Gliadin Peptide Pools  
(median change Day 6 vs Day 0, n=10)




Figure 31. Coeliac HLA-DQ2 Subjects: Change in IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools (median change Day 6 vs Day 0, n=6)




Figure 32. Individual Peptide Contributions to "Summed"  
Gliadin Peptide Response




Figure 33. Coeliac: HLA-DQ2/8 Subject C08: Gluten challenge induced IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools




Figure 34. Coeliac HLA-DQ2/8 Subject C07: Change in IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools




Figure 35. Coeliac HLA-DQ8/7 Subject C12: Gluten challenge induced IFNgamma ELISpot Responses to tTG-deamidated Gliadin Peptide Pools





Figure 36. Coeliac HLA-DQ6/8 Subject C11: Change in IFNgamma  
ELISpot Responses to tTG-deamidated Gliadin Peptide Pools





# INTERNATIONAL SEARCH REPORT

Application No

PCT/GB 03/02450

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/415 A61K39/35 G01N33/68 C12N15/82 A01H5/10  
A23L1/025

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, PAJ, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/25793 A (HILL ADRIAN VIVIAN SINTON ;ISIS INNOVATION (GB); ANDERSON ROBERT P) 12 April 2001 (2001-04-12) cited in the application	1-5, 11, 13-19, 25-42, 44-64, 67-84
Y	page 1-20; claims 1-59; figures 12G, 14-28; examples 3, 8; tables 7-9	6-10, 20-24, 43, 65
	--- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

7 June 2004

Date of mailing of the international search report

09.07.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Moonen, P

## INTERNATIONAL SEARCH REPORT

Application No

PCT/GB 03/02450

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PIPER JUSTIN L ET AL: "High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: Implications for Celiac Sprue" BIOCHEMISTRY, vol. 41, no. 1, 8 January 2002 (2002-01-08), pages 386-393, XP002267668 ISSN: 0006-2960	28,30, 32-34
Y	Abstract, Introduction, Discussion the whole document	1-11, 13-27, 44-58, 60-64,67
X	ARENTZ-HANSEN H ET AL: "THE INTESTINAL T CELL RESPONSE TO ALPHA-GLIADIN IN ADULT CELIAC DISEASE IS FOCUSED ON A SINGLE DEAMIDATED GLUTAMINE TARGETED BY TISSUE TRANSGLUTAMINASE" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 191, no. 4, 21 February 2000 (2000-02-21), pages 603-612, XP000986723 ISSN: 0022-1007 cited in the application	28,30, 32-34
Y	Abstract, Table II, Fig.4, Discussion	44-58, 60-64,67
X	ANDERSON R P ET AL: "IN VIVO ANTIGEN CHALLENGE IN CELIAC DISEASE IDENTIFIES A SINGLE TRANSGLUTAMINASE-MODIFIED PEPTIDE AS THE DOMINANT A-GLIADIN T-CELL EPITOPE" NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 6, no. 3, March 2000 (2000-03), pages 337-342, XP000982628 ISSN: 1078-8956 abstract; figure 1	28,30, 32-34
Y		44-58, 60-64,67
X	EP 0 905 518 A (UNIV LEIDEN ;ACADEMISCH ZIEKENHUIS LEIDEN (NL)) 31 March 1999 (1999-03-31)  Paragr. '0001!-'0014!; SEQ ID NOs:11,12,14,15,16 claims 11-14; figures 3,5	1-11, 13-28, 30, 32-34, 44-58, 60-64,67
	--- -/-	

## INTERNATIONAL SEARCH REPORT

Application No

PCT/GB 03/02450

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VADER L W ET AL: "Specificity of tissue transglutaminase explains cereal toxicity in celiac disease" JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 195, no. 5, 4 March 2002 (2002-03-04), pages 643-649, XP002204499 ISSN: 0022-1007 cited in the application Abstract, Page 645, Figure 1	1-11, 13-28, 30, 32-34, 44-58, 60-64,67
Y	WIESER H ET AL: "COELIAC ACTIVE PEPTIDES FROM GLIADIN: LARGE-SCALE PREPARATION AND CHARACTERIZATION" ZEITSCHRIFT FUER LEBENSMITTELUNTERSUCHUNG UND -FORSCHUNG, XX, XX, vol. 194, no. 3, 1992, pages 229-234, XP002072056 ISSN: 0044-3026 Summary; sequence B3143	1-11, 13-28, 30, 32-34, 44-58, 60-64,67
Y	KUMAR R ET AL: "Human Genome Search in Celiac Disease: Mutated Gliadin T-cell-like Epitope in Two Human Proteins Promotes T-cell Activation" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 319, no. 3, 30 May 2002 (2002-05-30), pages 593-602, XP004449660 ISSN: 0022-2836 Abstract; pages 597-599	12,29, 31-33, 35-42, 59,64, 68-84
Y	& KUMAR ET AL: "Human Genome Search in Celiac Disease: Mutated Gliadin T-cell-like Epitope in Two Human Proteins Promotes T-cell Activation" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, 'Online! 30 May 2002 (2002-05-30), doi:10.1016/S0022-2836(02)00366-2 Retrieved from the Internet: <URL:www.sciencedirect.com> 'retrieved on 2004-06-01!	
Y	MOUSTAKAS A K ET AL: "STRUCTURE OF CELIAC DISEASE-ASSOCIATED HLA-DQ8 AND NON-ASSOCIATED HLA-DQ9 ALLELES IN COMPLEX WITH TWO DISEASE-SPECIFIC EPITOPES" INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 12, no. 8, August 2000 (2000-08), pages 1157-1166, XP001021489 ISSN: 0953-8178 the whole document	12,29, 31-33, 35-42, 59,64, 68-84

-/--

## INTERNATIONAL SEARCH REPORT

Application No

PCT/GB 03/02450

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JUNG G ET AL: "From combinatorial libraries to MHC ligand motifs, T-cell superagonists and antagonists" BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 29, no. 3-4, September 2001 (2001-09), pages 179-181, XP002242277 ISSN: 1045-1056 the whole document	12,29, 31-33, 35-42, 59,64, 68-84
Y	MOWAT A M: "Coeliac disease-a future for peptide therapy?" LANCET, XX, XX, vol. 356, no. 9226, 22 July 2000 (2000-07-22), pages 270-271, XP004263756 ISSN: 0140-6736  the whole document	1,2,4-7, 9-11, 13-16, 18-21, 23-28, 30, 32-34, 44-58, 60-64,67
Y	MADSEN LARS S ET AL: "A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor" NATURE GENETICS, vol. 23, no. 3, November 1999 (1999-11), pages 343-347, XP002283438 ISSN: 1061-4036 the whole document	43,65
A	O'KEEFFE J ET AL: "T CELL PROLIFERATION, MHC CLASS II RESTRICTION AND CYTOKINE PRODUCTS OF GLIADIN-STIMULATED PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC)" CLINICAL AND EXPERIMENTAL IMMUNOLOGY, OXFORD, GB, vol. 117, no. 2, August 1999 (1999-08), pages 269-276, XP000989621 ISSN: 0009-9104 the whole document	
A	WAL VAN DE Y ET AL: "Coeliac disease: it takes three to tango " GUT, BRITISH MEDICAL ASSOCIATION, LONDON,, GB, vol. 46, 2000, pages 734-737, XP002204498 ISSN: 0017-5749	

-/-

## INTERNATIONAL SEARCH REPORT

Application No

PCT/GB 03/02450

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	<p>ARENTZ-HANSEN HELENE ET AL: "Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues"  GASTROENTEROLOGY,  vol. 123, no. 3, September 2002 (2002-09),  pages 803-809, XP009024146  ISSN: 0016-5085</p> <p>abstract; table 1</p>	<p>1,2,4-7,  9-11,  13-16,  18-21,  23-28,  30,  32-34,  44-58,  60-64,67</p>
Y,P	<p>WO 02/083722 A (KONING FRITS ;ACADEMISCH ZIEKENHUIS LEIDEN (NL); DRIJFHOUT JAN WOU)  24 October 2002 (2002-10-24)  page 1-15; claims 1-52</p>	<p>1</p>
E	<p>WO 03/066079 A (KONING FRITS ;ACADEMISCH ZIEKENHUIS LEIDEN (NL); DRIJFHOUT JAN WOU)  14 August 2003 (2003-08-14)  &amp; EP 1 332 760 A (ACADEMISCH ZIEKENHUIS LEIDEN) 6 August 2003 (2003-08-06)  SEQ ID NOs: 2,21,38,42,43,46,59,73  figure 2B</p>	<p>1-11</p>
E	<p>WO 03/096984 A (HAUSCH FELIX ;QUARSTEN HANNE (NO); SOLLID LUDVIG M (NO); UNIV LELA) 27 November 2003 (2003-11-27)</p> <p>page 1-18; claims 1-18</p>	<p>12,29,  31-33,  35-42,  59,64,  68-84</p>

# INTERNATIONAL SEARCH REPORT

application No.  
PCT/GB 03/02450

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-14: 67  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 66  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Claims Nos.: 1-14; 67

Although claims 1-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the agent.

Although claim 67 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

## Continuation of Box I.2

Claims Nos.: 66

Present claim 66 relates to a product defined by reference to a method of identification having the desirable characteristic of being of use in a method of preventing or treating coeliac disease.

The claim covers all products having this characteristic, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products mentioned in Table 9 of the description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1-2, 4-7, 9-11, 13-16, 18-21,  
23-28, 30, 32-34, 44-58, 60-64, 67, all partially

All embodiments concerning in particular the closely related wheat sequences SEQ ID NOS:18-20, 31 and 34-35, HLA-DQ2-restricted.

Invention 2: claims 1-2, 4-7, 9-11, 13-16, 18-21,  
23-28, 30, 32-34, 44-58, 60-64, 67, all partially

All embodiments concerning in particular the closely related wheat sequences SEQ ID NOS:21-22, 42, 43 and 46, HLA-DQ2-restricted.

Invention 3: claims 1-2, 4-7, 9-11, 13-16, 18-21,  
23-28, 30, 32-34, 44-58, 60-64, 67, all partially

All embodiments concerning in particular the wheat sequences SEQ ID NOS:32-33 and 36, HLA-DQ2-restricted.

Invention 4: claims 1-4, 6-11, 13-16, 18, 20-28,  
30, 32-34, 44-58, 60-64, 67, all partially

All embodiments concerning in particular the rye secalins and barley hordeins SEQ ID NOS:39-41, HLA-DQ2-restricted.

Invention 5: claims 1, 3-11, 13-15, 17-28, 30,  
32-34, 44-58, 60-64, 67, all partially

All embodiments concerning in particular the epitope SEQ ID NO:44 bioactive in HLA-DQ8+ patients.

Invention 6: claims 12, 29, 31, 35-42, 59, 68-84,  
completely; claims 32-33, 64, partially

All embodiments referring to antagonists or mutated gliadin proteins.

Invention 7: claims 43, 65-66



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Concerning mammals expressing a T cell receptor that  
recognises a peptide.

# INTERNATIONAL SEARCH REPORT

information on patent family members

Application No

PCT/GB 03/02450

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0125793	A	12-04-2001	AU 7539400 A CA 2386089 A1 EP 1218751 A2 WO 0125793 A2 JP 2003511670 T	10-05-2001 12-04-2001 03-07-2002 12-04-2001 25-03-2003
EP 0905518	A	31-03-1999	EP 0905518 A1	31-03-1999
WO 02083722	A	24-10-2002	CA 2443886 A1 EP 1377604 A2 WO 02083722 A2 NO 20034588 A	24-10-2002 07-01-2004 24-10-2002 10-12-2003
WO 03066079	A	14-08-2003	EP 1332760 A1 WO 03066079 A2	06-08-2003 14-08-2003
WO 03096984	A	27-11-2003	WO 03068170 A2 WO 03096979 A2 WO 03096984 A2 US 2003215438 A1	21-08-2003 27-11-2003 27-11-2003 20-11-2003

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**